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ABSTRACT
Colorectal cancer (CRC) is the second most common cancer in both men and

women in Australia. The upregulation of cyclooxygenase-2 (COX-2), an enzyme

involved in the inflammation response, has been linked to a number of cancers,

including CRC. This has prompted a number of epidemiological and clinical studies

that suggest that prolonged administration of non-steroidal anti-inflammatory drugs
(NSAIDs) can reduce the incidence of cancer, in particular, CRC. However, side effects

such as gastrointestinal (GI) bleeding limit the prolonged daily use of (NSAIDs) for the
chemoprevention of cancer.

Bismuth, a group 15 post-transition metal, has been used for centuries to treat an

array of GI diseases. The Bi formulations exhibit an acceptable toxicity profile when
administered at low doses over extended periods. Thus, it is hypothesised that the

combination of Bi and NSAID in a single compound may potentially relieve the adverse
GI side effects of NSAIDs if used daily as a chemopreventive agent.

The aim of this Thesis was to determine the suitability of Bi complexes of NSAIDs

(BiNSAIDs) as potential chemotherapeutic or chemopreventive agents. The starting

point was to assess the ability of BiNSAIDs to interact with transformed cells (HCT-8

human ileocecal colon cancer cells) using a selection of BiNSAIDs of the general
formula [Bi(L)3]n, (where L = diflunisal (difl), mefenamate (mef) or tolfenamate (tolf)).

The hydrolytic stability of the BiNSAIDs in cell medium was investigated to

determine the biologically relevant structures that the cancer cells were exposed to in
the cell assays.

NMR spectroscopy of high concentrations of BiNSAIDs in cell

medium (24 h, 37 °C) indicated that their structural stability and interactions with cell

medium components were specific to the complex. Specifically, Bi(tolf)3 appeared to

remain intact, whereas Bi(mef)3 and Bi(difl)3 were affected by interactions with the

cell medium.

The in vitro cytotoxicity, mode of cell death, and the ability of the BiNSAIDs to

inhibit COX in HCT-8 cells were investigated. Assessment of cell viability using the

[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium] bromide (MTT) assay showed

that the toxicity ranking of the BiNSAIDs paralleled those of the respective free
NSAIDs: diflH < mefH < tolfH. While the IC50 values of the BiNSAIDs (ranging between
16 and 81 μM) were lower than the free NSAIDs (ranging between 37 and 403 μM),

it was apparent that the toxicity of the BiNSAIDs was in reasonable agreement with
the molar ratio of the three NSAIDs per BiNSAID, with the exception of Bi(difl)3.

ii

Phase contrast microscopy and Annexin-V/7AAD staining showed that treatment with

all BiNSAIDs and NSAIDs induced morphological changes indicative of cell death via

apoptosis. Recognising that over-expression of COX-2 is associated with CRC, the
ability of the BiNSAIDs to inhibit the production of PGE2 (and COX) in HCT-8 cells was

assessed. It was observed that the inhibition of PGE2 production by the BiNSAIDs

paralleled that of the respective free NSAIDs: diflH < mefH < tolfH. These results

indicated that the COX inhibition of the examined NSAIDs was not substantially
diminished by their coordination to Bi (in the BiNSAIDs).

Bismuth uptake was quantified using graphite furnace atomic absorption

spectroscopy (GFAAS) to establish whether BiNSAID stability and toxicity correlated

with cellular uptake. The highest cellular Bi content was observed following

treatment with Bi(tolf)3. Since NMR studies indicated that Bi(tolf)3 was the most
stable BiNSAID it appears that Bi uptake is assisted by the NSAID. Furthermore,

microprobe synchrotron radiation X-ray fluorescence (SRXRF) imaging was utilised to

determine the subcellular fate of the Bi contained in the BiNSAID complexes.
Microprobe SRXRF imaging showed that Bi generally accumulated in the cytoplasm

within 24-h exposure regardless of the BiNSAID treatment. The size and location of
the hot spots (0.3–5.8 μm2) were consistent with two intracellular fates. The first is

accumulation into lysosomes, which would be indicative of a cellular detoxification

mechanism. The second relates to the hot spots that are in close proximity to the

nuclear membrane (and potentially COX-2), which indicates the intracellular

movement of Bi. However, the specific targeting of COX-2 by the BiNSAID would
require further investigation.

Synchrotron radiation infrared microspectroscopy (SR-IRMS) was utilised in

order to assess the global biomolecular changes induced by BiNSAID treatment
compared to NSAIDs alone. Live HCT-8 cells were examined using a demountable cell

holder in order to maintain hydration. The results from 4-h experiments differed to

24-h experiments suggesting that the cells undergo time-dependent changes. In most

cases, it was observed that BiNSAID or NSAID treatment substantially affected the IR
bands associated with lipids.

Based on the results from the SR-IRMS study and literature precedence, the

effects of BiNSAID- and NSAID-induced cell death on the distribution and quantity of
three glycerophospholipids, phosphatidylcholine (PC), phosphatidylethanolamine

(PE) and phosphatidylserine (PS), in the HCT-8 cells was examined using electrospray
iii

ionisation tandem mass spectrometry (ESI-MS/MS). The results showed that
treatment with Bi(tolf)3 or Bi(difl)3 caused alterations to the profile and concentration

of individual PC, PE and PS molecules. Additionally, specific trends were identified,
whereby changes to the saturation levels of the fatty acids comprising the PC, PE and

PS were observed. Treatment with both BiNSAIDs or NSAIDs caused an increase in
the proportion of the ether-linked PC and PE molecules relative to the overall profile

of PC and PE in the HCT-8 cells, which was accompanied by a significant increase in

the relative concentration of ether-linked PE molecules (but not PC) in the

BiNSAID-treated cells.
the

Encouraged by the promising in vitro anti-cancer activity of the BiNSAIDs against
HCT-8

cells,

several

Bi(III)

derivatives

of

aminoarenesulfonates,

indole-carboxylates, hydroxamates were screened for anti-cancer activity using the

MTT assay. A small selection of complexes from each class showed promising in vitro
toxicity, that warrants further investigation into the chemotherapeutic potential of

non-NSAID Bi(III) complexes.

The results presented in this Thesis reveal that BiNSAIDs, Bi(tolf)3, Bi(mef)3 and

Bi(difl)3, exhibit promising anti-cancer action against CRC cells in vitro. These findings
set the precedence to establish if the chemotherapeutic and chemopreventive
potential of the BiNSAIDs translates to an in vivo model of CRC.
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Chapter 1.
Introduction

Colorectal cancer (CRC) is the second most common cancer in both men and women in

Australia. Since the incidence of CRC has not improved since the 1980s, prevention

strategies are needed to reduce the burden of this disease. The upregulation of

cyclooxygenase-2 (COX-2), an enzyme involved in the inflammation response, has
been linked to a number of cancers, including CRC. This has led to a large number of

studies that subsequently showed that several over-the-counter non-steroidal

anti-inflammatory drugs (NSAIDs) reduced the risk of CRC when taken regularly over
periods of months to years. This Chapter provides a review of the relevant literature

with a focus on the potential use of NSAIDs as chemopreventive and chemotherapeutic
agents for CRC, the advantages of coordinating NSAIDs to metals, and finally, the
medicinal use and anti-cancer activity of bismuth(III) complexes, including Bi(III)
complexes of NSAIDs (BiNSAIDs).

Chapter 1. Introduction

1.1 Cancer
Cancer, in the simplest of terms, is a genetic disease that is characterised by the

uncontrolled propagation of cells that have acquired defects in regulatory circuits that

control normal cell proliferation and homeostasis [1]. The accumulation of sequential

chromosomal mutations allows a cancer cell to resist cell death, undergo limitless
cycles of cell division, resist anti-growth signals, maintain autonomous growth

signaling, sustain angiogenesis (the formation of blood vessels in the tumour), and

eventually acquire metastasis (the ability to invade tissues at distal locations) [1].

Collectively, these six features are described as the “hallmarks of cancer” [1]. Over 100

distinct types of cancer have been identified and the order of acquisition of the

aforementioned characteristics varies considerably between cell types [1].
The American Cancer Society estimates that cancer causes the death of one in seven

people worldwide [2]. In 2012, cancer represented the second leading, and third
leading, cause of death in economically developed, and economically developing

countries, respectively, highlighting the serious global nature of this disease [2].
1.1.1 Colorectal cancer

Worldwide, colorectal cancer (CRC) or bowel cancer, is the third most common

cancer in men (following lung and prostate cancers), and the second most common

cancer in women (following breast cancer) [2]. CRC commonly develops from

adenomatous polyps, which are non-malignant growths that propagate in the

epithelium of the digestive tract [3]. Owing to the slow accumulation of multiple

genetic mutations, conservative estimates suggest that adenomatous polyps can
remain non-malignant for periods of 5–10 years, or more [4]; this is reflected in the

diagnosis of over 90% of CRC cases in individuals over the age of 50 [5].

Alarmingly, Australia and New Zealand exhibit the highest incidence (per 100,000

people) of CRC in the world [6]. In Australia alone, CRC represents the second most

common cancer in both men and women [7]. Approximately 31% of individuals

diagnosed with CRC do not survive beyond five years [7]. In 2017, the Australian
Institute of Health and Welfare reported that a total of 4,144 deaths were directly

attributable to CRC [7]. Despite reductions in the age-standardised mortality rates

from CRC in Australia (Fig. 1.1) over the past three decades, the age-standardised

incidence of CRC has remained steady between 1982–2014 (Fig. 1.1) [7], with 16,682
new cases of CRC diagnosed in Australia in 2017 [7].
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Figure 1.1: Age-standardised incidence and mortality rates (1982–2014) of colorectal cancers
by sex in Australia. Source: Australian Institute of Health and Welfare [7].

Although the estimated lifetime risk of developing CRC in the general population

is 5.6% [8], 70–80% of CRC cases occur in individuals with no family history of the

disease [9, 10]. Largely preventable lifestyle factors, including high alcohol

consumption, diet (high fat, high intake of red and processed meats) and lack of

physical activity, are believed to contribute to the development of CRC [5].

Family history accounts for approximately 20% of CRC cases, while 5–10% of cases
are associated with the genetic syndromes, familial adenomatous polyposis (FAP) and

Lynch syndrome (also called hereditary non-polyposis CRC) [9, 10]. The estimated

lifetime risk of developing CRC in genetically susceptible subpopulations increases to
17% for individuals with two affected first-degree relatives, and up to 95% and 70%
for individuals with FAP and Lynch syndrome, respectively [11].

Successful methods of early detection such as faecal occult blood testing and

endoscopic surveillance (flexible sigmoidoscopy and colonoscopy), and the removal of
pre-carcinogenic

lesions

(polypectomy)

are

available

in

Australia

[12-14].

However, primary prevention strategies have been suggested as an important
complement to established screening methods to reduce the incidence of CRC [15],
and

an

alternative

approach

to

reducing

mortality

from

cancer

[16].

Chemoprevention, which is the use of a pharmacological or nutritional agent to

prevent, reverse, or delay the progression of carcinogenesis, represents one example

of a primary prevention strategy that has been widely studied in the context of

CRC [16]. Ideally, chemopreventive agents should be effective, easily administered
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(i.e. oral administration), of low cost, involve a dosing schedule that enables

compliance (no more than once daily), and have no or limited side effects (i.e. the
benefit to risk ratio must be high) [16]. Therapeutic and nutritional agents that have

been shown to reduce CRC incidence in observational studies include non-steroidal
anti-inflammatory drugs (NSAIDs), folic acid, calcium (in conjunction with vitamin D in

some studies), antioxidants (including vitamins A, C, and E, beta-carotene or

selenium), statins and bisphosphonates [15]. Of the aforementioned agents, calcium

and vitamin D appear to exhibit modest clinical benefit, while NSAID therapies appear

to reduce the incidence of CRC substantially [15].

NSAIDs are readily available over-the-counter drugs that are commonly used to

relieve the symptoms of inflammation, pain, redness, swelling, and calor [17].

NSAIDs are commonly used for the treatment of pain and inflammation associated

with transient inflammatory conditions and tissue damage (including post-operative

pain, dysmenorrhoea, headaches, migraines, and pericarditis), and chronic conditions,

including osteoarthritis and rheumatoid arthritis [17]. The chemopreventive and

chemotherapeutic potential of NSAIDs, and the drawbacks of NSAID use, will be the
focus of discussion in Section 1.2.

1.2 Non-Steroidal Anti-Inflammatory Drugs
The term NSAID describes several classes of organic molecules that exert their

quintessential anti-inflammatory, anti-pyretic and analgesic actions through the

inhibition of the cyclooxygenase-1/-2 (COX-1/-2) enzymes [17]. This subsequently
decreases the production of prostaglandins, the potent lipid autocrine and paracrine

factors involved in the mediation of the inflammatory response [18]. Over 30 million

people worldwide are estimated to use prescription NSAIDs on a daily basis [19],

making NSAIDs one of the most commonly used pharmaceutical class in the world. In

the USA alone, more than 111 million prescriptions are written for NSAIDs annually; in
addition, NSAIDs that are purchased over-the-counter account for approximately 60%
of all analgesics sold in the USA [20].

Historically, NSAID administration can be traced back thousands of years to the

use of bark from the white willow (Salix alba) by the physicians, Hippocrates (~460–

377 BC) and Dioscorides (~40–90 AD), for the alleviation of fever and musculoskeletal
pain [21]. Salicylic acid (2-hydroxybenzoic acid), a derivative of the active ingredient

salicin was first produced industrially in 1874 [22]; however, due to poor palatability,
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acetylsalicylic acid (Fig. 1.2) was developed by Felix Hoffman in 1897, and marketed

by Frederick Bayer & Company as aspirin (aspH) in 1899 [23]. Non-salicylate NSAIDs,

indomethacin (indoH, Fig. 1.2) and ibuprofen (ibuH, Fig. 1.2), were first introduced to

the market in 1964 and 1969, respectively [24]. This was followed by the introduction
of diclofenac (dicloH, Fig 1.2) and ketoprofen (ketoH, Fig 1.2) in the mid-1970s [24].

As shown in Figure 1.2, arylalkanoic acids (of the general formula ArCRHCOOH,

where Ar = aryl or heteroaryl; R = H, CH3, alkyl), including salicylic acids (e.g. aspH,
diflunisal (diflH), and salsalate), indolic acids (e.g. indoH), acetic acids (e.g. sulindac),

propionic acids (e.g. ibuH, naproxen (napH), flurbiprofen, and ketoH), and fenamates

(e.g. mefenamic acid (mefH), tolfenamic acid (tolfH), flufenamic acid (fluH),
meclofenamic acid (mecloH), and dicloH), comprise the largest chemical group of

NSAIDs [25]. Notably, the arylalkanoic acid-based NSAIDs contain a carboxylate

moiety (Fig. 1.2). The selectivity preference of NSAIDs from these structural classes

for COX-1 and COX-2 varies depending on the individual NSAID [26, 27].

In the 1980s, Pfizer developed enolic acid NSAIDs, termed ‘oxicams’, which are

derivatives of 4-hydroxy-1,2-benzothiazine 3-carboxamides [28]. Piroxicam (pirox,

Fig. 1.2), marketed as Feldene® (Pfizer, New York, USA), was successfully introduced
into the market in 1982 [28]. Shortly following this other oxicams including

meloxicam (melox, Fig. 1.2), isoxicam (isox), lornoxicam, and tenoxicam (tenox) were

introduced to the market [28]. Oxicams are able to interact with both COX

isoforms [27, 29]; for instance, pirox has been shown to bind preferentially to
COX-1 [27], while melox has been shown to be moderately selective for COX-2 [29].

NSAIDs that are highly selective for COX-2 (termed ‘coxibs’, Fig. 1.2), celecoxib

(Celebrex®, Pfizer, New York, USA), rofecoxib (Vioxx®, Merck & Co. Inc., New Jersey,

USA), and parecoxib (Dynastat®, Pfizer, New York, USA), were introduced to the
market in the late 1990s [30]. The coxibs incorporate a sulfonyl moiety in their

chemical structures (Fig. 1.2), an important chemical feature that allows the molecules

to interact preferentially with the COX-2 active site [30]. The concept of COX-1 and
COX-2 selectivity, and the subsequent physiological consequences, will be discussed

further in Section 1.2.1.
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Figure 1.2: Chemical classes of non-steroidal anti-inflammatory drugs (NSAIDs). The chemical
structure, generic name and IUPAC name of selected NSAIDs representative of each class are
presented to highlight the diversity of molecules that comprise NSAIDs [25, 31].
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1.2.1 Mechanism of action of NSAIDs
Studies performed by Vane and colleagues in the 1970s established that the

primary mechanism through which NSAIDs exert their therapeutic action was through

the inhibition of prostaglandin endoperoxide G/H synthase, the enzyme commonly
referred to as COX [18, 32]. In the early 1990s, several studies established that there

were two distinct forms of the COX enzyme, COX-1 and COX-2 [33-35]. Importantly,

COX-1 and COX-2 differ in their subcellular location, constitutive levels of expression

in tissues throughout the body, and the structure of their active sites.

Immunocytofluorescence studies have established that both isoforms are present in
the endoplasmic reticulum [36]. COX-1 is also located close to the plasma membrane,

whereas COX-2 is specifically associated with the nuclear envelope [37]. COX-1 is

constitutively expressed in most human tissues and is responsible for regulating
essential physiological functions, including platelet aggregation, gastric protection,

and renal function [38]. Conversely, under normal physiological conditions, COX-2

expression is low to negligible in most tissues [39]. Growth factors, as well as
cytokines (including tumour necrosis factor-α, interferon-γ, and interleukins (ILs),

IL-1α and IL-1β) stimulate COX-2 expression [39]. As such, COX-2 is commonly

referred to as the ‘inducible’ form of the enzyme. It is notable that COX-2 is

constitutively expressed in specific regions of the brain [40] and renal tubular cells
[41]. The upregulation of COX-2 occurs primarily in response to inflammatory stimuli

and thus plays a crucial role in mediating pain and inflammation [39]. It is notable

that COX-3, a splice-variant of COX-1 has been identified [42]. Interestingly, some

NSAIDs including dicloH, and the non-NSAID acetaminophen, have been shown to

interact preferentially with COX-3 in vitro [42]; however, the physiological significance
of COX-3 in humans remains poorly understood [43].

COX-1 and COX-2 consist of two catalytic sites, one with COX activity, and the

other with peroxidase (POX) activity, which are located in two narrow channels on
opposite sides of the catalytic domain [44]. The COX catalytic site is responsible for
the oxidation of arachidonic acid to prostaglandin G2 (PGG2). Subsequently, this short-

lived intermediate is reduced to PGH2 by the POX catalytic site (Fig. 1.3) [38]. The
second intermediate, prostaglandin H2 (PGH2), is used as the substrate to form a

number of prostaglandins, namely prostaglandin D2 (PGD2), prostaglandin E2 (PGE2),

prostaglandin F2α (PGF2α), and prostaglandin I2 (PGI2) via prostaglandin-specific
synthases, and thromboxane A2 (TXA2) via thromboxane synthase (Fig. 1.3) [38].
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Figure 1.3: The conversion of arachidonic acid to prostaglandins via the COX and POX active
sites of COX-1/-2. Adapted from Vane et al. [38].

The eicosanoids (the collective term for prostaglandins, thromboxanes and
leukotrienes) are autocrine and paracrine factors that are responsible for the

mediation of specific physiological processes, including maintenance of gastric
mucosa, platelet aggregation, bronchoconstriction, and vascular patency [45].

NSAIDs explicitly interact with the active site in the COX channel, leaving the POX

catalytic site unaffected, preventing the conversion of arachidonic acid to
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PGG2 [38]. The COX-selectivity of NSAIDs is based on the structure of the NSAID, and

the structure of the COX active sites. The homology of the COX active site is highly
conserved, except for the substitution of a few key residues, as demonstrated in

Figure 1.4 [30]. Specifically, the substitution of Ile523 (COX-1) for Val523 (COX-2)

allows unhindered access of bulkier substituents into a side pocket in the COX-2
channel due to the reduced size of the Val residue (Fig. 1.4) [30]. Additionally, the

substitution of Phe503 (COX-1) for Leu503 (COX-2) increases the space available at

the top of the COX-2 channel (Fig. 1.4) [30]. Non-selective NSAIDs are able to interact

with both the COX-1 and COX-2 active sites via interactions with Arg120 and
Tyr355 (Fig. 1.4), which are stabilised by the carboxylate moiety present in the NSAID

structures, while the phenyl group interacts with Tyr385 further up the hydrophobic
channel (Fig. 1.4) [30].

The ‘coxibs’ incorporate sulfonyl moieties by design to specifically interact (via

hydrogen bonding) with Arg513 in the accessible side pocket (Fig. 1.4), hence their

high selectivity for COX-2 [30]. The majority of NSAIDs interact reversibly with the

COX active site, thus competing with the natural substrate, arachidonic acid [46]. The

exception is aspH, which irreversibly inhibits COX activity via the acetylation of

Ser530 in COX-1 [47] and Ser516 in COX-2 [48]. The irreversible inhibition of COX by

aspH triggers de novo synthesis of COX by cells [49].

Figure 1.4: The key structural residues of the COX-1 and COX-2 active sites. Notably, substitution
of Phe503 for Leu503, and Ile523 for Val523 increases the size of the COX-2 active site allowing for
the incorporation of bulkier side groups present in COX-2 selective inhibitors. An equivalent
numbering system for both isoforms was adopted for clarity. Adapted from Flower [30].
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1.2.2 NSAIDs: Chemopreventive agents for CRC?
Numerous observational, epidemiological, and clinical studies collectively suggest

that daily use of NSAIDs reduces the occurrence of adenomatous polyps, and

decreases the overall incidence and mortality of CRC in both high- and average-risk

populations ([50], references within). Since Narisawa et al. [51] first described the

suppression of chemical-induced carcinoma in rats by indoH in 1981, over 40 other
rodent studies have shown that NSAIDs (including aspH, indoH, sulindac, ibuH, ketoH,

pirox and celecoxib) inhibit CRC or aberrant crypt formation induced by injection of

azoxymethane or other chemicals known to induce carcinogenesis ([50], references

within).

The chemopreventive effect of sulindac in humans was first recognised by

Waddell et al. [52, 53], whereby sulindac was effective in reducing the number of

polyps in patients with FAP in clinical studies. Given the inherent risk of developing
CRC by the third or fourth decade of life for FAP sufferers [54], a number of studies

focusing on the use of NSAIDs in this population have been performed. Several studies

in ApcMin mice and other murine models of human FAP have shown significant

inhibition of tumour development by NSAIDs including aspH [55], sulindac [56, 57],

and celecoxib [58]. One of the largest randomised, placebo-controlled trials conducted

in the setting of FAP (n = 133), the Colorectal Adenoma/Carcinoma Prevention

Programme [59], found no significant reduction in polyp number in the rectum and

sigmoid colon with daily aspH (600 mg) treatment over a period of one to seven years,

although a trend of reduced polyp size was observed. The suppression of the

formation of adenomatous polyps, and regression of existing polyps by sulindac has
been demonstrated in a number of randomised clinical trials in patients with

FAP [60-62], although one study [63] reported no significant reduction in the
formation of adenomas between the sulindac-treated and placebo groups. In the late

1990s, 77 patients participated in a pivotal trial that demonstrated that compared to
the placebo, a twice-daily dose of celecoxib (100 mg or 400 mg) over six months

significantly reduced the mean number of colorectal polyps and polyp burden [64].
The U.S. Food and Drug Administration (FDA) approved the use of celecoxib as an

adjunctive treatment for FAP (in conjunction with usual care procedures) under
subpart H (accelerated approval) in 2000; however, permanent FDA approval was not
pursued by the manufacturer and the preliminary approval was removed in 2011 [65].
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The NSAID, aspH, has been shown to reduce the incidence and recurrence of CRC

in individuals with Lynch syndrome [66], and previous adenomatous polyps [67]. The
second Colorectal Adenoma/Carcinoma Prevention Programme trial [66] investigated

the effects of aspH on 1,000 individuals with Lynch syndrome, which was the first
large-scale genetically targeted chemoprevention trial of aspH with cancer as the
primary endpoint. The results suggested that following an average observation period

of 55.7 months cancer incidence was substantially reduced in hereditary CRC carriers

dosed with 600 mg of aspH once daily for a minimum of two years [66]. In a

randomised, double-blind study involving 635 patients that had previously suffered

from CRC [67], those dosed with aspH 325 mg once daily exhibited a significantly

lower risk of recurring colon adenomas (17% incidence of adenomas compared to

27% with the placebo). Furthermore, a randomised, placebo-controlled study, the

Adenoma Prevention with Celecoxib trial [68], evaluated the ability of celecoxib to

reduce the occurrence of endoscopically detected colorectal adenomas. Celecoxib

administration in patients who had previously had adenomatous polyps removed,

showed that following three years the incidence of recurrence of adenomas was
reduced in celecoxib-treated groups to 43.2% (200 mg twice daily) and 37.5%

(400 mg) compared to the placebo group (60.7%) [68]; however, the authors

concluded that due to cardiovascular (CV) risks celecoxib could not be recommended
for routine use for CRC prevention [68].

The results from 35 non-randomised epidemiological studies collectively suggest

that regular use of NSAIDs lowers the incidence of adenomatous polyps, and reduces

the incidence and mortality from CRC in individuals in the general population ([50],

references within). These observations are promising since the highest incidence of

CRC occurs in non-genetically predisposed populations. A recent meta-analysis [69]

compared data from observational studies to data from randomised controlled

trials. Encouragingly, the results from methodically rigorous observational studies

were consistent with the data obtained from randomised trials that regular use of

aspH reduces the long-term risk of CRC (and several other cancers) and the risk of

distant metastasis [69]. However, two large scale randomised placebo-controlled

studies, the Physicians’ Health Study (325 mg aspH, every other day) [70] and the
Women’s Health Study (100 mg of aspH, every other day) [71], showed no reduced

risk of CRC in individuals dosed with aspH compared to the placebo group. The lack of

effect has been debated in the literature; for instance, it is plausible that alternate day
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dosing and relatively short follow-up periods may not produce a significant

result [72]. Importantly, a significant reduction in mortality from CRC was not
observed until 10 to 20 years post-intervention in a pooled analysis of three trials

examining the effect of daily aspH use [73].

Interestingly, the analysis of data from randomised trials that examined daily

aspH use for other endpoints, such as vascular events, have provided a large
population of aspH-dosed subjects in order to assess anti-cancer effects as a secondary

end point. For instance, pooled analysis of 34 randomised trials of daily aspH for

prevention of vascular events showed that risk of mortality from all cancers decreased
following a follow up period of more than five years [74]. Additionally, pooled analysis

of five large randomised trials (n = 17,285) of daily aspH (≥ 75 mg) versus placebo for

the prevention of vascular events suggested that daily aspH use could reduce the risk

of cancer with distant metastasis [75]. It should be noted that these analyses excluded

results from the Women’s Health Study [72].

In conclusion, the results from numerous epidemiological studies suggest there is

an inverse relationship between the regular use of NSAIDs and the incidence of CRC

and adenomas in a variety of populations. However, given the lack of strong clinical

evidence (from randomised placebo-controlled studies) to show an unequivocal

reduction in the CRC incidence of NSAID-treated subjects, combined with the risk of

adverse side effects, such as gastrointestinal (GI) bleeding, there are currently no
recommendations for the use of NSAIDs in CRC prevention [76, 77].
1.2.3 The role of COX-2 in CRC

In 1994, Eberhart et al. [78] determined that COX-2, but not COX-1, gene

expression was upregulated in approximately 86% of human colorectal carcinomas

and approximately 50% of adenomas compared to levels in adjacent healthy mucosal

cells. Other investigators [79-81] have confirmed the upregulation of COX-2

expression in CRC in human colon cancer tissues and animal models. Additionally,
elevated COX-2 expression has been identified in other types of cancer tissue including

non-small cell lung [81, 82], bladder [83], breast [81, 84], and head and neck [85]
cancers. A number of studies [86-88] have suggested that elevated COX-2 expression

in tumour tissue is associated with increased tumour invasiveness and poor prognosis
for the patient. As demonstrated in Figure 1.5, several molecular pathways are

impacted by the over-expression of COX-2 that ultimately promotes cancer cell growth
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by: (i) mounting resistance to cell death, (ii) increasing cell proliferation,
(iii) increasing angiogenesis, and (iv) increasing the ability of the cells to metastasise.

Perhaps the most obvious effect of COX-2 over-expression is the increased

production of prostanoids. As demonstrated in Figure 1.5, the production of TXA2,
PGE2 and PGI2 collectively stimulate the normal growth of endothelial cells; however,
in the neoplastic environment, an over-production of prostaglandins can promote

cancer cell growth and proliferation [89]. In particular, an increase in PGE2
concentration triggers an increase in anti-apoptotic B-cell lymphoma 2 (Bcl-2) levels

resulting in the closing of mitochondrial pores, reducing the release of pro-apoptotic

cytochrome C, and thereby diminishing apoptosis [89]. Additionally, there is evidence
to suggest that the delayed progression of the cell cycle may also play a role in the

growth of COX-2 over-expressing cancer cells by increasing the resistance of cells to
apoptosis, thus increasing their tumourigenic potential [90]. The over-production of

PGE2 is believed to suppress dendritic cells, natural killer cells, T cells, and type-1
immunity, but promote type-2 immunity, which promotes tumour immune

evasion [91].

Figure 1.5: Selected molecular pathways affected by the over-expression of COX-2 in
neoplasia [89-97]. Bcl-2 = B-cell lymphoma 2; Hp = haptoglobin; IL = interleukin; MMP =
metalloproteinase; PGE2 = prostaglandin E2; PGI2 = prostaglandin I2, TXA2 = thromboxane
A2; VEGF = vascular endothelial growth factor.
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The over-expression of COX-2, and subsequently, the increased levels of TXA2,

a critical intermediary of angiogenesis [92], and PGE2, which is associated with

increased expression of vascular endothelial growth factor (VEGF) in human tumour
mucosa [93], promotes the production of blood vessels (angiogenesis) necessary for
tumour growth and survival. Additionally, the increased production of PGE2 induces

IL-6, which subsequently induces haptoglobin (Hp), an important protein involved in

angiogenesis [89]. Matrix metalloproteinases (MMPs), which are enzymes that assist

in tumour and vascular cell invasion, have also been shown to be upregulated in COX-2
expressing tumours [91, 94].

A reduction in the expression of IL-12, a potent

anti-angiogenic cytokine, has also been observed in cells expressing COX-2 [95].

The pro-angiogenic effects of COX-2 were demonstrated in one study that employed
COX-2 over-expressing Caco-2 cells (versus low COX-2 expressing Caco-2 cells)

co-cultured with HUVEC endothelial cells [96]. The results showed that when

compared to the low COX-2 expressing Caco-2 cells, the endothelial cells were able to

penetrate a matrix eight-fold faster when co-cultured with COX-2 over-expressing

Caco-2 cells [96], suggesting COX-2 over-expression promotes a local environment

conducive to tumour growth.

The ability of cancer cells to invade distal tissue is an important feature of

metastatic cancers. Experimental evidence suggests that COX-2 over-expression is

associated with increased invasiveness of cancer cells [97]. The activation of MMP-2
and increased RNA levels for the membrane-type MMP-1 were observed in Caco-2

cells programmed to constitutively produce COX-2, compared to regular, low COX-2

producing Caco-2 cells [97]. The production of enzymes such as MMP-2 is associated
with the ability of cancer cells to invade basement membranes through the proteolysis
of aminin, fibronectin, type IV collagen, and proteoglycan [97].

1.2.4 NSAIDs mediate cell death via COX, and non-COX related mechanisms
Given the role that COX-2 plays in many cancers, it is implied that the

anti-neoplastic effects of NSAIDs are potentially associated with the inhibition of

COX-2 in cancer cells. The reversal of the pro-neoplastic effects of COX-2
over-expression has been demonstrated by NSAIDs in a number of studies [92, 96-99].

For instance, increased invasiveness and PGE2 production of Caco-2 cells programmed

to constitutively produce COX-2 was dose-dependently reversed by sulindac

treatment [97].

Additionally, treatment with aspH or the COX-2 inhibitor,
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NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide), inhibited PGE2

production in a dose-dependent manner in the same COX-2-expressing Caco-2 cell

line [96]. Experiments performed by Chan et al. [98] suggest that indoH and sulindac

sulfide mediate colon cancer cell death by increasing arachidonic acid levels (rather

than a decrease in prostaglandin levels), which stimulates the conversion of

sphingomyelin to ceramide, a known mediator in apoptosis. In another study [92] the
selective COX-2 inhibitor, VU08 (N-(2-phenylethyl)indomethacin amide), decreased
TXA2 production which resulted in reduced endothelial migration and a decline in

fibroblast growth factor-induced corneal angiogenesis. Finally, the inhibition of COX-2
by celecoxib has been shown to reduce tumour growth and metastasis in xenograft

tumour models and suppress basic fibroblast growth factor 2-induced angiogenesis of
the rodent cornea [99].

The concept that inhibition of COX-2 in cancer cells contributes to the anti-cancer

activity of NSAIDs is somewhat oversimplified; an abundance of experimental

evidence suggests that not all NSAIDs induce cell death via COX-2 regulated pathways.
For instance, a number of studies have shown that NSAIDs are toxic towards tumour

cells that exhibit little to no COX-2 expression [100-102]. Furthermore, exogenously
applied prostaglandins have failed to prevent the inhibitory effects of NSAIDs on
cancer cell growth [103, 104]. The diversity of molecular pathways that NSAIDs affect
is presented in Table 1.1 (for more detailed reviews refer to [105] and [106]).
1.2.5 The drawbacks of prolonged NSAID use
The prolonged use of NSAIDs is associated with a number of side effects. These

side effects are mainly attributable to the mechanism of action of the NSAIDs
responsible for the desired therapeutic effects, and as such, the cells that produce

constitutive COX-1 (GI mucosa, kidneys, and platelets) can be affected adversely by
prolonged NSAID use. The decrease in the constitutive expression of protective
prostaglandins in the gastric mucosa as a result of COX-1 inhibition is understood to

be responsible for the manifestation of GI symptoms, including ulceration, perforation
and bleeding in the GI tract [107]. Of concern, the risk of GI bleeding associated with

aspH therapy has been shown to increase with age [108]. The GI side effects induced

by NSAID use encompass mild symptoms, including heartburn, nausea, dyspepsia and
abdominal pain, as well as endoscopically identified mucosal lesions and serious GI
complications [19].

NSAID-related GI problems are estimated to account for
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Table 1.1: The major COX-2 dependent or independent pro-apoptotic pathways induced
by NSAIDs.
Apoptosis-inducing pathways

NSAIDs

COX-2-dependent

COX-2 dependent accumulation of arachidonic acid and
ceramide synthesis
Inhibition of IL-1β and phorbol 12-myristate 13-acetate
induction preventing COX-2 mRNA and protein
expression
COX-2-independent
Oxidative stress and disruption of redox balance
Inhibition of Wnt/β-catenin signalling
Modulation of cyclins

Depletion of polyamines

Inhibition of proteasomal function
Increased expression of mda/IL24
Depletion of survivin

sulindac [98], indoH [98]
aspH [109],
sodium salicylate [109]

aspH [110], sulindac [111],
indoH [112], tolfH [113]
aspH [114], indoH [114],
dicloH [115], sulindac [116]
sulindac [117], tolfH [118]
aspH [119], sulindac [120],
indoH [121]
aspH [122]
sulindac [123]

Mitogen activated protein kinase modulation

aspH [124], tolfH [125]
aspH [126], sulindac [127],
ibuH [128], indoH [129],
dicloH [115], tolfH [130]
aspH [131], indoH [132]

Increased activity of caspase-3 to cleave PARP1

mefH [136]

Modulation of nuclear factor kappa B signalling
Caspase activation and Bcl-2 protein modulation
Inhibition of store-operated calcium entry

Interactions with cell membrane phospholipids
Suppression of specificity protein 1

Activation of NSAID-activated gene-1

Increased production of gastric glutathione-S-transferase

aspH [133, 134], indoH [134]
sulindac [135], mefH [135]

mefH [137], celecoxib [138]
tolfH [139]

tolfH [113], sulindac [140]
aspH [141], ibuH [141],
indoH [141]

100,000 hospitalisations per year in the USA [19]. Additionally, an estimated 16,500

deaths per year in the USA are attributable to NSAID use [142]. The production of
prostaglandins (particularly PGE2 and PGI2) by COX-1 in the kidneys is important for

renal function; inhibition can lead to dysfunction of normal renal regulation of blood
pressure [143]. The inhibition of TXA2 production by COX-1 in platelets can result in

prolonged bleeding time and a mild, systemic haemostatic defect [144].

In the case of selective COX-2 inhibition, PGI2 production is decreased and TXA2 is

left unchecked leading to the development of CV issues [145]. While a number of

clinical studies have shown that COX-2 selective inhibitors, celecoxib and rofecoxib,
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reduce the risk of GI and renal toxicity, their long-term use has been associated with

an increased risk of CV events [146, 147]. In 2004, Merck announced the early

termination of the Adenomatous Polyp Prevention on Vioxx trial [148]. In this trial,

2,586 patients with a history of colorectal adenomas received either 25 mg of

rofecoxib daily (n = 1,257) or placebo (n = 1,299) [146]. The trial was terminated due

to an increased risk of CV events (including myocardial infarctions and ischemic

cerebrovascular events) in patients receiving the drug for more than 18 months [148].
Vioxx (rofecoxib) was subsequently withdrawn from the market [148]. This prompted

an investigation into the risk of CV events for patients prescribed celecoxib in the

Adenoma Prevention with Celecoxib trial [147]. Celecoxib (200 mg or 400 mg, twice
daily) was also determined to increase the risk of CV events 2.5-fold and 3.4-fold,

respectively, compared to the placebo group leading to the discontinuation of the trial
in late 2004 [147] and the FDA issuing a black box warning for celecoxib in

2005 [149]. One report suggests that the CV risk of the non-selective NSAID, dicloH, is

comparable to the COX-2 selective NSAID, rofecoxib [150]. Due to elevated risks of

hepatotoxicity, the COX-2 selective NSAID, lumiracoxib, was not approved for use in

the USA, and was withdrawn from the market in Australia and Europe in 2007 [151].

Additionally, a several non-selective NSAIDs (including dicloH, sulindac, and

nimesulide) are associated with increased risk of liver toxicity resulting in function
abnormalities and fatal liver injury [152, 153].

Given the current risk of side effects, it has been argued that the daily use of

NSAIDs for chemoprevention in the general population (where the risk of developing

CRC is less than 6%) would not be beneficial unless other health endpoints could be

achieved [50]. As such, the safety of NSAIDs needs to be improved. Strategies to
improve NSAID safety include: (i) the synthesis of novel modified NSAIDs, including

nitric oxide releasing NSAIDs [154], phospho-NSAIDs [155], and sulfide releasing
NSAIDs

[156];

(ii)

the

development

of

dual

COX

and

lipoxygenase

inhibitors [157-160]; and (iii) the coordination of NSAIDs to metal ions. The latter
approach is the focus of this Thesis.

1.3 Metal complexes of NSAIDs (metal-NSAIDs)
The coordination of organic ligands to a metal ion(s), offers a number of potential

medicinal

advantages

over

the

administration

of

organic

ligands

alone.

These advantages include: (i) the alleviation of undesirable side effects; (ii) sustained
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in vivo delivery of the organic ligand, i.e. increased/prolonged bioavailability (thus the

metal complex essentially acts as a ‘pro-drug’); and (iii) synergism between the metal

and the organic ligand resulting in the improvement of the original intended biological
effect. A wide variety of metal-NSAID combinations have displayed biological actions

including

anti-inflammatory

activity

[161-169],

analgesia

[164],

anti-ulcer

activity [161-165], anti-cancer activity [162], and anti-microbial activity [170-175]

(for concision, the latter will not be discussed). Of particular interest to the research
presented in this Thesis is the complexation of metals with phenylalkanonic acids, and

more specifically, fenamic acid NSAIDs (i.e. fluH, mecloH, mefH and tolfH) and

salicylates (i.e. aspH and diflH). For brevity, the following Sections will focus on the

discussion of data from studies pertaining to metal complexes with phenylalkanonic

acid NSAIDs, with brief mention of some studies examining metal-NSAIDs containing
oxicam ligands.

1.3.1 Anti-inflammatory and anti-ulcerative properties of metal-NSAIDs
A number of metal-NSAID complexes have shown improved (or similar) in vivo

anti-inflammatory and analgesic activities compared to their parent NSAID [161-169],

as summarised in Table 1.2. One of the perceived advantages of the employment of

metal-NSAIDs over uncomplexed NSAIDs is the alleviation of common dose-limiting

side effects, in particular, GI ulcerations. Encouragingly, in vivo studies performed

using rodent models [161, 162, 164, 165] have shown that gastric ulceration induced

by commonly used NSAIDs (including ibuH, indoH and napH) was reduced by

complexation with Cu(II), Ru(II), and Zn(II), as demonstrated by a decrease in lesion

index scores (Table 1.2). Additionally, [Cu2(indo)4(DMF)2] (where DMF = N,N-

dimethylformamide) and [Zn2(indo)4(DMA)2] (where DMA = N,N-dimethylacetamide)
have been shown to reduce intestinal ulceration in rats when compared to indoH

alone [163]. However, unlike [Cu2(indo)4(DMF)2], the [Zn2(indo)4(DMA)2] complex

induced the same degree of ulceration in the stomach as indoH alone [163]. As
demonstrated in Table 1.2, this result was in concordance with previous studies [169].

These results validate the importance of the choice of the metal centre on the
biological

activity

of

the

complexes.

The

Ru(III)-oxicam

complexes,

[RuCl2(piroxH2)(piroxH)] and [RuCl2(tenoxH2)(tenoxH)], demonstrated significant

anti-inflammatory activity in the carrageenan-induced rat paw oedema assay, albeit a

smaller

effect

was

achieved

than

equimolar pirox [176].

The

authors
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Number of abdominal
constrictions in 20 min
(mean ± s.e.m.)

Increase in paw volume (%)

Analgesia: Acetic acid-induced
abdominal constriction in mice. Oral
dosage

Inflammation: Carrageen-induced rat
paw oedema

Zn-nap†

Analgesia: Tail-flick test in mice
Dose = 10 mg/kg, i.p.

Ulceration: Gastric ulcers were
scored in rats restrained for 17-h at
30-min post dose

Maximum possible effect of
analgesia (%)

Lesion index (ulcers scored
based on size/severity)

Increase in paw volume
(mean % ± s.e.)

Inhibition of carrageeninduced rat paw oedema (%
 compared to salinetreated control paw)

Inflammation: Carrageen-induced rat
paw oedema. Dose: 13.5 mg/kg ibuH,
15.6 mg/kg (1), 17.3 mg/kg (2)

Inflammation: Carrageen-induced rat
paw oedema. Dose: 10 mg/kg acecH
and molar equivalent [Zn(acec)2]

(1) [Cu2(ibp)4]
(2) [Ru2Cl(ibp)4]

[Zn(acec)2]

Inhibition of carrageeninduced rat paw oedema (%
 compared to untreated
control paw ± S.D.)

Inflammation: Carrageen-induced rat
paw oedema. Dose: 0.1 mmol/kg (1)
and (3), (2) was tested at
0.01 mmol/kg due to toxicity

(1) [Co(mef)2(H2O)2]
(2) [Ni(mef)2(H2O)2]
(3) [Zn(mef)2]

45.2 ± 1.9 %

1 h, 73.48 %
6 h, 91.98 %
24 h, 97.04 %

61.5 ± 2.3 %

597.2 ± 43.5

66.2 %

A similar dose-dependent decrease in paw
volume was observed between Zn-nap and
napH on an equivalent molar basis

86.5 %

Negative control 180.9 ± 37.4
5 mg/kg, 28.2 ± 2.4
5 mg/kg, 26.3 ± 0.9
10 mg/kg, 19.0 ± 1.5
10 mg/kg, 24.4 ± 1.0
20 mg/kg, 13.2 ± 1.0
20 mg/kg, 16.8 ± 0.9
40 mg/kg, 10.6 ± 1.6
40 mg/kg, 15.8 ± 1.2

(1) 290.5 ± 31.3
(2) 325.5 ± 14.4

Negative control 65.3 ± 1.4 %

(1) 44.9 ± 3.3 %
(2) 46.0 ± 2.7 %

1 h, 74.91 %
6 h, 86.98 %
24 h, 97.04 %

(1) 71 ± 1.1 %
(2) 17.5 ± 0.4 %
(3) 81.5 ± 1.3 %

[164]

[161]

[165]

[168]

Table 1.2: Results from selected in vivo studies comparing the anti-inflammatory, analgesic, or anti-ulcerative activity of metal-NSAID complexes
and uncomplexed NSAIDs.
Metal-NSAID*
Assay/Model
Endpoint measured
Results
Ref
Metal-NSAID
NSAID
[167]
Inhibition of carrageen(1) [Co(tolf)2(H2O)2]
Inflammation: Carrageen-induced rat induced rat paw oedema (%
(1) 82.6 ± 0.8 %
(2) [Zn(tolf)2(H2O)]
76 ± 0.8 %
paw oedema. Dose: 0.1 mmol/kg
 compared to untreated
(2) 93± 0.9 %
control paw ± S.D.)

Chapter 1. Introduction

19

Mean gastric ulceration
(summation of the area of
macroscopic ulceration)
Mean intestinal ulceration
(summation of the area of
macroscopic ulceration)
Lesion index (ulcers scored
based on number and size)

25 % (d)/11 % (v)

8 mg/kg, 4.5± 0.7
16 mg/kg, 7.0 ± 0.8

36 mm2

140 mm2
25 % (d)/11 % (v)

9.83 mg/kg, 69.26

9.83 mg/kg, 70.80
3.29 mg/kg, 0.75

Negative control, 2.20

Negative control 1 mm2

135 mm2

mm2

39 mm2

3 mm2

Negative control 3

37 mm2

Negative control 48 % (d)/60 % (v)

18 % (d)/10 % (v)

Negative control: 0 mm2

5 mm2

Negative control: 0 mm2

5 mm2

Negative control: 48 % (d)/60% (v)

30 % (d)/15 % (v)

8 mg/kg, 1.5 ± 0.0
16 mg/kg, 2.7± 1.5

[169]

[163]

[162]

[163]

[164]

Ref

*Deprotonated NSAIDs: acec = aceclofenac; diclo = diclofenac; ibp = ibuprofen; indo = indomethacin; mef = mefenamic acid; nap = naproxen; tolf = tolfenamic acid.
DMF = N,N-dimethylformamide; DMA = N,N-dimethylacetamide. †Chemical composition not defined.

Ulceration: Gastric ulcers were scored in
rats dosed 4 times over 2 days. Dose =
indoH 9.83 mg/kg, Zn-Indo 3.75 mg/kg

Ulceration: Gastric ulcers were scored in
rats sacrificed 3-h post-dose; intestinal
ulcers were scored in rats sacrificed 24h post-dose. Dose = indoH 10 mg/kg

Increase in paw volume (d)
and volume (v) (% 
compared to baseline)

Inflammation: Carrageen-induced rat
paw oedema. Dose = indoH 10 mg/kg,
[Zn2(indo)4(DMA)2] = 13.3 mg/kg

[Zn2(indo)4(DMA)2]

Mean intestinal ulceration
(summation of the area of
macroscopic ulceration)

Mean gastric ulceration
(summation of the area of
macroscopic ulceration)

Ulceration: Gastric ulcers were scored in
rats sacrificed 3-h post-dose; intestinal
ulcers were scored in rats sacrificed
24-h post-dose

Increase in paw diameter
(d) and volume (v) (% 
compared to baseline)

Lesion index (ulcers scored
based on size and severity)
(mean ± s.e.m.)

Inflammation: Carrageen-induced rat
paw oedema. Dose = indoH 10 mg/kg,
[Cu2(indo)4(DMF)2] = 11.7 mg/kg

Ulceration: Gastric ulcers in rats were
scored following dosing over 7 days

[Cu2(indo)4(DMF)2]

Zn-nap†

Table 1.2 (cont.): Results from selected in vivo studies comparing the anti-inflammatory, analgesic, or anti-ulcerative activity of metal-NSAID
complexes and uncomplexed NSAIDs.
Metal-NSAID*
Assay/Model
Endpoint measured
Results
Metal-NSAID
NSAID

Chapter 1. Introduction

20

Chapter 1. Introduction
concluded that the two complexes were superior anti-inflammatory agents compared

to pirox due to the reduction in gastric damage in rats treated with the two complexes
compared to the damage induced by pirox alone.

The in vivo success of [Cu2(indo)4(DMF)2] has led to the development of

commercially available therapeutic products. For instance, these Cu-based NSAIDs

have been used in oral dosage forms for veterinary use, and for topical human
use [31]. An ethanolic gel-base of Cu-salicylate (marketed as Alcusal® by Australian

company Mentholatum) was formerly available for topical temporal relief of pain and
inflammation in humans [31]. Cu-Algesic® (containing [Cu2(indo)4(DMF)2]) is

available for veterinary use (dogs and horses) in Australasia, South East Asia and
South Africa due to its low toxicity profile compared to uncomplexed indoH [31].
1.3.2 Chemotherapeutic properties of metal-NSAIDs

Given the considerable evidence that NSAIDs possess chemopreventive and

chemotherapeutic properties (discussed in Section 1.2.2-1.2.4), it is reasonable to

hypothesise that metal-NSAID complexes may also possess this property. To this end,
a number of studies [167, 168, 175, 177-180] have assessed the toxicity of
metal-NSAIDs towards transformed (cancer) cells in vitro. As shown in Table 1.3, the

IC50 values (i.e. the concentration of drug required to produce 50% inhibition)

obtained from in vitro cancer cell studies allow a direct comparison of the toxicity of

the metal-NSAIDs to the analogous free NSAID, and the commonly used anti-cancer

drug, cisplatin (cis-diamminedichloroplatinum(II)). Encouragingly, a number of metal-

NSAID complexes possess improved (or similar) potency compared to the analogous
free NSAID (when considering the molar ratio of NSAID in the metal-complex) and
cisplatin against a number of cancer cell lines in vitro (Table 1.3). Many of these

studies varied the metal centre while employing the same NSAID ligands, revealing the

importance of the identity of the metal centre and the anti-cancer potential of the

complexes (Table 1.3).

These studies also reveal that each of the metal-NSAID

complexes showed increased potency (i.e. selectivity) towards specific cancer cell lines
(Table 1.3).

Recently, a series of organometallic Ru(II)- and Os(II)-p-cymene complexes were

studied where the NSAIDs, indoH or dicloH, were attached to the organometallic
moieties via monodentate (pyridine/phosphine) or bidentate (bipyridine) ligands,
producing piano-stool Ru(II) and Os(II) arene complexes [181]. The modified NSAIDs
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Table 1.3: Results from in vitro studies comparing the anti-cancer activity of metal-NSAID
complexes with uncomplexed NSAIDs, and the anti-cancer agent, cisplatin (CisPt).
Metal-NSAID*

Cell line†

[Co(tolf)2(H2O)2]

T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
A549
L-929
T-24
MCF-7
T-24
MCF-7
A549
L-929

[Cu(tolf)2(H2O)]2
[Mn(tolf)2(H2O)2]
[Ni(tolf)2(H2O)2]
[Zn(tolf)2(H2O)]
[Co(mef)2(H2O)2]
[Cu(mef)2(H2O)]2
[Mn(mef)2(H2O)2]
[Ni(mef)2(H2O)2]
[Zn(mef)2]
[Cd(mef)2(CH3OH)]n
[Ph3Sn(mef)]

Assay‡

Time

MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
SRB
SRB
SRB
MTT
MTT
MTT
SRB
SRB
SRB

72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h
72 h

IC50 value (μM)
NSAID
38.3
62.4
44.9
87.9
76.8
145
33.4
214
13.9
62.4
26.1
87.9
31.4
145
5.3
214
3.9
62.4
41.6
87.9
65.3
145
149
214
35.3
62.4
54.5
87.9
54.1
145
100.1
214
41.0
62.4
41.3
87.9
57.9
145
123
214
27.0
81.2
93.6
149.2
115.9
168.3
< 174.4
178.2
7.77
81.2
25.1
149.2
< 100.3
168.3
19.5
178.2
35.1
81.2
72.6
149.2
< 175.6
168.3
< 175.6
178.2
24.0
81.2
59.3
149.2
86.6
168.3
63.4
178.2
37.7
81.2
40.7
149.2
111.2
168.3
74.4
178.2
0.86
81.2
0.12
149.2
0.29
80.1
0.68
146.4
7.21
167.8
7.23
168.5

M+-NSAID

CisPt
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
41.7
8.0
1.5
0.7
40.9
1.84
7.99
41.66
0.69
1.53

Ref

[167]
[167]
[167]
[167]
[167]
[168]
[168]
[168]
[168]
[168]
[175]
[177]
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Table 1.3: (cont.) Results from in vitro studies comparing the anti-cancer activity of
metal-NSAID complexes with uncomplexed NSAIDs, and the anti-cancer agent, cisplatin
(CisPt).
Metal-NSAID*

Cell line†

Assay

Time

IC50 value (μM)
Ref
M+-NSAID
NSAID CisPt
[Ph3Sn(flu)]
T-24
MTT
72 h
4.78
99.6
7.99 [177]
MCF-7
SRB
72 h
1.26
120.9
41.66
A549
SRB
72 h
60.44
171.8
0.69
L-929
SRB
72 h
5.85
192.0
1.53
[Cd(meclo)2(H2O)2]
T-24
MTT
72 h
3.3
70.2
41.7 [178]
MCF-7
SRB
72 h
5.1
63.1
8.0
A549
SRB
72 h
29.8
139.1
1.5
L-929
SRB
72 h
22.7
133.0
0.7
[Cu(meclo)2(H2O)2]
T-24
MTT
72 h
5.3
70.2
41.7 [178]
MCF-7
SRB
72 h
38.2
63.1
8.0
A549
SRB
72 h
41.2
139.1
1.5
L-929
SRB
72 h
61.9
133.0
0.7
[Mn(meclo)2]
T-24
MTT
72 h
3.8
70.2
41.7 [178]
MCF-7
SRB
72 h
39.8
63.1
8.0
A549
SRB
72 h
27.4
139.1
1.5
L-929
SRB
72 h
25.3
133.0
0.7
[Zn(meclo)2(H2O)2]
T-24
MTT
72 h
3.2
70.2
41.7 [178]
MCF-7
SRB
72 h
32.5
63.1
8.0
A549
SRB
72 h
>244
139.1
1.5
L-929
SRB
72 h
24.2
133.0
0.7
[Ph3Sn(meclo)]
T-24
MTT
72 h
0.29
63.1
7.99 [177]
MCF-7
SRB
72 h
0.68
70.2
41.66
A549
SRB
72 h
7.21
133
0.69
L-929
SRB
72 h
7.23
139.1
1.53
[Cd2(diclo)41.5(MeOH).
T-24
MTT
72 h
4.4
71.2
40.9 [179]
2(H2O)]n
MCF-7
SRB
72 h
5.8
62.8
7.8
A549
SRB
72 h
30.2
138.9
1.5
L-929
SRB
72 h
24.6
132.8
0.7
cis-[Pt(NH3)2(melox)2]
CH1
MTT
96 h
0.6
>160
0.16 [180]
HeLa
MTT
96 h
92
230
0.37
SW480
MTT
96 h
96
≥285
3.5
HCT-15
MTT
96 h
194
≥300
n.d.
HCT-11
MTT
96 h
119
>320
2.7
cis-[Pt(NH3)2(isox)2]
CH1
MTT
96 h
0.37
>80
0.16 [180]
HeLa
MTT
96 h
3.5
>160
0.37
35
SW480
MTT
96 h
>320
3.5
HCT-15
MTT
96 h
116
>320
n.d.
HCT-116
MTT
96 h
90
>320
2.7
* In this instance the NSAID is deprotonated: tolf = tolfenamic acid; mef = mefenamic acid; flu =
flufenamic acid; meclo = meclofenamic acid; diclo = diclofenac; tolm = tolmetin; indo =
indomethacin; melox = meloxicam; isox = isoxicam. en = ethylenediamine. †A549 = human small
cell lung cancer; C6 = rat glioma; CH1 = human ovarian carcinoma; HCT-116 = human colorectal
cancer; HCT-15 = human colorectal cancer; HeLa = human cervical cancer; L-929 = murine
fibroblast; MCF-7 = human breast cancer; SW480 = human colorectal cancer; T-24 = human bladder
cancer; T-47D = human breast cancer. ‡MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, SRB = sulforhodamine B. “n.d.” = not determined. Value in bold text indicates the metalcomplex IC50 value is comparable or superior to cisplatin.
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in complexation with Ru(II)- and Os(II) showed promising in vitro anti-proliferative

activity against human ovarian cancer cells (A2780, and cisplatin-resistant
A2780cisR) [181].

The Pt-oxicam complexes, cis-[Pt(NH3)2(melox)2] and cis-[Pt(NH3)2(isox)2],

demonstrated greater cytotoxicity compared to melox and isox alone against a panel
of cancer cell lines ([180], Table 1.3). The complexes were particularly effective

against CH1 human ovarian carcinoma cells, with IC50 values almost equal to that of

cisplatin [180]. The Cu(II), Zn(II), Co(II), and Ni(II) complexes of melox were found to

have a more pronounced cytotoxic/cytostatic effect than melox alone against HeLa
human cervical cancer cells and 8MGBA glioblastoma multiforme cells [182].

Pirox complexes with transition metal ions, V(IV), Mo(VI), Mn(II), U(VI) and Fe(III),
induce apoptosis within 24 h in HL-60 leukaemia cells, where little activity was
possessed by pirox until treatment for 57 h [183].

While there have been a substantial number of studies that have evaluated the

toxicity of metal-NSAIDs towards cancer cell lines in vitro (Table 1.3), the in vivo
anti-cancer effects of these complexes have been marginally explored. The effects of

[Cu2(indo)4(DMF)2] or indoH on the prevention of aberrant crypt foci (ACF) formation

in the colon of rats has been evaluated [162]. In the study, male Sprague-Dawley rats
were dosed with [Cu2(indo)4(DMF)2] for a 4-week period in conjunction with

azoxymethane (an inducer of ACF formation). The results from the study showed that

[Cu2(indo)4(DMF)2] treatment (3.8 mg/kg) reduced the formation of ACF by 43%,

while indoH treatment (3 mg/kg) resulted in 73% reduction. Although indoH was

more effective at preventing ACF formation, the [Cu2(indo)4(DMF)2]-treated rats

suffered significantly less gastric and intestinal ulceration ([162], Table 1.2).
1.3.3 Other biologically relevant properties of metal-NSAIDs

It is notable that a variety of metal-NSAIDs have shown strong protein binding

in vitro, and exhibited the ability to intercalate with DNA and exacerbate free radical

scavenging properties. These properties have been particularly well-studied in

metal-NSAID complexes of Co(II) or Cu(II) containing dicloH [184], diflH [185],

fluH [186], indoH [187], mefH [188], napH [184, 189], or tolfH [190, 191] ligands, or

the complexes, [M(II)(NSAID)n(L)n], where L represents incorporated nitrogen donor
heterocyclic ligands such as 2,2’-bipyridine (bipy), 1,10-phenanthroline (phen), and
pyridine (py). Additionally, the DNA binding activity of Mn(II) or Ni(II) derivatives
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containing dicloH [192, 193], mefH [194] or nifH have been reported [195].

For instance, the Co(II) derivative of mef, [Co(mef)2(MeOH)4] (MeOH = methanol), and
Co(II)-mef

complexes

incorporating

nitrogen

donor

heterocyclic

ligands,

[Co(mef)2(bipy)(MeOH)2], [Co(mef)2(phen)(MeOH)2] and [Co(mef)2(py)2(MeOH)2],
possess relatively strong binding affinities for calf thymus DNA [188]. The four Co(II)mef

complexes

exhibited

relatively

high

DNA

binding

constants

(Kb);

however, [Co(mef)2(py)(MeOH)2] was the only complex with increased DNA binding
affinity compared to mefH alone (Kb values of 3.32 × 105 M−1 and 1.05 × 105 M−1,

respectively) [188]. Furthermore, competitive studies with ethidium bromide

indicated mefH and the Co(II)-mef complexes most likely interact with calf thymus
DNA by the intercalative mode [188]. Additionally, all four Co(II)-mef complexes
exhibited superior superoxide and free radical scavenging ability, and similar or

superior hydroxyl free scavenging ability in comparison to mefH [188]. Given that

NSAIDs exhibit anionic charge in vivo (deprotonated at pH 7) their interaction with the
polyanionic backbone of DNA is unlikely [196]. Uncharged metal-NSAIDs, however,

might overcome these repulsion forces [196], depending on their intracellular

stability. The ability of the aforementioned metal-NSAIDs to intercalate with DNA

with high binding affinity may be an important chemotherapeutic property given that
many clinically established anti-cancer agents exert their anti-neoplastic effects

through DNA interactions.

1.4 Bismuth

One vital consideration in the rational drug development of metal-NSAIDs is the

choice of metal centre, since many metals are inherently toxic at low doses. Bi has no
essential physiological role [197]. However, Bi induces therapeutic effects in humans

and has been used in healthcare for centuries, predominantly to treat GI disorders, and

as an anti-microbial agent ([198] and references within). Bi remains employed in

contemporary medicine primarily for its anti-ulcerative and anti-bacterial actions
(discussed in Sections 1.4.1.2 and 1.4.1.3, respectively). Importantly, the use of Bi in
medicinal formulations is associated with low systemic toxicity and transient side
effects [199].

Several novel Bi compounds show promising in vitro and in vivo

anti-cancer activity (discussed in Section 1.4.1.4). As such, complexation of Bi with

NSAIDs may prove to be a successful strategy to reduce NSAID-induced GI injury and
improve the desired chemopreventive and chemotherapeutic activity of the NSAID.
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Located in group 15 of the periodic table, Bi (atomic number 83) is considered

metallic (or semi-metallic) in character, as opposed to other group 15 elements,
arsenic and antimony, which are classified as metalloids [200]. Bi is found in the

trivalent or pentavalent oxidation state (Bi(III) and Bi(V)), where the former is the

more stable and the most biologically relevant oxidation state [201]. Given Bi(V)

possesses powerful antioxidant properties in aqueous solution (Bi(V)/Bi(III) potential
E° = 2.03 V), Bi(V) is not believed to be stable in biological systems [201]. Bi(III) is

readily hydrolysed (pKa = 1.51) in aqueous solution, and has a high affinity for oxygen,
nitrogen and thiolate containing ligands [201]. It is thought that the Bi(III) ion has
high mobility within cells due to the kinetic lability of thiolate ligands and resultant

millisecond

time

scale

required

for

exchange

with

free

thiols

[202].

Furthermore, there is a wealth of experimental evidence that shows that the

therapeutic and anti-bacterial actions of Bi arise primarily through interactions with
proteins (discussed further in Sections 1.4.1.1–1.4.1.3).
1.4.1 Bismuth in medicine

Louis Odier first described the use of bismuth subnitrate for medicinal purposes

in 1786 as a treatment for dyspepsia [203]. For over two centuries, Bi preparations

have been used medicinally to treat an assortment of diseases, primarily

gastroenterological and microbiological in nature, as demonstrated in Table 1.4.
Currently, three Bi drugs are marketed for the treatment of GI conditions and

Helicobacter pylori infection in combination therapies with antibiotics. These include:

bismuth subsalicylate (BSS; Pepto-Bismol®, the Procter & Gamble Company,

Cincinnati, Ohio, USA), colloidal bismuth subcitrate (CBS; De-Nol®, Gist Brocades, Delft,

The Netherlands), and ranitidine bismuth citrate (RBC; Tritec® and Pylorid®,
GlaxoWellcome, Hertfordshire, UK) [204]. RBC combines the mucosal protection of Bi

with the anti-secretory properties of ranitidine (N,N-dimethyl-5-(3-nitromethylene-7-

thia-2,4-diaaoctyl)-furan-2-meth-amine) [204]. The chemical structures of bismuth

salicylate (bismuth 2-hydroxybenzoate), bismuth citrate (bismuth 2-hydroxypropane1,2,3-tricarboxylate) and RBC are shown in Table 1.4. The ‘sub’ prefixes of BSS and

CBS refers to the poorly understood chemical structure of the formulations, although

recent studies have shed light on the possible conformation and polymerisation of BSS
[205] and CBS [206] in acidic environments.
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Table 1.4: Historical and currently used medicinal bismuth compounds.
Compound;
trade name/s
Bibrocathol;
Noviform®,
Posiformin®

Chemical structure*

Medical disorder
Eye infections [207]

Bismuth
potassium (or
sodium) tartrate

Syphilis [208]

Bismuth
subcarbonate

Antacid [208]
Gastric/duodenal
ulcer [209]
Gastritis [208]
Wounds [208]
Syphilis [208, 210]
Malaria [211]

Bismuth sodium
thioglycollate;
Thio-Bismol,
Bistrimate®
Bismuth
subgallate;
Devrom®
Bismuth
subnitrate

Bismuth
subsalicylate,
BSS; PeptoBismol®

Gastritis [208]
Haemostatic adjunct
during tonsillectomy [212]
Internal
deodorant [213, 214]
Wounds [208]
Gastritis [208]
Gastric/duodenal
ulcer [215, 216]
H. pylori
infection [215-217]
Hypertension [218]
Wounds [208, 219]
Diarrhea [220, 221]
Gastric/duodenal
ulcers [222]
H. pylori infection [223]
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Table 1.4: cont. Historical and currently used medicinal bismuth compounds.
Medical disorder
Compound;
Chemical structure*
trade name/s
Colloidal
Dyspepsia [224]
bismuth
Gastric/duodenal
subcitrate (CBS);
ulcers [225, 226]
H. pylori infection [227]
De-Nol®
Bismuth
tribromophenate; Xeroform®
dressing gauze

Wounds [208, 228]

Ranitidine
bismuth citrate
(RBC); Tritec®,
Pylorid®

Gastric/duodenal ulcers [229]
H. pylori infection [223, 229]

*Basic chemical structure shown. The exact chemical structures of the compounds with the
“sub” prefix are generally unknown or poorly defined.

The development of new Bi drugs with superior activity against H. pylori has been

an active area of research over the past decade (recently reviewed in [200] and [230]).

It is notable that recent in vitro studies have shown that Bi-containing complexes

possess anti-fungal (Saccharomyces cerevisiae) [231], anti-viral (severe acute
respiratory syndrome coronavirus) [232, 233] and anti-parasitic (Leishmania

major) [234-236] activities, highlighting the broad medicinal potential of Bi

compounds. The following Sections of this review will briefly describe the current

primary medicinal use of Bi as a GI protective (Section 1.4.1.2), and an anti-bacterial
agent (Section 1.4.1.3), and the potential use of Bi complexes as anti-cancer
agents (Section 1.4.1.4).

1.4.1.1 Absorption, transport and distribution of Bi(III)
The mechanisms of absorption, transport and systemic distribution of Bi(III) in

mammals are poorly understood. Studies have shown that up to 99% of ingested Bi is
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passed through the feces without alteration [237]. However, it has also been reported
that Bi levels in the gastric mucosa significantly increase to a peak level of 30–60 μg/L
(0.14–0.28 μM) following a single oral dose of BSS, CBS or RBC [238]. Bi levels in the

blood have been reported to increase 51- to 1483-fold following ingestion [238], with
a relatively rapid rate of systemic uptake (15–60 min) [239]. Once absorbed, binding

to plasma proteins conceivably facilitates the systemic transport of Bi. Experimental

evidence suggests that Bi binds strongly to the iron transport enzyme, transferrin
[240, 241]. It has also been reported that Bi bound to lactoferrin (a member of the

transferrin family) was recognised by IEC-6 rat intestinal cells and blocked the uptake

of the native Fe–lactoferrin complex, leading to the suggestion that Bi is transported

into cells by transferrin receptor pathways [242]. Bi has also been shown to bind to

human serum albumin [243], one of the most abundant proteins in the bloodstream.

However, in the presence of a large excess of albumin (albumin/transferrin 13:1, at pH
7.4, 10 mM bicarbonate), 70% of Bi was bound to transferrin [243], suggesting
transferrin is the most likely target of Bi in the bloodstream.

In addition to iron transport proteins, Bi(III) has been shown to bind to other

cellular peptides and proteins that are believed to confer intracellular uptake

pathways. For instance, it has been reported [244] that Bi has a high affinity for

glutathione, a tripeptide that is present in cells in relatively high concentrations

(0.5–7 mM) and is believed to play a role in Bi transport in cells and biofluids.
Found in most tissues, metallothioneins (MTs), are low molecular mass proteins
(~ 60 amino acids) comprised of a cysteine-rich amino acid sequence [245].

The cysteine-rich character provides a high capacity for the metals ion (such as Zn(II),
Cu(I), Cd(II) and Bi(III)) to bind. As such, the primary functions of MTs are believed to

be metal sequestration, metal homeostasis and metabolism, and the detoxification of

metals [245]. Studies by Sun et al. [246] have shown that Bi binds strongly to the

cysteine residues of MT in a stoichiometry of Bi:MT = 7:1 and can readily replace

Zn(II) and Cd(II) ions. Additionally, Bi administration has been shown to increase MT

production in humans [247, 248]. A number of studies [249-253] suggest that
intracellular Bi accumulates in lysosomes, which are acidic organelles that are used to
remove debris from within the cell, most likely as part of cellular detoxification events.
1.4.1.2 Bismuth as a GI protective agent

The success of Bi as a GI protective agent is due in part to its anti-bacterial action

against H. pylori (discussed in more detail in Section 1.4.1.3). However, common Bi
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compounds such as BSS and CBS have been shown to exert non-bactericidal effects in

the GI system, and have been employed as clinically effective agents for the treatment

of a variety of GI ailments (Table 1.4). It has been suggested that the protective GI
properties of Bi compounds, such as those produced by BSS and CBS, are due to the

interaction of colloidal particles of Bi(III) with the acidic conditions of the stomach

resulting in the formation of precipitated polymeric Bi(III) structures [254].

For instance, BSS can undergo ligand exchange and form insoluble bismuth

oxychloride (BiOCl) ions in the stomach [255]. Studies performed with CBS led to the
suggestion that [Bi(cit)2Bi]2– molecules form colloidal particles such as [Bi6O4(cit)4]6–

and [Bi12O8(cit)8]12– at neutral pH [256], but rearrange to form sheets and 3D polymers
under acidic conditions due to ligand exchange reactions [206]. It is likely that the

precipitation of BSS or CBS products and the formation of a polymeric coating on ulcer

craters prevents further erosion of the mucosa [254].

Additionally, it has been

suggested that the stabilisation of the mucous layer by CBS increases the resistance to

back-diffusion of hydrogen ions without significantly modifying the ion-exchange

properties of the mucous [257]. Other means by which Bi has been suggested to

attenuate GI protection include scavenging reactive oxygen species (ROS) [258, 259],

inactivating the digestive enzyme pepsin [260, 261], stimulating luminal release of
PGE2

[226],

stimulating

epidermal

growth

factor

[262],

restoration

of

phosphoinositide specific phospholipase C activity in response to injury, thus

increasing mucosal cell proliferation [263], and the activation of the calcium-sensing

receptor and the intracellular increase in Ca2+ concentration, increasing mitogen-

activated protein kinase activity, which leads to the proliferation of normal human
gastric mucous epithelial cells [264].

1.4.1.3 Bismuth as an anti-bacterial agent
In 1984, Marshall and Warren discovered that H. pylori, a bacterium that localises

in human gastric mucosa, was present in the stomach lining of patients suffering from
gastritis and stomach ulcerations [265]. A decade later, the World Health Organisation

classified H. pylori as a class I carcinogen, since chronic infection can lead to the
formation of dysplasia and eventually gastric cancer if left untreated [266]. While only

a small proportion (< 3%) of individuals infected with H. pylori are expected to

develop gastric malignancies as a result of H. pylori colonisation, it is estimated that up
to 50% of the world’s population carry H. pylori [267].

Two Bi-based H. pylori
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treatment regimens were approved by the FDA in the mid-1990s [223].

These consisted of: (i) a two week course of RBC (400 mg twice daily), and

clarithromycin (500 mg three times daily), followed by a further two week course of

RBC (400 mg twice daily), or (ii) a two week quadruple regime combining
BSS (525 mg four times daily), metronidazole (250 mg four times daily), and

tetracycline (500 mg four times daily), in combination with a histamine-2 receptor

antagonist (ulcer healing agent) as directed over 4 weeks [223]. However, Bi-based

therapies were often employed in relapsed forms of H. pylori treatment after primary

treatment with a triple-therapy of antibiotics had failed [268].

More recently, concerns have been raised over increasing antibiotic resistance,

particularly clarithromycin resistance in H. pylori [268]. Given there is no evidence

that H. pylori are able to develop resistance to Bi, it has been suggested that Bi-based

regimes (including the Bi-based quadruple therapy, comprising of a three-in-one

capsule of potassium bismuth subcitrate, metronidazole, and tetracycline (marketed
as Pylera®), and a proton pump inhibitor) may be considered a more suitable

first-line treatment for H. pylori infection over the coming decades [268].

While many Bi compounds are active against H. pylori, the exact mechanism of

action remains unclear. Experimental evidence from in vitro studies suggests that the
anti-bacterial activity of Bi may be multimodal; for instance, proposed mechanisms

include the disruption of the glycocalyx cell wall through the formation of Bi

aggregates [269], disruption of the adherence of the bacterium to gastric cells [255],

cessation of ATP synthesis [270], the inhibition of urease, an enzyme which protects
the bacterium from the acidic environment of the stomach [271], and inhibition of
other enzymes which are responsible for toxicity to gastric mucosal cells, such as
bacterial alcohol dehydrogenase [272]. Additionally, evidence shows that H. pylori
sequesters iron through the utilisation of host-specific lactoferrin, thus Bi(III) binding
to lactoferrin may disrupt bacterial iron acquisition [273].

In many cases the

interaction of Bi with the cells is physicochemical in nature, thus potentially explaining

the lack of bacterial resistance to Bi compounds [269].

1.4.1.4 Bismuth as an anti-cancer agent: Diagnostic and therapeutic roles
In addition to the GI protective and anti-bacterial properties of Bi, there is

growing substantiation that Bi compounds have the potential to play a significant and

diverse role in cancer diagnostics and anti-cancer therapies. For instance, isotopes of
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Bi (212Bi or 213Bi) conjugated to various monoclonal antibodies have been investigated

as a method of targeted radiotherapy [274, 275]. Nanoparticles of Bi have shown

promise as contrast agents for computed tomography, providing equal or superior
quality imaging to currently used contrast agents, owing to the large atomic number of

Bi [276]. Bi has also displayed synergism when administered with chemotherapeutic

agents in vivo. For example, co-administration of Bi and cisplatin reduced the

nephrotoxic side effects induced by cisplatin [277-279]; Bi-induced MT synthesis was
determined as the primary mechanism of this effect [247, 248]. The induction of MT
synthesis by Bi has been shown to reduce the cardiotoxic side effects of adriamycin in

mice [280, 281].

A variety of novel Bi(III) complexes have shown promising in vitro

chemotherapeutic activity. Heterocyclic organobismuth(III) complexes, N-tert-butylbi-chlorodibenzo[c,f][1,5]azabismocine

(Fig.

1.6,

1),

bi-chlorodibenzo[c,f][1,5]-

thiabismocine (Fig. 1.6, 2) and bi-chlorophenothiabismin-S,S-dioxide (Fig. 1.6, 3) have
shown potent cytotoxicity against leukaemia cell lines; Molt-4, U937, HL-60, NB4 and

K562 [282]. Apoptosis induced by 2 (Fig. 1.6) in HL-60 cells and was associated with

enhanced generation of intracellular ROS, loss of mitochondrial transmembrane

potential (Δψm), cytochrome C release from the mitochondria to the cytosol, and

activation of caspases -3, -8, and -9, suggesting the main mechanism of action of the

compound involves mitochondrial damage. In further work, 2 (Fig. 1.6) was shown to

cause G2/M cell cycle arrest in HeLa cells at low concentrations (~1.0 µM) leading to
apoptosis [283]. This was accompanied by the disruption of the microtubule network

in the cells, suggesting the compound may be a novel tubulin polymerisation
inhibitor [283].
The

organobismuth

complex,

1-[(2-di-p-tolylbismuthanophenyl)diazenyl]-

pyrrolidine (Fig. 1.6, 4), showed anti-proliferative activity against several human

cancer cell lines (IC50 values 0.880−8.478 µM), with particularly high potency towards
the human acute promyelocytic leukaemia cell line, NB4 [284]. Treatment of the NB4

cells with 4 (Fig. 1.6) induced apoptosis, decreased Δψm and increased the production

of ROS, similar to the cellular effects induced by 2 (Fig. 1.6); however, 4 (Fig. 1.6) did

not show any disruption of tubulin polymerisation in vitro.

It is notable that

substitution of the metal centre of 4 (Fig. 1.6) with Sb(III) resulted in no cytotoxicity in

NB4 cells (up to 10 μM) suggesting the combination of the Bi(III) centre and the
conjugated structure of the diazenylpyrrolidine moiety were essential for bioactivity.
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Figure 1.6: Chemical structures of Bi compounds that have shown potential anti-cancer
activity in vitro.
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The [Bi(AcPhH)Cl2], [Bi(AcpClPhH)Cl2] and [Bi(AcpNO2PhH)Cl2] complexes

(Fig. 1.6, 5, where AcPhH2 = 2,6-diacetylpyridine bis(benzoylhydrazone), AcpClPhH2 =

2,6-diacetylpyridine bis(para-chlorobenzoylhydrazone), and AcpNO2PhH2 = 2,6-

diacetylpyridine

bis(para-nitrobenzoylhydrazone))

showed

enhanced

toxicity

compared to the free ligands and analogous Sb(III) complexes, against a panel of
human cancer cell lines (IC50 values ranging from 0.09−10.56 µM).

Importantly,

[Bi(AcpClPhH)Cl2] and [Bi(AcpNO2PhH)Cl2] showed relatively low potency towards

human peripheral blood mononuclear cells (IC50 values 117.0 µM and 22.94 µM,
respectively), demonstrating selectivity towards cancer cell lines [285].

recently,

the

same

research

group

synthesised

Bi(III)

complexes

More

with

2-acetylpyridine- and 2-benzoylpyridine-derived hydrazones [286], which also

showed promising cytotoxic activities against HL-60, Jurkat and THP-1 leukaemia

cells, and on MCF-7 and HCT-116 solid tumour cells. The IC50 values of the
AcpNO2PhH2 ligand and [Bi(2AcpNO2Ph)Cl2] complex (where AcpNO2PhH2 =
2-acetylpyridine-para-nitro-phenylhydrazone) were three-fold smaller when HCT-116

cells were cultured in soft-agar (3D) than when cells were cultured in monolayer (2D),

suggesting these compounds may show potential against solid tumours in vivo [286].

In other studies, the seven-coordinated Bi(III) complex [Bi(L)(NO3)2(CH3CH2OH)]
(HL = 2-acetylpyridine

N(4)phenylthiosemicarbazone)

(Fig.

1.6,

6)

exhibited

comparable cytotoxicity to cisplatin (5.22 µM and 1.2 µM), and higher toxicity than the

free ligand (IC50 = 94.7 µM) [287]. The complex was also active against HCT-116, HeLa
and HepG2 cells [287]. Similar to other Bi(III) complexes discussed in this Section,
6 (Fig. 1.6) induced apoptotic cell death via an increase in ROS production and
reduced Δψm in HepG2 cells [287].

The Bi(III) complex, BiTPC (where TPC = 1,4,7,10-tetrakis(2-pyridylmethyl)-

1,4,7,10-tetraazacyclododecane) (Fig. 1.6, 7), a water soluble Bi compound, was found

to exhibit potent cytotoxicity towards melanoma B16-BL6 cells (IC50 = 41 nM) which

was 100 times more potent than cisplatin [288]. Although it is generally accepted that

the most likely targets of Bi compounds are proteins, DNA binding studies showed that
BiTPC

could

bind

conditions [288].

non-covalently

to

DNA

under

physiologically

relevant

While the aforementioned Bi complexes have demonstrated encouraging in vitro

activity, evaluation of a number of other Bi compounds have shown varied success in
animal models.

For instance, the arylbismuth(III) oxinates, Bi(Ox)3, Bi(Ox)2I,
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PhBi(Ox)2.EtOH, PhBi(MeOx)2, [NaPhBi(Ox)3] and [KPhBi(Ox)3] (where Ox =
quinolin-8-olate and MeOx = 2-methylquinolin-8-olate) showed promising anti-cancer

activity against murine leukaemia cells, L1210 (≤ 0.56 µM), the corresponding

cisplatin resistant cell line, L1210/DDP (≤ 0.37 µM), and human ovarian cancer cells,

SKOV-3 (≤ 2.9 µM) in vitro [289]. However, the compounds, PhBi(Ox)2.EtOH and
[KPhBi(Ox)3],

showed

no

significant

anti-tumour

activity

against

murine

plasmacytoma, and [KPhBi(Ox)3] showed no significant anti-tumour activity against

P388 leukaemia in murine models [289]. The lack of in vivo activity was attributed to

problems with delivery of the compounds due to their poor solubility in biological
fluids [289].

Similarly, dithiocarbamate Bi complexes including, Bi(N,N-dimethyldithio-

carbamato)3, Bi(N,N-diethyldithiocarbamato)3, Bi(pyrrolidyldithio-carbamato)3 and

Bi(morpholidyldithiocarbamato)3 were found to be cytotoxic against several cancer

cell lines and, in many cases, more potent than established organic drugs [290].

Treatment with the Bi(N,N-diethyldithiocarbamato)3 complex slowed tumour growth

in mice inoculated with HT-29 cells relative to tumour growth in untreated mice [290].

The complex showed greater anti-tumour activity in OVCAR-3 inoculated mice
whereby tumour size began to reduce after 15 days of Bi(N,N-diethyldithiocarbamato)3 treatment [290].

Finally, a nine-coordinate Bi(III) complex, [Bi(H2L)(NO3)2]NO3 (where H2L = 2,6-

diacetylpyridine bis(4N-methylthiosemicarbazone)) (Fig. 1.6, 8) has been synthesised

and its in vitro and in vivo anti-cancer activity evaluated [291]. The IC50 value of

8 (Fig. 1.6) was approximately three times lower than the ligand alone against the
K562 cell line [291]. In mice xenografted with H22 (mice hepatoma) cells, tumour

growth was inhibited by 61.6% and 43.5% following 7-day treatment with 8 (Fig. 1.6,

10 mg/kg), and the anti-cancer drug mitoxantrone (0.4 mg/kg), respectively,

compared to the control group [291]. Despite promising in vitro activity and some
preliminary success with in vivo studies, currently there are no Bi-containing
complexes in clinical trials or used in therapies for the treatment of cancer [292].
1.4.2 Bismuth toxicity

It is generally reported in the literature that Bi possesses uncharacteristically low

toxicity, particularly when compared to the group 15 counterparts, arsenic and
antimony. Compared to many medications, the side effect profile for Bi (taken at the
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appropriate dose) is quite limited [237]; transient, harmless side effects such as
darkened stools [199] and blackening of the tongue [293] are the most commonly
reported. However, in the 1970s, concerns over the safety of Bi compounds (namely

bismuth subcarbonate, bismuth subgallate, and CBS) were raised due to cases of Bi
intoxication resulting in cases of encephalopathy in Australia [294, 295] and
France [296], which led to the withdrawal of some Bi medications from the market in

these countries. This severe side effect was reported in patients who consumed high

doses (3–20 g of Bi per day over a 6–36 month period) [296]. It is notable, however,

that Bi-induced encephalopathy can be reversed upon the cessation of Bi treatment,

with full restoration of neurological function over a few weeks [237].

A limited number of studies addressing the bioaccumulation of Bi in mammals

have been reported. Following a single dose of RBC in mice, Bi deposits have been

observed in the stomach, duodenum, ileum and kidney (2.5–10 h after dosing) [297].
Interestingly, Bi was evident in the lymph nodes, liver, spleen, kidney and

macrophages in the GI lamina propria 1–9 weeks following administration of RBC,

although Bi was absent from the GI epithelium (consistent with cellular
turnover) [297]. However, no signs of morphological changes in the Bi-treated tissues
or adverse effects in the behaviour of the mice were observed [297]. Although the link

between bioaccumulation and toxicity remains poorly understood, this study
highlights the potential for systemic accumulation of Bi, even with short-term
treatments. Another concern is the recent number of studies highlighting the

biotransformation of Bi into methylated species such as trimethylbismuth (Me3Bi) by

bacterial species present in intestinal flora in humans (recently reviewed in [255]).
Given evidence that Me3Bi species are more toxic to bacteria than inorganic

species [298], there may be implications for the regulation of gut flora in humans;

however, the health implications of the Me3Bi formation by human microflora requires

further investigation.

While the aforementioned toxicity of Bi raises some concern over the safety of

Bi-based medications, there is also evidence to suggest that when used periodically, Bi
drugs are generally safe and well tolerated. A systemic review and meta-analysis of

35 clinical studies concluded that Bi drugs (namely bismuth subnitrate, BSS, CBS, and

RBC, Bi dosage ranging from 400–1200 mg/day and duration from 7–56 days) used

for the treatment of H. pylori infection are safe and well-tolerated when administered
either alone, or in combination with antibiotics [199]. The only side effect that was
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significantly more common in patients assigned Bi-based therapies was darkened
stools (not to be confused with GI bleeding) [199]. Accordingly, Pepto-Bismol is

currently available over-the-counter without a prescription in the USA, Canada and

UK. Given that the majority of regimes employing Bi for treatment of H. pylori

infection require less than two weeks of administration, the use of Bi in prolonged
chemopreventive therapies (months to years) would require careful monitoring to
determine if any adverse side effects or signs of toxicity negate the potential positive
therapeutic effects.

1.5 BiNSAID Complexes
Despite experimental, epidemiological, and clinical evidence that indicates that

long-term use of NSAIDs is associated with reduced incidence of CRC (Section 1.2.2),

the prolonged use of NSAIDs for chemoprevention is not recommended for the general
population [77]. This is due, in part, to the risks that NSAIDs impose on the GI system.

It is, therefore, plausible to consider the combination of NSAIDs with GI protective Bi

(as a single therapeutic agent) in order to alleviate the GI side effects of NSAIDs [299].
Despite the specific GI protective advantage of Bi compared to other metals, and the

conceivable synergistic chemotherapeutic action of Bi coordinated to an organic

ligand, there are a limited number of reports [299, 300] detailing the synthesis and
biological activity of BiNSAID complexes, highlighting the potential for development in

this area.

The use of Bi(III) compounds for protection against NSAID-induced GI injury is

not without precedence. A number of studies have shown that pre-treatment or

co-administration with Bi compounds such as BSS [301, 302], CBS [303, 304], and

RBC [305] with NSAIDs reduces GI ulceration in vivo. In a double-blind randomised

three-way crossover study, healthy male volunteers (n = 24) received nine doses of
placebo, aspH (900 mg), or aspH and RBC (900 mg and 800 mg, respectively) at 12-h

intervals, with a two-week washout period between each treatment [305]. The

authors reported that co-administration with RBC significantly reduced the number of
aspH-induced erosions and micro-bleeding, suggesting RBC confers substantial

protection against aspH-related GI injury. In a more recent study, the GI-protective

effect of CBS, and other potential agents (misoprostol and omeprazole), against gastric
injury

induced

by

indoH

was

evaluated

in

Wistar

albino

rats

[306].

CBS (70 mg/kg/day and 15 mg/kg/day) was administered 30 min prior to indoH
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(5 mg/kg/day) once daily for five consecutive days. The authors report that the mean

ulcer scores achieved by CBS treatment were not significantly reduced compared to

indoH alone, although the mean ulcer scores and histopathological examination

suggests that the higher dose CBS had a greater effect than the lower dose CBS.
Pre-treatment with misoprostol (100 g/kg and 10 g/kg) or omeprazole (5 mg/kg)
were both found to significantly reduce mean ulcer scores [306].

The in situ synthesis of a 1:1 Bi-diclo complex via the addition of diclofenac

sodium to CBS aqueous solution (3:1 molar ratio, dicloH to Bi) has been

reported [300]. The study concluded that diclo coordinated through the carboxylate

moiety to Bi, although the exact composition of the complex was not established.
Unexpectedly, oral administration of the Bi-diclo complex resulted in a higher stomach
lesion index than rats treated with diclofenac sodium alone, while a physical mixture

of diclofenac sodium and CBS induced the lowest lesion index; however, no statistical

analysis was performed to validate the significance of these results. The authors
hypothesised that the ulcerogenic activity of the Bi-diclo complex arose from the

decomposition of the complex into diclo particles, which were over three times
smaller than the diclofenac sodium particles, hence allowing diclo from the

decomposed Bi(III) complex to cover a greater surface area of the stomach mucosa. If

such an observation holds merit, the stability and resultant decomposition products of
other BiNSAID complexes in gastric fluid could be understatedly important and should

be established prior to in vivo studies.

Several homoleptic Bi(III) tris-carboxylate complexes derived from the

deprotonated acids of NSAIDs have been synthesised, with the general formula

[Bi(L)3]n, where L = deprotonated 5-chlorosalicylic acid, diflH, fenbufen, fluH, ibuH,
ketoH, mefH, napH, sulindac, or tolfH [299]. Elemental analysis determined that three

NSAID moieties are present for each Bi(III) ion, while complementary infrared (IR)
and nuclear magnetic resonance (NMR) spectroscopic data suggested that Bi(III)

adopts a bidentate coordination with the NSAID ligands through the deprotonation of
the carboxylic acid moiety. Crystal structures of the complexes could not be obtained,

hence the exact structural and polymeric propensities of each of the BiNSAID
complexes has not been definitively ascertained. As such, a representation of the

prospective structures of Bi(tolf)3, Bi(mef)3 and Bi(difl)3 is shown in Figure 1.7.
The anti-bacterial activity of all ten BiNSAIDs against three laboratory strains of

H. pylori, B128, 251 and 26695, compared favourably to the anti-bacterial activity of
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BSS and [Bi(Hsal)3]n (≥ 6.25 µg/mL versus ≥ 12.5 µg/mL), while the NSAIDs alone

showed no inhibitory properties.

Figure 1.7: Representation of the chemical structures of: (a) Bi(tolf)3 and Bi(mef)3, and
(b) Bi(difl)3, as inferred by elemental analysis, IR and NMR data [299].

The effect of the BiNSAIDs on cancer cell lines is an area that is yet to be explored,

and subsequently forms the basis of the investigations of this Thesis. Specifically, the

in vitro anti-cancer potential of three of the aforementioned BiNSAIDs, Bi(tolf)3,
Bi(mef)3 and Bi(difl)3, will be investigated.

1.6 Project Aims

A number of epidemiological, observational, and clinical studies suggest that

NSAIDs are able to reduce the incidence of cancer, in particular, CRC; however, side
effects, such as GI bleeding, limit the prolonged daily use of NSAIDs. Bi has been used

to treat an array of GI diseases for centuries, with an acceptable toxicity profile at low

doses over extended periods of administration. Thus it is hypothesised that the
combination of Bi and an NSAID in a single compound may potentially prevent the
adverse GI side effects of NSAIDs, if used daily as a chemopreventive agent.

There are several in vitro aspects that need to be investigated before such claims

could be tested in vivo. The first of these is the recognition that when administering a

drug as a chemopreventive, it is expected that the patient is prone to developing

cancer (specifically adenomatous polyps). A starting point then is to look at the

39

Chapter 1. Introduction
interaction of BiNSAIDs with transformed (cancer) cells. As the primary proposed
mechanism for chemoprevention by NSAIDs is COX-2 inhibition.

Subsequently, the overarching aim of this Thesis was to investigate the in vitro

potency and biological effects of the BiNSAID complexes, Bi(tolf)3, Bi(mef)3 and

Bi(difl)3, against a human colon cancer cell line, HCT-8, and hence the suitability of the

complexes for in vivo studies.

The specific aims of the project were to:

1. Evaluate the hydrolytic stability of the complexes in cell medium using NMR
spectroscopy to ascertain the biologically available structures of the BiNSAIDs
(Chapter 2).

2. Evaluate the in vitro drug toxicity and mode of cell death of the BiNSAIDs
compared to uncomplexed NSAIDs in HCT-8 cells (Chapter 2).

3. Assess the ability of the BiNSAIDs to inhibit the production of PGE2 by HCT-8
cells in order to determine if the complexes exhibit COX inhibition (Chapter 2).

4. Determine the cellular uptake and subcellular localisation of the BiNSAIDs in
HCT-8 cells to establish whether stability and toxicity correlated with cellular

uptake and to determine the subcellular fate of the Bi contained in the BiNSAID
complexes (Chapter 3).

5. Assess the biomolecular changes induced by BiNSAID treatment compared to
NSAIDs alone in live HCT-8 cells using synchrotron radiation infrared

microspectroscopy (SR-IRMS) (Chapter 4).

6. Examine the effects of BiNSAID- and NSAID-induced cell death on the

distribution and concentration of abundant cellular glycerophospholipids (PC,

PE, and PS) using electrospray ionisation tandem mass spectrometry (ESIMS/MS) (Chapter 5).

7. Evaluate the in vitro toxicity of other previously untested Bi(III) complexes of

aminoarenesulfonic acids, indole-carboxylic acids, and hydroxamic acids
against HCT-8 colon cancer cells, and determine whether complexation with Bi
improves the potency of the ligands (Chapter 6).
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Chapter 2.
Influence of BiNSAID stability on the toxicity and
PGE2 inhibition in HCT-8 colon cancer cells

In order to determine whether BiNSAIDs are potential chemotherapeutics or

chemopreventives in vivo, the behaviour of the BiNSAIDs first needed to be studied
in vitro. In this Chapter, the stability of the BiNSAIDs in cell medium was examined to

determine the biologically available species. The HCT-8 colon cancer cell line was

employed to assess the toxicity of the BiNSAIDs compared to uncomplexed NSAIDs,

and cisplatin, a clinically used anti-cancer drug. Upon confirming the toxicity of the
BiNSAIDs, cell death assays were employed to determine the mode of cell death

induced by the BiNSAIDs in the HCT-8 cells. Finally, the ability of the BiNSAIDs to
inhibit the production of PGE2 is presented with the respect to the proposed

mechanism of NSAID chemoprevention, COX inhibition.
Sections of this Chapter have been published in:

Hawksworth, E. L., Andrews, P. C., Lie, W., Lai, B. & Dillon, C. T. (2014) Biological
evaluation of bismuth non-steroidal anti-inflammatory drugs (BiNSAIDs): stability,
toxicity and uptake in HCT-8 colon cancer cells, J. Inorg. Biochem., 135, 28-39.
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2.1 Introduction
As discussed in Section 1.2.2, the results from a number of epidemiological,

observational and clinical studies indicate that long-term administration of NSAIDs,
such as aspH, reduces the incidence and reoccurrence of CRC. There are two criteria
that are important for this: (i) eradication of already transformed cells, and
(ii) preventing the formation of transformed cells.

Previously, NSAIDs have been extensively studied in a number of cancer cell lines

(as described in Section 1.2.4) to explore both their ability to kill cancer cells and their

ability to prevent the transformation of normal cells to cancer cells. In addition, a
variety of Bi(III) complexes have also shown promising anti-cancer activity in vitro

and in vivo (discussed in Section 1.4.1.4) indicating their ability to kill transformed

cells. However, no work has been performed to establish the ability of BiNSAIDs to kill
cancerous cells or prevent their formation.

There are a number of factors that need to be addressed in order to determine the

suitability of BiNSAIDs as potential chemotherapeutic or chemopreventive drug

candidates including general factors such as: (i) solubility/bioavailability, and

(ii) stability; and specific factors relating to the chemoprevention criteria: (iii) toxicity

towards colon cancer cells, (iv) inhibition of COX (and subsequent reduction in PGE2

release), and (v) cellular uptake and intracellular distribution (discussed in
Chapter 3).

Factors (i) and (ii) are also important for in vitro testing whereby

compromises need to be considered for these purposes. As such, Sections 2.1.1–2.1.5
will present the current literature relevant to the optimal factors for BiNSAID

chemotherapeutic/chemoprevention suitability and the rationale for the methodology

behind the experiments described in this Chapter.
2.1.1 Solubility/Bioavailability

Oral administration is the most desirable route of administration of therapeutics

and preventives due to the ease of use for the patient [1]. The development of orally

administered drugs is often hampered by poor aqueous solubility and high

lipophilicity (logP > 3.5) which then leads to poor and variable absorption/
bioavailability [2]. Drugs with poor solubility can present in vivo issues including

reduced oral bioavailability, lack of efficacy, the need to develop expensive and often

problematic formulations, and the burden to patients through frequent dosing to
achieve therapeutic effectiveness [1]. Nonetheless, the requirement of the drug to
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traverse the cell membrane imposes a requirement for some degree of lipophilicity
such that a balance between aqueous solubility and lipophilicity is essential [3].

NSAIDs, which represent one of the most highly prescribed classes of drug in the

world [4], are generally administered orally [5]; however, they display poor aqueous
solubility and incomplete dissolution in the stomach [6]. In general, NSAIDs are

hydrophobic molecules, a property that is crucial for their mechanism of action as it

allows the molecules to approach the membrane-bound target enzyme, COX, and enter
its hydrophobic arachidonate-binding channel [6]. Despite these properties, NSAIDs

generally display 80–95% oral absorption and 99% plasma protein binding (mainly
to albumin) [6].

Similarly, commonly used bismuth drugs, BSS (Pepto-Bismol, Procter & Gamble

Company) and CBS (De-Nol®; Gist Brocades and Yamanouchi) exhibit poor aqueous

solubility and stability (discussed in more detail in Section 2.1.2). However, these

properties contribute to the gastroprotective nature of these drugs as the drug forms a

solid physical coating on the epithelial lining of the stomach subsequently providing
protection via a physical barrier [7].

While the poor aqueous solubility of the BiNSAIDs may not necessarily hamper

in vivo studies and potential patient administration, it does pose an issue for in vitro

testing. For instance, lead compounds displaying poor aqueous solubility are often

considered less than ideal candidates for drug development as a number issues can

arise during in vitro testing, including; erratic assay results, artificially low potency,

and erroneous structure−activity relationships [1]. As such, the aqueous solubility of

the BiNSAIDs was a factor that required consideration for the assays reported in this

Chapter. Previous studies have shown that the BiNSAIDs, Bi(tolf)3, Bi(mef)3 and

Bi(difl)3, display poor solubility in deionized water [8] and thus would not dissolve in
the cell culture medium required for cell testing. Furthermore, BiNSAIDs display

limited solubility in organic solvents such as toluene, acetone and ethanol [8];
however,

all

three

BiNSAIDs

showed

appreciable

solubility

in

dimethyl

sulphoxide (DMSO) [8]. DMSO is often employed as a solvent for biological in vitro

testing of compounds with low aqueous solubility; the high solvating efficiency of
DMSO stems from its amphiphilic property, wide temperature range of the liquid state,

and high polarity [9]. DMSO is generally not favoured for oral administration to

humans as the metabolism of DMSO to dimethyl sulfide produces a sulphuric-like

odour on the skin and a garlic-like after-taste and breath odour that can persist for
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several days following DMSO administration [10]. In addition, DMSO is associated

with a number of side effects including sedation, nausea, headache, diarrhea, dizziness

and topical irritation [10]. However, DMSO is a commonly acceptable vehicle for

cell-based screening assays whereby the use of small volumes of DMSO is commonly

reported for the purpose of testing metal complexes [11-16] and poorly soluble
organic compounds [17-20].
2.1.2 Drug stability
There are a number of properties that can be exploited by the medicinal chemist

when designing/developing metal containing drugs. For example, the very nature of

metal-ligand complexes provides a scaffold whereby a metal centre can be conjugated

to an array of ligands with various geometries and dissociation rates. In order to

ensure the metal-complex reaches its biological target, the metal complex should have

a sufficiently high thermodynamic stability to deliver the metal to the biological target,
the metal-ligand binding should be hydrolytically stable, and understanding the
kinetics with which the metal ion undergoes ligation or dissociation reactions should

be considered [21]. While presenting a significant challenge, it is necessary to study

the stability of the metal-complexes in the biological environment to ensure the metal

complexes will survive long enough in vivo to reach their biological target and exert
the intended medicinal effects [22].

Generally, medicinal Bi compounds exhibit low aqueous solubility and lack

solution stability; however, as discussed in Section 1.4.1.2, low aqueous solubility may
be essential for the gastroprotective effects of Bi [7]. For instance, a number of studies

have explored the formation of BSS, CBS and RBC polymeric products in acidic
environments that mimic the stomach [23, 24]. The cell medium used to maintain in

vitro cell cultures is formulated to simulate the in vivo growth environment of the cells.

Buffers are present in the medium to maintain physiological pH 7.4, the ideal pH for

cells to grow. Due to the nature of Bi(III) carboxylates (that are common to the

BiNSAIDs) it is essential to determine the stability of the BiNSAIDs in the cell medium

in order to assess the structures of the biologically available species. Techniques often

used to study drug stability include ultraviolet-visible (UV-Vis) spectroscopy,

electrospray ionisation mass spectrometry (ESI-MS) and NMR spectroscopy. UV-Vis

spectroscopy is useful for determining if there is a change; however, the specific

chemical information is limited. ESI-MS is often utilised as a technique to characterise
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complexes based on the fragmentation pattern. However, ESI-MS is a poor technique

for the analysis of hydrophobic compounds in DMSO due to the non-volatile nature of
this solvent. NMR spectroscopy is also a technique that is commonly used to

characterise compounds, providing structural information based on the chemical

environment of the nuclei (commonly 1H and 13C). Importantly, DMSO (in the form of

deuterated DMSO, DMSO-d6) is a commonly employed solvent in NMR spectroscopy,
particularly for compounds that have difficulty dissolving in other organic solvents

such as methanol and chloroform. The use of DMSO-d6 as a NMR solvent is

particularly useful for compounds containing –OH and –NH2 groups due to the strong
hydrogen bonding between these proton donating groups and aprotic DMSO [9].
2.1.3 In vitro cytotoxicity towards colon cancer cells

As mentioned in Section 2.1, one of the criteria associated with the administration

of a CRC chemopreventive agent is its ability to eradicate already transformed cells.
This is important given that the cohort would generally include patients that are at
high risk of developing bowel cancer.

2.1.3.1 Assessing in vitro drug toxicity: The MTT assay
In order to assess the potential chemotherapeutic activity of novel compounds, it is

necessary to screen them using in vitro oncology-related assays [25]. Ideally, the assay

should be sensitive, reliable, inexpensive, have the capacity to test multiple
drugs/concentrations at the same time, and be relatively easy to perform [25]. First

described by Mosmann in 1983 [26], the MTT assay fits the aforementioned criteria
and is commonly performed using cancer cell lines to screen and compare the

chemotherapeutic potential of new compounds [25]. While there are several

variations of the assay protocol [26-30], they generally employ a water-soluble

substrate, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), as a

colorimetric measure of cell viability, proliferation or activation [25]. The assay is
based on the premise that only viable (or metabolically-active) cells are able to reduce
yellow

MTT

to

water-insoluble

purple

(E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-

diphenylformazan (formazan) by cleavage of the tetrazolium ring via the enzyme,
mitochondrial reductase (Scheme 2.1) [25].
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Scheme 2.1. The reduction of MTT to Formazan by the mitochondrial enzyme, mitochondrial
reductase, in living cells.
The water-insoluble formazan can be dissolved using an organic solvent or

detergent and analysed spectrophotometrically at 570 nm [26-30]. As the amount of

MTT reduced to formazan is directly proportional to the metabolic activity of the cells,

a concentration-response curve can be constructed based on the percentage of MTT
converted by cells treated with increasing concentrations of a drug. This can be
compared to the control cells that are treated with the vehicle.

As such, an

IC50 value (i.e. the concentration of drug required to inhibit 50% enzyme activity) can

be determined and used to compare the toxicity of multiple compounds against the
same cell line.

2.1.3.2 Modes of cell death
The identification of the mode of drug-induced cell death can be a useful for

determining the affected intracellular biochemical processes resulting from the
interaction of a drug within a cell. While there are several distinct modes of cell death

that can be distinguished due to distinct differences in morphological effects and

biochemical changes [31], apoptosis and necrosis are the two most common and

well-characterised modes of cell death that can be triggered in cancer cells due to a

chemotherapeutic agent. As apoptosis and necrosis result in different anti-tumour

responses, it is important to determine which mode of cell death is triggered by
anti-cancer therapies.

Apoptosis is often considered a ‘programmed’ form of cell death and occurs during

development and aging to maintain normal or healthy tissue populations of

cells [32, 33]. Apoptosis can also be triggered as a defence mechanism due to immune
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responses, cell damage via disease, or noxious stimuli [32]. Notably, not all cells
respond

to

apoptotic

stimuli

in

the

same

manner;

for

instance,

some

chemotherapeutic drugs can initiate apoptosis in cancer cells, without affecting

normal cells [32]. Distinguishing features of early apoptosis include reduction of

cellular volume (pyknosis) and cell rounding, retraction of pseudopods, reduction in

nuclear volume, externalisation of phosphatidylserine (PS), and minor modification of
cytoplasmic organelles [31]. Later stages of apoptotic cell death can be identified by

nuclear fragmentation (karyorrhexis), membrane blebbing, loss of plasma membrane
integrity, and engulfment by resident phagocytes in vivo [31]. Apoptosis is one of the

most common mechanisms of chemotherapy-induced cell death [33]. In cancer cells,
normal apoptotic pathways are often compromised [33], which is advantageous to the

fortification of cancer cells against cell death. As such, chemotherapeutics are often
designed to target a specific part of the apoptotic pathway in order to circumvent the
defunct signaling pathways and restore apoptosis [33].

In contrast, necrosis is a form of cell death that is morphologically and

biochemically distinct from apoptosis. While it is often considered an ‘accidental’,
uncontrolled form of cell death, accumulating evidence suggests that transduction

pathways and catabolic mechanisms are involved in regulating necrosis [31]. Clearly

distinct key features of necrotic cell death (as opposed to apoptosis) include

cytoplasmic swelling (oncosis), rupture of plasma membrane (occurs early, as
opposed to a late stage step in apoptosis), swelling of cytoplasmic organelles, and
moderate chromatin condensation [31]. Unlike apoptosis, necrosis releases the
intracellular content and tumour antigens, which attracts immune cells to the site of

the tumour to help drive anti-tumour immune responses [33]. While several

anti-cancer compounds have been shown to induce cell death via necrosis [34-36],
triggering apoptosis is generally described a safer mechanism for the death of the

cancer cells [37].

The most common method of assessing the mode of cell death is via flow cytometry

coupled with staining for markers specific to the events associated with apoptosis or
necrosis [31]. Two fluorescent probes, fluorescein isothiocyanate (FITC)-labeled

Annexin V (referred to herein as AnnV) and 7-aminoactinomycin D (7AAD), are

commonly used to distinguish between apoptotic cells and necrotic cells. AnnV is
utilised as it is a Ca2+ dependent phospholipid-binding protein with high affinity for

PS [38]. During the early stages of apoptosis, PS translocates from the inner leaflet of
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the plasma membrane to the outer leaflet [39]. AnnV binding to PS is not exclusive to
apoptosis. During the later stages of necrosis the cells increase in permeability

allowing entry of AnnV which can bind to PS on the inner leaflet [38]. In contrast to
this, during the early stages of necrosis, cells lose their membrane integrity and

become permeable, while this event does not occur until the later stages of
apoptosis [31]. Hence, the assessment of cell death is performed with AnnV in

combination with another fluorescent dye that is excluded by an intact plasma

membrane, but is able to diffuse through pores of a compromised cell membrane [38].
Traditionally, propidium iodide or 7AAD are employed to this end; these molecules

increase in fluorescence intensity when they intercalate with DNA following entry

through the compromised cell membrane, and provide a measure of loss of membrane
integrity [40, 41].

An example of the flow cytometry data obtained from AnnV and 7AAD co-stained

cells is shown in Figure 2.1. Viable cells maintain an intact plasma membrane and PS

remains on the inner leaflet, thus viable cells do not bind AnnV and exclude 7AAD,
such that these cells exhibit low fluorescent intensity (AnnV−/7AAD−); and can be

identified as the population in the bottom-left quadrant of the bivariate plot (Fig. 2.1).
In the early stages of apoptosis, PS translocates from the inner leaflet of the plasma

membrane to the cell surface allowing AnnV to bind; however, the plasma membrane

remains intact excluding 7AAD from the cell (AnnV+/7AAD−). As shown in Figure 2.1,
these cells are located in the bottom-right quadrant of the bivariate plot. In the later
stages of apoptosis pores appear in the cell membrane allowing 7AAD to enter. The

population in the top-right corner is indicative of late apoptosis or late necrosis
(AnnV+/7AAD+, as shown in Fig. 2.1). In necrosis the loss of plasma membrane

integrity occurs before the translocation of AnnV (AnnV−/7AAD+). As such, early
necrotic cells appear in the top-left quadrant in Figure 2.1.
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Figure 2.1: The use of flow cytometry to distinguish modes of cell death using AnnV and 7AAD.
The presence of AnnV (depicted in green) bound to PS (depicted in blue) and 7AAD (depicted
in red) bound to DNA in the cell nucleus (depicted in light grey) in the cell is dependent on the
mode of cell death the cells have undergone.

2.1.4 Inhibition of COX: Reduction of PGE2 production
Since one of the proposed mechanisms of chemoprevention by NSAIDs is the

inhibition of COX-2, it is important to establish whether BiNSAIDs can inhibit COX at
comparable concentrations. This information can provide preliminary evidence to

determine their potential usefulness as chemopreventive agents and form a guide for

future studies. As discussed in Section 1.2.3, the upregulation of COX-2 production has

been established in a number of cancer cell lines. The upregulation of COX-2, in turn,
results in the overproduction of PGE2, a PG that is associated with fortifying cancer

cells against cell death and increasing the invasiveness of cancer cells (as

demonstrated in Fig. 1.5). While it is of interest to study COX inhibition by incubation

of the BiNSAIDs with purified COX-1 and COX-2 enzymes, these experiments would
not take into account the conditions that the NSAISDs and BiNSAIDs would be

subjected to in a cellular environment (i.e. cell permeability and metabolic pathways).

The disadvantage of utilising a cell system to determine COX inhibition is that COX-1

versus COX-2 inhibition cannot be distinguished. However, this study will directly
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compare BiNSAID versus NSAID, as it is important to establish if the BiNSAIDs can

provide equal or superior COX inhibition in the cellular environment. Thus the ability
of BiNSAIDs to inhibit PGE2 production (and subsequently the ability to inhibit COX) in

a transformed cell line will be assessed in this Chapter.
2.1.5 Chapter aims

The establishment of the in vitro activity is the first step to determine whether

BiNSAIDs will be suitable candidates for in vivo studies as chemotherapeutic or
chemopreventive agents for CRC, and ultimately, whether BiNSAIDs should be

investigated as a potential medication for the reduction of the accompanying GI side

effects of long-term NSAID use. The experiments described in this Chapter can be

divided into two purposes: (i) to establish the chemotherapeutic potential of BiNSAIDs
by determining whether BiNSAIDs are able to kill transformed cells (toxicity and cell
death assays), and (ii) to establish whether BiNSAIDs demonstrate chemopreventive

potential by determining whether BiNSAIDs are able to inhibit the production of PGE2
(and thus inhibit COX) in transformed cells. A human epithelial ileocecal colon cancer
cell line, HCT-8, was employed as a model CRC cell line for the evaluation of the

BiNSAIDs, Bi(tolf)3, Bi(mef)3 and Bi(difl)3 and the respective uncomplexed NSAIDs,

tolfH, mefH and diflH.

The specific aims of this chapter were to:
1.

2.
3.
4.

Investigate the stability of Bi(tolf)3, Bi(mef)3 and Bi(difl)3 in cell medium

using NMR spectroscopy in order to elucidate the biologically active form of
the complexes in the in vitro assays.

Assess the in vitro toxicity of the BiNSAIDs, Bi(tolf)3, Bi(mef)3 and Bi(difl)3,

and compare to the uncomplexed NSAIDs against human colon cancer cell
line, HCT-8.

Determine whether the BiNSAIDs, Bi(tolf)3, Bi(mef)3 and Bi(difl)3, induce the

same type of cell death (apoptosis or necrosis) as the respective NSAIDs in
HCT-8 cells.

Ascertain whether complexation with Bi affects the ability of the NSAIDs,

tolfH, mefH and diflH, to interact with COX in vitro, by quantifying PGE2

production by HCT-8 cells.
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2.2 Materials and methods
2.2.1 Materials
The Bi complexes of tolfH, mefH and diflH (Bi(tolf)3, Bi(mef)3 and Bi(difl)3,

respectively) were chosen for this study. TolfH has been extensively studied in vitro

against a number of different types of human cancer cell lines [42-50]. MefH is

structurally similar to tolfH (both belonging to the structural class called fenamic
acids, Fig. 1.2) and was tested as a direct comparison to tolfH; additionally, mefH

exhibits toxicity in cancer cell lines in vitro [51, 52]. DiflH was investigated as it is a
salicylate

to (Fig. 1.2).

which

is

the

same

chemical

class

that

aspH

belongs

Additionally, reports suggest that diflH exhibits gastroprotective

properties [53, 54]. The BiNSAIDs, Bi(tolf)3, Bi(mef)3 and Bi(difl)3, were synthesised,

purified and characterised by Dr Ish Kumar (School of Chemistry, Monash University)
and Dr Amita Pathak (School of Chemistry, Monash University) as previously

published by Andrews et al [8]. The NSAIDs, diflH (≥98%), mefH (≥98%), and
tolfH (≥98%), were purchased from Sigma-Aldrich (St Louis, USA).

In addition,

bismuth salicylate was chosen to represent the marketed Bi drug, BSS. Bismuth

chloride (BiCl3) was chosen to represent a simple Bi compound with no expected anti-

cancer activity or toxicity stemming from the anion (Cl−). Cisplatin was employed to

provide a comparison of the BiNSAIDs to a standard chemotherapeutic drug. The
chemicals, BSS (99.9%), BiCl3 (≥98%) and cisplatin (99.999%) were purchased from

Sigma-Aldrich (St Louis, USA).

MilliQ™ (18.2 MΩ/cm resistivity, Millipore) water was used to prepare all aqueous

solutions. DMSO (99.8%) was obtained from Thermofisher Scientific (Waltham, USA).

The chemicals, acetylsalicylic acid (aspH, ≥99.0%), deuterated DMSO (DMSO-d6,

99.9%), D-(+)-glucose (≥99.5%), 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid

(HEPES, ≥99.5%), MTT (98%), and trypan blue (0.5% in phosphate buffered saline

(PBS) solution) were purchased from Sigma-Aldrich (St Louis, USA). Absolute ethanol

was sourced from Ajax Finechem (Seven Hills, Australia). PBS tablets (1 tablet per

100 mL of MilliQ water contains 0.8 g sodium chloride; 0.02 g potassium chloride;
0.115 g di-sodium hydrogen phosphate; 0.02g potassium dihydrogen phosphate) were

obtained from Oxoid (Basingstoke Hampshire, England). Annexin V binding buffer

and AnnV were acquired from BioLegend (San Diego, USA), and 7AAD was purchased

from Enzo Life Sciences (Plymouth Meeting, USA). Arachidonic acid (0.1 M in ethanol,
Item No. 460103), potassium hydroxide (0.1 M, Item No. 460105), and the
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Prostaglandin E2 EIA kit – Monoclonal kits (Item No. 514010) were obtained from
Cayman Chemical (Ann Arbor, USA).

The materials used in the cell culture assays including, Roswell Park

Memorial Institute (RPMI)-1640 medium, penicillin/streptomycin (10,000 IU/mL,

10,000 μg/mL), trypsin (2.5% w/v in PBS) and GlutaMAX™ (200 mM L-alanyl-Lglutamine dipeptide in 0.85% NaCl) were acquired from Life Technologies (New York,
USA).

Australian certified fetal bovine serum was purchased from Thermofisher

Scientific (Waltham, USA) and was heat-inactivated before use (60 °C, 1 h).
CELLSTAR® 96-well cell culture plates, CELLSTAR® 60-mm culture dishes, and

CELLSTAR® filter cap cell culture flasks (75 cm2) were sourced from Greiner
Bio-One (Kremsmünster, Austria).

2.2.2 Stability studies
The stability of BiNSAIDs in RPMI-1640 (referred to herein as cell medium) was

assessed by comparison of the NMR spectra with those for the uncomplexed NSAIDs to

determine whether the NSAID dissociated from Bi. These studies were initially

performed by dissolving the NSAIDs or BiNSAIDs in accordance with the procedure

and concentrations used for the cell assays (i.e. < 100 µM, 2% d6-DMSO/98% D2O);

however, only very weak 1H NMR signals of the NSAIDs were detected. Subsequently,
the concentrations of the NSAIDs or BiNSAIDs were increased such that 10–40 mg was

dissolved in d6-DMSO (200 µL) and the resultant solution was added to

RPMI-1640 (1.8 mL). The resultant suspensions were vortexed and incubated (37°C,
24 h). Following incubation, the suspended compounds were collected by

centrifugation (300 g, 5 min) and dried under a nitrogen atmosphere. The 1H and 13C

NMR spectra of the BiNSAIDs, NSAIDs and the redissolved products resulting from

incubation in medium were recorded using a 500 MHz Varian spectrometer in

d6-DMSO at 25°C, referenced to DMSO (δH 2.49, δC 39.5). NMR assignments were

confirmed with 2D-NMR, specifically homonuclear correlation spectroscopy (COSY),
heteronuclear single quantum coherence spectroscopy (HSQC), and heteronuclear
multiple-bond correlation spectroscopy (HMBC).

2.2.3 Cell culture
The human ileocecal colon cancer cell line, HCT-8, was chosen to represent a

human bowel cancer cell line and since a number of publications report that COX-2 is
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expressed in the HCT-8 cell line [55-57]. The cell line was kindly provided by

Associate Professor Ronald Sluyter (School of Biological Sciences, University of

Wollongong), and was originally sourced from the European Collection of
Authenticated Cell Cultures (ECACC). All experimental work involving the culture and

treatment of HCT-8 cells, and the subsequent handling and preparation of HCT-8 cell

samples was performed under sterile conditions in a biological safety cabinet (Class II,

Email Westinghouse Pty Ltd). HCT-8 cells were cultured in growth medium that

consisted of RPMI-1640 medium supplemented with 10% fetal bovine serum,
GlutaMAX™ (2 mM), penicillin and streptomycin (final concentration 200 IU/mL and

200 µg/mL, respectively). Cells were incubated in a 5% CO2 atmosphere at 37 °C and
passaged every 3–4 days (when confluent) after harvesting with trypsin (0.25% in PBS

solution).

2.2.4 In vitro cytotoxicity towards cancer cells: MTT assay
The toxicities of Bi(tolf)3, Bi(mef)3, Bi(difl)3, tolfH, mefH, diflH, BSS and cisplatin

were assessed using adaptations of the MTT assay described by Mosmann [26], and

Carmichael et al [29]. Briefly, cells were seeded in 96-well plates at a density of
4 × 104 cells per well in growth medium (100 μL) and were incubated for 24 h to allow

cell adhesion to occur. Stock solutions (typically 50 µM to 100 mM) of the NSAIDs,

BiNSAIDs, BiCl3 and BSS, were prepared in DMSO. These solutions (20 μL) were

pipetted into RPMI-1640 (980 μL), vortexed, and the resultant solutions (100 μL
treatment solution, final concentration of drug typically 1 to 2000 µM) were added

into the wells of the 96-well plate. Control cells were incubated with the vehicle

(DMSO (2 μL) and RPMI-1640 (98 μL)) containing no test compounds. In order to

avoid any potential ligand exchange reactions between DMSO and the labile Cl− groups

resulting in the deactivation of the drug in the cell medium [58], cisplatin was
prepared in RPMI-1640 (typical stock concentration 2−4 mM) and serially diluted in

RPMI-1640. The 96-well plate was incubated (37 °C) for 24 h, after which the

treatment medium was removed and the cells were washed twice with sterile PBS

solution. Fresh RPMI-1640 (100 μL) was added to each well, followed by the addition

of MTT solution (50 μL, 2 mg/mL in PBS). The 96-well plate was incubated (37 °C) for

4 h, after which the medium was removed and DMSO (200 μL) was added to each well.
The 96-well plate was agitated for 25 s and the absorbance of each well was recorded
at 570 nm and 630 nm using a POLARstar Omega microplate reader with Omega
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software (Version 1.1.2, BMG Labtek GmbH, Ortenberg, Germany). The results were

expressed as percent MTT conversion, which is proportional to the number of healthy

cells (Equation 1):

MTT conversion % =

!!"# !!!"# !"#$!#% !"##$

!!"# !!!"# !"#$%&#%' !"##$

× 100

(1)

The calculated cell viability was plotted against the treatment concentrations using

Microsoft EXCEL™ (Version 12 for Windows 2007, Microsoft, Redmond, USA) to
determine the IC50 value of each compound. The MTT assays were performed in

triplicate for each compound.
2.2.5 Cell death assays

2.2.5.1 Morphological analysis by phase contrast microscopy
HCT-8 cells were plated in 60-mm cell culture dishes (2 × 106 cells, 5 mL) in

growth medium and maintained at 37 °C, 5% CO2 overnight. The cells were washed

twice with PBS solution and the treatment solutions (3 mL) were then added. The
treatment concentrations were the approximate IC50 doses of each BiNSAID dissolved

in treatment medium (2% DMSO v/v) as determined by MTT assays (Section 2.3.2), or

the equimolar concentration of the corresponding free NSAID, as denoted in the
figures and text. A minimum of three fields of view were examined for each sample

using a Motic Binocular AE20 Inverted light microscope equipped with a 20× objective
lens. Images were recorded using a Moticam 2000 2.0 MP Live Resolution camera

with Motic Images Plus Version 2.0 for Windows (Motic China Group Co., Ltd., Xiamen,

China).

2.2.5.2 Measurement of cell death by cytofluorometric assay
HCT-8 cells were plated in 60-mm cell culture dishes (1 × 106 cells, 5 mL) in

growth medium and maintained at 37 °C, 5% CO2 overnight. The cells were washed

twice with PBS solution and treatment solutions were added (3 mL RPMI-1640,
2% DMSO v/v). Cells were treated with the approximate IC50 doses of the BiNSAID

(Bi(tolf)3, Bi(mef)3 or Bi(difl)3) as determined by MTT assays (Section 2.3.2), or

equimolar concentrations of the corresponding free NSAID (tolfH, mefH or diflH).

Following incubation (37 °C, 24 h), the treatment solutions and PBS solution washes
were collected and the remaining cells were detached using trypsin (0.25% in PBS

solution). The detached cells were combined with the cells in the treatment solution

washings and the resultant suspension was centrifuged (300 g, 5 min) to ensure
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collection of all cells (live and dead). Cell death was determined by quantitative

measurement using flow cytometry. The collected HCT-8 cells were washed twice

with HEPES-buffered saline solution (145 mM NaCl, 5 mM KCl, 10 mM HEPES, pH 7.4,
1 mL), followed by Annexin V binding medium (1 mL). The cells were incubated with

AnnV (5 µL) and 7AAD (1 mg/mL in PBS solution, 1 µL) at room temperature

protected from light for 15 min. Following staining, AnnV binding medium (400 µL)

was added to each tube and events (20,000 per sample) were collected using a LSR II
flow cytometer (BD Biosciences, San Diego, CA) using an excitation wavelength of

488 nm and emission collected with 515/20 and 695/40 band pass filters for AnnV

and 7AAD, respectively. The mean fluorescent intensity (MFI) of AnnV and 7AAD was
determined using FloJo software (Tree Star, Ashland, OR). Quadrant markers were
used to determine the percentage of AnnV‒/7AAD‒ (viable), AnnV+/7AAD‒ (early

apoptotic), AnnV+/7AAD+ (late apoptotic/late necrotic), and AnnV‒/7AAD+ (early

necrotic) cells.

2.2.6 COX inhibition: Prostaglandin assays
HCT-8 cells (1 × 106 cells, 5 mL) were seeded into 60-mm cell culture dishes and

were incubated for 24 h, after which the growth medium was removed and the cells

were washed twice with PBS solution. The BiNSAID (Bi(difl)3, Bi(mef)3, or Bi(tolf)3),

NSAID (diflH, mefH or tolfH), aspH or BSS treatments in DMSO (5 µM to 50,000 µM)

were added to each dish as a solution in RPMI-1640 (2mL, 2% DMSO v/v; final
concentration of drug 0.1−1000 µM), while the control cells were incubated (37 °C)
with the vehicle (2 mL RPMI-1640, 2% DMSO v/v) for 4 h. AspH was chosen as a

positive control as it is a well-established COX inhibitor, and clinical evidence suggests

that aspH may possess chemopreventive properties (as discussed in Section 1.2.2).

BSS was chosen to represent a marketed anti-ulcer Bi medication. Following the

incubation period, the treatment medium was removed and the cells were washed
twice with PBS solution. Fresh arachidonic acid solution was prepared according to

the manufacturer’s instructions. Arachidonic acid (0.1 M in ethanol, 20 µL) was

diluted by the addition of potassium hydroxide (0.1 M, 20 µL) and the resultant

solution was added to RPMI-1640 (960 µL). Fresh RPMI-1640 medium (1980 µL) and

arachidonic acid solution (20 µL; final concentration 20 µM) was added to the cells

and the 60-mm dishes were incubated (37 °C) for 30 min. The cell medium was
collected and centrifuged (11 000 g, 30 sec) to remove any cellular material, and the
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supernatant was stored at −80 °C until the assay was performed. PGE2 production was

assayed using a Prostaglandin E2 EIA Kit in accordance with the manufacturer’s

instructions. Briefly, the absorbance of each well was recorded at 420 nm using a

POLARstar Omega microplate reader with Omega software (Version 1.1.2,
BMG Labtek). The PGE2 concentration (pg/mL) of each sample was calculated using

GraphPad Prism Version 5.04 for Windows (GraphPad Software, La Jolla, USA), and

PGE2 release was expressed as a percentage of control PGE2 production. The

sensitivity of the assay, as reported by the manufacturer, was 15.6 pg PGE2/mL.
2.2.7 Statistical analysis

Statistical analysis of the results of the AnnV/7AAD assays was performed by

one-way ANOVA, followed by the Tukey-Kramer Multiple Comparison Test, using

GraphPad Prism, Version 5.04 for Windows (GraphPad Software, La Jolla, USA).

The results were analysed as vehicle versus BiNSAID versus the corresponding NSAID,
in order to draw a statistical comparison at the same NSAID concentration. A value of
P ≤ 0.05 was considered statistically significant.
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2.3 Results
2.3.1 Stability of BiNSAIDs in cell medium
Features of the 1H NMR spectra (aromatic region only, presented for clarity; Figure

2.2a–d) of tolfH and Bi(tolf)3 as obtained in DMSO-d6 prior to and after incubation in

cell medium are summarised in Table 2.1. It is apparent that there is no proton signal

corresponding to the –COOH in the Bi(tolf)3 spectrum, which is consistent with
previous studies [8], and corresponds to the expected absence of the proton

subsequent to coordination to Bi. As shown in Table 2.1, the

13C

NMR spectra of

Bi(tolf)3 also confirm the complexation to Bi, with downfield shifts observed from

170.1 ppm to 174.0 ppm for the resonance corresponding to the carboxylate carbon,
C14 (C–OOBi), in comparison with uncomplexed tolfH; additionally, a substantial shift
in the resonance of the quaternary carbon C1 (C–COOBi) was observed from

112.3 ppm to 118.6 ppm. The majority of the signal shifts relating to the introduction

of the d6-DMSO solution of tolfH and Bi(tolf)3 to cell medium were observed for the
aromatic protons, as shown in Figure 2.2b and d. Small downfield shifts in the 1H NMR

signals of tolfH incubated in cell medium occurred for H5, and H8 which overlapped

with the signal of H4 (Fig. 2.2b), indicating that there were some changes in the

chemical environment surrounding these atoms following incubation of the NSAID in

cell medium compared to the original NSAID (Fig. 2.2a). In addition, the proton signal
at 13.11 ppm related to –COOH disappeared and there was broadening and a
downfield shift of the signal associated with –NH in the 1H NMR spectra obtained from

the precipitated tolfH (and Bi(tolf)3). These observations are attributed to the

presence of a small amount of water in the sample and subsequent exchange with H2O
protons. Following incubation in cell medium, the
Bi(tolf)3 (Fig. 2.2d) showed some differences from

1H

NMR spectrum of

the initial spectrum

of

Bi(tolf)3 (Fig. 2.2c), most substantially for the 1H signals of H4, H8, H9 and H10.

However, the

13C

NMR spectrum (Table 2.1) obtained for Bi(tolf)3 after incubation in

cell medium showed minimal shift in the C14 (C–OOBi) signal (174.0 to 173.8 ppm).

Additionally, there was minimal shift in the C1 signal (Table 2.1) suggesting that
following incubation of the complex in cell medium, the interaction between the
carboxylate group and Bi remains intact.
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Figure 2.2: 1H NMR spectra of the aromatic region (6.6–8.0 ppm) of: (a) tolfH; (b) tolfH
collected after incubation in cell medium (24 h, 37 °C); (c) Bi(tolf)3 and, (d) Bi(tolf)3 collected
after incubation in cell medium (24 h, 37 °C). All samples were analysed in d6-DMSO at 25 °C
(referenced to DMSO, 2.49 ppm).
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dbr

13.11 s
9.56 s

2.23 s

7.28 d (6.75)
7.21 m (7.5)
7.21 m (7.5)

7.90 d (8)
6.75 t (7.25)
7.33 t (7.75)
6.80 d (8)

tolfH
None
DMSO
1H
112.3
131.8
117.3
134.2
113.6
147.6
140.5
124.9
127.5
122.1
134.5
129.8
14.7
170.1

13C

Cell medium (24 h)
DMSO
1H
13C
113.0
7.90 d (7.5)
131.8
6.75 t (7.5)
117.4
7.33 m (8)
134.0
6.84 d (8)
113.7
147.4
140.7
7.30 m (7)
124.7
7.20 m (6.75) 127.6
7.20 m (6.75) 121.7
134.4
129.6
2.24 s
14.7
170.2
n.o
9.90 br s
n.o
9.64 s

2.07 s

7.21 d (7)
7.13 m (7.5)
7.13 m (7)

7.84 d (8.5)
6.76 t (6.75)
7.30 t (7)
6.92 d (8)

Bi(tolf)3
None
DMSO
1H
118.6
131.9
117.5
133.4
114.0
146.0
141.0
123.7
127.3
119.6
134.3
128.1
14.2
174.0

13C

n.o
10.20 br s

2.14 s

7.23 d (8)
7.12 t (8)
7.07 m (8)

7.86 d (7.5)
6.72 t (7)
7.23 m (n.o)
6.93 d (7.5)

Cell medium (24 h)
DMSO
1H
13C

118.8
131.9
117.4
132.5
113.8
145.9
141.5
123.2
127.3
118.9
134.3
127.9
14.4
173.8

shift (δ) in ppm; bMultiplicity is given as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; cCoupling constants are in parentheses 3J(1H,1H);
is “broad signal”; en.o is “not observed”.

aChemical

Compound
Treatment
Solvent
Atom
1
2
3
4
5
6
7
8
9
10
11
12
13
14
OH
NH

Table 2.1: 1H and 13C NMR dataa,b,c,d,e of tolfH and Bi(tolf)3 in d6-DMSO, before and after suspension in cell medium (24 h).
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The 1H NMR spectra of mefH and Bi(mef)3 (aromatic region only presented for

clarity, Figure 2.3a–d), as obtained in d6-DMSO prior to and after incubation in cell
medium, are summarised in Table 2.2. Prior to incubation in cell medium it is

apparent that there is no signal corresponding to the proton of –COOH in the Bi(mef)3
spectrum, which is consistent with the absence of coordination of the NSAID to Bi [8].

As shown in Table 2.2, the 13C NMR spectra of Bi(mef)3 also confirm the complexation

to Bi, with downfield shifts observed from 170.2 ppm to 175.5 ppm for the resonance
corresponding to the carboxylate carbon, C15 (C–OOBi), in comparison with
uncomplexed mefH. The 1H NMR signals of Bi(mef)3 (Table 2.2) were shifted upfield

in comparison to free mefH (with the exception of H3 and NH). The most obvious

difference between the 1H NMR spectra of mefH and Bi(mef)3 is the chemical shift of
H5 (Fig. 2.3 a and c). After incubation in cell medium, there appeared to be little

change to the 1H NMR spectrum of mefH (Fig. 2.3b, Table 2.3). Comparatively, Figure

2.3d shows that the H5 signal overlaps with the H3 signal after incubation of Bi(mef)3
in cell medium which was accompanied by additional downfield shifts in the majority

of the other 1H NMR signals (Table 2.3). Furthermore, the

13C

NMR signals revealed

that after the incubation of Bi(mef)3 in cell medium, the C–OOBi signal shifted upfield

to 170.8 ppm (Table 2.3). Overall, these results suggest that following incubation of

Bi(mef)3 in cell medium there is liberation of mef from the Bi complex.

The 1H NMR spectra of diflH and Bi(difl)3 (aromatic region only, presented for

clarity; Fig. 2.4a–d), as obtained in d6-DMSO prior to and after incubation in cell

medium, are summarised in Table 2.3. Interestingly, reference to the spectrum of

diflH prior to incubation in cell medium indicates the absence of the proton signal of
the –COOH (of C13) and –OH (of C10); however, solid IR analysis (data not shown)
confirmed the presence of –OH in the diflH structure. Additionally, the C10, C11 and

C13 (–COOH) signals of Bi(difl)3 were not observed (Table 2.3, Fig. 2.4a). This

phenomenon is most likely a result of the slower tumbling of a larger molecule and

hence the broadening of some of the 13C signals, thereby decreasing their detectability;
this is further evidenced by the broadening of the H8, H9 and H12 signals observed in

the 1H NMR spectrum of Bi(difl)3 (Fig. 2.4c). The 24-h incubation of diflH in cell

medium resulted in upfield shifts of the proton signals associated with the phenyl ring
containing the –COOH moiety (Fig. 2.4d). Following the incubation of Bi(difl)3
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Figure 2.3: 1H NMR spectra of the aromatic region (6.6–8.0 ppm) of: (a) mefH; (b) mefH
collected after incubation in cell medium (24 h, 37 °C); (c) Bi(mef)3, and (d) Bi(mef)3 collected
after incubation in cell medium (24 h, 37 °C). All samples were analysed in d6-DMSO at 25 °C
(referenced to DMSO, 2.49 ppm).
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dbr

12.9 s
9.43 s

2.27 s
2.08 s

7.06 d (5)
7.11 m (6.75)
7.09 m (6.75)

7.87 d (7)
6.67 m (7)
7.29 t (7.25)
6.69 m (8)

mefH
None
DMSO
1H
111.2
131.7
116.2
134.2
113.1
148.7
131.2
122.2
126.4
126.0
137.9
138.3
20.2
13.6
170.2

13C

Cell medium (24 h)
DMSO
1H
13C
111.6
7.88 d (7.5)
131.8
6.67 m (8.5)
116.3
7.26 t (7.5)
134.1
6.64 m (7)
113.1
148.8
131.2
6.98 d (6)
122.1
7.08 m (7.25) 126.3
7.06 m (7.25) 126.1
137.9
138.4
2.24 s
20.3
2.07 s
13.7
170.4
n.o
9.50 br s
n.o
9.45 s

2.13 s
1.91 s

6.90 d (5.5)
7.03 m (7.25)
7.00 m (7.25)

7.83 d (8)
6.68 t (7.25)
7.24 t (7.5)
6.78 d (8.5)

Bi(mef)3
None
DMSO
1H
n.o
131.9
116.3
133.4
113.2
147.5
130.0
120.4
125.7
125.4
137.6
138.8
20.1
13.2
175.5

13C

n.o
9.65 br s

2.26 s
2.08 s

6.99 d (5)
7.10 m (n.o)
7.10 m (n.o)

7.87 d (8)
6.69 m (7.5)
7.27 t (7)
6.65 m (7)

Cell medium (24 h)
DMSO
1H
13C

112.7
131.7
116.2
133.8
113.1
148.5
131.0
121.7
126.1
126.0
137.8
138.6
20.2
13.7
170.8

shift (δ) in ppm; bMultiplicity is given as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; cCoupling constants are in parentheses 3J(1H,1H);
is “broad signal”; en.o is “not observed”.

aChemical

Compound
Treatment
Solvent
Atom
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
OH
NH

Table 2.2: 1H and 13C NMR dataa,b,c,d,e of mefH and Bi(mef)3 in d6-DMSO, before and after suspension in cell medium (24 h).
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in cell medium, a pronounced upfield shift in the H8, H9 and H12 1H NMR signals

was observed (Fig. 2.4d), in comparison to free diflH (Fig. 2.4b). Additionally, the
carbon signals for C10, C11 and the –COOH were observed (Table 2.4) suggesting an
alteration in structure. However, the C11 signal of the Bi(difl)3 differs substantially to

that of diflH after incubation (120.4 ppm and 115.9 ppm) which suggests that difl may
remain coordinated to Bi.

Interestingly, weak yet observable signals were detected in the 1H NMR from

another molecule(s) present in the Bi(difl)3 sample after incubation in cell medium

which were not detected in any other sample studied. Complete characterisation

could not be achieved due to the low concentration of the molecule(s). Nonetheless,

the appearance of weak 1H NMR signals of the unknown molecule(s) suggested that

only molecules with concentration comparable to the concentration of Bi(difl)3 in the

cell medium would be detected, in particular D-glucose or HEPES. Reference to the 1H

NMR spectra of D-glucose or HEPES (alone) in d6-DMSO, suggested that the potential
identity of the molecule(s) in the incubated Bi(difl)3 sample consisted of

D-glucose (Fig. 2.5). Overall, the changes observed in the 1H and

13C

NMR signals of

the incubated Bi(difl)3 complex compared to the original compound may suggest that
the coordination of Bi to the difl ligands is altered following incubation in cell medium

due, possibly, to subsequent interactions with D-glucose.

As well as the DMSO-soluble species described above (Fig. 2.2–2.5, Table 2.1–2.3),

it was noted that a DMSO-insoluble species was present upon preparation of the

samples for NMR analysis (after collection and drying following incubation in cell

medium). The formation of the white precipitate was not observed upon incubation of
the free NSAID in cell medium and consequently implied that at least some of the

BiNSAID must be interacting with other species present in the solution. High

concentrations of anions such as phosphate, chloride, sulphate and carbonate are
present in the inorganic salts found in RPMI-1640. Given that Bi(III) has a particularly

high affinity for phosphate ions, it is envisaged that the precipitation could be

insoluble Bi(III) phosphate. Identification of the species was attempted using IR
spectroscopy; however, the dominating signals in the spectrum originated from DMSO
that proved difficult to remove due to its non-volatile nature. Attempts to repeatedly
wash the precipitate with MilliQ water were performed; however, due to the
low quantity of the solid produced, isolation of a sufficient quantity of dried
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Figure 2.4: 1H NMR spectra of the aromatic region (6.6–8.0 ppm) of: (a) diflH; (c) diflH
collected after incubation in cell medium (24 h, 37 °C); (d) Bi(difl)3, and (f) Bi(difl)3 collected
after incubation in cell medium (24 h, 37 °C). All samples were analysed in d6-DMSO at 25 °C
(referenced to DMSO, 2.49 ppm).
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n.o

7.90 s

7.64 d (8.5)
7.04 d (8)

7.29 t (10.25)

diflH
None
DMSO
1H
7.54 q (8.2)
7.13 t (8.5)
131.5
112.0
161.5
104.4
159.3
123.7
125.1
135.8
117.6
160.7
113.2
130.3
171.6

13C

Cell medium (24 h)
DMSO
1H
13C
7.48 m (8.5)
131.7
7.10 td (8.5)
112.3
161.4
7.23 t (10)
104.6
159.4
124.4
124.5
7.52 m (7.25) 134.8
6.94 d (9)
117.5
161.5
115.9
7.87 s
130.6
172.0
n.o
n.o

7.85 br s

7.51 m (12)
6.93 br s

7.27 t (10)

Bi(difl)3
None
DMSO
1H
7.46 m (7)
7.10 t (8)
131.3
111.9
161.2
104.3
160.0
124.2
125.0
134.4
117.2
n.o
n.o
130.4
n.o

13C

Cell medium (24 h)
DMSO
1H
13C
7.47 q (8)
131.2
7.10 t (7.75)
111.8
161.7
7.25 t (10)
104.3
159.8
126.2
121.6
7.29 d (8)
131.7
6.70 d (8.5)
116.2
163.2
120.4
7.82 s
130.5
171.0
n.o

shift (δ) in ppm; bMultiplicity is given as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; cCoupling constants are in parentheses 3J(1H,1H);
dbr is “broad signal”; en.o is “not observed”; f 13C doublet due to 13C-19F coupling.

aChemical

Compound
Treatment
Solvent
Atom
1
2
3f
4
5f
6
7
8
9
10
11
12
13
OH

Table 2.3: 1H and 13C NMR dataa,b,c,d,e of diflH and Bi(difl)3 in d6-DMSO, before and after suspension in cell medium (24 h).
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Figure 2.5: 1H NMR spectra of: (a) unknown molecule present in the sample containing
Bi(difl)3 collected after incubation in cell medium (24 h, 37 °C) (l indicates signals
corresponding to D-glucose, × indicates unassigned signals); and (b) D-glucose. All samples
were analysed in d6-DMSO, 25 °C, referenced to DMSO (2.49 ppm).

compound to produce good quality IR spectra was not possible. Whether phosphate
(or any other ion) has an effect on the BiNSAIDs at low concentrations in cell medium

(i.e. biologically relevant concentrations) will need to be confirmed in further studies.
2.3.2 In vitro cytotoxicity towards cancer cells

To evaluate the effects of the BiNSAIDs and NSAIDs on cell viability, HCT-8 cells

were exposed to the compounds for 4 h or 24 h, following which the conversion of

MTT by functioning mitochondria was measured. As DMSO was necessary to
solubilise the BiNSAIDs and NSAIDs, the MTT assay was performed to determine the

tolerance of HCT-8 cells to increasing concentrations of DMSO in the cell medium.
A representative concentration-response curve is shown in Appendix 1.1. Following

24-h exposure to DMSO, the viability of the HCT-8 cells decreased in a concentrationdependent manner. At DMSO concentration of 1% v/v approximately 95% of
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mitochondrial activity was maintained compared to the control cells (treated with cell
medium in the absence of DMSO). Increasing the concentration of DMSO to 2% v/v

resulted in a decrease in viability to approximately 78% of mitochondrial activity
compared to the control cells; further increasing the concentration of DMSO resulted

in a further reduction in mitochondrial activity. Despite a minor impact on

mitochondrial activity, a concentration of 2% v/v DMSO was chosen for compound

delivery in order to maximize the dissolution of the highly water-insoluble BiNSAIDs
and NSAIDs in the cell medium.

The concentration-response curves shown in Appendix 1.2 and Figure 2.6 are

graphed for the NSAID concentration (acknowledging that there are 3 mole of NSAID

present in each BiNSAID complex) following 4-h or 24-h treatment, respectively.
As shown in Appendix 1.2, no appreciable loss of mitochondrial activity was observed
in HCT-8 cells following 4-h treatment with any of the BiNSAIDs or NSAIDs up to the

highest tested concentrations (300 µM or 1000 µM). However, following 24-h

exposure to BiNSAIDs the viability of HCT-8 cells decreased in a concentration-

dependent manner (Figure 2.6). The IC50 values determined after 24-h exposure to

the BiNSAID complexes and reference compounds (cisplatin, BiCl3, and BSS) are
summarised in Table 2.4. Notably, the compounds, Bi(tolf)3, Bi(mef)3, and tolfH

(Table 2.4, Fig. 2.6), were more toxic to HCT-8 cells than the anti-cancer drug, cisplatin

(Table 2.4, Appendix 1.3). Bismuth salicylate, which was used to mimic the anti-ulcer

drug, BSS, showed little effect on the viability of the HCT-8 cells up to 2000 µM (Table
2.4, Appendix 1.3). However, the Bi compound, BiCl3, showed moderate toxicity

(IC50 = 383 μM) towards the HCT-8 cells (Table 2.4, Appendix 1.3). Following close

inspection of the results obtained from the BiNSAIDs it is apparent that their
IC50 values are lower than the respective free NSAIDs (Table 2.4), ranging from

16–81 μM (BiNSAIDs) to 37–403 μM (NSAIDs). Importantly, the toxicity of the
BiNSAIDs increased in the order: Bi(difl)3 < Bi(mef)3 < Bi(tolf)3 paralleling the

response exhibited by the free NSAIDs (diflH < mefH < tolfH). Figure 2.6 demonstrates
that the toxicity profiles of the BiNSAIDs, Bi(tolf)3 and Bi(mef)3, were similar to the

respective free NSAIDs (tolfH and mefH) whereby the BiNSAIDs were approximately
three times more toxic than the respective free NSAIDs (representative of the molar
ratio of NSAID contained in the BiNSAID complexes). The results of the assay for

Bi(difl)3 differ, however, whereby the binding of difl to bismuth enhanced the toxicity
of the NSAID (Fig. 2.6).
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Figure 2.6: Concentration-response curves obtained from the MTT assays of HCT-8 cells
treated (24 h) with tolfH, Bi(tolf)3, mefH, Bi(mef)3, diflH, or Bi(difl)3. Error bars represent the
standard deviation from the mean (n = 6). One representative of three independent
experiments is shown.

Table 2.4: IC50 values determined by MTT toxicity assays following the 24-h treatment of
HCT-8 colon cancer cells with the specified compounds.

a IC50

tolf
mef
difl
cisplatin
BiCl3
BSS

IC50 (µM)a
Ligand (LH)
Complex [Bi(L)3]
37 ± 2
16 ± 1
118 ± 2
44 ± 5
403 ± 6
81 ± 6
50 ± 5
383 ± 38
> 2000

IC50 ratio
LH:Bi(L)3
2.3
2.7
5.0

value was determined using at least three independent MTT assays.

2.3.3 Cell death assays
2.3.3.1 Phase contrast microscopy
In order to determine whether the mode of cell death of the BiNSAIDs was the

same as the respective NSAIDs, phase contrast microscopy was initially performed to

assess the morphological changes of the HCT-8 cells. As observed in Figure 2.7a, the

vehicle-treated cells maintain their normal fibroblastic intact shape and close contact
with neighboring cells. Following 24-h treatment with the approximate IC50 doses of

the BiNSAIDs, or the equivalent molar concentration of the NSAIDs (as determined by
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MTT assays, Section 2.3.2), an increased proportion of HCT-8 cells had detached from

the dish surfaces and were observed floating in the medium of all drug-treated

samples. The floating debris could be identified as intact cells and apoptotic bodies as
indicated by the variation in size of the material. As observed in Figure 2.7b–g, an

increased proportion of BiNSAID- and NSAID-treated cell populations appeared to be
rounded and smaller in size, in contrast to the cells treated with vehicle alone

(Fig. 2.7a). Morphological changes of the cell membrane are consistent with apoptosis

and include the formation of blebs, which were clearly evident in HCT-8 cells after

treatment with BiNSAIDs or NSAIDs (Fig. 2.7b–g). These were seldom observed in the

vehicle-treated dishes (Fig. 2.7a). The diflH-treated (Fig. 2.7g) cells showed less
evidence of cell membrane blebbing compared to the other compounds tested, which

is reflective of the lower toxicity of diflH towards the HCT-8 cells determined using

MTT assays. Furthermore, a proportion of the diflH-treated cell population,
maintained their fibroblastic shape (Fig. 2.7g), an expected observation given that the
diflH-treated cells were treated at a concentration lower than the IC50 value

determined by MTT assay (225 μM and 401 μM, respectively).
2.3.3.2 AnnV/7AAD assays

Flow cytometric analysis employing the use of the fluorescent probes AnnV and

7AAD was used to determine whether BiNSAIDs and NSAIDs induce the same mode of
cell death in HCT-8 cells. As demonstrated in Figure 2.8a, 24-h treatment with
Bi(tolf)3, Bi(mef)3, Bi(difl)3 or the respective free NSAIDs resulted in a substantial

increase in the proportion of cells in the AnnV+/7AAD− population (bottom right
quadrant), and AnnV+/7AAD+ population (top right quadrant), but no appreciable
increase in AnnV-/7AAD+ population (top left quadrant). As an appreciable increase in

the population of AnnV+/7AAD− cells was observed, with little increase in the

AnnV−/7AAD+ population, it appeared that cells were proceeding through an apoptotic

pathway and thus AnnV+/7AAD+ could be defined as late apoptotic (rather than late

apoptotic/necrotic). The overall proportions of dying cells (encompassing early

apoptotic, late apoptotic and early necrotic cell populations) were significantly higher

(P ≤ 0.001) in all BiNSAID- or NSAID-treated cells compared to the control
cells (Fig. 2.8b). When the total population of dying cells induced by each BiNSAID
was compared to that for the respective free NSAID, only Bi(difl)3-treated cells showed
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Figure 2.7: Morphological effects following 24-h treatment with: (a) vehicle (DMSO 2% v/v);
(b) Bi(tolf)3 (15 μM); (c) tolfH (45 μM); (d) Bi(mef)3 (40 μM); (e) mefH (120 μM); (f) Bi(difl)3
(75 μM); and (g) diflH (225 μM). Images were viewed using the 20× objective lens on a light
microscope equipped with a Moticam 2000, 2.0MP Live Resolution camera system.
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a significantly higher proportion of cell death (P ≤ 0.01) compared to the diflH-treated

cells. Following 24-h treatment with the vehicle, the majority of the HCT-8 cells were

viable (Fig. 2.8b and Table 2.5). In comparison, treatment with Bi(tolf)3 (15 μM, 24 h)

resulted in significant increases in the populations of early apoptotic, and late
apoptotic cells (P ≤ 0.001 and P ≤ 0.05 respectively, Table 2.5). TolfH-treated cells

showed a significant increase in early apoptotic and late apoptotic populations

compared to vehicle-treated cells (P ≤ 0.001 and P ≤ 0.01, respectively, Table 2.5).
While no statistical difference was found between the proportion of early apoptotic

cells induced in Bi(tolf)3-treated cells compared to tolfH-treated cells (Table 2.5), tolfH

treatment induced a significantly greater number of late apoptotic cells (P ≤ 0.05). The
total percentage of dying cells following treatment with Bi(mef)3 and mefH were

similar (Fig. 2.8b, Table 2.5, P > 0.05). A significant increase in the proportion of early
apoptotic cells was observed in the Bi(mef)3- and mefH-treated cells compared to
vehicle-treated cells (both P ≤ 0.01, Table 2.5) , although mefH-treated cells induced a

higher proportion of early apoptotic cells compared to Bi(mef)3 (P ≤ 0.01). Notably,
there was a 3-fold increase in the percentage of late apoptotic cells in the Bi(mef)3-

treated cell population compared to the mefH-treated cell population (P ≤ 0.01,

Table 2.5). While both treatments increased the proportion of late apoptotic cells,
only the Bi(mef)3-treated cell population was found to be significant compared to the

control (P ≤ 0.001, Table 2.5). Following 24-h treatment with Bi(difl)3 or diflH,
significant increases in the percentage of early apoptotic cells (both P ≤ 0.001) were
observed (Table 2.5); however, treatment with Bi(difl)3 induced a 2.4-fold increase in

the proportion of late apoptotic cells (P ≤ 0.001 compared to the control; Fig. 2.8b)

compared to treatment with diflH (P ≤ 0.001 compared to Bi(difl)3; Fig. 2.8b).

Importantly, no significant increase in the proportion of early necrotic cells was
observed in any of the BiNSAID- or NSAID-treated cell populations (Table 2.5). Overall
these results indicate that Bi(tolf)3, Bi(mef)3, Bi(difl)3, and the respective free NSAIDs,

induce cell death via apoptosis.
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Figure 2.8: Flow cytometric analysis of cell death in HCT-8 cells treated for 24 h with
vehicle (RPMI-1640, 2% v/v DMSO; Control), BiNSAIDs (Bi(tolf)3 (15 µM), Bi(mef)3 (40 µM) or
Bi(difl)3 (75 µM)); or the respective equimolar free NSAIDs. (a) Bivariate flow cytometric plots
of AnnV fluorescence versus 7AAD fluorescence. Bottom left quadrant represents viable
cells (AnnV−/7AAD−); bottom right quadrant represents early apoptotic cells (AnnV+/7AAD−);
top right quadrant represents late apoptotic/late necrotic cells (AnnV+/7AAD+); top left
quadrant represents early necrotic cells (AnnV−/7AAD+). Data are representative of n = 3
replicates. (b) Percentage of early apoptotic and late apoptotic cells based on flow cytometry
analysis. Each segment represents the mean ± s.d. (n = 3 replicates from one experiment).
Statistical significance of the population of dying cells (encompassing early apoptotic, late
apoptotic and necrotic cell populations) compared to the control is indicated by
*** = P ≤ 0.001. Statistical significance of the BiNSAID-treated samples compared to the
respective NSAID-treated samples is indicated by ‡ = P ≤ 0.001. The viable (AnnV−/7AAD−) and
early necrotic (AnnV−/7AAD+) cell populations have been omitted from the graph for clarity.
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Table 2.5: Cell populations determined by flow cytometric analysis of HCT-8 cells treated
for 24 h with: vehicle (RPMI-1640, 2% v/v DMSO), BiNSAIDs (Bi(tolf)3 (15 µM),
Bi(mef)3 (40 µM), or Bi(difl)3 (75 µM)), or the respective equimolar free NSAIDs.
Treatment
Vehicle
Bi(tolf)3, 15 µM
tolfH, 45 µM
Bi(mef)3, 40 µM
mefH, 120 µM
Bi(difl)3, 75 µM
diflH, 225 µM

Viable
AnnV–/7AAD–
86.7 ± 1.0
46.4 ± 12.2
29.5 ± 3.1
40.9 ± 3.8
41.9 ± 7.0
53.2 ± 3.1
63.3 ± 2.8

Percentage of cells (%)
Early apoptotic
Late apoptotic
AnnV+/7AAD–
AnnV+/7AAD+
7.8 ± 0.5
4.8 ± 0.8
41.0 ± 6.9***
12.3 ± 5.8*
48.7 ± 2.2***
21.5 ± 1.4** †
39.6 ± 4.6***
18.8 ± 0.8***
6.15 ± 1.4 ‡
51.5 ± 6.1*** †
26.2 ± 2.0***
19.5 ± 1.7***
27.5 ± 1.5***
8.20 ± 2.4 ‡

Early necrotic
AnnV–/7AAD+
0.7 ± 0.2
0.3 ± 0.2
0.3 ± 0.2
0.8 ± 0.4
0.6 ± 0.3
1.2 ± 0.3
1.1 ± 0.7

Each value represents mean ± s.d. (n = 3 replicates from one experiment).
Statistical significance compared to the control is indicated by * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001.
Statistical significance of the BiNSAID compared to the corresponding free NSAID is indicated by
† = P ≤ 0.05, or ‡ = P ≤ 0.001.

2.3.4 The effect of BiNSAIDs on PGE2 production by HCT-8 cells
The production of PGE2 by HCT-8 cells was determined in order to establish

whether BiNSAIDs were able to inhibit arachidonic acid conversion to PGE2 by COX at

a similar extent to the respective free NSAIDs. As shown in Figure 2.9, the

concentration-response

curves

are

presented

for

the

NSAID

concentration

(recognising that there are 3 mole of NSAID per mole of BiNSAID). Figure 2.9a shows

that the Bi(tolf)3 and Bi(mef)3 complexes inhibited PGE2 production in a
concentration-dependent manner, which paralleled the inhibition displayed by tolfH

and mefH alone, respectively. The concentration-response curve of Bi(difl)3 also

mirrored the inhibition of diflH (Fig. 2.9b). However, PGE2 production increased

comparative to control cells at treatment concentrations of 1–100 µM difl, but
decreased at higher concentrations (300–1000 µM difl). Although the concentrationresponse curve obtained for Bi(difl)3 mirrored the effect of diflH, PGE2 production was

less effectively inhibited at higher concentrations of Bi(difl)3 compared to

diflH (Fig. 2.9b). The concentration-response curve of aspH exhibited a concentrationdependent decrease in PGE2 production (Fig. 2.9b) similar to tolfH and mefH.

Inspection of the IC50 values (50% reduction of PGE2 production compared to the

control) determined from the PGE2 assays (Table 2.6) showed that the COX inhibition

of the BiNSAIDs/NSAIDs in HCT-8 cells increased in the order: difl < mef < tolf, which

paralleled the toxicity response determined by the MTT assays (Section 2.3.2).
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The PGE2 production IC50 values for tolfH and Bi(tolf)3 were lower than that of

aspH (Table 2.6), while mefH and Bi(mef)3 showed comparable inhibitory activity
to aspH (Table 2.6). Substantially higher PGE2 production IC50 values were observed

for diflH and Bi(difl)3 compared to aspH (Table 2.6). Treatment with BSS (1–300 µM)
caused no significant reduction in PGE2 production compared to control

cells (Appendix 1.4).

Figure 2.9: Concentration-response curve obtained from the PGE2 assays of HCT-8 cells
treated (4 h) with: (a) tolfH, Bi(tolf)3, mefH, Bi(mef)3; and (b) diflH, Bi(difl)3, and aspH,
followed by arachidonic acid (20 µM, 30 min). Results are expressed as the mean ± s.d. (n = 3
from three independent experiments, with the exception of aspH, n = 2 from two independent
experiments).
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Table 2.6: IC50 values determined by PGE2 assays following 4-h treatment of HCT-8 cells
with the specified compounds.
Treatment
tolf
mef
difl
asp
BSS

aIC50

IC50 (µM)a
Ligand (LH)
Complex [Bi(L)3]
1.3 ± 0.7
0.5 ± 0.3
23 ± 16
10 ± 8
340 ± 180
203 ± 32
13 ± 4
n.d.

IC50 ratio
LH:Bi(L)3
2.6
2.3
1.7

value was determined from three independent experiments (with the exception of aspH, which was
determined from two independent experiments). n.d. = not determined.
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2.4 Discussion
2.4.1 NMR stability studies
NMR spectroscopy was used to investigate the structural stability of BiNSAIDs in

RPMI-1640 cell medium to gain an understanding of the possible biologically active
species and interactions that give rise to the observed toxicity (examined in

Section 2.3.2), cell uptake and localisation of the Bi (discussed in Chapter 3). The

sparing solubility of BiNSAIDs in aqueous solutions and a number of common organic
solvents (such as methanol, acetonitrile and chloroform) limited the analytical
techniques which could be used for the stability studies; however, the high solubility

of the compounds in DMSO meant that NMR spectroscopy was suitable.
Unfortunately, the low sensitivity of 1H NMR spectroscopy for the complexes at the

low concentrations employed in cell assays (40 μM) meant that it was necessary to use

higher concentrations of the BiNSAIDs. It should be noted that little to no precipitate
was observed in the cell medium at the BiNSAID concentrations used for cell assays
and as such the NMR study (~ 600 μM Bi) represents the most extreme case scenario

performed in order to explore what potential products might form.
13C

The NMR studies were limited to studying the chemical shifts of the 1H and
signals. Theoretically, the

209Bi

signal (chemical shift range of ~ 5000 ppm) could

be used to study the environmental symmetry of the Bi nuclei, and hence any changes
in the complexation of the NSAIDs. Bi has ideal properties for NMR studies due to
100% natural abundance of

209Bi

and its high receptivity (0.144 relative to 1H, and

8.48 × 102 relative to 13C) [59, 60]. An attempt was made to study the 209Bi nuclei in

the present study; however, this proved unsuccessful due to difficulties tuning to

209Bi

nuclear resonance frequency with the broadband probe of the NMR

spectrometer used for the NMR studies (Dr Wilford Lie, personal communication).

In the absence of instrument limitations, a recent review [60] commented on the
difficult nature of recording 209Bi spectra due to the broad signal that it produces,

and as a result there are few Bi NMR studies reported in the literature.

The NMR results (Section 2.3.1) indicated that the stability of the BiNSAIDs in cell

medium might be influenced directly by the structure of the NSAID ligands, since a
marked effect in the stability of the BiNSAIDs was observed by the substitution of

–Cl (tolfH) for –CH3 (mefH). The difference in the stability of Bi(tolf)3 and Bi(mef)3 is
unlikely to be related to physicochemical properties of the free NSAIDs because
similar values are reported for both the pKa [61-63] and logP [64] values of tolfH
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and mefH. It is notable that the tolfH and mefH molecules differ only by the presence
of an electron-withdrawing group (–Cl) and an electron-donating group (–CH3).

However, these groups are located on the opposite phenyl ring of molecule to the Bi–
carboxylate bond; as such the atomic distance is likely to be too far away to have any

through-bond influence that affects the stability of the Bi–carboxylate bond.

Ultimately, further studies would be required to determine the exact nature of the
interaction of Bi(tolf)3 and Bi(mef)3 in cell medium.

The NMR studies suggested that following incubation of Bi(difl)3 in cell medium,

ligand exchange reactions may be facilitated by the high concentrations of D-glucose

present in RPMI-1640 (~11 mM [65]). It is postulated that partial substitution by

glucosyl on to the Bi complex could potentially result in the formation of Bi(difl)2glu or

Bi(difl)glu2 (where glu = glucosyl) complexes; however, further studies would be

required to confirm this. The involvement of glucose should be further studied to
explore the likelihood of this occurring in blood wherein the normal blood glucose
concentration is approximately 5 mM [66].

While the NMR studies performed in the current study provide some useful

insights into the stability of the BiNSAIDs in cell medium, it has been suggested that
the use of solid-state NMR could be another suitable technique to study the stability of

the BiNSAIDs following incubation of the complexes in various biological
media (Professor Philip Andrews, personal communication). One of the disadvantages
of solid-state NMR is that it can take up to three days to run one some sample, and 3-h

warm-up time is required prior to replacing the cryo-probe with an ambient
temperature

solid-state

probe

(Dr

Wilford

Lie,

personal

communication).

Additionally, given that inorganic samples typically require 100–200 mg of compound

for each measurement [67] and the limited quantities of BiNSAIDs synthesised for the
studies described in this Thesis, the use of solid state NMR was unfeasible.

2.4.2 In vitro cytotoxicity towards cancer cells
In order to determine if a lead compound has any potential for development as a

chemotherapeutic drug, the in vitro toxicity towards tumour cell lines needs to be
determined first [68]. As discussed in Section 2.1.2, the BiNSAIDs exhibit limited

solubility in aqueous solutions (including biological medium) and some organic

solvents. Following range finding studies to determine feasible DMSO concentrations,
the BiNSAIDs were solubilised in DMSO (final concentration 2% v/v) prior to their
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addition to cell medium for in vitro testing against the HCT-8 cells. While the use of

DMSO should be revisited for in vivo testing, the solubility of the BiNSAIDs was

substantially improved in order to introduce the complexes into the cell medium for in

vitro testing. In addition, the range finding ensured the optimal balance between

minimal DMSO toxicity and maximal solubilisation of the BiNSAIDs and NSAIDs,

allowing for the successful determination of IC50 values (Table 2.4) and comparison of
the toxicity of the BiNSAIDs to each other and the respective NSAIDs.

The MTT assays (Section 2.3.2) showed that the order of toxicity of the BiNSAIDs

paralleled the response exhibited by the free NSAIDs (tolfH > mefH > diflH), suggesting

that NSAIDs are primarily responsible for the toxicity of the BiNSAIDs. Additionally, if
the IC50 ratio LH:BiL3 was close to 3, it may be assumed that the NSAIDs are
predominantly responsible for the toxicity of the BiNSAIDs (acknowledging there are

3 mole of NSAID per mole of Bi). The IC50 ratios of tolfH:Bi(tolf)3 and mefH:Bi(mef)3

were found to be 2.3 and 2.7, respectively (Table 2.4). While Bi(tolf)3 exhibited the

highest IC50 value of the three BiNSAIDs tested, the IC50 ratio tolfH:Bi(tolf)3 potentially

indicated that tolf is slightly less toxic to HCT-8 cells when complexed to Bi.
Alternatively, the IC50 ratio of mefH:Bi(mef)3 was closer to 3, potentially indicating

that complexation of mef to Bi had little effect on the toxicity of mefH. Although

Bi(difl)3 was the least toxic of the three BiNSAIDs when the ratio of the IC50 values was

considered (diflH:Bi(difl)3 = 5.0, Table 2.4), Bi(difl)3 showed substantially higher
toxicity than that expected for diflH, indicating that difl was more toxic when

complexed to Bi. There are a number of factors that may influence the toxicity of the

BiNSAIDs

towards

the

HCT-8

colon

cancer

cells

and

the

observed

differences/similarities to the NSAIDs: (i) stability in cell medium (Sections 2.3.1.1

and 2.4.1), (ii) intrinsic physicochemical properties, and (iii) cellular uptake (to be
discussed in Chapter 3).

The NMR stability studies suggested that Bi(tolf)3 displayed greater stability than

Bi(mef)3 following incubation in cell medium (Section 2.3.1.1); however, the overall

coordination (or lack thereof) of Bi to the NSAID appeared to have little influence on

the toxicity of Bi(tolf)3 and Bi(mef)3 compared to the corresponding free NSAIDs.

As the toxicity of Bi(tolf)3 was slightly lower than the corresponding concentration of

tolfH, it is plausible that the increased stability of Bi(tolf)3 may be influencing the

toxicity of the tolf ligands.
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In contrast, Bi(difl)3 was substantially more toxic than the analogous diflH. There

are two possible reasons for this; the first explanation is the contributing toxicity of Bi.

Reference to Table 2.4 shows that diflH exhibits an IC50 value of 403 µM. When

considering BiCl3, which possesses a conceivably non-toxic anion (Cl−), it is noted the

IC50 value (IC50 = 383 µM) is comparable to diflH that indicates that an additive effect

would be more noticeable. The second possible explanation for the increased toxicity

of Bi(difl)3 (versus diflH) towards HCT-8 cells is the NMR evidence for glucose in the

sample obtained from the incubation of Bi(difl)3 in cell medium. This raises the
question of whether glucose is potentially coordinating with Bi(difl)3 and increasing

its toxicity compared to free diflH. For instance, it might be possible that the

coordination of glucosyl ligands to Bi assists the uptake of the complex via glucose

uptake mediated transporters. This would be expected to be greater in cancer cells

since they have a high affinity for glucose [69, 70]. In other studies by Dillon and co-

workers [71], Bi(difl)3 showed 1.2-fold lower toxicity against HepG2 liver cancer cells
compared to HCT-8 cells, as assessed by the MTT assay. Additionally, proportional

enhancement of toxicity (Bi:NSAID IC50 ratio 3.6) was observed [71]. One hypothesis

put forth to rationalise this observation was the content of glucose in the cell

medium [71]. Interestingly, the culture medium that was used to maintain the HepG2

during the MTT assays contained a lower concentration of D-glucose than RPMI-1640

used in the present study (5.5 mM and 11.1 mM, respectively). Therefore it may be

possible that the increased concentration of D-glucose in RPMI-1640 increases the

propensity of Bi(difl)3 to undergo ligand exchange reactions with glucose [71].

In future experiments, NMR studies could be performed to validate this hypothesis.
This would involve studies of Bi(difl)3 in DMEM for comparison to the result obtained

in this Thesis.

The order of toxicity of tolfH > mefH > diflH, may be related to the physicochemical

properties of the molecules. The reported logP values of tolfH, mefH and diflH are
very similar (4.94, 4.79 and 5.20, respectively) [64]. These minor variations in logP
and the lack of correlation with the toxicity suggest the logP is not accountable for the

observed differences in toxicity or cellular uptake. Additionally, the NSAIDs have
reported pKa values in a similar range (3.5–4.3) [61], all of which lie well below

pH 7.4 (the pH of RPMI-1640). The main differences in the NSAID structures include

the structural incorporation of the diphenylamine (tolfH and mefH) or the diphenyl
(diflH) [72-74]. Diphenylamine NSAIDs (such as tolfH and mefH) were shown to
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induce lactate dehydrogenase leakage in primary cells obtained from isolated rat
hepatocytes, more significantly than diflH, at the same concentration [72]. The
absence of an amine in the structure of diflH might, therefore, result in the reduced

toxicity observed in this study. The current study showed that the substitution of

–CH3 (mef) for –Cl (tolf) resulted in almost a 3-fold increase in toxicity associated with

both the free NSAID and BiNSAIDs. This result parallels other studies whereby tolfH

reportedly exhibited higher activity than mefH against BT474 and SKBR3 breast

cancer cells [52].

The toxicity of the BiNSAIDs was substantially higher than the two reference Bi

compounds, BiCl3 and BSS. Notably, the IC50 values obtained for the BiNSAIDs are

comparable to that of the range of the anti-cancer drug, cisplatin, although it should be

recognised that cisplatin has achieved greatest clinical effectiveness against testicular
and ovarian cancers [75]. Although nanomolar toxicity is desirable when screening
for lead compounds for anti-cancer drug development, the moderate toxicity displayed
by the BiNSAIDs and the similar toxicity compared to cisplatin is an encouraging

result. Ultimately, the BiNSAIDs will need to be evaluated for chemotherapeutic,
chemopreventive and gastroprotective activity in animal models in order to determine

whether they have any potential use as chemotherapeutic or chemopreventive drugs
in humans. However, the in vitro cytotoxicity of the BiNSAIDs determined in this study

suggests that further study is warranted into the interactions of the BiNSAIDs in
biological systems.

2.4.3 Cell death assays
The results from the phase contrast microscopy and the AnnV/7AAD assays

indicated that apoptosis is the primary mode of cell death induced by exposure of
HCT-8 cells to Bi(tolf)3, Bi(mef)3, or Bi(difl)3, and the respective free NSAIDs. These

results are important as they show that all three BiNSAIDs induce the same mode of
cell death as the respective uncomplexed NSAIDs. These results were also in

agreement with a number of published studies that have reported apoptosis as the

mode of cell death induced by NSAIDs, including tolfH [42, 44, 45, 48, 50, 76-79],

mefH [51, 80] and diflH [80, 81] in other cancer cell lines in vitro. Additionally, a

number of Bi compounds have been reported to induce cell death via apoptosis in a

number of cancer cell lines in vitro [82-86]. The results from the AnnV/7AAD assays

were in agreement with the toxicity determined by the MTT assays, whereby the
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Bi(tolf)3 or tolfH, Bi(mef)3 or mefH, and Bi(difl)3 treatments induced apoptosis in

approximately 47–70% of the HCT-8 cell populations when treated with the

approximate IC50 concentration (as determined from the MTT assay). Additionally, the

diflH treatment resulted in a smaller increase in the proportion of apoptotic cells

(approximately 37% of the cell population), which is also consistent with the lower

toxicity as the concentration of diflH applied in the assay (225 μM) was lower than its
IC50 value (403 μM), and the healthier physical appearance of the cells observed using

phase contrast microscopy (presented in Section 2.3.3.1).

The present study confirmed that apoptosis is the mode of cell death induced by

BiNSAID and NSAID treatment in HCT-8 cells. As discussed in Section 2.1.3.2,
apoptosis is often described as a ‘programmed’ form of cell death. Apoptosis can occur

via two distinct pathways termed ‘extrinsic’ and ‘intrinsic’. Apoptosis via an extrinsic

signaling pathway results from transmembrane receptor-mediated interactions

involving death receptors that are members of the tumor necrosis factor receptor gene
superfamily [32].

Alternatively, apoptosis initiated via the intrinsic signaling

pathways are mitochondrial-initiated events involving non-receptor-mediated stimuli
that produce intracellular signals that act directly on targets within the cell (further

details on these mechanisms are reviewed in [32]). The MTT assay is a useful
indicator of toxicity, which relies on functioning mitochondria in metabolically active
cells to convert MTT to formazan (discussed in Section 1.2.3.1). When considered with

the results from the cell death studies, the reduction in mitochondria function
observed in the MTT assays may suggest that the mitochondria are involved in

BiNSAID- and NSAID-induced apoptosis, and thus the BiNSAIDs/NSAIDs may trigger

cell death through the intrinsic apoptotic pathway. While it is recognised that COX-2

contributes to the anti-apoptotic effects and proliferation of cancer cells, there are

reports that suggest that NSAID-induced cell death is also mediated via non-COX-2

regulated pathways (discussed in Section 1.2.4). In the present study, the BiNSAIDs
and NSAIDs inhibited the production of PGE2, suggesting the compounds inhibit the

COX enzymes (discussed further in the next Section 2.4.4). However, it cannot be

ignored that numerous studies have reported that diphenylamine NSAIDs (such as
tolfH and mefH) can also cause uncoupling of oxidative phosphorylation in

mitochondria [73, 74, 87-89]. Furthermore, mefH and diflH showed uncoupling effects
on oxidative phosphorylation in isolated rat mitochondria [90], and primary cells from

isolated rat hepatocytes [72] resulting in depletion of ATP. Overall, the exact
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mechanisms by which the NSAIDs and BiNSAIDs induce apoptosis and why the three

NSAIDs in this study show variation in toxicity cannot be drawn conclusively without
further investigation. Further investigation could be performed in the future to

determine the detailed molecular pathway involved in BiNSAID/NSAID induced
cell death.

2.4.4 PGE2 production
As discussed in Section 2.1.4, the increased expression of COX-2 has been

established in many cancer cell types and the subsequent production of

prostaglandins, including PGE2, is advantageous for neoplastic cell survival and

proliferation. As such, studying the ability of the BiNSAIDs to inhibit PGE2 production
is important for determining the chemopreventive potential of the complexes.

The PGE2 concentration-response curves showed that the BiNSAIDs mirrored the

effects of the free NSAIDs after 4 h exposure to the HCT-8 cells. This is an important
result as it demonstrates that administration of the BiNSAID (wherein the NSAID does

not initially posses a free carboxylate) does not hinder the ability of the NSAID to

target

the

COX

enzymes.

As

no

appreciable

loss

of

cell

viability

was

observed (Appendix 1.2a–c), it could be concluded that the reduction of PGE2

production at increasing concentrations of BiNSAIDs/NSAIDs was not due to cell

toxicity. Additionally, no appreciable decrease in the viability of the HCT-8 cells was
observed following 24-h treatment with aspH (Appendix 1.5); as such no decrease in

viability was expected following only 4-h treatment, confirming toxicity of aspH was
not associated with reduced PGE2 production.

When the PGE2 production concentration-response curves (Fig. 2.9a) are

compared to the MTT assay concentration-response curves (Fig 2.6), it is clear that
Bi(tolf)3 and Bi(mef)3 paralleled the respective free NSAIDs whereby the BiNSAIDs

were approximately three times more toxic than the respective free NSAIDs

(representative of the molar ratio of NSAID per BiNSAID). The results of the PGE2

production concentration-response curves of Bi(difl)3 differed (Figure 2.9b), however,
whereby diflH appeared to have slightly enhanced PGE2 inhibition compared to

Bi(difl)3 (at higher concentrations of NSAID). Additionally, the potency of the
reduction in PGE2 occurred in the same order as the toxicity of the NSAIDs (tolfH <

mefH < diflH), which may suggest a correlation between PGE2 production and cell

health. It was observed that the IC50 values associated with the PGE2
100

Chapter 2. Stability, toxicity and PGE2 inhibition of BiNSAIDs
inhibition (Table 2.6), were lower than the IC50 values required to induce toxicity in

the HCT-8 cells (Table 2.5).

The time frame of the PGE2 assays compared to the MTT assays used to determine

the IC50 values of the compounds (4 h versus 24 h) reveals some insight into the
intracellular stability of the complexes. It has been established that NSAIDs must have

a free carboxylate in order to interact with the COX-1/-2 active site [91]. Given that

the BiNSAIDs decreased PGE2 production in a similar manner compared to the
analogous NSAIDs, it is reasonable to assume that the NSAID ligand must be liberated

from the BiNSAID complex, allowing a free carboxylate to interact with the COX. This
is particularly significant in the case of Bi(tolf)3 and Bi(difl)3 as the stability results

described in Section 2.3.1 suggest that these complexes remain intact in the medium;
however, they can undergo hydrolysis/dissociation once inside the cells following

interaction with enzymes and competing ligands. Subsequently, it seems likely that

the Bi(tolf)3 and Bi(difl)3 complexes are metabolised by intracellular processes
relatively quickly (i.e. < 4 h).

The ability of the BiNSAIDs and NSAIDs to inhibit PGE2 in the HCT-8 cell line was

studied in order to ensure that BiNSAIDs showed comparable activity within a cancer

cell line, and thus provide information on the ability to reduce PGE2 in a malignant cell

for chemopreventive potential. It is important to note that HCT-8 cells have been

shown to express higher levels of COX-1 than COX-2 [55, 56, 92]; hence the preference
for BiNSAIDs or NSAIDs for COX-2 over COX-1 in HCT-8 cells cannot be evaluated from

the present study. Further work needs to be performed to determine the expression

of COX-1 and COX-2 in the HCT-8 cells used in this study, especially as the level of

expression of COX-1/-2 by HCT-8 cells varies between reports [55-57, 92, 93].
It would also be of value to study the inhibitory activity of the BiNSAIDs compared to

the NSAIDs with purified COX enzymes in an acellular environment to determine if the

selectivity for COX-1/-2 is affected by the complexation of the NSAID to Bi. However,

this assay would not take into account the conditions experienced by the BiNSAIDs in
the cell environment. For instance, the stability of the complexes in cell medium and

the intracellular fluids, cell uptake and any alterations in structure following cell
uptake and subsequent intracellular metabolism are important factors that affect COX
inhibition. As such, the cell-based assay as performed in the present study, and an

enzyme-based assay utilizing purified COX-1/-2 would provide complementary results
and should be evaluated in conjunction. The results from the present study utilising
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the HCT-8 cell model should be compared to other cell lines that display high levels of
COX-2, and cells with essentially no COX-2 expression (currently being performed by
Brown, Dillon and Ranson, personal communication).

Of final note was the finding that diflH increased the amount of PGE2 production by

HCT-8 cells at low concentrations ranging from 1−100 μM (Fig. 2.9). The increased

production may be related to the gastroprotective activity reported by other
authors [53, 54]. This result may indicate that the concentration of Bi(difl)3 needs to

be considered carefully if the complex is tested in vivo for cancer prevention as

treatment with a dose that increases the production of PGE2 may have the opposite

result to the intended therapeutic effect. This is clearly an observation that will

require further investigation.
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2.5 Chapter summary
The main aim of this chapter was to use in vitro assays to determine whether the

BiNSAIDs, Bi(tolf)3, Bi(mef)3, and Bi(difl)3, possess any chemotherapeutic or
chemopreventive potential in a colon cancer (HCT-8) cell line. To this end, the

following studies were performed with the subsequent outcomes:
i.

NMR spectroscopic determination of the BiNSAID stability in RPMI-1640
cell medium showed that Bi(tolf)3 is relatively stable, whilst mef appeared

to dissociate from Bi. The 1H NMR spectrum of Bi(difl)3 suggested that

D-glucose in the cell medium may interact with the complex resulting in the
ii.

formation of a new species.

Examination of in vitro toxicity towards cancer cells using the MTT assay

demonstrated the ability of the complexes to eradicate transformed cells.
Specifically, the BiNSAIDs displayed moderate toxicity towards HCT-8 cells

with the IC50 values ranging between 16–81 µM. The order of toxicity of the

BiNSAIDs was Bi(difl)3 < Bi(mef)3 < Bi(tolf)3, which paralleled the order of

toxicity of the free NSAIDs. When considering the molar ratio of NSAID

contained in the BiNSAID complexes, Bi(tolf)3 and Bi(mef)3 showed similar

activity to the free NSAIDs; the activity of diflH was improved when

iii.

complexed to Bi.

The mode of cell death was determined using phase contract microscopy

and flow cytometric experiments. Phase contrast microscopy showed that
the morphological changes in HCT-8 cells indicative of apoptosis (including

cell rounding, shrinking and membrane blebbing) were induced by the

BiNSAIDs and the respective uncomplexed NSAIDs. Flow cytometric

analysis of co-stained (AnnV and 7AAD) cells confirmed that both BiNSAIDs

and their respective NSAIDs induced cell death through apoptosis rather

iv.

than necrosis.

The ability of BiNSAIDs to inhibit COX and reduce PGE2 production in

HCT-8 cells was determined. The BiNSAIDs inhibited the production of

PGE2 by the HCT-8 cells at treatment concentrations comparable to the free
NSAIDs. The order of PGE2 inhibition was Bi(difl)3/diflH < Bi(mef)3/mefH <

Bi(tolf)3/tolfH.
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Although the results from the NMR studies suggest that the BiNSAIDs have limited

stability in RPMI-1640 cell culture medium, the BiNSAIDs (or the biologically active

forms of these complexes) elicited micromolar toxicity towards HCT-8 cells (as
demonstrated in the MTT assays) that were comparable or better than the respective

NSAIDs. Importantly, the presence of Bi did not adversely affect the toxicity or the
ability of the NSAIDs to induce apoptosis or inhibit PGE2 production. The superior

stability in cell medium, increased toxicity, and highest PGE2 inhibition of Bi(tolf)3

compared to the Bi(mef)3 and Bi(difl)3, suggests that Bi(tolf)3 might be the best

candidate for further testing using in vivo systems. However, the diversity in the

results warrants further investigation into how the three BiNSAIDs interact with the

HCT-8 cells. Further work will be required to determine whether the molecular

mechanisms involved in apoptosis are analogous between each BiNSAID and
respective free NSAID.
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Chapter 3.
Uptake and localisation of Bi by BiNSAID-treated
HCT-8 cells

Having established the stability of the BiNSAIDs in cell medium and the toxicity of the

BiNSAIDs towards HCT-8 cells in Chapter 2, it was of interest to investigate the uptake

of the complexes. The focus of this work was to quantify the cellular Bi following

treatment with BiNSAIDs to determine if there were any correlations between Bi

uptake and BiNSAID stability or toxicity.

Additionally, studies of the subcellular

distribution of Bi were performed on HCT-8 cells and the results were discussed with
respect to the stability results (Chapter 2) and potential intracellular targets of the
BiNSAIDs.

Parts of this Chapter have been published in:
Hawksworth, E. L., Andrews, P. C., Lie, W., Lai, B. & Dillon, C. T. (2014) Biological
evaluation of bismuth non-steroidal anti-inflammatory drugs (BiNSAIDs): Stability,
toxicity and uptake in HCT-8 colon cancer cells, J. Inorg. Biochem., 135, 28-39.
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3.1 Introduction
As introduced in Section 2.1, there are a number of factors that need to be

addressed in order to determine the suitability of BiNSAIDs as potential
chemotherapeutic or chemopreventive candidates. The cellular uptake and

intracellular distribution of a drug is an important criteria that requires examination,
particularly in the context of chemoprevention as it is important to establish: (i) the

quantity of the drug that can enter the cell (i.e. how much is required to induce the

desired therapeutic effect); and (ii) where the drug distributes in the cell (i.e. if it
localises at the desired biological target or indiscriminately throughout the cell).

Having investigated the stability of the BiNSAIDs in cell medium, and the toxicity of

the BiNSAIDs and PGE2 inhibition towards HCT-8 cells in Chapter 2, it was of interest

to quantify the uptake of the BiNSAIDs to determine if there were any correlations
between uptake and the stability and toxicity of the BiNSAIDs. Additionally, assessing

the intracellular distribution of Bi in HCT-8 cells was of interest in order to provide

insight into the intracellular targets of Bi and potentially the BiNSAIDs (in the instance
of the complex remaining intact).

Beneficially, BiNSAIDs contain two components that can be used to determine drug

uptake and intracellular distribution, the inorganic Bi atom and the organic NSAID

molecule. The studies described herein focused on the uptake and distribution of Bi

within the HCT-8 cells following treatment with BiNSAIDs. While it will be important
in future work to focus on the uptake and distribution of the NSAIDs, there were a few

reasons why it was initially important to study the uptake and intracellular fate of Bi.

Firstly, given the potential for Bi accumulation within mammalian cells and the
potential for Bi toxicity (discussed in Section 1.4.2), it is important to determine the

quantity of Bi that enters cells at the BiNSAID concentration required to cause

cytotoxicity. Secondly, organic molecules (including NSAIDs) are generally comprised
of endogenous elements that are found within cells (C, H, O, N) that make it difficult to

detect drug molecules inside cells without using labeling techniques. Radioactive
labeling (e.g. 3H) overcomes this issue, but is more advantageous for whole body or

tissue imaging rather than the micron resolution required for intracellular imaging [1].

Thirdly, chemical labeling, such as the use of fluorophores, involves altering the

chemical structure and often increasing the molecular weight of the molecule, which

can potentially alter the uptake and distribution of the drug [2]. In contrast,
metal/metalloid complexes offer an advantage in this instance, as many metals are
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often found endogenously within cells in trace quantities. The presence of a

metal/metalloid in the compound, therefore, negates the need to label the drug. The
limitation of this approach is that it is not possible to tell whether the metal/metalloid

is still attached to the organic ligands.

There are a number of analytical techniques that can be used to detect trace

quantities of metals/metalloids in cell samples including atomic absorption
spectroscopy (AAS; discussed in Section 3.1.1.) and microprobe synchrotron radiation

X-ray fluorescence (SRXRF) spectroscopy (discussed in Section 3.1.2).

3.1.1 Atomic absorption spectroscopy for studying cellular uptake of inorganic
complexes/drugs
Establishing the uptake of drugs entering cancer cells is important to determine

their effectiveness, whereby the focus of bowel cancer chemopreventives is to provide

insight into their toxicity towards bowel cancer cells (Section 2.3.2) and their ability to

inhibit PG production through the inhibition of COX-2 (Section 2.3.4). The cellular

uptake of inorganic complexes/drugs containing non-endogenous elements (such as

As, Bi, Co, Cr, Ni, Pd, Pt, Rd, Ru and Rh) can be monitored by a number of analytical
techniques.

A common choice is AAS, which uses either a flame (FAAS), or an electrothermal

source, also known as graphite furnace atomic absorption spectroscopy (GFAAS), to

analyse metals/metalloids [3]. The sample is atomised using high temperatures

(2,000−3,000 K) to produce ground state free atoms in the vapour state [3]. A light
source (generally a hollow cathode lamp), which produces the characteristic

wavelengths of light specific to the analyte, is used to quantify the element in the
sample [3]. The techniques known as inductively coupled plasma-atomic emission

spectroscopy (ICP-AES) and inductively coupled plasma-mass spectrometry (ICP-MS),
employ a plasma source as the sample atomiser. A plasma source reaches

temperatures that exceed twice the temperature of a combustion flame

(6,000−10,000 K) [3].

A number of factors are important when determining the suitability of these

techniques for analysing metals in cell samples, including; sensitivity, sample volumes

and chemical matrix/interference. The typical detection limits of the aforementioned

techniques vary depending on the element of interest, and the particular brand of
instrument employed for the analysis [4]. The typical detection limits of Bi are
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50 parts per billion (ppb), 0.3 ppb, 18 ppb, and 0.01-0.1 parts per trillion (ppt) for
FAAS, GFAAS, ICP-AES, and ICP-MS, respectively [4]. GFAAS has a detection limit up to

1000 times greater than FAAS [4]. The greater density of atoms generated by the
graphite tube and improved residency time of the analyte in the optical path (< 1 s in

FAAS versus several seconds in GFAAS) contribute to the superior detection limit of
GFAAS [3, 4]. As such, GFAAS [3-9] and multi-element GFAAS [10] have been used

successfully to determine the concentration of Bi in biological samples with adequate
detection limits (≤ 1 μg/L).

Additionally, GFAAS only requires small sample volumes (approximately 20 μL per

detection) for accurate elemental detection, whereas 1−2 mL of sample is required for
FAAS [3]. As atomisation of the sample occurs in discrete steps, selective removal of

matrix components can be performed with the aid of chemical modifiers. The use of

chemical modifiers reduces the effect of chemical interferences arising from

components of the sample matrix, which would otherwise cause issues with
determining the concentration of the element of interest [4].

The main disadvantages of GFAAS are its low dynamic range (102), which means

that the concentrations of the analyte must be kept within a narrow range, and the

amount of time that it takes to analyse the samples (> 5 min per sample) [4]; the
length of time taken to analyse one sample is a particular disadvantage if more than

one element is to be studied. ICP-MS has the advantage, over GFAAS, of greater

sensitivity (parts per trillion for some elements), a greater dynamic range, and rapid

multi-element detection; however, there are a number of limitations associated with
ICP-MS. These include high instrument cost, spectral interferences, and high sample

volume; the latter being a crucial determining factor for the analysis of cell
samples. With these advantages and disadvantags in mind, GFAAS was selected as the

most appropriate method by which to examine the uptake of Bi by HCT-8 cells in the

present study.

3.1.2 Microprobe synchrotron radiation X-ray fluorescence imaging for
studying intracellular metal localisation
While Section 3.1.1 described highly sensitive techniques for the quantification of

metal/metalloids within biological samples, the aforementioned techniques cannot be

used to determine the cellular localisation and consequently potential intracellular

targets of the metal/metalloid. Microprobe SRXRF spectroscopy (also known as
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microprobe synchrotron radiation-induced X-ray emission (SRIXE) spectroscopy) is
an analytical technique that can provide images of intracellular metal localisation and

colocalisation information with respect to other elements.

Techniques such as

microprobe SRXRF spectroscopy remove the need for labeling the drug, due to the
direct analysis of the element of interest [5-8].

A number of studies have used

traditional staining and microscopy techniques such as autometallography (which

involves silver enhancement of bismuth sulfide/selenide clusters) to determine the

subcellular location of Bi following the treatment of various cell lines [9, 10],

animal [11-15] and human tissues [16].

However, microprobe SRXRF offers the

advantage of multi-element detection mapping and quantification [5-8]. This allows
researchers to study the changes in distribution and semi-quantitatively determine

fluctuations in concentrations of endogenous elements (such as Ca, Fe, P, S and Zn)

that are involved in important cellular processes, and hence the effects of the drug on
the distribution of these elements [5-8].

Figure 3.1 illustrates the basic principle of XRF with respect to the Bohr atom

model [17]. Ejection of a core shell electron (generally a K or L shell electron) from an

atom occurs when photons of an X-ray beam possess a high enough energy (i.e. greater

than the binding energy [18]; in the hard X-ray region, > 1 keV) to excite the electron.
The ejection of the electron leaves a vacancy in the shell. An electron from an outer

orbital can then fill the vacancy and restore stability to the atom.

The process results

Figure 3.1: Bohr atom model illustrating the basic principle of X-ray fluorescence.
(a) An X-ray possessing energy that is equal to or greater than the binding energy of the
electron results in ejection of that electron into the continuum. (b) An electron from an outer
shell fills the vacancy left by the ejected electron resulting in the emission of a fluorescence
photon with an energy that is equal to the difference in the energy of the two shells associated
with the transition. Adapted from Fahrni [17].
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in the emission of a photon with energy equal to the difference in binding energies of
the two shells involved in the transition. The binding energy of each electron is
proportional to the squared nuclear charge; for example, the analysis of Bi requires

energy of 10.7 keV (the binding of the Lα2 electrons). In addition, every element

possesses unique binding energies and characteristic photon emissions (fluorescence)

enabling detection of the relevant elements in the sample. Furthermore, the relative

quantities of the elements can be determined since the fluorescence emission is
directly proportional to the amount of an element present in a sample.

The use of X-rays produced at a synchrotron offers a number of advantages over

conventional bench-top X-ray sources. These include the capability of generating

X-rays up to 12 orders of magnitude brighter than a conventional X-ray source [19],
and following the advances in modern X-ray optics, the ability to focus the X-rays to a

submicron spot on a sample with the use of devices such as a Kirkpatrick-Baez mirror

[20] or Fresnel zone plate [21]. Both of these factors have facilitated the development
of microprobe SRXRF spectroscopy. Detection sensitivities in the ppb range can be

routinely obtained from using microprobe SRXRF, in comparison to the ppm

sensitivities of alternative microprobe (particle induced X-ray emission) and

nanoprobe (electron dispersive X-ray analysis) techniques. The improved sensitivity

of microprobe XRF stems from the absence of the continuum background radiation
that is a feature of the spectra obtained from the use of charged particle beams, and
the increased X-ray flux on the sample associated with the use of third generation
synchrotron facilities ([22] and references within).

The achievement of submicron resolution with microprobe SRXRF combined with

the high sensitivity and penetration depth of hard X-rays makes the technique highly

amenable to the study of single mammalian cells [22]. Raster scanning produces

quantitative information from an entire scanned area of a specimen resulting in the
generation of elemental maps. Depending on the particular element, detection

sensitivities have been reported in the range of 10−17−10−14 g for mammalian cell

studies ([22] and references within). Microprobe SRXRF has been applied to the study

of the intracellular fate of both marketed and potential metal-based drugs containing

Pt [6, 23, 24], Cr [5], Ru [8, 25], Se [26, 27], Gd [28, 29], and As [30] in a number of

cancer cell lines.

distribution

of

However, to date there are few, if any, reports assessing the

Bi-based

microspectroscopy.

drugs

in

human

cells

using

microprobe

SRXRF
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3.1.3 Chapter aims
Having established the stability of the BiNSAIDs, Bi(difl)3, Bi(mef)3 and Bi(tolf)3, in

cell medium, and the toxicity of the BiNSAIDs towards HCT-8 cells, it was of interest to

quantify the cellular Bi content following treatment with BiNSAIDs to determine if

there were any correlations between cellular uptake versus stability and/or toxicity.

Assessing the subcellular distribution of Bi was of interest in order to provide insight

into the intracellular targets of the BiNSAIDs, Bi(difl)3, Bi(mef)3 and Bi(tolf)3, in HCT-8
cells. The specific aims of this Chapter were to:
1.

2.

Quantify Bi uptake by the HCT-8 cells using GFAAS in order to determine

whether Bi uptake correlates with BiNSAID stability and toxicity.

Ascertain the subcellular location of Bi in HCT-8 cells following treatment

with BiNSAIDs using microprobe SRXRF imaging to assess how this might

influence toxicity towards the cancer cells and how this might influence the
targeting of COX.
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3.2 Materials and methods
3.2.1 Materials
The materials used for the cell culture experiments described in this Chapter have

been previously described in Section 2.2.1. The chemicals, ammonium acetate

(≥98%), sodium chloride (99.999% trace metal basis), and trypan blue (0.5% in PBS)
were purchased from Sigma-Aldrich (St Louis, USA). Pyroneg detergent was sourced

from DiverseyLever Australia Pty Ltd (Smithfield, Australia). Analytical grade ethanol

(absolute,

≥99.5%)

and

nitric

acid

(68−70%)

were

sourced

from

Ajax

Finechem (Seven Hills, Australia). A certified Bi standard solution (1004 ± 3 mg/mL,
2% HNO3 v/v) was acquired from PerkinElmer Instruments (Massachusetts, USA),

while the magnesium (Mg(NO3)2, 10 mg/mL) and palladium matrix modifier solutions
(Pd(NO3)2, 5 mg/mL) were procured from Astral Scientific (Taren Point, Australia).
Analytical volumetric flasks (Class A) were purchased from GlassCo (Dandenong

South, Australia). Tracepur nitric acid (69%) was sourced from Merck (Darmstadt,
Germany). A Bi hollow cathode lamp and standard transversely heated graphite

atomizer tubes (inserted pyrolytic L’vov platform) were obtained from Perkin Elmer
Instruments (Victoria, Australia).

Glutaraldehyde (25% solution), Spurr's low

viscosity embedding resin and toluidine blue were sourced from Proscitech (Kirwan,

Australia). Silicon nitride (Si3N4) membranes (frame size, 5 × 5 mm2; sample surface

area, 1.5 × 1.5 mm2; membrane thickness, 500 nm; and frame thickness, 200 nm) were

manufactured by Silson Ltd (Northampton, England).
3.2.2 Cell culture procedures

HCT-8 cells were sourced and employed as described in Section 2.2.3.

3.2.3 GFAAS uptake studies

3.2.3.1 Preparation of cell digests
Cell digests were prepared for GFAAS analysis using a similar procedure to that

documented previously [23]. Briefly, HCT-8 cells (2 × 106 cells, 5 mL) were seeded
into 60-mm cell culture dishes and incubated for 24 h, after which the growth medium

was removed and the cells were washed twice with PBS. The control cells were

incubated with vehicle (5 mL RPMI-1640, 2% DMSO v/v) for 24 h, while treatment
solutions of Bi(difl)3, Bi(mef)3, Bi(tolf)3 or BSS were added to the other dishes (15 µM

or 40 µM Bi in 5 mL RPMI-1640, 2% DMSO v/v) for 24 h. The two treatment
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concentrations were approximately equal to the two lowest IC50 values obtained from

the toxicity studies (Section 2.2.4). Triplicate dishes were prepared for the control
and each treatment. Following the treatment period, the solutions were removed and

the cells were washed twice with PBS (2 mL), harvested with trypsin (0.25%, 2 mL)

and centrifuged (300 g, 5 min). The cells were resuspended in RPMI-1640 (1 mL) and
trypan blue exclusion assays were performed by removing the resultant cell

solution (50 µL) from each sample and mixing with trypan blue (50 µL, 0.5% w/v in
PBS). The populations of intact cells and disrupted cells were scored using a

haemocytometer (100× magnification), whereby cells that appeared blue represented

uptake of trypan blue and loss of membrane integrity (dead cells) while those that

were colourless represented cells with an intact membrane (healthy cells). The cells
in the main suspensions were washed twice with sterile PBS solution (2 mL), followed

by two washes with sterile saline solution (0.9%, 2 mL). The final saline solutions
were drained from the pellets and the cells were freeze-dried for 2 h. Nitric acid

(Tracepur, 69% v/v) was added to each Eppendorf tube (43 µL) and the pellets were
digested overnight.

The digested pellets were transferred to volumetric flasks

(prewashed with a solution of Pyroneg detergent (72 h), followed by nitric acid (72 h),

and MilliQ water (72 h) and rinsed 5 times with MilliQ water) and the volume was

adjusted to 5.00 mL (using MilliQ water) or 25.00 mL (using MilliQ water and nitric
acid (177 µL, Tracepur, 69% v/v)), to obtain a final HNO3 concentration of 0.6% v/v.

3.2.3.2 Preparation of fixed/dehydrated cell digests
It has been previously reported that formalin fixation can cause metal and trace

element leaching from tissues [31]. In this study, the integrity/effect of the
glutaraldehyde fixation and ethanol dehydration process used for preparation of
thin-sectioned cell samples for microprobe SRXRF analysis was investigated to

determine if there was any change in Bi uptake. As such, the cell samples were
prepared as outlined in the previous section but with the following changes. After the
final PBS wash of the treated cells, the cells were resuspended in glutaraldehyde

(1 mL, 2% v/v in PBS) and fixed for 2 h at room temperature. Dehydration of the cells
was performed incrementally using increasing ethanol concentrations (in MilliQ

water; 30% ×2, 50% ×2, 70% ×2, 80% ×2, 90% ×2, 95% ×2, 100% ×4) with

centrifugation, and removal of the supernatant and cell resuspension after each step.
The pellets were then freeze-dried after the final ethanol wash and digested as
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described in Section 3.2.3.1.
3.2.3.3 Graphite furnace atomic absorption spectroscopy
Digested cell solutions were analysed for Bi using a PerkinElmer AAnalyst 600

atomic absorption spectrometer equipped with the Winlab 32 AA Furnace program

incorporating Zeeman-effect background correction, an AS-800 autosampler and an

AA Accessory cooling system. A Bi hollow cathode lamp (PerkinElmer) was used at

223 nm, using a slit width of 0.7 nm, to give an instrument energy reading of
approximately 35 W. A certified Bi standard solution was employed to prepare the
stock Bi standard (100 µg/L, 0.6% HNO3 v/v) for the calibration curve (correlation

coefficients: 0.993−0.997). The autosampler volumes consisted of the chemical
modifier (5 µL, 0.005 mg/mL Pd(NO3)2 and 0.003 mg/mL Mg(NO3)2), followed by the

standard or sample (20 µL).

Bi was atomised from the surface of the pyrolytic

graphite-coated tubes using the furnace operating conditions described in
Appendix 2.1. The analyte reading was performed during atomisation (1700 °C) and

Ar gas was supplied to the instrument during analysis. After analysis of each digested

cell sample, a blank (containing 0.6% HNO3 v/v) was analysed to minimise

interference from previous samples and ensure that Bi detection returned to
background levels.

3.2.4 Microprobe SRXRF analysis of Bi-treated cells
3.2.4.1 Preparation of thin-sectioned cell samples
Thin-sectioned cells were prepared for microprobe SRXRF analysis using

procedures documented previously [5, 6, 32, 33]. Briefly, cells were seeded in cell

culture flasks (75 cm2) and grown to 80% confluence. Treatment solutions of Bi(difl)3,

Bi(mef)3, Bi(tolf)3 or BSS (40 µM Bi, 10 mL RPMI-1640, 2% DMSO v/v) were applied to

the cell culture flasks, while control cells were incubated with vehicle (10 mL

RPMI-1640, 2% DMSO v/v) for 4 h or 24 h. The treatment concentration of the

complexes was chosen based on the uptake results obtained from the toxicity and

GFAAS experiments (Sections 2.3.2 and 3.3.1) to ensure that detectable concentrations

of Bi (suitable for microprobe SRXRF imaging) were present in the cells following

treatment. The cells were washed twice with PBS and harvested using trypsin (0.25%

in PBS). The harvested cells were washed twice with sterile PBS using centrifugation

and the final cell pellet was fixed in glutaraldehyde (1 mL, 2% v/v in PBS) for 2 h at
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room temperature; and dehydrated in ethanol (30% ×2, 50% ×2, 70% ×2, 80% ×2,
90% ×2, 95% ×2, 100% ×4).

Infiltration was achieved by rocking the cells in

50% ethanol/50% Spurr’s resin overnight and then replacing with 100% Spurr’s
resin (×2 over 2 days) to ensure the removal of all traces of water. On the final day,
the cells were embedded in 100% Spurr’s resin, centrifuged (8000 g, 1 h) and cured at
60 °C overnight in a Beem capsule. Thin sections (1 µm) of the cell pellet were cut

using an ultramicrotome (Leica EM UC7).

The thin-sections were stained with

toluidine blue before mounting on silicon nitride membranes.
3.2.4.2 Microprobe SRXRF analysis of thin-sectioned cells

Silicon nitride membranes were attached to kinematic mounts designed to fit both

the light microscope (Leica DMXRE Epi-fluorescence/visual microscope) and the X-ray

microprobe (2-ID-D). Optical micrographs and XY coordinates were obtained in order
to locate suitable cells for analysis. Those cells that exhibited an intact appearance, a

clearly defined nucleus and were located away from other cells and cellular debris
were chosen for analysis.

Microprobe SRXRF was performed at beamline 2-ID-D at the Advanced Photon

Source, Argonne National Laboratory (Lemont, IL, USA). The 13.45 keV X-ray beam
was focused to a spot size of 0.3 × 0.3 µm2 using two zone plates. The samples were

housed in a helium atmosphere and the distributions of the elements from P (2.1 keV)

to Bi (13.45 keV) were mapped by raster scanning the sample in 0.3 µm steps, with the

aid of a XYZ motorised stage. Fluorescent X-rays were detected using a dwell time of

2.5 s/pt and an energy dispersive Vortex EM (Hitachi High-Technologies Science

America, Northridge, CA) silicon drift detector. Elemental distribution maps were

processed using MAPS Version 1.7.3.02 software package provided by Dr Stefan Vogt

(Advanced Photon Source) [34]. Conversion of elemental fluorescence intensities to
absolute densities in microgram per square centimetre (µg/cm2) was performed by

comparing X-ray fluorescence intensities with those from thin film standards,
NBS-1832 and NBS-1833 (NIST, Gaithersburg, MD, USA). The elemental quantification

of specific regions of the elemental distribution maps (i.e. the nucleus and cytoplasm)

was performed by selecting the region of interest (ROI) and extracting the

quantification information for the ROI using MAPS Version 1.7.3.11 software package
provided by Dr Stefan Vogt (Advanced Photon Source) [34].
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3.2.5 Statistical analysis
Statistical analysis of the results of the trypan blue exclusion assays, the GFAAS

assays and the microprobe SRXRF elemental quantification were performed using

one-way ANOVA, followed by the Tukey-Kramer Multiple Comparison Test, using
GraphPad Prism, Version 5.04 for Windows (GraphPad Software, La Jolla, USA). The

trypan blue exclusion assay and GFAAS results were analysed as two treatment

sets (i.e. control and 15 µM, or control and 40 µM treatment samples) in order to draw
a statistical comparison at the same Bi treatment concentration. Results are presented

as mean ± standard deviation (s.d.). A value of P ≤ 0.05 was considered statistically
significant.
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3.3 Results
3.3.1 GFAAS analysis of cellular Bi
Figure 3.2 shows the results of the trypan blue assay and the corresponding Bi

detected in cells treated with the vehicle, BiNSAIDs or BSS (15 µM and 40 µM Bi).

The trypan blue positive cells (Fig. 3.2a) formed a relatively low proportion (<1%) of

the total number of control and BiNSAID-treated cells, indicating that the membrane

integrity of the majority of the cells was uncompromised. This is an important result
because it establishes that any cellular Bi detected (Fig. 3.2b) is not the result of rapid

uptake due to loss of cell membrane integrity. Notably, significant decreases in the cell
populations were observed following treatment with Bi(mef)3 (40 µM Bi, P ≤ 0.01) and

Bi(tolf)3 (15 µM Bi, P ≤ 0.01; 40 µM Bi, P ≤ 0.001, Fig. 3.2a). The number of

Bi(tolf)3-treated cells (15 µM Bi) was approximately 45% of the number of control

cells and further decreased to approximately 20% with increased Bi treatment
concentration (40 µM Bi, Fig. 3.2a). The cell population observed following treatment

with Bi(mef)3 (40 µM Bi, 24 h) was approximately 43% of the population of
vehicle-treated cells (Fig. 3.2a). The lower cell populations observed for Bi(mef)3- and

Bi(tolf)3-treated cells (40 µM, Figure 3.2a) were consistent with the results of the MTT
assay (Fig. 2.6, Table 2.4) that showed that Bi(mef)3 and Bi(tolf)3 were the more toxic

complexes.

In the treatment group exposed to 15-µM Bi, the cellular Bi (Fig. 3.2b) was more

than three times higher in Bi(tolf)3-treated cells than in the Bi(difl)3- and

Bi(mef)3-treated cells. Interestingly, BSS-treated cells exhibited the highest amount of
cellular Bi (three times higher than Bi(tolf)3), and displayed the only statistically

significant (P ≤ 0.001) increase above the control for the 15-µM treatment group.
Increasing the treatment concentration from 15 µM to 40 µM resulted in an increase in

cellular Bi content in all Bi-treated cells (Fig. 3.2b). Treatment with the most toxic
BiNSAID, Bi(tolf)3 (40 µM, 24 h), showed the highest Bi concentration per cell

(P ≤ 0.001 compared to the control, and the other Bi treatments), which was
approximately 70 times higher than the cellular Bi associated with Bi(difl)3- and

Bi(mef)3-treated cells (40 µM, 24 h) and approximately 340 times higher than the

cellular uptake of Bi(tolf)3-treated cells at 15 µM. The cellular uptake of Bi(difl)3-,

Bi(mef)3-, and BSS-treated cells increased only approximately 9, 18 and 5 times,

respectively, in comparison to cells treated with 15-µM of the compounds (P > 0.05).
Interestingly, despite the differences in the toxicities of the 40-µM treatments with
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Bi(difl)3 or Bi(mef)3 (whereby 40-µM represents a sub-toxic concentration and the IC50

value, respectively; Fig. 2.6, Table 2.4), Bi(mef)3-treated cells only exhibited 1.5 times
the cellular Bi concentration of the Bi(difl)3-treated cells.

Figure 3.2: Trypan blue exclusion assay and GFAAS analysis of HCT-8 cells treated with Bi
compounds. (a) Cell populations obtained from trypan blue exclusion assays of vehicle- and
Bi-treated cells (15 and 40 µM, 24 h). Results are expressed as mean ± s.d. (n = 3 replicates
from one experiment). Error bars represent the standard deviation from the mean of the
negative and positive trypan blue cells. (b) GFAAS detection of Bi in HCT-8 cells following
exposure to vehicle (2% DMSO v/v) and specified Bi compounds (15 μM and 40 µM) for
24 h. Results are expressed as mean ± s.d. (n = 3 replicates from one experiment). Statistical
significance with respect to the control is indicated by ** P ≤ 0.01 or *** P ≤ 0.001.
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3.3.2 The dependence of cell preparation on the cellular uptake of Bi
Figure 3.3 shows the results of the Bi cell uptake studies performed on cells that

were prepared using the fixation and dehydration protocol employed for preparation

of thin-sectioned cells for the microprobe SRXRF analyses compared with the protocol
typically used for GFAAS analysis. There were no significant differences (P > 0.05) in

the amount of cellular Bi detected after fixation and dehydration compared to the
analogous non-fixed and non-dehydrated cells.

This is an important result as it

establishes that there is no loss of intracellular Bi due to leaching following

preparation of thin-sectioned cells for microprobe SRXRF analysis. Conversely,

samples treated with BSS showed a decrease in the amount of Bi contained per cell
compared to the normally washed cells; however, this result was not statistically
significant (P > 0.05).

Figure 3.3: GFAAS detection of Bi in HCT-8 cells following exposure to the specified Bi
compounds (40 μM, 24 h) prepared by normal washing method or prepared following fixation
with glutaraldehyde (2% in PBS, 2 h) and dehydration with ethanol. Results are expressed as
mean ± s.d. (n = 3 replicates from one experiment).
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3.3.3 Microprobe SRXRF spectroscopy
Figure 3.4a shows the elemental maps for P, S, Zn, Ca, and Bi generated from

microprobe SRXRF imaging of a thin-section prepared from a typical vehicle-treated
HCT-8 cell. The concentration range of each element detected within the scanned

region is specified above each elemental map (Fig. 3.4 and Appendix 2.2). High

concentrations of the endogenous elements, P, S, Zn, and Ca, were detected in the

vehicle-treated cells (Fig. 3.4a). Inspection of the micrograph (top panel, Fig. 3.4a)
reveals the overall size and shape of the cell, which correlates well with endogenous

elements S, P, Zn and Ca. Proteins found in both the nucleus and cytoplasm contain S;

additionally, S is also associated with the toluidine blue stain (which targets DNA),
which was necessary to locate the cells for the microprobe SRXRF imaging due to their
translucent appearance. The position of the nucleus is also defined by the high

presence of P and Zn; P is a fundamental element in the backbone of DNA [35], while

Zn plays an important role in DNA binding proteins (known as zinc fingers) that are

localised in the nucleus [36]. Distinctly dense areas of P (observed as the dense region
of green/red/yellow pixels) inside the nuclear membrane can be attributed to the

densely packed DNA regions known as the heterochromatin [37]. In addition, the
dense spherical structure in the top left of the nucleus (Fig. 3.4a) is the nucleolus

(observable in the S and Zn maps as yellow/red pixels). Both, the heterochromatin

and the nucleolus correlate with the dark stained regions in the micrograph image that
represent dense DNA material. As observed in the vehicle-treated cells, Ca appears to

be evenly distributed throughout the cytoplasm and the nucleus (Fig. 3.4a). Only very

low concentrations of Bi were present within the scanned region of the vehicle-treated

cells (maximum Bi 0.00431 μg/cm2, Fig. 3.4a, and 0.00469 μg/cm2, Appendix 2.2a),
and are not distinctly associated with the cells against the background regions.

Figure 3.4b shows the elemental map of typical Bi(difl)3-treated cells following

24-h treatment. The Bi(difl)3-treated cell samples showed evidence of intracellular
accumulation of Bi in ‘hot spots’ (areas of high Bi concentration) distributed
throughout the cytoplasm (Fig. 3.4b, bottom panel).

The Bi(difl)3-treated cells

(Fig. 3.4b and Appendix 2.2b) contained several hot spots ranging from approximately

0.3−1.5 μm2 in size. The maximum cellular Bi detection was 0.0578 μg/cm2 (Fig. 3.4b)
and 0.106 μg/cm2 (Appendix 2.2b).
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Figure 3.4: Microprobe SRXRF elemental maps for thin-sectioned HCT-8 cells following 24-h
treatment with: (a) vehicle only (DMSO 2% v/v); (b) Bi(difl)3 (40 μM); (c) Bi(mef)3 (40 μM);
(d) Bi(tolf)3 (40 μM); and (e) BSS (40 μM). The detected elements are specified to the left of
each row. Operating conditions include: beam energy = 13.45 keV; beam size = 0.3 × 0.3 μm2;
step size = 0.3 μm; dwell time = 2.5 s/pt; and scan dimensions (H × V) = (a) 20 × 17μm2;
(b) 19 × 16 μm2; (c) 22 × 15 μm2; (d) 31 × 21 μm2 and (e) 14 × 12 μm2.
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Figure 3.4c shows the elemental map of typical Bi(mef)3-treated cells following

24-h treatment. There were substantial differences observed in the distribution and

maximum Bi detected between Cell A and Cell B (Fig. 3.4c). The maximum Bi detected
in Cell A was 0.128 μg/cm2, twice the amount de
te
cte
d in Ce
ll B (maximum

0.06136 μg/cm2). Additionally, Bi was distributed throughout Cell A, with the highest

concentration of Bi localised in the nucleus and considerable Bi also present in the

cytoplasm (Fig. 3.4c). It should be noted that this was the only BiNSAID-treated cell

where the Bi localisation was observed in both the nuclear and cytoplasmic regions.

The majority of the Bi present in the cytoplasm of Cell B appears to be concentrated in

one large hot spot, approximately 5.8 μm2 in size (Fig. 3.4c). A similar result was
observed in a third Bi(mef)3-treated cell (24 h), whereby one large hot spot was

observed in the cytoplasm (Appendix 2.2c). Notably, there was little evidence of Bi

accumulation within the Bi(mef)3-treated cells following 4-h treatment (maximum Bi
0.0065 μg/cm2 and 0.0134 μg/cm2, Appendix 2.3).

The 24-h Bi(tolf)3-treated cell samples also showed evidence of intracellular

accumulation of Bi in hot spots distributed throughout the cytoplasm. The maximum

Bi detected in Bi(tolf)3-treated cells (Fig. 3.4d) was 0.0496 μg/cm2 (Cell A) and

0.0408 μg/cm2 (Cell B), 10 times greater than the amount of Bi detected in vehicletreated cells (Fig. 3.4a). A third Bi(tolf)3-treated cell (Appendix 2.2d) contained the

largest amount of Bi of all the BiNSAID-treated cells analysed (1.01 μg/cm2), which

appeared to be localised in one cytoplasmic hot spot. The Bi hot spots ranged in size
from approximately 0.7 μm2 to 2.8 μm2 in the Bi(tolf)3-treated cells.

Figure 3.4e shows that there was no evidence of accumulation of Bi in cells treated

with BSS (24 h). The maximum Bi counts detected were 0.005 μg/cm2 (Fig. 3.4e) and
0.006 μg/cm2 (Appendix 2.2e), similar to the Bi content of the vehicle-treated cells

(Fig. 3.4a and Appendix 2.2a).

Across all BiNSAID-treated cells, many of the Bi hot spots showed close proximity

to the nucleus; the colocalisation maps with P and Zn, confirmed the spots were
located close to the nuclear membrane in a number of cells (Appendix 2.4 a(i), b(i),

b(ii) and c(i)). Analysis of the microprobe SRXRF elemental maps also revealed that

the Ca distribution of all the Bi-treated HCT-8 cells (Fig. 3.4b-e and Appendix 2.2b-e)

differed compared to the vehicle-treated cells (Fig. 3.4a and Appendix 2.2a).

For instance, in the case of all Bi-treated cells (Fig. 3.4b-e and Appendix 2.2b-e),
cellular Ca concentration appeared higher than the vehicle-treated cells (Fig. 3.4a and
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Appendix 2.2a) as evident in the Ca range (maximum quantity detected in vehicle-

treated cells ranged from 0.027−0.0344 μg/cm2, Bi-treated cells 0.0507−0.371
μg/cm2) and the higher definition in the Ca maps.

The elemental quantifications of the cytoplasmic and nuclear regions of the thin-

sections obtained from vehicle-, BiNSAID- and BSS-treated HCT-8 cells are presented
in Figure 3.5. Since quantification of the entire cellular contents is not possible from a

thin-section, the quantifications are represented per unit area (μm2). Statistical

analysis shows that there were no significant differences in the cytoplasmic or nuclear

P concentrations in the vehicle-treated cells compared to the Bi-treated cells

(Fig. 3.5a). The concentration of Zn was significantly elevated in the cytoplasm of the
Bi(difl)3-treated cells, and the nucleus of the Bi(mef)3-treated cells compared to the

vehicle-treated cells (P ≤ 0.05 and P ≤ 0.01, respectively); however, no significant
changes were observed in the Zn content of the Bi(tolf)3-treated cells compared to the

vehicle-treated cells (Fig. 3.5b).

The concentration of Ca was significantly increased in the cytoplasm and nucleus

of the Bi(mef)3-treated cells (both P ≤ 0.001) compared to the vehicle-treated cells

(Fig. 3.5c). There were no significant fluctuations in Ca in the cytoplasm of any of the
other Bi-treated cells (Fig. 3.5c). An increase in Ca (1.4–1.8 fold) was observed in the

nucleus of the other Bi-treated cell groups (Fig. 3.5c), although this increase was only
significant in the Bi(difl)3-treated cells (P ≤ 0.05). Negligible levels of intracellular Bi

were detected in the cytoplasm and nucleus of the vehicle- and BSS-treated cells (Fig.

3.5d); however, the BiNSAID-treated cells showed large fluctuations in the
intracellular levels of Bi in both the cytoplasm and the nucleus.
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Figure 3.5: Quantifications of: (a) P; (b) Zn; (c) Ca; and (d) Bi, in the cytoplasmic and nuclear
regions of the HCT-8 thin-sectioned cells following 24-h treatment with vehicle
(2% DMSO v/v), or the specified Bi compounds (40 μM). All data were collected using a 0.3 μm
stepsize and a 2.5 s dwell time. Data are presented as mean ± s.d. where n = 3 (except Bi(tolf)3,
n = 4, and BSS, n = 2). Significance with respect to the vehicle-treated sample is indicated by
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. The cytoplasm and nucleus were analysed as separate
groups.
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3.4 Discussion
3.4.1 GFAAS uptake studies
Quantitative studies of the cellular uptake of Bi resulting from treatment of HCT-8

cells with BiNSAIDs were performed to determine whether there was any correlation

between Bi uptake, and the stability and/or toxicity of the BiNSAIDs (results

presented in Chapter 2). It is important to note that the trypan blue exclusion assays

(Fig. 3.2a) showed that the membrane integrity remained intact in the majority of the
cells; therefore, uptake of the BiNSAIDs most likely occurs through an uncompromised

cell membrane. In order to rationalise how the BiNSAIDs enter the HCT-8 cells, the
documented mechanisms by which Bi(III) complexes and NSAIDs enter mammalian

cells must also be considered in the following discussion.

The results from the GFAAS studies showed that 24-h treatment of HCT-8 cells

with 15-μM or 40-μM Bi(tolf)3 resulted in substantially higher Bi uptake compared

with the analogous concentrations of the other Bi complexes (Fig. 3.2b). Importantly,

the results from the NMR stability studies (Section 2.3.1) of Bi(tolf)3 also indicated

that Bi remains coordinated to tolf in the cell medium for the duration of the 24-h
treatment. Accordingly, the Bi uptake associated with Bi(tolf)3 treatment must be

facilitated by the NSAID or the overall lipophilicity of the complex. There are at least
two known mechanisms of NSAID diffusion across the membranes of the cells in the
upper and lower intestines. The first is the monocarboxylate/H+ transporters [38]

while the second is a pH-dependent, but non-carrier mediated absorption of
NSAIDs [39]. The first mechanism is highly unlikely for the intact Bi(tolf)3 as the tolf

carboxylate necessary for interaction with monocarboxylate/H+ transporters is

unavailable due to the coordination to Bi. Given that the complex likely remains intact

in the cell medium, it is more likely that the lipophilicity of the complex, imparted by

the coordinated tolf, is facilitating interaction and diffusion through the cell
membrane. A passive transport mechanism for Bi compounds has been observed in

recent studies performed by other researchers. Hong et al. [40] have shown that HK-2

human proximal tubular cells treated with CBS (0.5 mM) over 24 h, exhibited a pattern
of Bi saturation that was consistent with the profile of passive transport.

More

recently, neutron reflectometry experiments performed by Brown and Dillon ([41]
and unpublished work) showed that Bi(tolf)3 interacted with the head groups of lipid

bilayer membrane mimics and partitioned into the tail region of the membranes

(comprised of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) molecules).
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While these experiments were performed in a non-cell system, they showed that
Bi(tolf)3 was able to displace lipid molecules, which provides credence to the

hypothesis that passive diffusion is a potential uptake mechanism employed by
Bi(tolf)3 to pass through the cell membrane and accumulate in HCT-8 cells.

The much lower Bi uptake associated with the Bi(mef)3- and Bi(difl)3-treated

cells (Fig. 3.2) can probably be attributed to the differing stability and reactions of the
complexes

in

the

cell

medium

as

observed

by

NMR

spectroscopic

investigations (Section 2.3.1). Given the structural similarities in the tolf and mef, one

would expect that Bi uptake would be similar for both Bi(tolf)3 and Bi(mef)3

treatment. However, the lower Bi uptake is consistent with the Bi(mef)3 NMR stability

studies (Section 2.3.1) that indicated that mef dissociates from Bi. As such, the Bi

uptake would not be facilitated by the lipophilicity that would be imparted by mef and

its subsequent interactions with the membrane.

Interestingly, Bi(mef)3-treated cells only exhibited 1.5 times greater Bi uptake

compared with the Bi(difl)3-treated cells despite the more substantial difference in

toxicity of 40-μM Bi(mef)3- and Bi(difl)3- (approximately 50% versus 20% reduction

of MTT conversion, respectively (Section 2.3.2).

The NMR results indicated that

glucose may interact with the Bi(difl)3 complex. It might be possible that glucose may

facilitate uptake of any Bi(difl)2(glu) or Bi(difl)(glu)2 species that are formed.

Unfortunately, given that the glucosyl 1H NMR signals only represented approximately

1/6 that of the difl signals, one would not expect a significant increase in the
detectable Bi found in the cells.

Another observation from this study was the high Bi detected for the BSS-treated

cells. For instance, the cellular Bi was approximately 4−10 times higher than all

BiNSAID-treated cells for the 15 μM treatment, and approximately 4 times higher than

Bi(mef)3 and Bi(difl)3 for the 40 μM treatment. It is proposed that the increased

cellular Bi associated with the BSS-treated cells (as compared to the BiNSAID-treated

cells) was due to extracellular bound Bi that could not be completely removed by

washing the cells using the protocol employed for GFAAS cell sample preparation

(Section 3.2.3.1). Inspection of the treatment dishes revealed that BSS was far less
soluble than the BiNSAIDs as noted by the precipitation in the treatment medium. The
adherence of metal complexes to the exterior of the cell membrane has been observed

in other studies [42]. Specifically, it was observed that during the preparation of

Cr(NO3)3.9H2O-treated A549 lung cancer cell samples for GFAAS analysis, the cell
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pellets appeared blue in colour after several washes with PBS, followed by sterile

saline [42]. When GFAAS analysis was performed on only the intracellular contents of

the A549 cells, the Cr content of the Cr(NO3)3.9H2O-treated cells was reduced to the

same quantity as the other Cr(III) complexes tested [42], indicating that the majority

of the Cr was associated with the cell membrane. Unfortunately, BSS is white such that

its appearance in the cell pellet is not as easily discerned. It is noteworthy, however,

that the GFAAS analysis of the BSS-treated cells differed when the more extensive
washing, fixation and dehydration protocol used for microprobe SRXRF analysis was
employed (Fig. 3.3). In contrast, no change was observed in the cellular Bi following

treatment with the soluble BiNSAIDs (Fig. 3.3). In addition, the maximum Bi counts

detected in BSS-treated thin-sectioned cells were similar to the Bi content of the
vehicle-treated cells (Fig. 3.4) indicating there was negligible intracellular Bi.

It is important to note that the GFAAS analyses do not provide information about

the mechanisms by which “unbound” Bi enters and accumulates in cells.

While

beyond the scope of this study, some assumptions can be made based on the literature.
Importantly, the mechanisms of uptake, accumulation and metabolism of Bi by

mammalian cells are poorly understood. There is evidence that suggests that Bi binds
strongly to the enzyme transferrin (discussed in Section 1.4.1.1), which cycles in and

out of cells as a method of iron transport [43].

Acknowledging that transferrin

receptors are overexpressed in cancer cells [44-46] it is feasible that in the serumdeficient (and Fe-deficient) cell medium used during treatment that Bi may be

substituted into transferrin for uptake into the cells. Additionally, it has been reported

that Bi has a high affinity for glutathione, a tripeptide that is present in cells in

relatively high concentrations (0.5–7 mM) and is believed to play a role in Bi transport
in cells and biofluids [47]. Recently, the importance of the role of glutathione in the

intracellular transport of Bi was examined in HK-2 cells treated with CBS, whereby it
was apparent that glutathione depletion adversely affected the ability of the cell to

detoxify itself of Bi [40]. As such, it is plausible that glutathione present in the cells

may assist in transporting unbound Bi (in the case of Bi(mef)3) in the HCT-8 cells.
Furthermore, if Bi(tolf)3 enters the cell intact, as indicated by the NMR stability

studies, it could be postulated that cellular processes result in the release of tolf from

Bi, whereby the mechanism of Bi release may be a result of the strong affinity of Bi for

other more abundant intracellular ligands such as glutathione, metallothionein, or

other metal-binding proteins that are responsible for intracellular transport of
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endogenous metal ions (such as Zn(II) and Fe(III)). The exact uptake and metabolism
pathways of the BiNSAIDs will need to be examined in future studies.

One final consideration stemming from the GFAAS analysis of the Bi-treated cells is

the impact resulting from the Bi accumulation in the cells. At the lower treatment

concentration (15 μM Bi, which reflects the IC50 value of Bi(tolf)3), the Bi uptake

following Bi(tolf)3 treatment was only three times higher than that observed for the
other BiNSAID treatments.

Treatment with the higher concentration (40 μM),

however, resulted in substantial Bi accumulation in the cells in high quantities. These
results highlight the question as to where the Bi is localising in the cells with respect to
the mechanisms of action of the BiNSAIDs, as addressed in Section 3.4.2.
3.4.2 Microprobe SRXRF spectroscopy of thin-sectioned cells

Microprobe SRXRF was utilised as a sensitive technique to determine subcellular

location of Bi in thin-sectioned HCT-8 cells to glean some information regarding
mechanisms of action of the BiNSAIDs. The results from the GFAAS cellular uptake

studies (Section 3.3.2) demonstrated that the total cellular Bi concentration remained

essentially the same following a comparison of the cell preparation procedures used
for thin-sectioning versus normal washing procedures (with the exception of BSS-

treated samples; Section 3.2.3.1 and 3.4.1), suggesting that there was no significant

difference in Bi leaching from the cells using the fixation procedures employed for

sample preparation for the microprobe SRXRF imaging. However, it should be noted

that it can be assumed that under those conditions Bi does not leach into any of
solutions used during the washing steps in the normal GFAAS sample preparation
method (Section 3.2.3.1).

The consistent trend observed from the microprobe SRXRF imaging of thin-

sectioned cells was that the intracellular fate of Bi was essentially the same, regardless

of the BiNSAID administered. In the majority of BiNSAID-treated cells discrete Bi hot

spots were detected in the cytoplasm; however, there was some evidence that Bi

might accumulate in (or around) the nucleus. These findings need to be considered

with respect to a number of potential chemotherapeutic targets including (i) the

nucleus, (ii) COX, and (iii) mitochondria, and potential detoxification mechanisms via

accumulation in (iv) lysosomes.

The first potential target for discussion is the cell nucleus, which is relevant due to

the fact that it is a common target for anti-cancer agents. It was noted that there was
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disperse distribution of Bi throughout the cell nucleus in one BiNSAID-treated cell,
(Bi(mef)3-treated Cell A, Fig. 3.4c).

Of the approximately twenty cells studied,

however, this result was atypical and raises the question of whether this occurs in a
greater number of cells (if a larger sample size was studied). In other microprobe

SRXRF studies of the clinically-used drugs, arsenite [30] and cisplatin [23],

colocalisation of As and Pt (respectively) was evident in the nucleus of a high

proportion of the drug-treated cells, which is consistent with the main mechanism of
anti-cancer action of these compounds, whereby DNA is the relevant target. Given that

there is little evidence of Bi accumulation in the nucleus of the other BiNSAID-treated

cells (very low proportion of Bi-treated cells compared to every cell analysed

following treatment with Pt drugs [23] and As compounds [30]), it appeared unlikely
that the main target of BiNSAIDs was DNA in HCT-8 cells.

As described in Sections 1.2.3 and 1.2.4, the chemopreventive/chemotherapeutic

nature of NSAIDs is perceived from their ability to inhibit COX-2. The COX enzymes

are membrane-bound enzymes, specifically located on the endoplasmic reticulum

(COX-1 and COX-2), plasma membrane (COX-1 and COX-2) or the nuclear membrane

(COX-2 only) [48, 49]. The colocalisation maps (Appendix 2.4) indicated that Bi hot
spots were not located in close proximity to the plasma membrane. However, a

number of Bi hot spots were located in close proximity to the nucleus as shown in the

colocalisation maps (Appendix 2.4 a(i), a(ii), b(i), b(ii), and c(i)). While this does not

provide indisputable evidence of BiNSAID localisation at the site of COX, it does

provide evidence that places Bi in the vicinity of COX-2. In the instance that the
BiNSAID remains intact, this suggests that the mobility is such that there is potential

for the interaction with COX. It is important to note that it is likely that the BiNSAID

also dissociates inside the cell as implied by the PGE2 production assays (Section 2.3.4)

as a free carboxylate is required to interact with the COX-2 active site. Consequently, it
would be beneficial to study the location of the NSAID. Unfortunately, direct probing

of the NSAID using microprobe SRXRF is not feasible as the chemical elements of the
NSAIDs are endogenous to the cell and cannot be discerned. An alternative study
worth considering might be the substitution of an element such as Br for Cl (in the
instance of tolf). Additionally, the use of COX-2-specific antibody with Au nanoparticle

labelling and microprobe SRXRF could be used to image Au and Bi and determine
colocalisation akin to an experiment reported by Yuan et al. [50].
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Due to beam time restrictions, the amount of samples that could be analysed was

limited.

Samples for microprobe SRXRF were prepared following 4-h or 24-h

treatment with the Bi compounds, however, only 4-h Bi(mef)3-treated samples were

analysed (Appendix 2.3). Negligible Bi was observed in the 4-h Bi(mef)3-treated cell
microprobe SRXRF elemental maps (Appendix 2.3), indicating that any Bi taken up by
the cells is lower than the detection limit. There are two notable observations from

these results. Firstly, given that the NMR studies (Section 2.3.1) suggested that

Bi(mef)3 is unstable in the cell medium, the uptake and localisation of Bi may not be
indicative of COX. Secondly, it would appear that a longer incubation time (> 4 h) is

required for significant uptake of Bi (Fig. 3.5 and Appendix 2.2) if it is not bound to an

NSAID. Further beam time would be required to study the elemental distribution of
the 4-h Bi(tolf)3- and Bi(difl)3-treated cells in order to determine the concentration

and location of Bi of the stable complexes.

The third potential mechanism of action of BiNSAIDs that is worth addressing is

targeting the mitochondria. The validity of this mechanism stems from results

reported in Chapter 2 (toxicity and cell death assays) since the intrinsic pathway of

apoptosis is inextricably linked with mitochondrial health [51]. The size of some of
the hot spots detected in the microprobe SRXRF studies are similar to the size

reported for mitochondria (0.5−10 μm) [52, 53]. A means for determining if Bi was
located in the mitochondria is to examine whether it is colocalised with Fe since the

mitochondria primarily consume Fe for the synthesis of heme and Fe–S clusters and as
such serve as the centre for cellular Fe homeostasis [54]. A study by

Morrison et al. [28] showed that Gd(III) from several Gd(III) complexes colocalised
with Fe that was contained in the mitochondria of T98G human glioblastoma

multiforme cells. Unfortunately, examination of the thin-sectioned cell maps in the

current study failed to discriminate Fe from the background (data not shown), thus

the colocalisation of Fe with other elements (such as Bi) could not be definitively

established. Alternatively, Ca has been shown to localise in the euchromatin and

mitochondria [55]. Mitochondria are vital for maintaining Ca2+ homeostasis and play

an important role in Ca2+ storage in the cell [56]. However, there was little evidence to

show colocalisation of Ca and Bi in the cytoplasm where mitochondria would be found.

For example, only one Bi(mef)3-treated cell showed any colocalisation with Ca

(Appendix 2.4, Fig. 3.4, Cell A). Coincidentally, this was the only Bi-treated cell that
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displayed nuclear Bi localisation, which was an exception compared to the other
BiNSAID-treated cells.

The final site of possible Bi intracellular localisation that needs to be considered is

the lysosomes.

Lysosomes are membrane-bound, acidic organelles that play an

important role in removing cellular waste. Lysosomes contain acid hydrolases, which

are responsible for the degradation of unwanted cellular biomolecules [57]. Previous

reports following autometallography studies have shown that Bi accumulates in

lysosomes of various cell types, including kidney cells, macrophages, motor neurons,

ganglion, Leydig and Sertoli cells in rats as part of a detoxification process [10-12, 16].
More recently, Hong et al. [40] have performed fluorescence microscopy experiments

that showed that Bi colocalised in lysosomes of CBS-treated (0.5 mM) HK-2 (human

proximal tubular) cells. The microprobe SRXRF results are consistent with these
observations since the small hot spots of the Bi are similar in size to lysosomes (50–

500 nm diameter) [58, 59]. There are two possible explanations for the diversity in

the size and number of the Bi hot spots that were observed in the BiNSAID-treated

cells in this study; firstly, since the thin-section represents a 1-μm slice of the cell,
there may be heterogeneous distribution throughout the cell. Secondly, the variation

in the size of lysosomes could be the result of certain cellular events; for instance

events leading to the fusion of multiple lysosomes with autophagosomes resulting in

autolysosomes with increased size and reduced lysosome number [60]. It is unknown
whether these lysosomes are excreted from the cells over time, which may also

account for the diversity in the distribution and the number of the lysosomes present.

Unfortunately, due to the limitation in spatial resolution (beam dimensions (0.3 ×

0.3 μm2) and step size (0.3 μm) associated with this technique, any lysosomes smaller

than 300 nm would not be easily detected. Given the evidence in the literature that
shows that Bi localises in lysosomes of many other cell types, and without evidence of
colocalisation with mitochondrion-related elements (Fe & Ca), it is rational to

conclude that the Bi hot spots observed in the present study are indicative of
lysosomes rather than mitochondria. Further experiments such as transmission

electron microscopy could be performed to unequivocally confirm this is the case.

There were a few interesting observations emanating from the microprobe SRXRF

imaging with respect to the distribution and changes in Ca concentration that warrant

discussion. The first observation was the increase in nuclear Ca localisation of the

Bi-treated cells (Fig. 3.5). This observation has been reported by Lui and Huang [61]
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and Munro et al. [30] in arsenite-treated CHO-K1 and Hep-G2 cells, respectively. Both
studies [30, 61] concluded that the mechanism of toxicity of arsenite might involve

disturbances in intracellular Ca homeostasis, a known indicator of apoptosis [62]. The
results obtained from the toxicity assays in Chapter 2 indicated that the health of the

cells was affected in all BiNSAID treatments at the treatment concentration and

treatment time chosen for the microprobe SRXRF cell sample treatment (40 μM, 24 h).

Additionally, the redistribution of Ca as indicated by the microprobe SRXRF studies

reported herein, coupled with the cell death studies in Chapter 2, suggests that

BiNSAID-induced apoptosis is associated with a disruption of Ca homeostasis. Similar

to the conclusions drawn by Munro et al. [30], it is unclear from the present study

whether the redistribution of nuclear Ca is related to drug-induced mitochondrial

damage or another intracellular source of Ca such as disruption to the endoplasmic
reticulum leading to the release of Ca into the cytosol [63].

The increase in Ca concentration in the nucleus of the BSS-treated cells was the

second interesting observation, since low toxic effects were observed in HCT-8 cells
following treatment with BSS (40 μM, 24 h) in the toxicity assays reported in Chapter

2. It has been observed in normal human gastric mucous epithelial cells that
treatment with BSS increased intracellular Ca2+ [64]. The increased concentration of

Ca2+ promoted p44/p42 and p38 MAP-kinase activation, and subsequently stimulated

the growth of the gastric mucous epithelial cells [64]. Given that the metabolism of

normal cells differs to that of cancer cells [65], further studies would be needed to

determine the significance of intracellular Ca2+ flux in BSS-treated HCT-8 cells.
Additionally, it cannot be ruled out that the Ca redistribution within BSS-treated

HCT-8 cells may alternatively be due to salicylate rather than Bi.

Thirdly, elemental quantification of the thin-sectioned cells showed that Bi(mef)3

significantly increased cytosolic and nuclear levels of Ca compared to the

vehicle-treated cells. As such, this might suggest that Bi(mef)3 induces apoptosis via a

pathway which is attenuated to the effects of Ca2+ compared to Bi(tolf)3 and Bi(difl)3.
Given that Bi(mef)3 caused such a significant increase in [Ca2+]i compared to the other
Bi compounds at the same treatment concentration, it seems unlikely that Bi alone
would be the cause of the increase. This raises the question as to whether the effect on

[Ca2+]i is due to the ligand alone or the combination of Bi and ligand. As such, further
experiments could be performed to shed more light on the effects of Bi- and

NSAID-induced toxicity on intracellular Ca concentration and distribution. One
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approach could be the preparation of NSAID-treated samples for microprobe SRXRF

analysis to compare to the BiNSAID-treated samples (Fig. 3.4 and Appendix 2.2).
Alternatively, bulk cell assays (with the advantage of increased statistical power)
could be performed to quantify [Ca2+]i levels using a technique such as flow cytometry

and a Ca fluorescent probe such as Fluo-4-AM [63]. Additionally, co-stained cells

containing a calcium fluorescent probe and a nuclear dye such as Hoechst 33342 could
be analysed using fluorescence microscopy [66].
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3.5 Chapter summary
The aim of this Chapter was to quantify Bi cellular uptake and the localisation in

HCT-8 cells following treatment with BiNSAIDs to further examine potential
mechanisms of cell toxicity. Specifically:
i.

The most striking result from the GFAAS study was that Bi uptake was

influenced by the treatment concentration, whereby a higher treatment

concentration (40 µM) resulted in increased Bi uptake by BiNSAID-treated cells

(ranging from 5 to 340 times) compared to the lower concentration (15 µM).
The most toxic BiNSAID, Bi(tolf)3, showed the highest concentration of cellular

Bi at both treatment concentrations 15 µM and 40 µM (24 h), while the

Bi(mef)3- and Bi(difl)3-treated cells showed similar quantities of cellular Bi at

both treatment concentrations tested. The uptake of Bi may be influenced by

stability, whereby Bi(tolf)3 showed substantially greater Bi uptake and was the
most stable of the BiNSAIDs as determined by NMR spectroscopy (Chapter 2).

ii. The microprobe SRXRF imaging of thin-sectioned cells showed that Bi
generally accumulates in discrete hot spots found in the cytoplasm. The size of
the hot spots is consistent with two possible intracellular fates. The first is the

accumulation of Bi within that of the cells detoxification organelles, lysosomes.

Additionally, the close proximity of the Bi hot spots to the nuclear membrane

(and location of COX-2), may suggest that intracellular movement of Bi can
occur. However, this second proposition requires further investigation.

While the GFAAS results indicated substantially greater Bi uptake for Bi(tolf)3

(versus Bi(mef)3 and Bi(difl)3), which paralleled the greater toxicity and greater

inhibition of PGE2 production of the former complex, the microprobe SRXRF results

showed less compelling differences with respect to the toxicities. Of course greater

insight into the disparity between the cellular quantities of Bi associated with the

different BiNSAID treatments could be obtained following studies of NSAID uptake,
which is challenging work and has been commenced by Spremo and Dillon ([67] and
unpublished results) and is continued Brown and Dillon ([41], and unpublished
results).
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Chapter 4.
Synchrotron radiation infrared microspectroscopy
studies of live HCT-8 cells treated with BiNSAIDs
and NSAIDs

In the last decade there has been an increase in the use of synchrotron radiation
infrared microspectroscopy (SR-IRMS) for the study of single mammalian cells to
discern biomolecular changes that are associated with disease and disease treatment.
This Chapter describes live cell SR-IRMS experiments performed at the Australian
Synchrotron (Clayton, Australia) for the analysis of HCT-8 cells following exposure to
BiNSAIDs or NSAIDs in order to: (i) study global biomolecular variations,
(ii) determine whether any changes are reflective of the mechanisms of cell death, and
(iii) identify whether the coordination of NSAIDs to Bi results in alterations in the
biomolecular effects of NSAIDs.

A multivariate approach, Principal Component

Analysis (PCA), was applied to discriminate the spectral differences associated with
the different cell treatments.
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4.1 Introduction
Identifying cellular events that occur as a result of exposure to a
chemotherapeutic agent is necessary to understand how the drug affects a cancer cell.
Specific biological assays can be used to probe mechanisms of action, a selection of
which are discussed in Chapter 2. Alternatively, Fourier transform infrared (FTIR)
spectroscopy, which probes chemical changes, is being increasingly utilised as a rapid,
non-destructive, label-free technique for studying the biochemistry of biological
materials [1]. The coupling of FTIR spectroscopy with microscopy and synchrotron
light has allowed researchers to simultaneously probe a large number of
macromolecules present within a single cell [1].

Importantly, detection of

simultaneous changes in the molecular composition of single cells can assist in the
identification of biological processes that can then be probed further using
complementary techniques.

4.1.1 FTIR spectroscopy of biological molecules
FTIR spectroscopy is a technique traditionally employed by chemists and
materials scientists for the identification and molecular analysis of chemicals. Selected
frequencies (energies) of IR radiation are absorbed by molecules at energies required
to cause vibrational excitation of bonds within a molecule [2]. The characteristic
vibrations of each chemical group give rise to a spectrum that enables elucidation of
the identity of a molecule [2]. As demonstrated in Figure 4.1, IR active molecules
display two fundamental modes of vibration which include: (i) stretching vibrations
(symmetric or asymmetric motion of two or more atoms bonded to a central atom)
resulting from a change in bond lengths, and (ii) bending vibrations (including out of
plane motions, twisting and wagging, and in plane motions, rocking and scissoring)
resulting from a change in bond angles [2].
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Figure 4.1: Fundamental modes of vibration of IR active molecules.

The IR spectrum can be subdivided into three regions, the near-IR, mid-IR and
far-IR regions, encompassing the red end of the visible spectrum at 769 nm
(13000 cm−1) to the beginning of the microwave region at 0.1 mm (100 cm−1) [2]. The
mid-IR range (4000–400 cm−1) encompasses the molecular ‘fingerprint’ region that is
frequently used to study structural and chemical information of organic molecules and
biological samples alike [2].
Eukaryotic cells are comprised of protein, DNA, RNA, carbohydrates, and lipids.
Each of these biomolecules produces a unique, yet complex IR spectrum due to the
distinctive molecular bonds present in their structures, as demonstrated in Figure 4.2.
As such, the IR spectrum of a mammalian cell exhibits a superposition of all of the
biomolecules contained in the cell (Fig. 4.2).

Generalised assignments for

characteristic IR bands associated with biological materials, including eukaryotic cells,
are presented in Table 4.1.
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Figure 4.2: Typical IR signatures of biological materials. Adapted from Miller et al. [3].
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Table 4.1: Generalised assignments of characteristic IR bands of biological and eukaryotic
cell spectra [2, 4].
Wavenumber
Assignment
Associated
(cm−1)
biomolecule
2955
νas(C−H) of CH3
Lipid/phospholipid
2930
νas(C−H) of CH2
Lipid/phospholipid
2898
ν(C−H) of methine
Lipid/phospholipid
2870
νs(C−H) of CH3
Lipid/phospholipid
2850
νs(C−H) of CH2
Lipid/phospholipid
1740
ν(C=O) ester
Lipid/phospholipid
1720
ν(C=O) ester
DNA
1680–1715
ν(C=O)
Nucleic acids
1653
ν(C=O)/ν(C−N)/δ(N−H), amide I
Protein
1567–1520
ν(C−N)/δ(N−H), amide II
Protein
1515
Tyrosine band
Protein
1470
δas(C−H) of CH2
Lipid/phospholipid
1420
νs(COO−)
Protein
1310–1240
ν(C−N)/δ(N−H)/ν(C=O)/ν(O=C−N), amide III
Protein
−
1232
νas(PO2 )
Nucleic acids
1170
νas(CO−O−C)
Lipid
1080
ν(C−O−P), νs(PO2−)
Nucleic acids
1050
ν(C−O)
Carbohydrate
Key: ν = stretching vibrations, δ = bending vibrations, s = symmetric, as = asymmetric.

4.1.2 FTIR microscopy and synchrotron sources
The coupling of modern FTIR spectrometers with purpose built IR microscopes,
has allowed researchers to study samples on a microscopic scale [1, 5]. One of the
limitations of conventional lab-based FTIR microspectroscopy is the low intrinsic
brightness which limits the smallest practical spot size (defined by the microscope
masking aperture) to approximately 20–40 μm at the expense of signal-tonoise [1, 5]. This represents a major limitation when examining cells and cell
organelles [1, 5]. Conversely, a synchrotron light source produces light with higher
brilliance (increased photon flux) which when focused to narrow range emission
angles [5] with microscope apertures (5–20 μm) results in the inherently bright and
highly focused synchrotron light that facilitates the analysis of micrometre samples
with high signal-to-noise [1].

The main restrictions, however, stem from the

diffraction limit [1]. For instance, the diffraction limit in the mid-IR region (3500–
650 cm−1) is approximately 1.4–7.7 μm for a conventional confocal microscope which
approaches λ/2 [1].
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4.1.3 Infrared microspectroscopy studies of drug effects on cancer cells
More recent developments of infrared microspectroscopy (IRMS) in conventional
lab-based settings, and the increasing utilisation of synchrotron radiation (SR) light
sources has allowed a number of researchers to study the effects of clinically-used (or
potential) anti-cancer drugs on cancer tissue or cells, at single-cell (and even
subcellular) resolution [6-14]. The study of drug effects on cancer cells using the IRMS
approach has a number of perceived advantages in a clinical setting. For instance, in
cancer treatments where multiple drug combinations are recommended for the
treatment of specific types of cancer (such as non-small cell lung cancer), it has been
proposed that IRMS could potentially be employed to determine the most effective
combination of drugs to administer to each individual patient [6]. Additionally, IRMS
could

provide

information

on

early

cellular

events

to

varied

doses

of

chemotherapeutics which could allow clinicians to determine the minimum effective
dose to administer, reducing the severity of chemotherapeutic side effects [9]. In this
context, IRMS conceivably provides a rapid, sensitive and effective means to improve
the treatment of cancer with long-term beneficial outcomes for patients [6].
As IRMS can provide a global view of the effects of drug treatment on all cellular
biomolecules (i.e. proteins, lipids, nucleic acids, carbohydrates), it is considered that
the technique could potentially be used to identify possible modes of action of the
drug, as changes to IRMS spectra may be correlated to alterations in biological
function specific to the mode of action [8]. A recent review discusses the potential use
of IRMS as a fast and easy technique to determine the mechanisms of action of
prospective candidate compounds in drug discovery programs [15], whereby the
authors propose that IRMS this could help widen the screening process beyond
conventional toxicity screening methods. In order to develop IRMS for clinical use, the
characterisation and interpretation of the spectral changes induced by drug treatment
on cancer cells needs to be fully developed. To this end, a number of research groups
have used IRMS or SR-IRMS to study the effects of various chemotherapeutic agents on
cancer cells in vitro [6-14]. A selection of these studies is summarised in Table 4.2. On
the cellular level, IRMS has been used to study events which are important for the
fundamental understanding of cellular processes such as apoptosis/necrosis [16-21]
and stages of cell cycle [16, 22], the differences between proliferating and quiescent
cells [23], differentiation of stem cells [24, 25] and blood cells [17], and the effects of
ultraviolet B radiation on cells [26, 27].
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Table 4.2: Summary of some IRMS or SR-IRMS studies that examined the effects of
chemotherapeutic agents (either potentially or clinically-used) on cancer cells.
Author
Bellisola
et al.
[14]

Drug (mechanism of
action) and
Cell line (cancer type)
• Imatinib mesylate
(inhibits ABL tyrosine
kinase activity)
• K562 (human
erythroleukemic)

ChioSrichan
et al. [7]

• Hypocrellin A (HA, lipidsoluble peryloquinone
derivative, isolated from
Hypocrella bambusae)
• HeLa (human cervical
cancer)

Derenne
et al.
[10]

• Methotrexate (MTX,
antimetabolite – inhibits
folic acid metabolism)
• PC-3 (human prostate
cancer)

Draux
et al.
2009 [9]

• Gemcitabine (GMB,
pyrimidine
antimetabolite – inhibits
DNA replication and
repair)
• Calu-1 (non-small cell
lung cancer)
• KF0101 (cytotoxic gold
complex), cisplatin, MTX,
paclitaxel (inhibits
tubulin destabilisation)
and 5-fluorouracil
(irreversible inhibitor of
thymidylate synthase)
• A2780 (human ovarian
cancer)
• Ouabain (inhibits
sodium pump activity)
• PC-3 (human prostate
cancer)

Flower
et al.
[12]

Gasper
et al. [8]

SuléSuso
et al. [6]

• GMB (pyrimidine antimetabolite)
• A549 and Calu-1 (nonsmall cell lung cancers)

Key observations
• Hierarchical Cluster Analysis showed clustering of
the spectra of single K562 cells treated with the drug
into two distinct groups corresponding to living and
to apoptotic cells
• The amide I peak was shifted to a lower wavenumber
and there was a difference in the absorbance
associated with the ν(C=O) mode of phospholipids at
1736 cm−1 in the apoptotic cell population
• Principal component analysis (PCA) showed spectra
collected in the nucleus differed to those of the
cytoplasm (nucleus = Ó β-type protein structure)
• Irradiated, HA-treated (6 h) nuclear spectra
separated from non-irradiated control, and HAtreated (30 min, 6 h and 24 h) spectra. The loadings
plot indicated irradiation caused a change in protein
secondary structure (Ó β-type structure)
• Student t-tests indicated that the most significant
differences caused by MTX over 24 h were located
between 1300–1000 cm−1
• MTX treatment for 48 h caused significant change in
the protein region with limited changes in the nucleic
acid region compared to 24 h MTX-treated spectra
• The results suggested that MTX metabolic
perturbations occur in two steps over 48 h
• Spectral effects of GMB were detectable, and
classifiable (using cluster analysis) at sub-lethal
doses that induced weak-moderate growth inhibition
(0.1–1 nM, 48–72 h, but not 24 h) and high growth
inhibition (10–100 nM, 24–72 h)
• Effects observed on cell populations were similar to
those observed on single cells
• Several hundred single control cell spectra were
required due to cell cycle heterogeneity among cells
• PCA showed that drug-treated cell spectra clustered
in well-defined areas indicating a cell cycle specific
response. This overlapped with a small region of
control cells with some spectra appearing outside the
control cell cluster, deemed to be “cell cycle plus”
behaviour, i.e. due to drug response not cell cycle
• Early ouabain treatment (6 h) induced limited
changes, mainly to amide I and fingerprint region
(1500–1200 cm−1) compared to 0 h spectra
• Extended ouabain treatment (24 h) caused obvious
changes to lipid-related bands, and a shift in the
amide I band compared to 6-h ouabain-treated
spectra. However, few further effects were observed
between 36 h vs. 24 h ouabain-treated spectra
• Increased intensity of 1080 cm−1 following GMB
treatment in both cell lines
• Increased 1080/1050 cm−1 band ratio up to LD50
doses, plateaued at higher doses in both cell lines
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Notably, the studies presented in Table 4.2 were performed on fixed or dried cell
samples. Traditionally, IRMS sample preparation of mammalian cells involves
chemical fixation (with chemicals such as formalin or ethanol) onto an IR-transparent
substrate (such as MirrR Low-E coated slides, zinc selenide (ZnSe), barium fluoride
(BaF2), or calcium fluoride (CaF2) windows) [28]. While a general consensus in the
literature supports the validity of results obtained from fixed samples, interest in the
use of FTIR microspectroscopy studies employing live cells has grown in the last
decade [29-40]. The advantages and limitations of SR-IRMS studies of hydrated live
cell samples will be discussed in the following section.

4.1.4 SR-IRMS of live cells: advantages and disadvantages
The IRMS analysis of living cells versus fixed cells has gained attention in the last
decade for several reasons. These include: (i) the elimination of artefacts arising from
chemical fixation, (ii) the minimisation of physical artefacts such as resonant Mie
scatter (RMieS) in the spectra, and (iii) the analysis of cells in real-time, providing a
means to monitor the biomolecular effects of cell events or drug treatment in
situ [41-43]. It is generally recognised that a bright light source of IR photons, such as
a synchrotron, is required to obtain good signal-to-noise from single live cell spectra
due to attenuation of the IR signal caused by the IR beam as it passes through two IR
transparent windows, cell medium and the hydrated cell [28]. However, it should be
noted that the collection of live cell spectra has also been successfully performed using
conventional bench-top IR light sources [33, 35].
In the past decade, live cell experiments have been made possible by the
development and fabrication of purpose-built chambers for the maintenance of cell
hydration during data collection. The simplest designs involve placing the cells
between two IR transparent windows (e.g. CaF2, ZnSe, or diamond) separated by a
spacer (< 12 μm) in a demountable holder. These setups have been utilised in a
number of studies [16, 32, 44-49] wherein these devices have been employed
successfully for short-term analyses of live cells.

The holders are not generally

suitable for long-term (> 2 h) measurements due to the loss of cell medium [50]. To
this end, more elaborately designed micro-machined thin-reservoirs have been
employed for live cell studies [23, 33], while a multi-faceted, fully sealed fluidic device
was designed and employed in studies reported by Vaccari et al. [34]. In the latter
system, the cells are introduced into the device via a syringe pump. Additionally,
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lithographed biocompatible materials were used to create separate chambers for the
cells, fresh cell medium and air background measurements [34]. Other groups have
developed more complex flow chambers with an open-channel geometry [51, 52].
One of the reasons that significant effort has focused on maintaining hydration is
to simulate the biochemistry of mammalian cells, and their biomolecules, in particular
nucleic acid bands. For instance, Whelan et al. [42] reported that dehydration causes a
B-like to A-like transition in the DNA of several eukaryotic cells and that the reverse
A-like to B-like transition occurs upon rehydration. This work also showed that upon
rehydration of the cells, sharp DNA-specific bands were observed; however, these
bands were previously broader and less intense when dehydrated. Furthermore,
Vaccari and co-workers [34] performed a study to investigate the effects of cell
fixation methods (air drying, ethanol, and formalin) on the SR-IRMS spectra of U937
monocytes compared to the SR-IRMS spectra of the living U937 cells. Importantly, this
study showed that while formalin fixation produced spectra that were the most
similar to those from live cells (particularly in the lipid and protein regions), effects
were observed in the DNA absorptions. For instance, the band centred at 1717 cm−1
(reflective of base pairing of nucleic acids in the B-form) was pronounced in the live
cell spectra, but absent in the chemical-fixed and dried cell spectra.
The second advantage of performing SR-IRMS studies of live, hydrated cells is the
minimisation of dispersion effects, which is an issue that affects fixed cell studies.
Dispersion artefacts such as RMieS can arise in the spectra of single cells, which are
typically 8–30 μm in diameter (and spherical) and occurs when there is a difference in
the refractive index between the cells and the surrounding environment [53]. This
occurs when the IR wavelength (typically 3–10 μm, or 3333–1000 cm−1) is similar in
size to the diameter of the cell such that the incident IR beam is scattered as it contacts
the outer edges of the cell resulting in the distortion of the collected IR spectrum [53].
Consequently, RMieS can be observed in a single cell spectrum as a highly distorted
baseline (particularly, between 2800–1700 cm−1) and derivative-like peak shapes
arising from predominant bands [54, 55]. Such distortion can lead to alterations in the
position and intensity of spectral features, in particular the amide I band, which is an
important biomarker for diagnostics and an indicator of therapeutic response [53].
The recent development of an algorithm to correct for the effects of RMieS has allowed
researchers to remove the effects of RMieS from single cell spectra [53, 56]. However,
dispersion effects such as RMieS are generally minimised in live cell studies since the
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refractive index of the aqueous background closely matches that of the cell [28].
Therefore, there is no need to apply any RMieS compensation methods, saving analysis
time.
Traditional IRMS studies of fixed cells only allow for static measurements and do
not allow the same cells to be studied at continuous time points. In contrast, in situ
measurements associated with live cell studies are ideal for tracking drug-induced
changes in the same cell over the course of a treatment period. For instance, the effect
of arsenite treatment (100 μM) on K562 leukaemia cells has been analysed in
real-time in a purpose-built micro-fabricated chamber [32] at the Australian
Synchrotron [31]. The authors were able to track spectral changes consistent with the
biochemistry of apoptosis induced by arsenite treatment. Specifically, following
40 min of exposure, a decrease in the ν(C=O) band at 1742 cm−1 in the arsenite-treated
cell spectra was consistent with lipid membrane changes, while the decrease in the
intensities of the νs(PO2−) and νas(PO2−) was attributed to the IR opaqueness of DNA in
an increasingly condensed state. Following 100 min incubation with arsenite, the
intensity of the νs(PO2−) and νas(PO2−) was attributed to DNA fragmentation, an event
in later stages of apoptosis. A significant shift in the amide I band from 1642 cm−1 to
1650 cm−1 in the arsenite-treated cell spectra was observed suggesting arsenate
induces changes in the composition of proteins in the cell (from primarily β-sheet to
α-helix/random coil).
The IRMS analysis of live cells is not without its disadvantages; one particularly
difficult challenge to overcome is the strong IR absorptivity of the water molecule in
aqueous media. The normal modes of liquid water include the asymmetric stretching
mode, the symmetric stretching mode, and the deformation (bending) mode that
appear at ~3600 cm−1, ~3450 cm−1, and ~1643 cm−1, respectively [41]. A broad band
centred at ~2125 cm−1, which is comprised of a combination of a bending band and
the librational modes of water, can also be visualised in cell spectra between 2500–
1800 cm−1 [57]. The water band of particular concern for IRMS spectra is the strong
deformation band at 1640 cm−1 which completely overlaps with the amide I band and
partially with the amide II band of proteins (Fig. 3.3a), resulting in the distortion of the
intensity ratio of the amide I/amide II bands (Fig. 4.3b) [33]. There is currently no
general consensus on the approach to take to correct the effects of water saturation
from the spectrum of a cell, although a number of groups have developed MATLAB
algorithms to correct for the absorption of water [33, 34]; other groups have opted to
154

Chapter 4. Synchrotron radiation infrared microspectroscopy

omit the amide region from chemometric analysis altogether due to the uncertainty
surrounding the influence of water on this region of the spectrum and a lack of a
reliable compensation method [43]. Studies assessing the use of non-aqueous media
have also been performed as an alternative to address the problems associated with
water contribution. For instance, Soh et al. [58] have tested the effects of incubation of
MGH-U1 urothelial cancer cells and Caco-2 cells with paraffin mineral oil or
Fluorolube for up to 120 min. The results showed that cell viability was unaffected
following 2-h incubation in Fluorolube, and differential uptake of drugs was similar
between cells incubated with or without Fluorolube [58]. FTIR mapping of cells
incubated in Fluorolube was performed in reflectance and transmission modes,
whereby the authors claimed that the latter proved best for spectroscopy [58].
However, a comparison between the spectral differences between Fluorolube and cell
medium was not performed or commented on [58]. While oil-based materials could
potentially be employed for the analysis of some clinical samples, ideally cell medium
would be best employed for cell studies measuring time-dependent effects of drugs in
order to maintain an environment that closely matches the conditions employed in
other cell based assays, particularly in the case of longer treatment periods (> 4 h).

Figure 4.3: (a) A single fixed HCT-8 cell spectrum (— ) superimposed with a spectrum
collected from cell medium (— ). The overlap of the bending mode of H2O with the amide I
band of the cell spectrum can be visualised around 1620 cm−1. (b) The distortion of the
amide I to amide II band intensity ratio of an uncorrected, single live HCT-8 cell spectrum
collected in cell medium (cell medium was used for background reference during spectral
acquisition).
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4.1.5 Chapter aims
The work in the previous Chapter suggests that the BiNSAIDs, Bi(tolf)3 and
Bi(mef)3, cause toxicity towards HCT-8 cells that is approximately equivalent to the
respective free NSAIDs, tolfH and mefH, while Bi(difl)3 induced a greater toxic
response compared to diflH. However, the exact mechanisms by which the BiNSAIDs
cause toxicity to the HCT-8 cells are currently unknown. It is, therefore, important to
determine whether BiNSAIDs elicit toxicity through similar or new mechanisms of
action compared to the uncomplexed NSAIDs.
While several groups have recently reported the results from SR-IRMS studies
that employ live cells, and specifically the effects of drug compounds on cancer cell
lines, there are currently no studies that have examined Bi(III) complexes or NSAIDs
on live cancer cells using this technique. Additionally, there is no current consensus
on the pre-processing approach required to reduce the influence of strong
absorptivity of water bands arising from the aqueous environment. As the use of
SR-IRMS for studying the global biomolecular effects of drug-treated cells is still in
relative infancy, the current study was performed to determine the usefulness of
SR-IRMS for the investigation of dominant biomolecular changes that occur following
drug administration, with the focus on the BiNSAIDs and NSAIDs relevant to this
Thesis.
Thus the specific aims of this Chapter are:
1.

To discern any differences in the results of principal component analysis
(PCA) performed on SR-IRMS spectra of HCT-8 cells using two different
approaches aimed to minimise the effects of background water: (i) preprocessing using a water band subtraction method, or (ii) omission of the
amide region from the analysis.

2.

To establish spectroscopically if the biomolecular responses of BiNSAIDs in
HCT-8 cells can be differentiated from those of the corresponding free
NSAIDs following short (4 h) and prolonged (24 h) periods of drug exposure.

3.

To determine whether any observed changes induced by BiNSAID/NSAID are
consistent with known mechanisms of cell death.
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4.2 Materials and Methods
4.2.1 Materials
The materials employed for these studies are described in Sections 2.2.1 and
3.2.1.

Additional materials (specific to the experiments in this Chapter) include

CELLSTAR®

24-well

tissue

culture

plates

sourced

from

Greiner

Bio-One

(Kremsmünster, Austria) and polished CaF2 windows (12 mm diameter, 0.5 mm
thickness) manufactured by Crystran Limited (Poole, England).
4.2.2 General cell culture
Live HCT-8 cells were transported to the Australian Synchrotron (Clayton,
Australia) and cultured onsite using the cell culture procedures described in
Section 2.2.3.
4.2.3 SR-IRMS studies
4.2.3.1 Preparation of cell samples
HCT-8 cells (2.5 × 105 cells, 1 mL growth medium) were grown directly onto CaF2
windows (12 mm diameter, 0.5 mm thickness) that were located in 24-well cell
culture plates. Since the cells did not adhere to the windows rapidly, a stainless steel
spacer with a 5 mm diameter hole was placed on top of each CaF2 window to create a
confined area for the cells to attach. Once the HCT-8 cells had adhered, the spacers
were removed and the cells were incubated for a further period of time.

No

differences in cell morphology were noted between the method employed in this
Chapter and the traditional cell culture method.

Prior to treatment, the growth

medium was removed and the compounds (initially dissolved in DMSO, and added to
1 mL RPMI-1640 medium to produce a final DMSO concentration of 2% v/v) or vehicle
(1 mL RPMI-1640, 2% v/v DMSO) were added to the well. HCT-8 cells were treated
with each BiNSAID at a concentration equal to the approximate IC50 (as determined by
MTT assays, Section 2.3.2), or an equimolar concentration of the corresponding free
NSAID. At the end of the 4- or 24-h period, the cells were washed once with PBS
solution.
SR-IRMS spectra of live HCT-8 cells were collected using the demountable liquid
cell shown in Figure 4.4, details of which (design and specification) have been
described elsewhere [32]. Firstly, the 0.5-mm thick CaF2 window onto which the HCT8 cells were grown was placed at the bottom of the sample holder with the cell surface
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facing upwards. A drop of cell medium (20 μL) was deposited in the centre of the CaF2
window directly above the cells. On top of this was placed the 0.5-mm CaF2 window
with the spacer that had been patterned by polymer spin coating and UV
photolithography. This second CaF2 window was orientated such that the polymer
spacer was in contact with the underlying CaF2 window (Fig 4.4a). Next, a plastic
spacer was placed on top of the CaF2 windows (Fig. 4.4b), after which was placed the
top of the Thermo micro-compression cell (Fig. 4.4c). Excess liquid was expressed
through a gap in the micro-fabricated spacer [32] as the sample holder was tightened
and as the cells came into contact with the top window. It should be noted that HCT-8
cells are generally observed as a mixture of individual cells or as monolayers of cells,
which is typical for the growth pattern of the cell line. Cells that grew in monolayers
appeared to flatten when the sample holder was tightened. It was also observed that
the monolayers showed signs of detachment after treatment, which would account for
this observation. No differences to the morphology of the single cells were noted. In
order to obtain results representative of the entire population, effort was taken to
collect cell spectra from both single cells and cells that could be defined as individual
cells in the cell monolayer.

Figure 4.4: Construction of the compression cell holder components employed for SR-IRMS
measurements: (a) The CaF2 window onto which a spacer had been patterned by polymer spin
coating and UV photolithography was placed on top of the window onto which the HCT-8 cells
were grown. The cells were housed in the centre of the CaF2 window and the channels etched
into the spacer enabled a fully aqueous environment to be maintained; (b) A plastic spacer was
placed on top of the etched CaF2 window; (c) The top of the Thermo micro-compression cell
was placed on top of the CaF2 windows and plastic spacer and tightened until the cells were
observed to come into contact with the top etched CaF2 window.
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The live cell SR-IRMS analyses were limited to approximately 100 min for each
sample due to the loss of cell medium from the demountable liquid cell used in the
present study. As such, the cells were treated in cell culture plates for the desired
period (4 h or 24 h), and the CaF2 substrate with the droplet of fresh cell medium was
placed in the demountable cell for analysis.

4.2.3.2 SR-IRMS data collection
All FTIR spectroscopy measurements were recorded in transmission mode at the
IRM beamline at the Australian Synchrotron (Clayton, Australia). The setup employed
a Bruker Vertex V80v spectrometer coupled to a Hyperion 2000 microscope with a
liquid nitrogen cooled narrow-band mercury cadmium telluride (MCT) detector. The
microscope XYZ stage was housed in a nitrogen-purged atmosphere to minimise
interference from atmospheric water vapor and carbon dioxide. Spectra were
acquired at 4 cm−1 resolution over the range 3800–700 cm−1 (Blackman–Harris
3-Term apodization, Mertz phase correction and a zero fill factor of 2) using OPUS 6.5
software (Bruker Optics GmbH, Ettlingen, Germany). The knife-edge aperture was set
to 5 × 5 µm2 and centred over each cell to ensure only cell material was analysed. Each
cell spectrum was recorded using 128 co-added scans. A background spectrum (128
co-added scans) of cell medium was recorded after collecting every two cell spectra.
Cell spectra were generally collected within 20–100 min after assembly of the sample
holder as the cell medium began to evaporate from the edges of the sandwiched CaF2
windows after this period.
4.2.3.3 SR-IRMS spectral processing and chemometric analysis
The first stage of FTIR spectral processing was performed using OPUS Version 7.0
(Bruker Optics GmbH, Ettlingen, Germany) software. All spectra were restricted to
3020–1000 cm−1. Although the samples were analysed in a N2 purged environment,
weak CO2 bands were observed in a number of the spectra. As such the atmospheric
compensation was applied to minimise the appearance of CO2. In addition, a reference
spectrum collected from the cell medium background for each sample (using the
conditions described in Section 4.2.3.2) was subtracted from each individual cell
spectrum. This was performed in the interactive mode using iterative steps to ensure
that the effects of the water spectrum were minimised without undue
overcompensation of the cell spectrum (Fig. 4.5); the correction value generally varied
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from 0 to −0.09.

Following water subtraction, each spectrum was rubberband

baseline corrected using 64 baseline points.

The Unscrambler X software,

Version 10.2 (Camo, Oslo, Norway) was employed for chemometric analysis. The
spectra were analysed by PCA (full cross validation, 7 PCs) following derivatisation
(second derivative, Savitzky-Golay algorithm, 13 smoothing points) and unit vector
normalisation.

Figure 4.5: Individual cell spectrum (— ) before (top panel) and after (bottom panel) water
subtraction to a correction value of −0.04 using OPUS 7.0. A reference spectrum collected from
the cell medium background is represented in the top panel (— ).
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4.3 Results
4.3.1 Comparison of spectral correction factors used for data analysis
In this Section the SR-IRMS spectra of HCT-8 cells treated with RPMI-1640
containing DMSO (2% v/v, referred to herein as vehicle) and HCT-8 cells incubated
with RPMI-1640 (without fetal bovine serum, penicillin/streptomycin or GlutaMAXTM
solutions, referred to herein as cell medium) have been used to: (i) describe and justify
the correction processes used for the spectral data analyses presented in this Chapter
(Sections 4.3.1.1 and 4.3.1.2), and (ii) produce control data to establish whether any
differences could be detected in the biomolecular signatures of the treated HCT-8 cells
over the course of the drug treatment periods (4 h, Section 4.3.2, or 24 h,
Section 4.3.3).
In general, the SR-IRMS spectra collected from the HCT-8 cells (typical example
shown in Fig. 4.6a) exhibited water saturation. This was observed as the νs(OH) band
typically centred around 3400 cm−1 (not shown in Fig. 4.6a), a decrease in the
intensity ratio of the amide I/amide II bands, and the presence of the water
combination band between 2500–1800 cm−1, which creates a characteristic broad
curve in the spectrum (indicated by the leftmost arrow in Fig. 4.6a). As explained in
Section 4.1.4, the presence of the water band overlapping the amide I band (and to a
lesser extent the amide II band) presents one of the biggest challenges when
interpreting SR-IRMS spectra of live cells. Two approaches were taken in an effort to
extract and interpret the biomolecular differences between the SR-IRMS spectra of the
cell samples: (i) water band correction using spectral subtraction, and (ii) omission of
the amide I and amide II band region (1709–1486 cm−1) from PCA. In addition to the
presence of strong water bands in the SR-IRMS spectra, high noise was observed
below 1150 cm−1 as a result of the poor transmission of IR light. This was due to the
combination of the two CaF2 windows and the small aperture window (5 × 5 μm2)
used in these experiments. As such, spectral data at wavenumbers below 1150 cm−1
were omitted before performing the PCA presented in this Chapter.

4.3.1.1 Water band correction using a spectral subtraction method
The averaged, baseline corrected and vector normalised SR-IRMS spectra of
HCT-8 cells incubated with cell medium (4 h), before and after water band subtraction
are shown in Figure 4.6a. As indicated by the arrows in Fig. 4.6a, the most striking
difference observed between the non-subtracted and water band subtracted SR-IRMS
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spectra was the decrease in the absorbance of the amide II band (1548 cm−1) in
comparison to the amide I band (1653 cm−1), and the flattening of the water
combination band between 2500–1800 cm−1 (this result was expected as the water
combination band was used to determine the amount of correction to apply)
producing a SR-IRMS spectral profile in the amide region more representative of that
observed from fixed cell spectra (see Fig. 4.2).

Figure 4.6: (a) Averaged (n = 59), baseline corrected (rubberband baseline corrected,
64 baseline points), vector normalised HCT-8 cell spectra following 4-h incubation in cell
medium before (— ), and after (— ), water band subtraction. Black arrows indicate the
spectral feature changes substantially affected by water band subtraction. (b) Unit vector
normalised, second derivative of the spectra shown in (a). The wavenumbers in black
represent the non-corrected band positions, while wavenumbers in red represent the water
band subtracted band positions. The black arrows denote bands affected by water band
subtraction.
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Figure 4.6b shows the averaged, normalised, second derivative spectra of the
same

SR-IRMS

spectra

presented

in Figure

4.6a.

The

second

derivative

representations of the averaged SR-IRMS spectra were typically examined as they
resolve the overlapped absorption components, which provide clearer elucidation of
band positions and band shifts [59, 60]. Compared to the non-subtracted second
derivative spectrum, a very slight reduction in the intensity of the amide II band
(1551 cm−1), the region between the amide I and amide II bands (1601–1591 cm−1),
and the ν(C=O) band (1714 cm−1) were observed following water band subtraction (as
indicated by the arrows in Fig. 4.6b). Importantly, however, no differences were
observed in the band positions between the non-subtracted and water band
subtracted spectra (Fig. 4.6b). Following the application of water band subtraction,
these observations were similarly noted when the averaged, normalised, second
derivative SR-IRMS spectrum of the 4-h vehicle-treated cells was examined
(Appendix 3.1), suggesting that the routine application of the water band subtraction
method produces a consistent response across different samples.
When the average SR-IRMS spectrum of HCT-8 cells treated with cell medium was
compared to that of the vehicle, before water band subtraction (Appendix 3.2), there
was only a slight difference in the intensities of the major bands. Additionally, band
shifts of only 1–2 cm−1 were observed in the bands in the CH2/CH3 stretching
region (3000–2800 cm−1), the lipid ν(C=O) band (1742 cm−1) and the amide I band
(1653 cm−1), as indicated in Appendix 3.2a. Given the noise observed in the SR-IRMS
spectra below 1150 cm−1, any shifts in the νs(PO2−) band at 1088 cm−1 are unlikely to
be reliable and these observations have not been discussed further. Following the
application of water band subtraction, the intensities of the SR-IRMS spectra of cell
medium- and vehicle-treated cells showed closer agreement (Appendix 3.2b),
particularly in the fingerprint region (1750–1000 cm−1); however, there was an
increase in the absorbance of the lipid bands, νas(CH3) and νas(CH2) at 2958 cm−1 and
2926 cm−1, respectively, in the average vehicle-treated spectrum. It is noteworthy that
the ν(C=O) bands of lipids and DNA at 1742 cm−1 and 1714 cm−1, respectively, were
less defined following water band subtraction (Appendix 3.2b); although, examination
of the second derivative spectra showed no shift in wavenumber in relation to these
bands (Appendix 3.3a-b). In fact, very little difference was observed between the
averaged second derivative spectra of cell medium- and vehicle-treated cells (4 h)
before and following water band subtraction (Appendix 3.3a-b).
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4.3.1.2 Statistical analysis of data: Principal component analysis (PCA)
The multivariate data analysis technique, PCA, was employed in this study as a
means to distinguish any biomolecular differences between the cell populations
treated with BiNSAIDs or NSAIDs, or within the cell populations themselves. As the IR
spectra contain thousands of wavenumbers (or variables) a statistical method such as
PCA is employed to reduce the complexity of the data set, by creating a small number
of uncorrelated artificial variables, or principal components (PCs), that will account for
most of the variance in the observed variables [60]. The sample variance of the PCs
are represented by eigenvalues and are ranked according to their magnitude, where
the first eigenvalues account for a large portion of the variance of the data [60].
As such, the first PC (PC-1) is the linear combination with maximal variance (the
largest eigenvalue), and the second PC (PC-2) represents the next highest variance in
an orthogonal direction to PC-1 [60, 61]. PCA displays the main patterns as a scores
matrix (or plot), where each point (score) on the plot represents one cell spectrum; as
such, similar spectra cluster together, while dissimilar spectra appear further away
from each other [61, 62]. Additionally, PCA produces loadings plots that provide
information on the variables (spectral bands arising from differences in the
biomolecular groups within the samples in the case of SR-IRMS data), which are the
determinants for the clustering visualised in the scores plots [62]. In this work, PCA
was performed on second derivative SR-IRMS spectra. As such, positive loadings are
associated with scores in the negative space of the scores plot, and negative loadings
are associated with positive scores [31]. Using PCA, the most significant spectral
differences and trends can be identified [62].
The starting point was to use PCA as a tool to evaluate the effect of water band
subtraction. PCA scores plots were generated from spectra without and with water
band subtraction and compared. While it would be ideal to check each non-subtracted
cell spectrum against the water band subtracted spectrum of each individually
corrected cell, this process would be extremely time-consuming given the number of
spectra collected. The average spectra of the cell medium and vehicle-treated cell
spectra (Appendix 3.2 and Appendix 3.3) represent the average of over 50
unsynchronised living HCT-8 cells; as such, differences between the spectra of cells
within the population need to be examined in order to determine whether cells
subjected to different conditions represent biochemically distinct populations.
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Figure 4.7 shows the PCA scores plot and corresponding loadings plots (3000–
2800 cm−1, 1790–1150 cm−1) comparing cell medium- and vehicle-treated cell spectra,
without (Fig. 4.7a) and with (Fig. 4.7b) water band subtraction applied. While some
slight changes to the coordinates of several of the scores can be observed (Fig. 4.7b),
the overall distribution of the scores appears very similar to the scores plot obtained
from the spectra without water band subtraction (Fig. 4.7a). Additionally, the same
bands in the loadings plots of both the non-subtracted (Fig. 4.7a), and water band
subtracted cells (Fig. 4.7b) were responsible for the distribution of the scores along
the PC-1 and PC-2 axes. Consequently, these results indicate that there is negligible
difference to the outcome of the PCA when water band subtraction is applied to the
SR-IRMS spectra of the HCT-8 cells compared to non-subtracted spectra.

Figure 4.7: PCA scores plot (left) and corresponding PC-1 (— ) and PC-2 (— ) X-loadings plots
(right) of second derivative (Savitzky Golay, 13 smoothing points), unit vector normalised
SR-IRMS spectra obtained from HCT-8 cells treated for 4 h with cell medium (n), or vehicle
(RPMI-1640, DMSO 2% v/v) (l): (a) before water band subtraction, and (b) after water band
subtraction. PCA was performed on the spectra, encompassing all biological regions of interest
(3000–2800 cm−1, 1790–1150 cm−1).
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When the amide bands were omitted (1709–1486 cm−1) from the PCA (Fig. 4.8) of
second derivative SR-IRMS 4-h cell medium- or vehicle-treated spectra, without
(Fig. 4.8a) and with (Fig. 4.8b) water band subtraction applied, there was negligible
difference observed between the scores plots of the non-subtracted or water band
subtracted spectra. Additionally, negligible difference was observed in the loadings
plot of the water band subtracted spectra (Fig. 4.8b) compared to the non-subtracted
spectra (Fig. 4.8a). Consequently, the analysis presented in the remainder of this
Chapter was performed on non-subtracted spectra.

Figure 4.8: PCA scores plot (left) and corresponding PC-1 and PC-2 X-loadings plots (right) of
second derivative (Savitzky Golay, 13 smoothing points), unit vector normalised SR-IRMS
spectra obtained from HCT-8 cells treated for 4 h with cell medium (n), or vehicle
(RPMI-1640, DMSO 2% v/v) (l). PCA was performed on the spectra (3000–2800 cm−1, 1790–
1710 cm−1, and 1485–1150 cm−1) with the omission of the amide region (1709–1486 cm−1):
(a) before water band subtraction, and (b) after water band subtraction.

4.3.1.3 Effects of vehicle on live HCT-8 cells (4-h study)
Having shown the rationale for the data analysis, the next step was to interpret
the results with respect to the cell treatment. Figure 4.7a (Section 4.3.1.1) shows the
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PCA scores plot and corresponding loadings plots (3000–2800 cm−1, 1790–1150 cm−1)
that compare 4-h cell medium- and vehicle-treated cell spectra, without water band
subtraction applied. The scores plot shows complete overlap of the cell medium and
vehicle scores and no distinct clustering of either group. This result suggests that
there were no substantial biomolecular differences between the two treatment
groups, and that heterogeneity among the SR-IRMS spectra of the cells within each
sample is responsible for the distribution of the scores along both the PC-1 and PC-2
axis. The PC-1 loadings plot indicated that the lipid-related bands, νas(CH2), νs(CH2)
and ν(C=O) (2924 cm−1, 2852 cm−1 and 1743 cm−1, respectively), and loadings related
to the amide I band (1662 cm−1, 1649 cm−1 and 1637 cm−1) are the predominant bands
causing the distribution of the spectra along the PC-1 axis. The PC-2 loadings plot
(Fig. 4.7a) indicated that the lipid-related bands, νas(CH2), νs(CH2) and ν(C=O)
(2926 cm−1, 2854 cm−1 and 1745 cm−1, respectively), and loadings related to the amide
I band (1662 cm−1 and 1647 cm−1) and amide II band (1562 cm−1 and 1539 cm−1) are
the predominant bands causing the distribution of the spectra along the PC-2 axis.
These results suggest that variations in cellular proteins and lipids were present in
each population.

This result is not unexpected as the cells were not cell cycle

synchronised; thus the distribution of cells throughout different phases of the cell
cycle could be the likely cause of heterogeneity amongst the two populations. This is
also consistent with other live cell studies that have shown that cells have distinct
biomolecular signatures at different phases of the cell cycle [43].
Figure 4.8a shows the PCA scores and loadings plots of second derivative SR-IRMS
4-h cell medium- or vehicle-treated spectra following omission of the amide region
(3000–2800 cm−1, 1790–1710 cm−1, 1485–1150 cm−1), without water band
subtraction. Both the cell medium and the vehicle scores were distributed across both
the positive and negative PC-1 space. Once again, this suggests that heterogeneity
exists within both cell populations, and that the biomolecular differences that exist
within each sample are more dominant than the biomolecular differences that exist
between the two samples. In contrast to Figure 4.7a (amide region included), the
loadings plot in Figure 4.8a shows that there are strong lipid-related loadings at
2924 cm−1 (νas(CH2)), 2839 cm−1 (νs(CH2)), and 1745 cm−1 (ν(C=O)) and a weak loading
at 1464 cm−1 (δ(CH2)) that are responsible for the distribution of the scores along
PC-1. This observation suggests that variation in cellular lipids exists between the
SR-IRMS spectra in both the cell medium-, and vehicle-treated cell populations. Along
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the PC-2 space, there was no clear delineation of the two samples, although, the scores
obtained from the cell medium-treated cells appeared predominantly in the positive
PC-2 space, while the scores from vehicle-treated cells appeared predominantly in the
negative PC-2 space. Figure 4.8a shows that strong loadings in the region between
1250-1150 cm−1 were observed, which were not present in the loadings plot of the
PCA performed with the amide region included (Fig. 4.7a); the loadings at 1252 cm−1,
1238 cm−1, and 1227 cm−1 are associated with the νas(PO2−) band of nucleic acids.
Additionally, the derivative-like bands at 2931 cm−1 and 2847 cm−1 are indicative of
band shifts of lipids. These observations may indicate that the 4-h DMSO (2% v/v)
exposure may induce changes to lipid and nucleic acid concentrations in HCT-8 cells.

4.3.1.4 Effect of vehicle on live HCT-8 cells (24-h study)
HCT-8 cells were incubated with cell medium or vehicle for 24-h in order to
correlate with the treatment period employed in the toxicity and uptake experiments
performed with the HCT-8 cells (Chapter 2 and 3, respectively). The averaged,
baseline corrected and vector normalised SR-IRMS spectra of HCT-8 cells treated with
cell medium or vehicle (24 h), before and following water band subtraction are shown
in Appendix 3.4. Similar to the 4-h samples (Appendix 3.2), only small differences
could be observed when comparing the 24-h average cell medium and vehicle-treated
cell spectra, before or following water band subtraction (Appendix 3.4). Additionally,
the effects of water band subtraction were also consistent with the effects observed on
the 4-h samples (Appendix 3.2); specifically, the intensity ratio of the amide I/amide II
bands were affected, and the intensity of the ν(C=O) bands at 1743 cm−1 and
1715 cm−1 were slightly reduced (Appendix 3.4). A slight shift in the band centres of
the ν(C=O) bands was observed following water band subtraction (Appendix 3.4a
and b); however, no band shift was noted in the respective second derivative spectra
(Appendix 3.5a and b). Little difference was observed in the second derivative spectra
when comparing the cell medium- and vehicle-treated cells with the exception of the
line shape of the νas(PO2−) centred at 1240 cm−1 (and shoulder at 1227 cm−1)
(Appendix 3.5a and b). This might indicate that the presence of vehicle induces small
changes to the nucleic acid composition of the HCT-8 cells following 24-h incubation.
The PCA scores plot in Figure 4.9a, which includes the amide region (3000–2800 cm−1,
and 1790–1150 cm−1), showed there was no delineation of the 24-h cell medium and
vehicle scores along the PC-1 or PC-2 axes between the sample sets suggesting that the
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biomolecular differences that exist within each sample are more dominant than the
biomolecular differences that exist between the two samples. The PC-1 loadings (Fig.
4.9a) were attributable to CH2 stretches at 2924 cm−1 and 2852 cm−1 (νas(CH2) and
νs(CH2), respectively), and the ester stretch at 1743 cm−1 (ν(C=O)), which are bands
associated with lipids, amide-related bands at 1657 cm−1, 1549 cm−1, and 1398 cm−1
(amide I, amide II and νs(COO−)), and the ν(C=O) band at 1716 cm−1, related to DNA.
The

derivative-like

band

shapes

in

the

PC-2

loadings

plot

(Fig. 4.9a) indicated that shifts in the positions of the νas(CH2), ν(C=O), amide I,
amide II and νas(PO2−) bands were contributing to the distribution of the scores along
the PC-2 axis. These observations suggest that intra-sample variations in the
composition of lipid, protein, and the DNA exist within both of the cell populations.

Figure 4.9: PCA scores plot (left) and corresponding PC-1 (— ) and PC-2 (— ) X-loadings plots
(right) of second derivative (Savitzky Golay, 13 smoothing points), unit vector normalised
SR-IRMS spectra obtained from HCT-8 cells treated for 24 h with cell medium alone (n), or
vehicle (RPMI-1640, DMSO 2% v/v) (l): (a) including the amide region (3000–2800 cm−1,
1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1, 1790–1710 cm−1,
1485–1150 cm−1).
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Once again, this observation could potentially be attributed to the lack of cell cycle
synchronisation.
Figure 4.9b shows the PCA scores and loadings plots obtained using the cell
medium-, or vehicle-treated (24 h) SR-IRMS spectra presented in Figure 4.9a, but with
the omission of the amide region (1709–1486 cm−1). As with Figure 4.9a, the scores
plot showed no sign of delineation of the cell medium or vehicle scores from one
another (Fig. 4.9b); again intra-sample variation appeared to be the predominant
source of the biomolecular differences in these samples. In the absence of the amide
region, lipid-related bands (2924 cm−1 (νas(CH2)), 2854 cm−1 (νs(CH2)), and 1743 cm−1
(ν(C=O)) dominated the PC-1 loadings plot (Fig. 4.9b). Interestingly, omission of the
amide region resulted in tighter distribution of the scores along the PC-2 axis as
shown in the scores plot in Figure 4.9b. The results (Fig. 4.9a and b) indicate that the
strong amide I loadings may be responsible for the wider distribution of scores along
the PC-2 axis in the scores plot when the amide region is included (Fig. 4.9a).
As shown in Figure 4.9b, the most pronounced PC-2 loadings were the νas(CH2) and
νs(CH2) bands, which appeared as a derivative-like shape, indicative of a band shift.
Some weak PC-2 loadings contributions from the νas(PO2−) band (1259–1217 cm−1)
were also evident. Overall, the PCA performed without the amides present suggests
that intra-sample lipid variations exist in the cell spectra of the cell medium- and
vehicle-treated samples. As no separation of the cell medium- or vehicle-treated cell
spectra scores is evident, the PCA results suggest that the intra-sample spectral
variation within each of these treatment populations is dominant over any spectral
variations occurring as a result of the two treatments.
The PCA results appear to suggest that DMSO has little observable effect on the
SR-IRMS HCT-8 cell spectra following 24-h incubation, as compared to the SR-IRMS
spectra of HCT-8 cells incubated with cell medium alone.

4.3.2 Comparison of the effects of BiNSAIDs, and the respective NSAIDs, on SRIRMS spectra of live HCT-8 cells
4.3.2.1 Bi(tolf)3- and tolfH-treated cells (4-h treatment)
The averaged SR-IRMS spectra (29–54 spectra recorded for each treatment) of
vehicle-, Bi(tolf)3-, and tolfH-treated cells showed a few notable distinctions from each
other following 4-h treatment as shown in Appendix 3.6. Notably, the Bi(tolf)3- and
tolfH-treated average cell spectra showed an increase in intensity of the νas(CH2) and
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νs(CH2) bands (2924 cm−1 and 2853 cm−1, respectively) compared to the vehicletreated average spectrum (Appendix 3.6a). In addition, the average tolfH-treated
spectrum showed a distinctive shift in the νas(PO2−) band (from 1240 cm−1 to
1232 cm−1) when compared to the vehicle-treated average spectrum (Appendix 3.6a),
while the Bi(tolf)3-treated average spectrum showed only a slight shift to 1238 cm−1.
The substantial shift in the νas(PO2−) was also identifiable in the average second
derivative spectrum of tolfH-treated cells (Appendix 3.6b), with a less substantial shift
in the Bi(tolf)3-treated average spectrum compared to the vehicle (Appendix 3.6b).
A change associated with the nucleic acids is observed as a the frequency shift of the
ν(C=O) band from 1716 cm−1 (vehicle) to 1718 cm−1 and 1720 cm−1, in the
Bi(tolf)3- and tolfH-treated average spectra, respectively (Appendix 3.6b).
A comparison of the SR-IRMS spectra following 4-h treatment with vehicle,
Bi(tolf)3, or tolfH, is shown in the PCA (3000–2800 cm−1, 1790–1150 cm−1) scores and
loadings plots in Figure 4.10a. At first glance it was observed that both the Bi(tolf)3 or
tolfH scores overlap with the vehicle scores and that there is no clear delineation of
the clustering between the three populations. However, on closer inspection the tolfH
scores appear to show an increased proportion of positive PC-1 scores compared to
the vehicle (which appear to be predominantly negative PC-1 scores). There appears
to be even distribution of Bi(tolf)3 in both the negative and positive PC-1 scores. The
PC-1 loadings plot in Figure 4.10a shows that the positive PC-1 scores were associated
with strong negative loadings from methylene vibrations at 2924 cm−1 and 2854 cm−1
(νas(CH2) and νs(CH2), respectively), and moderate to weak negative loadings observed
at 1466 cm−1 (δ(CH2)) and 1745 cm−1 (ν(C=O)). These observations may indicate that
there was a difference in lipid composition in subpopulations of the tolfH-treated cells
and Bi(tolf)3-treated cells, compared to the majority of the vehicle-treated cells. Two
weak positive PC-1 loadings related to the amide I band, at 1693 cm−1 and 1620 cm−1,
were associated with the aforementioned scores, which may suggest a change in the
composition of cellular proteins following NSAID treatment. The negative PC-1 scores
(consisting of the majority of the vehicle scores, and some of the Bi(tolf)3 scores) were
correlated with moderate to weak positive loadings associated with proteins including
1662 cm−1 and 1639 cm−1 (amide I), 1549 cm−1 (amide II), and 1398 cm−1 (νs(COO−))
(Fig. 4.10a). A weak positive loading at 1248 cm−1 (νas(PO2−)), associated with nucleic
acids, was also correlated with the negative PC-1 scores. Along PC-2, there was no
clear distinction of the three sample groups; in fact, the relatively even distribution of
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the samples along PC-2 suggests intra-sample variation was greater for each of the
three samples than the inter-sample variation. The PC-2 loadings showed derivativelike loadings (indicative of band shifts) in the amide I region suggesting that cellular
protein composition was the greatest determinant of intra-sample variability. Weak
contributions from lipid loadings also contributed to intra-sample variability, with no
contributions from the lower wavenumber region of the spectrum (< 1500 cm−1)
evident in the loadings plot (Fig. 4.10a).

Figure 4.10: PCA scores plot and corresponding PC-1 and PC-2 X-loadings plots generated
from the second derivative (Savitzky Golay, 13 smoothing points), unit vector normalised
SR-IRMS spectra obtained from HCT-8 cells following 4 h treatment with vehicle (RPMI-1640,
DMSO 2% v/v) (n), Bi(tolf)3 (l), or tolfH (p) (45 μM NSAID); (a) including the amide region
(3000–2800 cm−1, 1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1,
1790–1710 cm−1, 1485–1150 cm−1).

Figure 4.10b shows the results of PCA comparing second derivative spectra
obtained from the 4-h vehicle-, Bi(tolf)3-, or tolfH-treated cells, with the omission of
the amide region (1709–1486 cm−1). As the PCA scores plot in Figure 4.10b shows, the
tolfH scores exhibit some delineation from both the vehicle and Bi(tolf)3 scores along
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PC-2 following removal of the amide region. However, closer inspection of the PCA
scores plot in Figure 4.10b reveals that a similar proportion of tolfH and Bi(tolf)3
scores appear on the opposite side of the PC-1 axis when compared to the PCA scores
plot in Figure 4.10a (albeit on the reverse side of the PC-1 axis). Additionally the two
PC-1 loadings plots in Figure 4.10 show comparable contributions from similar bands
(although the PC-1 loadings plot appears to be inverted in Fig. 4.10b). Thus, the
subpopulations of Bi(tolf)3 and tolfH scores were associated with strong positive
loadings from the νas(CH2), νs(CH2), and moderate to weak loadings from the ν(C=O)
and δ(CH2) bands of lipids, indicating a change in the lipid composition of
subpopulations of the NSAID-treated cells compared to the vehicle-treated cells. The
obvious change in the distribution of the tolfH scores along PC-2 was accompanied by
an increase in the PC-2 loadings contributions from bands in the 1465–1150 cm−1
region following the removal of the amide region from the PCA (Fig. 4.10b). The
positive PC-2 scores (vehicle and Bi(tolf)3 scores only) were associated with the strong
ν(C=O) loading at 1745 cm−1, the νas(PO2−) band of nucleic acids at 1246 cm−1; and the
νs(COO−) band at 1398 cm−1. These changes demonstrate that lipids, proteins, and
nucleic acids are differently affected by tolfH compared to Bi(tolf)3 in the HCT-8 cells
following 4-h treatment.

4.3.2.2 Bi(tolf)3- and tolfH-treated cells (24-h treatment)
The averaged SR-IRMS spectra of vehicle-, Bi(tolf)3, and tolfH-treated cells
(between 33–100 spectra recorded for each treatment) did not show very many
differences from each other following 24-h treatment, as displayed in Appendix 3.7. It
was evident that the average tolfH-treated cell spectrum showed reduced intensity in
the lipid region (3000–2800 cm−1), the ν(C=O) band (1740 cm−1) and the νas(PO2−)
band, indicating that tolfH treatment may reduce cellular lipid and nucleic acid
concentration. In contrast to the 4-h samples (Appendix 3.6), there were only subtle
differences in the line shape of the νas(PO2−) band in the 24-h second derivative
spectra of the average tolfH- and Bi(tolf)3-treated cells compared to the vehicletreated cells (Appendix 3.7).
Figure 4.11 shows the PCA comparison of the SR-IRMS spectra of the single HCT-8
cells following 24-h treatment with vehicle, Bi(tolf)3, or tolfH. The scores plot
(Fig. 4.11a) shows that the vehicle and Bi(tolf)3 scores were distributed across PC-1
with no delineation from each other; however, a small Bi(tolf)3 subpopulation cluster
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may be distinguished in the PC-1/PC-2 negative spaces (Fig. 4.11a). While there was
no obvious delineation of the tolfH scores from the other two samples, it was observed
that the tolfH scores appeared as predominantly positive PC-1 scores in a
comparatively tight cluster (Fig. 4.11a); additionally, the tolfH scores appeared
primarily in the negative PC-2 space.

The negative PC-1 scores (comprised of

subpopulations of vehicle and Bi(tolf)3 scores, Fig. 4.11a) were associated with strong
loadings from lipid bands including νas(CH2), νs(CH2), ν(C=O) and δ(CH2). Conversely,
negative PC-1 loadings indicative of proteins at 1655 cm−1, 1549 cm−1 and 1398 cm−1
(amide I, amide II, and νs(COO−), respectively) were correlated with the positive PC-1

Figure 4.11: PCA scores plot and corresponding PC-1 and PC-2 X-loadings plots of second
derivative (Savitzky Golay, 13 smoothing points), unit vector normalised SR-IRMS spectra
obtained from HCT-8 cells following 24 h treatment with vehicle (RPMI-1640, DMSO 2% v/v)
(n), Bi(tolf)3 (l), or tolfH (p) (45 μM NSAID); (a) including the amide region (3000–2800
cm−1, 1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1, 1790–
1710 cm−1, 1485–1150 cm−1).
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scores (comprised of a large tolfH population, Fig. 4.11a). These results suggest that
treatment with tolfH results in lipid and protein changes. The PC-2 loadings plot
showed that the majority of the tolfH scores and the Bi(tolf)3 subpopulation of scores
in the negative PC-2 space were associated with the νas(CH2), νs(CH2) and ν(C=O) lipidrelated bands (Fig. 4.11a). The derivative-like shift in the amide I and amide II bands
of the PC-2 loadings plot (Fig. 4.11a) suggests there is a band shift between the treated
populations in the PC-2 negative space and the vehicle (and some Bi(tolf)3 scores) in
the PC-2 positive space.
As shown in the scores plot in Figure 4.11b, the relatively tight clustering of the
tolfH scores was still apparent following the removal of the amide region (1709–
1486 cm−1) from PCA. The Bi(tolf)3 subpopulation could also be identified in the PC-1
negative/PC-2 positive space (Fig. 4.11b). Again, strong lipid loadings arising from
νas(CH2), νs(CH2), ν(C=O), and δ(CH2) bands (2924 cm−1, 2852 cm−1, 1743 cm−1, and
1466 cm−1, respectively) were observed and associated with the PC-1 negative scores
(comprised of subpopulations of vehicle and Bi(tolf)3 scores) in Figure 4.11b. The
removal of the amide region from the PCA increased the intensity of the nucleic acid
(νas(PO2−)) PC-2 loadings at 1239 cm−1 and 1227 cm−1 and the lipid-related
νas(CO−O−C) loading at 1160 cm−1 (Fig. 4.11b). Derivative-like loadings were observed
in the PC-2 loadings for the νas(CH2) and νs(CH2) lipid-related bands when the amides
were omitted (Fig. 4.11b), in contrast to the non-derivative bands in Figure 4.11a.
These observations suggest the lipid and nucleic acid SR-IRMS signatures of these
BiNSAID- and NSAID-treated subpopulations differed from the majority of the vehicletreated cell spectra following 24-h treatment.

4.3.2.3 Bi(mef)3- and mefH-treated cells (4-h treatment)
The averaged SR-IRMS spectra of vehicle-, Bi(mef)3, and mefH-treated cells
(between 42–83 spectra recorded for each treatment) showed some differences
following 4-h treatment as shown in Appendix 3.8. When compared to the average
vehicle-treated cell spectrum, the average Bi(mef)3-treated spectrum showed a
slightly increased intensity in the lipid region (3000–2800 cm−1) and the νas(PO2−),
whereas

the

average

mefH-treated

spectrum

showed

the

opposite

trend

(Appendix 3.8a). However, the average second derivative spectra of the Bi(mef)3- and
mefH-treated cells showed very little variation in line shape when compared to each
other (Appendix 3.8b); additionally, both the mefH and Bi(mef)3-treated average
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spectra showed the same variation in the line shape of the δ(CH2) and νas(PO2−) bands
when compared to the average vehicle-treated spectrum (Appendix 3.8b).
Figure 4.12a shows the PCA scores plot comparison of the SR-IRMS spectra
(3000–2800 cm−1, 1790–1150 cm−1) of single HCT-8 cells following 4-h treatment with
vehicle, Bi(mef)3, or mefH. There was no clear delineation observed between the
vehicle, Bi(mef)3 and mefH score populations; however, the majority of the Bi(mef)3
and mefH PC-1 scores were positive, whereas the vehicle PC-1 scores were
predominantly negative (Fig. 4.12a). The PC-1 loadings plot (Fig. 4.12a) indicated that
the majority of the Bi(mef)3 and mefH scores are associated with strong loadings
arising from the νas(CH2), νs(CH2), and νas(C=O) bands (2924 cm−1, 2852 cm−1, and
1743 cm−1, respectively), which may indicate that differences between the
mefH/Bi(mef)3-treated cells and the vehicle-treated cells were attributed to the lipid
bands. Conversely, the PC-1 scores primarily associated with vehicle-treated cells
were correlated with loadings attributed to amide I, amide II and νs(COO−) bands of
proteins at 1637 cm−1, 1533 cm−1, and 1396 cm−1, respectively (Fig. 4.12a).

The

relatively even distribution of the scores of all three samples across the negative and
positive PC-2 space suggests that intra-sample variation was dominant over intersample variation. Moderate PC-2 loadings attributable to lipids (2926 cm−1, 2854
cm−1, and 1745 cm−1) and strong derivative-like amide I loadings (1660 cm−1, 1647
cm−1, and 1635 cm−1) suggest variation in the lipid composition and protein structure
in the populations of each of the three cell groups.
As shown in Figure 4.12b, the PCA was performed with the omission of the amide
region (1709–1486 cm−1) on the same SR-IRMS spectra analysed in Figure 4.12a.
Notably, in Figure 4.12b the vehicle scores cluster was almost separated from that of
the Bi(mef)3 and mefH scores, which were completely overlapped.

A higher

proportion of vehicle PC-1 scores were positive, while the higher proportion of the
Bi(mef)3 and mefH PC-1 scores were negative; however, some intra-sample variation
was evident in PC-1, as indicated by the spread of the three separate populations over
the negative and positive sides of the PC-1 space. As shown in the PC-1 loadings plot
in Figure 4.12b, the majority of the Bi(mef)3 and mefH PC-1 scores were associated
with strong loadings arising from the νas(CH2), νs(CH2), and ν(C=O) lipid-related bands,
similar to the results of the PCA inclusive of the amides (Fig. 4.12a). In the PC-2
loadings plot (Fig. 4.12b) it was observed that the removal of the amide region from
the PCA increased the intensity of the nucleic acid νas(PO2−) loadings at 1244 cm−1 and
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1223 cm−1 and the lipid νas(CO−O−C) loading at 1176 cm−1. Derivative-like loadings
were observed in the PC-2 loadings for the lipid bands νas(CH2) and νs(CH2), and the
νas(PO2−) nucleic acid band, indicating a change in the band position between the
vehicle scores and the NSAID scores.

Figure 4.12: PCA scores plot and corresponding PC-1 and PC-2 X-loadings plots of second
derivative (Savitzky Golay, 13 smoothing points), unit vector normalised SR-IRMS spectra
obtained from HCT-8 cells following 4 h treatment with vehicle (RPMI-1640, DMSO 2% v/v)
(n), Bi(mef)3 (l), or mefH (p) (120 μM NSAID); (a) including the amide region (3000–
2800 cm−1, 1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1, 1790–
1710 cm−1, 1485–1150 cm−1).

4.3.2.4 Bi(mef)3- and mefH-treated cells (24-h treatment)
The averaged SR-IRMS spectra of vehicle-, Bi(mef)3, and mefH-treated cells
(between 54–95 spectra recorded for each treatment) also showed some differences
from each other following 24-h treatment as shown in Appendix 3.9. It was evident
that the average Bi(mef)3- and mef-treated cell spectra showed reduced intensity in
the νas(CH2), νs(CH2), and ν(C=O) bands, indicating that Bi(mef)3-treatment may
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reduce cellular lipid concentrations (Appendix 3.9a). Additionally, there were some
variations in the line shape of the νas(PO2−) band in the average second derivative
spectra of the mefH- and Bi(mef)3-treated cells (Appendix 3.9b) compared to the
vehicle-treated cells.
A comparison of the SR-IRMS spectra of the single HCT-8 cells following 24-h
treatment with vehicle, Bi(mef)3, or mefH, is shown in the PCA scores plot in
Figure 4.13a (examining the 3000–2800 cm−1 and 1790–1150 cm−1 regions). The
majority of the Bi(mef)3 scores appear in the negative PC-1 space and show some
delineation from the vehicle scores; however, the mefH scores appear to be
distributed across the positive and negative PC-1 space, overlapping with both the
Bi(mef)3 scores, and some of the vehicle scores.

Figure 4.13: PCA scores plot and corresponding PC-1 and PC-2 X-loadings plots of second
derivative (Savitzky Golay, 13 smoothing points), unit vector normalised SR-IRMS spectra
obtained from HCT-8 cells following 24 h treatment with vehicle (RPMI-1640, DMSO 2% v/v)
(n), Bi(mef)3 (l), or mefH (p) (120 μM NSAID); (a) including the amide region (3000–
2800 cm−1, 1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1, 1790–
1710 cm−1, 1485–1150 cm−1).
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The PC-1 loadings plot shows that νas(CH2), νs(CH2), and νas(C=O) lipid-related
loadings at 2924 cm−1, 2854 cm−1 and 1743 cm−1, respectively, are associated with the
vehicle and a proportion of the mefH scores on the positive PC-1 scores. The strong
loading originated from the amide I band at 1637 cm−1 and was associated with the
Bi(mef)3, negative PC-1 scores. Intra-sample variation was observed along PC-2,
resulting from moderate lipid loadings, and strong amide I and amide II protein
loadings.
As shown in Figure 4.13b, the PCA was performed with the omission of the amide
region (1709–1486 cm−1) on the same SR-IRMS spectra analysed in Figure 4.13a. The
majority of the Bi(mef)3 scores appear in the positive PC-1 space with a small number
extending into the negative PC-1 space that overlaps with the vehicle scores. Again,
the mefH scores appear to be distributed across the positive and negative PC-1 space,
overlapping with both the positive Bi(mef)3 scores, and some of the negative vehicle
scores. Similarly to the amide inclusive PCA (Fig. 4.13b), the PC-1 loadings plot shows
that lipid loadings at 2924 cm−1, 2854 cm−1 and 1743 cm−1 are associated with the
vehicle and the small proportion of the Bi(mef)3 and mefH scores on the positive PC-1
scores. With the omission of the amide region, the PC-2 loadings plot has some
obvious differences to the amide inclusive PC-2 loadings plot. Specifically, the νas(CH2)
and νs(CH2) bands are now derivative-like in shape, indicating a band shift within each
sample. Additionally, the intensity of the νas(PO2−) loadings at 1240 cm−1 and
1228 cm−1, and the νas(CO−O−C) loadings at 1184 cm−1 and 1158 cm−1 were increased.

4.3.2.5 Bi(difl)3- and diflH-treated cells (4-h treatment)
As shown in Appendix 3.10, the averaged Bi(difl)3- and diflH-treated cell spectra
showed a decrease in the intensity of the νas(CH2) and νs(CH2) bands (2624 cm−1 and
2952 cm−1) and lack of definition of the ν(C=O) band at 1745 cm−1 (particularly in the
case of diflH). The averaged Bi(difl)3-treated second derivative spectrum showed
substantial differences in the δ(CH2) and νas(PO2−) bands at 1466 cm−1 and 1248 cm−1,
respectively, compared to both the averaged vehicle- and diflH-treated second
derivative spectra (Appendix 3.10b). Also evident was the appearance of a slight
shoulder on the amide I band of the diflH-treated average second derivative
spectrum (Appendix 3.10b).
Individual second derivative spectra of vehicle-, Bi(difl)3- and diflH-treated cells
were examined using PCA, and the resulting scores and loadings plots (examining the
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3000–2800 cm−1 and 1790–1150 cm−1 regions) are presented in Figure 4.14a.
The diflH scores were spread across both sides of the PC-1 axis, whereas both the
vehicle and Bi(difl)3 scores showed a higher degree of clustering relative to the diflH
scores. Disparity among the amide I bands appears to be the major contributor to the
distribution of the scores along PC-1, particularly for the diflH scores. On the PC-2 axis
there was no clear delineation observed between the vehicle, Bi(difl)3 and diflH score
populations; however, for the majority of the Bi(difl)3 and diflH (the latter even more
so), the PC-2 scores were primarily positive values, whereas the vehicle scores
appeared as predominantly negative PC-2 values.

Figure 4.14: PCA scores plot and corresponding PC-1 and PC-2 X-loadings plots of second
derivative (Savitzky Golay, 13 smoothing points), unit vector normalised SR-IRMS spectra
obtained from HCT-8 cells following 4 h treatment with vehicle (RPMI-1640, DMSO 2% v/v)
(n), Bi(difl)3 (l), or diflH (p) (225 μM NSAID); (a) including the amide region (3000–
2800 cm−1, 1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1, 1790–
1710 cm−1, 1485–1150 cm−1).
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It was observed in the PC-2 loadings plot that the amide I and amide II bands
were the main source of the variation, with the derivative-like shape of the amide I
band, indicative of a band shift. The PC-2 loadings arising from lipid bands were
associated with the positive PC-2 scores, primarily composed of Bi(difl)3 and diflH
scores.
The PCA scores plot following the omission of the amide region (1709–
1486 cm−1) for the comparison of the vehicle-, Bi(difl)3, and diflH-treated cell
spectra (Fig. 4.14b) shows a substantial difference in the distribution of the three
sample populations compared to the amide inclusive PCA scores plot (Fig. 4.14a).
As observed in Figure 4.14b, the vehicle and diflH scores appear to completely overlap,
while the Bi(difl)3 scores are primarily distributed over negative PC-1 and PC-2 values
and only partially overlap with the other treatments. The distribution of the three
samples across the PC-1 axis suggests that intra-sample variation is predominant over
any inter-sample variations; the PC-1 loadings plot indicates that the lipid-associated
bands, νas(CH2), νs(CH2), and ν(C=O) bands (2926 cm−1, 2854 cm−1, and 1745 cm−1,
respectively) are the source of this variation (Fig. 4.14b). Inter-sample differences
could be observed by the minimal overlap of the Bi(difl)3 negative PC-2 scores from
the predominantly positive PC-2 vehicle and diflH scores (Fig. 4.14b). The PC-2
loadings plot indicates that the positive loadings attributable to lipids (δ(CH)2 at
1466 cm−1), proteins (amide III at 1321 cm−1), and nucleic acids (νas(C=O) at
1718 cm−1) are associated with the PC-2 negative Bi(difl)3 scores (Fig. 4.14b).
Negative PC-2 loadings designated to lipids (νas(CH2) at 2920 cm−1, and νs(CH2) at
2850 cm−1), proteins (νs(COO−) at 1396 cm−1) and nucleic acids (νas(PO2−) at
1246 cm−1) are associated with the positive scores, consisting primarily of vehicle and
diflH scores (Fig. 4.14b).

4.3.2.6 Bi(difl)3- and diflH-treated cells (24-h treatment)
As shown in Appendix 3.11a, a comparison of the average SR-IRM spectra of 24-h
vehicle-, Bi(difl)3- or diflH-treated cells revealed that the diflH-treated sample showed
a strong increase in the bands associated with lipids (3000–2800 cm−1 and 1740 cm−1).
Additionally, the averaged diflH-treated second derivative spectrum showed
substantial differences in the δ(CH2) band at 1466 cm−1 compared to both the
averaged vehicle- and Bi(difl)3-treated second derivative spectra (Appendix 3.11b).
Figure 4.15a shows the scores and loadings plots (examining the 3000–2800 cm−1
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and 1790–1150 cm−1 regions) obtained following PCA of the individual second
derivative spectra obtained from the vehicle-, Bi(difl)3- and diflH-treated cells.
Although there was substantial overlap of the clusters between the three samples on
the scores plot, the diflH scores appeared almost exclusively as negative PC-1 scores
(Fig. 4.15a). These scores were associated with strong νas(CH2), νs(CH2) and ν(C=O)
loadings of lipids. The positive PC-1 scores composed of vehicle and Bi(difl)3 scores
were associated with moderate loadings from the amide I and amide II bands of
proteins. All three samples showed scores distribution along the PC-2 axis suggesting
intra-sample variation appeared to be the predominant factor in the PC-2 distribution
of the samples. The loadings plot suggests that variations within the positions of the
νas(CH2), νs(CH2), and amide I bands existed within these populations.

Figure 4.15: PCA scores plot and corresponding PC-1 and PC-2 X-loadings plots of second
derivative (Savitzky Golay, 13 smoothing points), unit vector normalised SR-IRMS spectra
obtained from HCT-8 cells following 24 h treatment with vehicle (RPMI-1640, DMSO
2% v/v) (n), Bi(difl)3 (l), or diflH (p) (120 μM NSAID); (a) including the amide region
(3000–2800 cm−1, 1790–1150 cm−1), and (b) excluding the amide region (3000–2800 cm−1,
1790–1710 cm−1, 1485–1150 cm−1).
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The PCA results obtained following omission of the amide region (1709–
1486 cm−1) from the vehicle, Bi(difl)3 and diflH SR-IRMS spectra are presented in
Figure 4.15b. Similar to Figure 4.15a, the diflH scores appeared almost exclusively as
PC-1 negative scores and remained associated with strong positive loadings arising
from lipids (νas(CH2), νs(CH2) and ν(C=O)). As was also observed in Figure 4.15a,
intra-sample variation appeared to be the predominant factor in the distribution of the
samples across PC-2; the loadings plot (Fig. 4.15b) indicated that this resulted from
variations within the positions of νas(CH2), νs(CH2) and ν(C=O) bands within the
samples. Relatively little change was observed from the loadings contributions in the
1485–1150 cm−1 region when comparing the amide inclusive or amide omitted PC-1
and PC-2 loadings plots (Fig. 4.15a and Fig. 4.15b, respectively). The scores plots
indicate that 24-h incubation with diflH produces biomolecular effects in HCT-8 cells
which are relatively distinct from Bi(difl)3- and vehicle-treated cells and appear to
result from lipid-related differences. However, no significant differences were
observed for the Bi(difl)3-treated SR-IRM spectra when compared to the vehicletreated SR-IRM spectra.

4.3.2.7 Summary of the IR spectral and PCA differences following BiNSAID and
NSAID treatment
The results described in Sections 4.3.2.1–4.3.2.6 have been summarised in
Table 4.3 for ease of reference in the Discussion (Section 4.4). Briefly, the key
observations emanating from the analysis of the SR-IRMS studies include:
(i) TolfH treatment (4 h and 24 h) of HCT-8 cells predominantly resulted in
changes to the lipid bands and possibly the amide bands.
(ii) Bi(tolf)3 treatment (4 h) caused some change in lipids; however, the effect was
less pronounced compared to tolfH. Additionally, the tolfH spectra were
distinguishable from Bi(tolf)3 and vehicle scores due to a change in lipids. The
24-h treatment resulted in Bi(tolf)3 scores that were widely scattered (compared
to the vehicle and tolfH scores) and populated areas of vehicle and tolfH scores.
(iii) MefH and Bi(mef)3 treatment (4 h and 24 h) induced variation in the
spectrum of HCT-8 cells compared to vehicle-treated cells, which was primarily
attributed to an effect on lipids. The response between mefH and Bi(mef)3 could
not be distinguished as the scores were overlapped.
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(iv) DiflH treatment (4 h) induced a difference in the spectrum of HCT-8 cells
compared to vehicle, which was primarily attributed to an effect on amides in the
amide inclusive PCA. When the amide bands were omitted from the PCA, no
distinction was observed between the diflH- and vehicle-treated cells. Following
24-h treatment, diflH induced a difference in the spectrum of HCT-8 cells
compared to vehicle that was due to an increase in the intensity of the lipid bands.
(v) PCA of the amide inclusive spectra suggested there was no difference between
vehicle and Bi(difl)3 scores (4 h). However, when the amides were omitted from
the PCA, 4-h Bi(difl)3 treatment induced a difference in the spectrum of HCT-8
cells compared to vehicle/diflH, which was primarily attributed to an effect on
lipids.

PCA suggests there was no difference between the 24-h vehicle and

Bi(difl)3 scores, and indicated Bi(difl)3 had a different effect to diflH at the chosen
treatment concentrations.
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Amide omitted

Result summary: TolfH treatment
induced a response in the spectrum of
HCT-8 cells compared to vehicle, which
was primarily attributed to an effect on
lipids

Intensity of PCA loadings bands: (s) = strong, (m) = moderate, (w) = weak

• • Avg. spectrum Bi(tolf)3:  intensity of
• • Vehicle scores largely PC-1 +ve, Bi(tolf)3
νas(CH2) and νs(CH2), shift in νas(PO2−)
scores largely PC-1 −ve (less delineation of
Bi(tolf)3 scores from vehicle scores
band (1240 cm−1  1238 cm−1) vs. vehicle
compared to tolfH vs. vehicle); some inter• • Vehicle scores largely PC-1 −ve, Bi(tolf)3
sample variation evident on PC-1
scores largely PC-1 +ve (although, greater
vehicle
• • PC-1 loadings: As tolfH, see above
overlap with vehicle than tolfH); some
vs.
inter-sample variation evident
• • No separation from vehicle on PC-2
Bi(tolf)3 • • PC-1 loadings: As tolfH, see above
(15 μM)
Result summary: Bi(tolf)3 treatment
Result summary: Bi(tolf)3 treatment
caused some change in lipids; however,
caused some change in lipids/proteins;
the effect was less pronounced compared
however, the effect was less
to tolfH. Additionally, the tolfH spectra
pronounced compared to tolfH
were distinguishable from Bi(tolf)3 and
vehicle scores due to a change in lipids

Result summary: TolfH treatment
induced a response in the spectrum of
HCT-8 cells compared to vehicle, which
was primarily attributed to an effect on
lipids with some contribution from
proteins

• • Avg. spectrum tolfH:  intensity of
• • Vehicle scores largely PC-1 and PC-2 +ve,
νas(CH2) and νs(CH2), shift in νas(PO2−)
tolfH scores largely PC-1 –ve;
inter-sample variation evident along both
band (1240 cm−1  1232 cm−1) vs. vehicle
PC-1 and PC-2
• • Vehicle scores largely PC-1 –ve, tolfH
• • PC-1 loadings: lipid, νas(CH2) (s), νs(CH2)
scores largely PC-1 +ve;
(s), ν(C=O) (m), δ(CH2) (w); protein,
inter-sample variation evident
νs(COO−) (w); nucleic acids, νas(PO2−) (w)
• • PC-1 loadings: lipid, νas(CH2) (s), νs(CH2)
vehicle
• • PC-2 loadings: lipid, ν(C=O) (s), and δ(CH2)
(s), ν(C=O) (m), and δ(CH2) (w); protein,
vs. tolfH
(m); protein, νs(COO−) (m); nucleic acids,
amide I (m), amide II (w), and νs(COO−)
(45 μM)
(w); nucleic acids, νas(PO2−) (w)
νas(PO2−) (m)

Amide included

Treatment time 4 h (Appendix 4.6 and Figure 4.10)

Result summary: Bi(tolf)3 scores were
widespread (compared to the vehicle and tolfH
scores) and populated areas of vehicle and tolfH
scores

Amide omitted

Result summary: Bi(tolf)3 scores
were widespread (compared to
the vehicle and tolfH scores) and
populated areas of vehicle and
tolfH scores

• Vehicle and Bi(tolf)3 distributed
relatively evenly across +ve and −ve
PC-1
• Greater number of Bi(tolf)3 scores
+ve PC-2, vehicle scores mainly −ve
PC-2
• PC-2 loadings: As tolfH, see above

Result summary: TolfH
treatment induced a response that
primarily affected the lipids

• • TolfH scores relatively clustered
+ve PC-1, vehicle distributed across
+ve and −ve PC-1
• • PC-1 loadings: lipid, νas(CH2) (s),
νs(CH2) (s), ν(C=O) (m), and δ(CH2)
(w); protein, νs(COO−) (w)
• • TolfH scores relatively clustered
+ve PC-2, vehicle scores mainly −ve
PC-2; inter-sample variation evident
• • PC-2 loadings: lipid, νas(CH2) (s),
νs(CH2) (m), ν(C=O) (m), and
νas(CO-O-C) (m); protein,
νs(COO−) (w); nucleic acids, νas(PO2−)
(s)

• • Little difference noted in the avg. spectrum of vehicle•
vs. Bi(tolf)3, except slight  in the intensity of ν(C=O)
and νas(PO2−) bands
• • Vehicle and Bi(tolf)3 scores distributed relatively
•
evenly across +ve and −ve PC-1; no clear delineation
or clustering
• • Greater number of Bi(tolf)3 scores −ve PC-2, vehicle •
scores mainly +ve PC-2
• • PC-2 loadings: As tolfH, see above

Result summary: TolfH treatment induced a
response in the spectrum of HCT-8 cells
compared to vehicle, which was attributed to an
effect on lipids and proteins

• • Avg. spectrum tolfH:  intensity of νas(CH2),
νs(CH2), ν(C=O), and νas(PO2−) bands
• • TolfH scores relatively clustered +ve PC-1, vehicle
scores distributed across +ve and −ve PC-1
• • PC-1 loadings: lipid νas(CH2) (s), νs(CH2) (s), and
ν(C=O) (m); protein amide I (m) and amide II (m)
• • TolfH scores relatively clustered −ve PC-2, vehicle
scores mainly +ve PC-2;
inter-sample variation evident
• • PC-2 loadings: lipid, νas(CH2) (m) and νs(CH2) (m);
protein, amide I (s) and amide II (m); nucleic acids,
ν(C=O) (m) and νas(PO2−) (w)

Amide included

Treatment time 24 h (Appendix 4.7 and Figure 4.11)

Table 4.3: Summary of average spectral trends and key PCA differences between vehicle-treated cell samples versus NSAID/BiNSAID-treated
cell samples.
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Result summary: MefH treatment induced a
response in the spectrum of HCT-8 cells that
differed to vehicle; this was primarily
attributed to an effect on lipids

Result summary: Same as mefH
result (see above)

Result summary: Same as mefH result (see
above)

• • Avg. spectrum: Bi(mef)3  intensity • • PC-1 scores and loadings observations: As
νas(CH2) νs(CH2), and νas(PO2−) bands
mefH, see above
vs. vehicle
• • PC-1 scores and loadings
observations: As mefH, see above

Result summary: MefH treatment
induced a response in the spectrum
of HCT-8 cells that differed to
vehicle; this was primarily
attributed to an effect on lipids

Amide omitted

• Avg. spectrum: mefH  intensity
• • Vehicle scores largely PC-1 –
νas(CH2), νs(CH2), and ν(C=O) bands
ve, mefH scores largely PC-1
vs. vehicle
+ve; some inter-sample
variation evident
• Vehicle scores largely PC-1 +ve, mefH
scores largely PC-1 –ve;
• • PC-1 loadings: lipid, νas(CH2)
some inter-sample variation evident
(s), νs(CH2) (s), ν(C=O) (m), and
δ(CH2) (w); protein, νs(COO−)
• PC-1 loadings: lipid, νas(CH2) (s),
νs(CH2) (s), ν(C=O) (m), and
δ(CH2) (w)
(w); protein, amide I (m),
amide II (w), νs(COO−) (w)
Result summary: MefH
treatment induced a
response in the spectrum of
Result summary: MefH treatment
HCT-8 cells that differed to
induced a response in the spectrum
vehicle; this was primarily
of HCT-8 cells that differed to
attributed to an effect on
vehicle; this was primarily attributed
lipids
to an effect on lipids

Amide included

Treatment time 24 h (Appendix 4.9 and Figure 4.13)

Result summary: Same as mefH
result (see above)
Result summary: Same as
mefH result (see above)

• • Avg. spectrum Bi(mef)3  intensity
• • Vehicle scores largely PC-1 –
νas(CH2), νs(CH2), and ν(C=O) bands vs.
ve, mefH scores largely PC-1
+ve; inter-sample variation
vehicle
evident
• • Vehicle scores largely PC-1 +ve,
Bi(mef)3 scores largely PC-1 –ve; inter- • • PC-1 loadings: As mefH, see
sample variation evident
above
• • PC-1 loadings: As mefH, see above

• • Vehicle scores largely PC-1 –ve, mefH scores
•
largely PC-1 +ve
• • PC-1 loadings: lipid, νas(CH2) (s), νs(CH2) (s),
ν(C=O) (m), and δ(CH2) (w); protein, νs(COO−) (w) •
• Vehicle scores largely PC-2 –ve, mefH scores
largely PC-2 +ve;
inter-sample variation evident along both PC-1 and•
PC-2
• • PC-2 loadings: lipid, νas(CH2) (s), νs(CH2) (m),
ν(C=O) (m), and νas(CO-O-C) (m); protein, νs(COO−)
(w); nucleic acids ν(C=O) (m), and νas(PO2−) (m)

• • Avg. spectrum: mefH  intensity
νas(CH2), νs(CH2), and νas(PO2−) bands
vs. vehicle
• • Vehicle scores largely PC-1 –ve,
mefH scores largely PC-1 +ve; intersample variation evident
• • PC-1 loadings: lipid, νas(CH2) (s),
νs(CH2) (s), ν(C=O) (w), and
δ(CH2) (w); protein, amide I (s),
amide II (w), and νs(COO−) (w)

Intensity of PCA loadings bands: (s) = strong, (m) = moderate, (w) = weak

vehicle vs.
Bi(mef)3
(40 μM)

vehicle vs.
mefH
(120 μM)

Amide omitted

Amide included

Treatment time 4 h (Appendix 4.8 and Figure 4.12)

Table 4.3 cont.: Summary of average spectral trends and key PCA differences between vehicle-treated cell samples versus NSAID/BiNSAIDtreated cell samples.
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Amide included

Amide omitted

Treatment time 24 h (Appendix 4.11 and Figure 4.15)

Intensity of PCA loadings bands: (s) = strong, (m) = moderate, (w) = weak

• • Little variation in the avg. spectrum of
• • Bi(difl)3 scores were overlapped
Bi(difl)3 vs. vehicle
with the vehicle scores along PC-1
• • Bi(difl)3 scores were overlapped with the • • Vehicle scores preferentially
vehicle scores along PC-1
appeared on +ve PC-2; this suggests
• • Vehicle scores preferentially appeared on that a subpopulation of Bi(difl)3
scores (–ve PC-2) differs from the
–ve PC-2; this suggests that a
subpopulation of Bi(difl)3 scores (+ve PC-2) vehicle scores
• • PC-2 loadings: lipid, νas(CH2) (s),
differs from the vehicle scores
νs(CH2) (m), and ν(C=O) (m), and
• • PC-2 loadings: lipid, νas(CH2) (s), νs(CH2)
δ(CH2) (w); protein, νs(COO−) (w);
(m), and ν(C=O) (m); protein, amide I (s),
nucleic acids νas(PO2−) (w)
and νs(COO−) (w); nucleic acids
Result summary: PCA suggests
νas(PO2−)(w)
there was no difference between
Result summary: PCA suggests there
vehicle and Bi(difl)3 scores, and
was no difference between vehicle and
indicated Bi(difl)3 had a different
Bi(difl)3 scores, and indicates Bi(difl)3
effect to diflH at the chosen
had a different effect to diflH at the
treatment concentrations
chosen treatment concentrations

• DiflH scores were overlapped with the • • Avg. spectrum diflH  intensity of the lipid • • Vehicle scores largely PC-1 +ve,
vehicle scores; both were distributed
bands, νas(CH2), νs(CH2), and ν(C=O) vs.
diflH scores PC-1 –ve; inter-sample
equally along PC-1. Intra-sample
variation evident
vehicle
variation was evident along PC-1. No
• • PC-1 loadings: lipid, νas(CH2) (s),
• • Vehicle scores largely PC-1 +ve, diflH
separation of diflH and vehicle scores
νs(CH2) (s), ν(C=O) (m), and
scores PC-1 –ve; inter-sample variation
along PC-2
δ(CH2) (w); protein, νs(COO−) (w)
evident
• PC-1 loadings: lipid, νas(CH2) (s),
• • PC-1 loadings: lipid, νas(CH2) (s), νs(CH2)
νs(CH2) (s), ν(C=O) (m), and δ(CH2) (w); (s), and ν(C=O) (m); protein, amide I (m),
protein, νs(COO−) (w); nucleic acids,
amide II (m), and νs(COO−) (w)
νas(PO2−) (w). Lipids were the primary
Result summary: DiflH treatment
source of intra-sample variation when
Result summary: DiflH treatment
induced a difference in the
the amide bands were excluded
induced a difference in the spectrum of
spectrum of HCT-8 cells compared
Result summary: PCA suggests
HCT-8 cells compared to vehicle, which
to vehicle, which was primarily
there was no difference between
was primarily attributed to an effect on
attributed to an effect on lipids
vehicle and diflH scores when the
lipids
amides were omitted

Amide omitted

• • Avg. spectrum Bi(difl)3:  intensity of νas(CH2) • • PC-1 scores and loadings
νs(CH2), and ν(C=O) bands vs. vehicle
observations as diflH (see above)
• • Bi(difl)3 scores were overlapped with the
• • Some delineation of Bi(difl)3 scores
vehicle scores along PC-1; well-clustered into
(–ve) from the vehicle (and diflH)
comparison to the diflH scores
scores (+ve) was evident along PC-2;
Vehicle
inter-sample variation was evident
• • Vehicle scores were largely PC-2 –ve, and
vs.
Bi(difl)3 scores were largely PC-2 +ve; some
• • PC-2 loadings: lipid, νas(CH2) (m),
Bi(difl)3
inter-sample variation evident in PC-2
νs(CH2) (m), δ(CH2) (w), and
(75 μM)
νas(CO-O-C) (m); protein, νs(COO−) (m);
• • PC-2 loadings: As diflH, see above
nucleic acids ν(C=O) (m), and
νas(PO2−) (m)
Result summary: PCA suggests there was
no difference between vehicle and Bi(difl)3
Result summary: Bi(difl)3 treatment
scores
induced a difference in the spectrum
of HCT-8 cells compared to
vehicle/diflH; which was primarily
attributed to an effect on lipids

• • Avg. spectrum: diflH:  intensity of νas(CH2), •
νs(CH2) and ν(C=O) bands vs. vehicle
• • Vehicle scores clearly clustered and diflH
scores distributed across –ve and +ve PC-1;
intra-sample variation evident. Variation in the
amide I band (s) appeared to be the cause of the
•
variation (diflH scores)
Vehicle
• • Vehicle scores were largely PC-2 –ve, and diflH
vs. diflH
scores were PC-2 +ve;
(225 μM)
inter-sample variation evident in PC-2
• • PC-2 loadings: lipid, νas(CH2) (m), and νs(CH2)
(m); protein, amide I (s) and amide II (m)
Result summary: DiflH treatment induced a
difference in the spectrum of HCT-8 cells
compared to vehicle, which was primarily
attributed to an effect on amides

Amide included

Treatment time 4 h (Appendix 4.10 and Figure 4.14)

Table 4.3 cont.: Summary of average spectral trends and key PCA differences between vehicle-treated cell samples versus NSAID/BiNSAIDtreated cell samples.
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4.4 Discussion
Previous in vitro studies have shown that NSAIDs can exert anti-neoplastic effects
through a number of biochemical pathways (discussed in Section 1.2.4). In this work
SR-IRMS has been employed to determine whether gross biomolecular changes
induced by NSAIDs/BiNSAIDs can be distinguished. This approach has been explored
based on previous studies by other researchers who have correlated biomolecular
effects observed by SR-IRMS with specific drug treatments (Table 4.2). SR-IRMS was
specifically employed in this study to determine whether the technique could be used
to: (i) observe global molecular changes in the live HCT-8 cells that have been exposed
to the NSAIDs or the corresponding BiNSAIDs, (ii) determine whether any observed
changes induced by the BiNSAID/NSAID are consistent with known mechanisms of
cell death, and (iii) determine whether BiNSAIDs/NSAIDs induce similar or different
biomolecular responses.
Live cell studies were performed in order to examine the cells in a state that most
closely mimicked that used for the other biochemical assays performed as part of this
Thesis, without any potential confounding IR effects from a fixation/drying process.
It was clear from the SR-IRMS study of live cells that a number of factors needed to be
considered when determining the usefulness of SR-IRMS for the abovementioned
purposes. These include: (i) the data analysis, specifically the water band correction
strategies (discussed in Section 4.4.1) and (ii) the significance of the biomolecular
changes induced by vehicle, and BiNSAID/NSAID treatments, with respect to
intra-sample variation (discussed in Section 4.4.2). Finally, the experimental
approach/design and improvements for future experiments with respect to the results
are discussed in Section 4.4.3.

4.4.1 Data analysis: Water absorption correction strategy
As previously highlighted in Section 4.1.4, the effects of the aqueous background
can create problems when analysing the SR-IRMS spectra of live cells in cell medium.
In particular, the water deformation band centred at 1620 cm−1, which overlaps with
the amide I absorbance band needs to be addressed. Many researchers [33, 43, 57]
have highlighted the issue of water absorption in the collection and processing of
SR-IRMS spectra obtained from living single cells. Conflicting approaches in the
literature led to the use of the two analytical strategies presented in this Thesis.
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In the present study it was observed that when comparing the average cell
spectra of a sample corrected for water band absorption to the same sample set
without water band correction, little to no differences in the position of the amide I
and amide II bands were observed in the second derivative spectra. This result is
similar to that reported by Marcsisin et al. [33], whereby the authors concluded that
the spectral integrity of the data was maintained; consequently, they employed
spectra without any water band correction in PCA. In the present study (Section
4.3.1), PCA was performed on spectra uncorrected, and corrected for the water
absorption, in order to further determine whether there were any differences in the
PCA scores and loadings plots following correction for the water absorption. Some
subtle differences were observed in the coordinates of some of the individual scores in
the PCA scores plot following correction for water absorption; however, the overall
trends remained the same regardless of whether water band correction was applied in
all of the sample sets tested. The results from the present study suggest that the
biomolecular information in the amide region contributed by cell SR-IRMS may remain
extractable using PCA, despite the contributions from the water band centred at
1620 cm−1.
Water correction strategies have been debated in a number of studies. For
instance, Whelan et al. [43] argue that any water band ratioing is unreliable as it is
unconventional.

Given that the water band influences the amide region, the

researchers excluded the amide region from PCA obtained from their live cell cycle
study [43]. Consequently, in the present study PCA was also performed on SR-IRMS
that excluded the amide region, and compared to the PCA performed on spectra that
included the amide region. In most cases, the scores plot was altered markedly when
the amide region was excluded, which can be expected as the amide I band is the
strongest band in the spectrum and the strongest measure of proteins in the spectrum.
However, in all cases the explained variance of PC-1 (observed on the x-axis of the
scores plots in Fig. 4.7−4.15) was substantially increased following the omission of the
amide region, which may indicate that the amide I region was contributing more noise
than information. Additionally, with the omission of the amide region, the loadings
plots showed predominant contributions from lipid-related bands, and in most cases
increased the strength of the contributions from bands between 1485–1150 cm−1.
There are two outcomes that require further examination. Firstly, the omission of
the amide bands appears to have a substantial effect on the outcome of PCA; thus the
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omission of the amide bands may in fact result in the oversight of useful data from PCA
producing results less representative of the true biomolecular differences between
samples. Secondly, the effectiveness of the water band correction is difficult to
evaluate and may still not provide a true biochemical representation.
In conclusion, the water band correction using spectral subtraction strategy
employed in the present study appears to have subtle effects on the outcome of the
PCA results when compared to the respective non-corrected spectra. If a suitable
water compensation strategy can be determined in the future, and employed
universally by researchers who perform SR-IRMS studies of live cells, the results
obtained in the present study should be reanalysed with this strategy. For the present
study, however, it was opted to perform PCA on SR-IRMS spectra that were not
corrected for the water band as the results in Section 4.3.1 revealed little difference in
the resultant PCA.

4.4.2 The biomolecular effects of treatment on live HCT-8 cells
4.4.2.1 Vehicle-treated cells
One of the notable results of the PCA of the SR-IRMS cell spectra, evident even
within control cell populations was intra-sample variation. There are a number of
reasons that can contribute to intrinsic variations within a cell population subjected to
the same treatment. Two well-studied causes are: (i) cell cycle, and (ii) biomolecular
changes due to cell death.
At any given time in an unsynchronised population of mammalian cells,
subpopulations of cells will be found in one of the different phases of the cell cycle:
gap 1 (G1), synthesis (S), gap 2 (G2), mitosis (M) or quiescence (G0) [43].
FTIR demonstrated that mammalian cells undergoing cell division show differences in
each different phase of the cell cycle [16, 22]. Furthermore, Whelan et al. [43] have
shown through live cell studies that biomolecular changes could be distinguished
within each specific phase by examining the SR-IRMS spectra of the cells every two
hours post-mitosis. In the present study no attempt was made to synchronise the cells
in any particular phase of the cell cycle, but instead the cells were prepared using a
similar procedure to that employed for all other assays performed in this Thesis. It is
reasonable to suggest that lipid, protein and nucleic acid content of the HCT-8 cells
will be influenced by the cell cycle phase and will therefore result in variations in the
SR-IRMS spectra of each individual cell within the population.
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Cell death is another factor that may influence the SR-IRMS spectra of individual
cells. For instance, studies have shown that apoptosis and necrosis can be
distinguished in the IRMS spectra of single cells [18, 20, 21]. Importantly, in the
present study, it was established from flow cytometry assays (presented in Chapter 2)
that late apoptotic/dead HCT-8 cells detached from the cell substrate. In the SR-IRMS
study reported in this Chapter any dead cells would have been removed by washing
steps performed prior to insertion into the cell chamber for analysis. Thus, the cell
population that remains adhered to the substrate primarily contains cells of relatively
good health or in the early stages of apoptotic cell death as confirmed by flow
cytometry analysis of the adherent cell population (Appendix 4.12).
While there are variations in the biochemistry of the cells due to cell cycle and cell
death (which correlates in variations in the SRIRMS spectra), the control cell samples
that were incubated with cell medium, in the absence of vehicle or drugs, would be
considered to be the ‘normal’ distribution of a culture of HCT-8 cells. Flower et al. [12]
also reported a similar heterogeneity in the scores plots of spectra associated with the
control cells. Encouragingly, the results from the PCA loadings plots generated in this
study (Fig. 4.9) indicate that the main source of variation of the cell medium and
vehicle cells is the lipid bands which causes the dominant variance across the
PC-1 axis. This is consistent with the PCA results of Whelan et al. [43] who reported
the same observation when they performed a PCA of G1, S, and G2 cells. It is, therefore,
likely that the distribution of the vehicle scores is indicative of cell cycle variation
within the population.
It was essential to prepare non-treated (cell medium only) cells and vehicletreated (DMSO 2% v/v in RPMI-1640) cells in order to determine if any biomolecular
changes occurred in response to DMSO exposure. It should be noted that all cell
experiments performed in this Thesis included a vehicle-treated ‘control’ in order to
directly compare with the BiNSAID/NSAID treatments (prepared as DMSO solutions in
cell medium to achieve dissolution of the drug). A shorter 4-h treatment timeframe
(as well as the typical 24-h treatment) was evaluated in order to determine whether
any spectral changes indicative of biomolecular changes could be detected in the
absence of cytotoxic effects (as indicated by MTT assays, Appendix 1.2). Vehicle
treatment appeared to effect the SR-IRMS spectra of the HCT-8 cells after 4-h as
evidenced by the PCA scores plots (Fig. 4.8); however, the delineation identified
between cell medium- and vehicle-treated cells was only observed when the strong
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loadings from the amide region (Fig. 4.7) were omitted from the PCA (Fig. 4.8).
Following omission of the amide region, the PC-2 loadings plots (Fig. 4.8) showed that
the νas(CH2), νs(CH2), νas(C=O), and νas(CO−O−C) bands, and the νas(PO2−) band, were
the primary contributors to the variance between the cell medium and vehicle scores.
DMSO is a water-miscible, polar solvent, which has often been used in cell biology
for the dissolution of hydrophobic compounds, cryoprotection, inducing cell
differentiation, free radical scavenging, membrane penetration, and as a cell
fusogen [63].

The effect of DMSO on lipids, and in particular, membrane

phospholipids, has been investigated in a number of studies [64-68].

Molecular

dynamic simulations performed using dioleoylphosphatidylcholine membranes mixed
with 20 mol% of cholesterol and low DMSO fractions (≤ 10 mol%) resulted in sporadic
and very transient hydrophobic pores which were arranged in the form of singlemolecule

water

columns

that

cross

the

membrane

and

disappear

[67].

In complimentary microscopy experiments, small undulations of the cell membrane of
DC-3F cells treated with 10 vol% (2.74 mol%) DMSO were identified following
1-h [67]. Gurtovenko et al. [69] report that atomic-scale molecular dynamic
simulations performed on lipid bilayers comprising dipalmitoylphosphatidylcholine in
aqueous solution with DMSO at low concentrations showed decreased membrane
thickness and increased membrane fluidity (2.5−7.5 mol%), while moderate
concentrations (10−20 mol%) induced formation of transient water pores, and high
concentrations (25−100 mol%) destroyed the bilayer structure of membranes.
More recently, neutron reflectometry studies assessing the effect of DMSO (2% v/v) on
lipid membrane mimetic bilayers comprised of POPC have been performed [68].
Interestingly, scattering length density profiles indicated that DMSO (2% v/v) in
D2O/PBS caused no structural changes to the bilayer. However, a substantial decrease
in the scattering length density profile of the hydrophobic tail region indicated that
DMSO enters the tail region of the POPC bilayer and subsequently displaces the D2O
molecules [68]. Given that the formation of transient hydrophobic pores across cell
membranes reportedly occurs at higher concentrations of DMSO (> 10 vol%) [69] than
that utilised in the present study, it is conceivable that variation in the SR-IRMS
spectra was potentially due to the occupation of DMSO below the head groups of
membrane phospholipids and the displacement of water molecules resulting in a
difference in the SR-IRMS signature observed in the lipid-related bands between the
4-h cell medium- and vehicle-treated PCA scores.
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Interestingly, no delineation between the cell medium-treated or vehicle-treated
scores was observed following 24-h treatment with or without the amide bands
included in the PCA (Fig. 4.9). Plasma membrane disruption is often accompanied by
rapid resealing of the cell membrane in order to ensure cell survival [70]. Work
performed by Togo et al. [71, 72] suggests that cells are able to reseal wounded
membranes more rapidly following repeated disruption to the cell membrane when
compared to the rate of repair following the initial wound due to an increase in
exocytosis. It is plausible that following an extended period of treatment (> 4 h) the
HCT-8 cells could become tolerant to DMSO exposure and the cell membrane may
‘recover’ to an extent. Perhaps the lack of biomolecular distinction as determined by
PCA between the spectra of cells treated with cell medium or vehicle following 24-h
may be due to gradual displacement of DMSO from the cell membrane. A recent
report [73] suggests that experimental quantification of the properties of DMSO–water
bonds at the lipid membrane surface remains poorly understood. Thus further work
is needed to explicitly confirm the present findings.
There are a number of reports [65, 74, 75] that discuss the varying tolerance and
biochemical effects exhibited by different cell lines when exposed to DMSO. For
instance, the effect of DMSO (2%) on the membrane dynamics and phospholipid
composition of the two different cell lines, FLC (Friend leukemia cells) and Raji
(lymphoblastoid) cells has been investigated [65]. Following 5-day incubation with
DMSO only the phospholipid composition of FLC cells, but not the Raji cells was
affected. The colon cancer cells, Caco-2/TC7, have been shown to be tolerant to DMSO
for concentrations up to 10% v/v without the induction of membrane leakage [74].
In another study, prolonged DMSO (2% v/v) treatment has been reported to induce a
number of biochemical changes in SW480 and SW620 cell lines (primary colonic
tumor and lymph node metastasis, respectively, isolated from the same patient) [75];
however, cell viability was not affected for up to four days following incubation in
DMSO [75]. Clearly previous research shows that the cell response to DMSO can be
variable, not only dependent on DMSO concentration and time of exposure, but also
dependent on the specific cell line. The results of the present study show that the
viability of DMSO-treated HCT-8 cells is slightly affected following 24-h treatment (as
shown by MTT assay, Chapter 2); however, no significant biomolecular differences
could be detected by PCA of the SR-IRMS spectra. For the purpose of the current
SR-IRMS study, the lack of distinction between cell medium and DMSO scores is an
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important result as it suggests that DMSO exposure of 24-h does not significantly alter
the SR-IRMS spectra and the biomolecular integrity of the HCT-8 cells using this tool.
This indicates that any biomolecular changes observed when comparing the
DMSO-treated cells to the BiNSAID or NSAID-treated cells are not dominated by
presence of DMSO.

4.4.2.2 BiNSAID/NSAID-treated cells
A few key observations resulted from the PCA analysis of vehicle-treated cell
spectra compared to BiNSAID/NSAID-treated spectra. These included the findings
that: (i) in most cases the removal of the amide region resulted in subtle changes to
the distribution of the scores plots, (ii) in most cases 4-h drug treatment caused subtle
biomolecular changes despite no obvious physical changes to the cells or viability loss
(described in Chapter 2), (iii) the changes observed following 24-h drug treatment
differed from the changes observed at 4-h, and (iv) differences could be observed
when comparing the BiNSAID scores to the respective NSAID scores.
It should be noted that the cell medium containing the drugs was removed
following the defined incubation periods (4 h or 24 h) and the cells were washed prior
to placement in the cell holder for SR-IRMS analysis. This was performed in order to
prevent any SR-IRMS detection of drug in the cell medium. Other researchers [35]
have reported that the detection limit of FTIR instrumentation is not sensitive enough
to detect the extremely low concentrations of drug that would reside in the individual
cell. This is an important point as it indicates that any significant changes detected in
the cell spectra were the result of the actions of the drugs within the cells and not due
to the detection of the drug itself.
When the spectral analyses were performed for the full spectral range
(3000−2800 cm−1, 1790−1150 cm−1) differences were commonly observed in the
amide bands following treatment with BiNSAID/NSAID versus vehicle. These
differences were most obvious for cells treated with Bi(tolf)3 (subtle for 4 h), tolfH
(subtle for 4 h and moderate for 24 h), Bi(mef)3 (moderate for 4 h), mefH (moderate
for 4 h), and diflH (strong for 4 h), and less so for Bi(difl)3, while no changes were
observed in Bi(tolf)3 (24 h). The most significant changes were observed as band
shifts in the amide I band from 1655 to 1653 cm−1 (tolfH and mefH (4 h), and Bi(mef)3
and diflH (24 h)) or were associated with the development of shoulders at ~1635 cm−1
in samples treated for 24-h with tolfH, Bi(mef)3 and mefH (24 h). The frequency of the
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amide I band has been reported to represent the dominant protein structures within
in a cell. For instance, common protein secondary structures and their corresponding
vibrational frequency ranges include: α-helix (1660−1649 cm−1), β-sheet (1637−1615
cm−1), random coil (1648−1638 cm−1), turn (1680−1660 cm−1), and β-antiparallel
(1692−1680 cm−1) [76]. Thus the development of a shoulder at ~1635 cm−1 in the
24-h tolfH-, Bi(mef)3-, and mefH-treated cell spectra is potentially indicative of an
increase in β-secondary structures. An increase in the proportion of β-sheet
structures has been identified in the early stages of apoptosis in A549 [77], HeLa [17]
and U-87 MG cells [78]. This is in agreement with the present study where a
substantial proportion of BiNSAID/NSAID-treated (at IC50 doses for 24 h) HCT-8 cells
were identified as early apoptotic in flow cytometry experiments (discussed in
Chapter 2). Unfortunately, however, as has been established by Vaccari et al. [34] and
Whelan et al. [43] in Section 4.1.4 the water band also effects the amide I and amide II
bands; as such, whilst it appeared that correction for the water band showed no effect
on these bands, it cannot be definitively proven that these changes are solely
attributed to molecular changes associated with amide bands.
In most cases the other biomolecular changes associated with BiNSAID/NSAID
treatment of cells were consistent regardless of whether the analysis was performed
for spectra which included or omitted the amide regions. The most significant changes
observed in both of these analyses were associated with CH2/CH3 region (3000−
2800 cm−1), ν(C=O) (1745 cm−1) and νas(PO2−) (1245 cm−1) that can be attributed to
lipids. There was only one instance where the lipid changes were not observed in both
data set analyses and this was the amide inclusive analyses of the 4-h Bi(difl)3/diflHtreated cell spectra (Fig. 4.14a). Instances where lipid changes were observed include:
tolfH (4 h and 24 h), Bi(tolf)3 (4 h), mefH (4 h and 24 h), Bi(mef)3 (4 h and 24 h), and
diflH (24 h).
Interestingly, the 4-h Bi(tolf)3/tolfH (Fig. 4.10) and 4-h Bi(mef)3/mefH (Fig. 4.12)
PCA results showed that the loadings bands associated with the lipids were also
strongly associated with the BiNSAID/NSAID-treated scores (as opposed to the vehicle
scores). Furthermore, it was observed in the average Bi(tolf)3-, tolfH and Bi(mef)3treated (Appendix 3.6 and Appendix 3.7) spectra that there was an increase in the
intensity of the νas(CH2) and νs(CH2) bands, a possible indication that lipid
concentration is increased in the BiNSAID/NSAID-treated cell populations. The 4-h
Bi(difl)3 (Fig. 4.14), showed the opposite trend whereby the lipid bands were
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associated with the vehicle spectra. This is not surprising given that the diflH
structure differs significantly from the structures of mefH/tolfH (Fig. 1.2).
Importantly, as no changes to the viability of the BiNSAID/NSAID-treated cells were
observed after 4-h treatment (as determined by MTT assays, Chapter 2), it is likely
that the biomolecular changes observed at this time-point are associated with
molecular events that precede apoptosis. Factors that effect lipids include: (i) changes
to the lipid membrane due to interaction/uptake of the drug molecules, or (ii) a
downstream metabolic effect once the drug is inside the cell (e.g. lipid synthesis).
The SR-IRMS spectral changes observed in the lipid bands detected in response to
NSAID treatment are consistent with reports [79-81] that NSAIDs are able to interact
with lipids, and in particular, phospholipids, which constitute a large proportion of the
lipids comprising the cell membrane. Experimental evidence [79] suggests that the
deleterious effects of NSAIDs on the GI tissue could be due to mechanisms that involve
direct disruption to the surface-active properties of phospholipids of the gastric
mucosa, in addition to COX-1 inhibition. Studies by Lichtenberger et al. [80] have
shown that 30-min exposure of AGS human gastric carcinoma cells to aspirin or
ibuprofen (both 0.5 mM), or naproxen (1.5 mM) altered the fluidity and packing
density of the cell membrane in a heterogeneous manner resulting in portions of the
membrane becoming hydrophilic. While the exposure time and treatment
concentrations varied from the present study there is clear evidence that NSAIDs can
directly disrupt the mammalian cell membrane. Suwalsky et al. [81] used X-ray
diffraction to show that mefH perturbed lipid membrane mimetics consisting of
dimyristoylphosphatidylcholine

or

dimyristoylphosphatidylethanolamine

bilayers. Additionally, the researchers used fluorescence resonance energy transfer
measurements to show that mefH was able to increase fluidity of the hydrophobic core
of dimyristoylphosphatidylcholine liposomes. It was determined that this occurred as
a result of intercalation of mefH into the hydrophobic acyl chains of the
dimyristoylphosphatidylcholine liposome [81].
Interestingly, the opposite trend (from that of the 4-h treatments) was observed
when examining the 24-h Bi(tolf)3/tolfH (Fig. 4.11) and 24-h Bi(mef)3/mefH
(Fig. 4.13) PCA results whereby the loadings bands associated with the lipids were
also strongly associated with the vehicle-treated scores (as opposed to the
BiNSAID/NSAID-treated scores). As such, the tolfH-, Bi(mef)3- and mefH-treated cells
appear to be associated with a lower lipid concentration than the vehicle-treated cells.
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This was supported by the reduction in the absorbance of the νas(CH2), νs(CH2) and
ν(C=O) bands in the SR-IRMS spectra (Appendix 3.7 and Appendix 3.9).

Flow

cytometry assays (Appendix 3.12) showed that following 24 h treatment with the
same BiNSAID/NSAID concentrations, there was an increase in the proportion of
apoptotic cells (~16−40% within the adherent cell population).

Phase contrast

microscopy also revealed morphological changes such as cell shrinkage and the
formation of membrane blebs (Fig. 2.7). Thus, in addition to changes to the lipid
membrane due to the interaction/uptake of the drug molecules, or effects on lipid
metabolism caused by drug uptake, it is feasible that the lipid bands will additionally
be altered as a result of apoptosis. The classic example of an alteration in lipid
distribution associated with cell apoptosis is the ‘flipping’ of phosphatidylserine
species from the interior cell membrane to the exterior leaflet of the cell
membrane [82]. Additionally, changes in membrane fluidity commonly occur in cells
undergoing apoptosis [83]. As such, the observed decrease in lipid absorbance may be
a result of apoptosis; however, this observation is in contrast to a number of fixed cell
studies that have demonstrated that the intensity of the lipid band increases in
apoptotic cells [17, 20, 84, 85]. Live cell studies performed by Birarda et al. [39] have
shown that serum starvation or carbonyl cyanide m-chlorophenylhydrazone exposure
induced apoptosis in U937 monocytes and caused an increase in cellular lipid
concentration. The authors speculated that the increase in the lipid content observed
by spectroscopic measurements was due to the accumulation of lipid droplets. The
decrease (rather than increase) in lipid absorbance in the present study may suggest
that lipid droplet accumulation is generally not an event associated with cell death in
the HCT-8 cell line.
Given the similarity in the structures of tolfH and mefH (Fig. 1.2), it is
unsurprising that tolfH and mefH would result in a similar biomolecular effect on
HCT-8 cells. Additionally, the overlap of the scores clusters in the Bi(mef)3/mefH
series is perhaps not surprising given the instability of the Bi(mef)3 complex
(concluded by the NMR data presented in Chapter 2) resulting in free mef in the
treatment medium. However, one of the most surprising results were those for the
24-h diflH treatment where it was observed that there was an increase in the lipid
intensity associated with diflH treatment, but no change associated with Bi(difl)3
treatment compared to the vehicle (Fig. 4.15 and Appendix 3.11). It was apparent
from the analyses that the diflH-treated HCT-8 cells showed differences from vehicle197
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treated cells but this was not the case for Bi(difl)3-treated cells. The SR-IRMS
differences observed for diflH- versus tolfH/mefH-treated cells cannot be explained by
the proportion of dying cells based on decreased toxicity since in all cases the IC50 was
applied. However, these differences might be explained by variations in the
mechanism of action of diflH compared to mefH and tolfH. This is not surprising given
the diflH structure differs significantly from the structures of mefH and tolfH (Fig. 1.2).
It is not clear why the 24-h diflH-treated cells showed such a strong increase in
the intensity of the CH2/CH3 band region. A live cell cycle study performed by Whelan
et al. showed that an increase in lipid band intensity in the SR-IRMS spectra of
synchronised cells appeared 17-h post-mitosis, i.e. in the late-S phase of the cell
cycle [43]. As such, it is plausible that the increase in the lipid band intensity of the
24-h diflH-treated cell spectra might be due to the accumulation of HCT-8 cells in the
S-phase of the cell cycle. However, NSAIDs with a similar chemical structure, including
aspirin and salicylate, have been reported to arrest the cell cycle in the G0/G1
phase [86-88]. The increased intensity of the CH2/CH3 band region, indicative of the
lipid band, was consistent with Birarda et al. [39] whereby the authors speculate that
the increase in the lipid content observed by spectroscopic measurements was due to
the accumulation of lipid droplets. Further experiments employing fluorescent probes
could be performed in the future to study cell cycle arrest and the possible formation
of lipid droplets in diflH-treated HCT-8 cells, in order to better understand this
SR-IRMS observation.

4.4.3 Limitations of the experimental approach and future improvements
The experimental design is an important factor that must be considered when
undertaking any scientific investigation. Mignolet et al. have recently commented
upon the variation in experimental design (and analysis procedures), cell handling,
and spectroscopy, in relation to the evaluation of data published in the field of
biospectroscopy [15]. The preparation of live cells for SR-IRMS analysis in the present
experiment was particularly challenging for a number of reasons.
Each treatment sample was prepared with a control that was prepared from the
same subculture, thus the passage number was kept consistent.

However, the

application of treatments had to be staggered by 2−3 hours given the time required to
assemble the cell holder (typically 15−20 min), set up the holder in the microscope
and collect the SR-IRMS spectra of the cells (typically 60−90 min). The cell samples
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prepared following 2−3 hours may, therefore, experience some changes in the cell
cycle progression and the concentration of metabolites in the cell medium. While the
experiments in Chapter 4 were designed to mimic those of Chapters 2 and 3 in
hindsight, one important consideration for future experiments might also be the
preparation of synchronised cell samples to try to reduce intra-sample variation. This
was not possible for the current study, however, due to beamtime limitations.
Vaccari and co-workers [89] have commented on the issues with demountable
liquid holders in recent publications. Essentially, the perfect closure of the
demountable device is not guaranteed, which can potentially result in variation in the
optical path length throughout the device. Importantly, water subtraction accuracy
can be affected by changes in path length between samples and buffer spectra [34].
Additionally, with the demountable design (such as the one used in the present study)
it is difficult to standardise ‘tightening’ when the device was assembled with a cell
sample contained inside [89]. Whelan et al. [43] performed live cell studies at the
Australian Synchrotron that employed the same device as the one in the present study
at the and have commented that its assembly could be a cause for variation between
replicate samples. Birarda et al. [89] have previously demonstrated that the
compression of U937 monocyte cells in a device that contained a chamber height less
than half that of the diameter of the cell (causing strong deformation of the cells) led to
changes in AmI/AmII, AmII/lipid and νas(PO2−)/νs(PO2−) ratios; thus mechanical stress
can induce cellular deformation and consequent biomolecular alterations that are
detectable using SR-IRMS. If future experiments were to be performed, the use of a a
multi-faceted, fully sealed fluidic device, such as that reported by Vaccari et al. [34]
may be more suitable.
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4.5 Chapter summary
SR-IRMS was employed for the analysis of live HCT-8 cells following exposure to
BiNSAIDs or NSAIDs in order to determine if it could be used to study global
biomolecular changes and allude to potential mechanisms of action of these
compounds. A multivariate approach, PCA, was applied to discern the spectral
differences associated with the analysis of the data and different cell treatments.
Specific observations regarding the analytical approach included the findings that the:
(i)

Subtraction of a water band spectrum from the cell spectrum of each
individual cell only subtly affected the PCA results.

(ii)

Omission of the amide region of the HCT-8 cell spectra from PCA caused
substantial changes to the distribution of the sample scores plot. In many
cases, weak loadings bands became more prominent in the loadings plot
upon omission of the amide bands.

The subsequent PCA showed that there was significant intra-sample variation,
although some delineation could be discerned in the following treatment groups:
(i)

The comparison of cell medium-only or vehicle-treated HCT-8 cell spectra
indicated there were subtle effects, attributable to the vehicle (2% v/v
DMSO in cell medium), on the spectra following 4-h treatment, but not 24-h
treatment.

(ii)

Following 4-h treatments:
a. Bi(tolf)3 and tolfH induced similar biomolecular effects on the HCT-8
cells in comparison to the vehicle, which were primarily attributed to
effects on the lipids with some contribution from proteins. However,
following removal of the amide region, discrimination between the two
compounds was apparent and attributable to ν(C=O) and νas(PO2−),
suggestive of difference in the effect of the two compounds on
phospholipids.
b. Bi(mef)3 or mefH induced similar effects on the HCT-8 cells, which were
primarily attributed to lipids.
c. DiflH induced biomolecular effects on the HCT-8 cells, which were
primarily attributed to proteins. However, following amide removal
from PCA analysis, diflH no longer showed any changes from the
vehicle. Treatment with Bi(difl)3 was distinguishable from diflH and the
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vehicle following amide removal, which was primarily attributed to
lipids.
(iii) Following 24-h treatments:
a. TolfH induced biomolecular effects on the HCT-8 cells, which were
primarily

attributed

to

lipids

with

some

contribution

from

proteins. Treatment of the cells with Bi(tolf)3 induced a varied
response within the Bi(tolf)3-treated population.
b. Treatment with Bi(mef)3 and mefH induced similar biomolecular effects
on the HCT-8 cells, which were primarily attributed to lipids.
c. Treatment with Bi(difl)3 resulted in no distinguishable difference from
the vehicle-treated cells.

However, treatment with diflH was

distinguishable from Bi(difl)3 and vehicle scores, which was primarily
attributed to lipids.
The ambiguity surrounding the inclusion or omission of amide bands from
SR-IRMS spectra obtained from live mammalian cells was investigated in the present
study using two methods reported in the literature. While this study may not
necessarily be used to provide further advice on the inclusion of amide bands in live
cell studies, and the validity of the biomolecular results they provide, this study has
provided a direct comparison adding credence to both procedures reported by other
investigators.
The SR-IRMS results obtained in the present study are preliminary in nature
showing intra- and inter-sample variations reflective of biomolecular differences in
the cell treatment groups. On the whole, the PCA results from the SR-IRMS study
suggest that treatment with BiNSAIDs or NSAIDs affect the lipids following 4-h and
24-h treatment. As SR-IRMS provided a global overview of all biomolecular changes
that occurred in the HCT-8 cells following treatment with vehicle, BiNSAIDs or
NSAIDs (including cell cycle, cell death and drug-induced biomolecular changes),
additional experimental techniques should potentially be employed to confirm these
observations. For instance, a study to compare the effects of the BiNSAIDs/NSAIDs on
lipids in isolated systems (e.g. cell-free lipid bilayers) is being conducted by Dillon and
Brown ([68] and unpublished results), and an additional in vitro lipidomic study has
been performed on isolated lipids from drug-treated cells (see Chapter 5).
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Chapter 5.
Lipidomic profiling of glycerophospholipids using
ESI-MS/MS of HCT-8 cells treated with BiNSAIDs
and NSAIDs

This Chapter describes shotgun lipidomic profiling of the organic extracts of HCT-8
cells using electrospray ionisation tandem mass spectrometry (ESI-MS/MS). This
study was undertaken to compliment SR-IRMS studies reported in Chapter 4 that
showed that the most prominent biomolecular changes in BiNSAID/NSAID-treated
cells was that associated with lipids. The purpose of the lipidomic study was to
determine how treatment with BiNSAIDs or NSAIDs affects the spectral profile and
cellular concentration of the common phospholipids, phosphatidylcholine (PC),
phosphatidylethanolamine (PE) and phosphatidylserine (PS).
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5.1 Introduction
Phospholipids are one of the major structural lipids found in eukaryotic cell
membranes and are essential for maintaining the biochemical and biophysical
properties of the cell membrane [1]. The eukaryotic cell membrane is comprised of a
phospholipid bilayer, embedded with other lipid molecules (namely sterols and
glycolipids) and membrane-embedded proteins [1]. The lipid bilayer provides
individual cells with a selective barrier from the extracellular environment and a
communication point between the intracellular and extracellular environments [1].
Additionally, lipid bilayers form discrete organelles within the intracellular space.
They are essential for compartmentalisation of specific chemical reactions, increasing
the biochemical efficiency within the cell [1]. As well as their structural role, many
phospholipids are the precursors for secondary messengers, which play an important
role in cellular functions including cell proliferation, apoptosis, signal transduction
pathways and the regulation of membrane trafficking [2].
Given the importance of phospholipids in maintaining the physical integrity and
homeostasis of cells, changes to the composition of phospholipids associated with
apoptosis, in particular drug-induced apoptosis, have been increasingly investigated
[3-5]. The apoptotic process causes changes to the phospholipid composition of the
outer surface of the cell membrane and the phospholipid distribution within the lipid
bilayer (most notably the externalisation of negatively-charged PS) [6]. Recently,
attention has focused on the importance of phospholipid composition in diseases,
including cancer and their associated treatment [7-9]. For instance, cancer cells that
have a higher abundance of saturated phospholipids [10], exhibit changes in lipid
membrane dynamics and protein signal transduction, which can protect the cancer
cell from oxidative stress by lowering the risk of lipid peroxidation. Additionally, as
lipids mediate a number of cellular processes through signaling pathways, alterations
in lipid composition and signaling can result in changes to the way the cancer cells
respond to certain chemotherapies [11].
The results from the SR-IRMS study (Chapter 4) implied that there was a global
effect on cellular lipids following HCT-8 cell treatment with BiNSAIDs/NSAIDs. The
anti-inflammatory effects of NSAIDs arise through the interaction with lipid mediators
resulting in downstream consequences for arachidonic acid, which is derived from
phospholipids in the plasma membrane via phospholipase A2 [12]. Additionally, there
are several studies [13-16] suggesting that NSAIDs are capable of interaction with
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phospholipids. These include their effect on hydrophobicity, fluidity and permeability
properties of membrane phospholipids; as such these effects could ultimately
contribute to the cell injury/toxicity observed following NSAID exposure.
Consequently, investigating changes to the cellular composition of common
phospholipids is a logical place to begin examining lipid-related effects of BiNSAIDs
and the respective free NSAIDs on the lipidome of HCT-8 cells.
Recently, lipidomics (or lipid profiling) has been increasingly utilised to study
various tissue and cellular lipidomes [17].

This has been aided by recent

advancements in mass spectrometry (MS) techniques, which have enabled researchers
to study lipids with high sensitivity, allowing for the accurate characterisation,
identification, and quantification of thousands of lipid species in biological
samples [17].
5.1.1 Shotgun lipidomics: Electrospray ionisation mass spectrometry (ESI-MS)
and tandem MS for the examination of phospholipids
While several MS approaches exist for the analysis of lipids, electrospray
ionisation tandem mass spectrometry (ESI-MS/MS) represents one of the most
commonly utilised techniques for achieving detailed structural analysis of
phospholipids in biological samples [18].

Two common approaches applied for

ESI-MS/MS analysis of lipids are: (i) the partial separation of the crude lipid extract via
high-performance liquid chromatography followed by infusion of the mobile phase
into the ESI source [18]; or (ii) the direct infusion of the sample into the ESI source
[19]. The latter approach, known as shotgun lipidomics [19], was the chosen approach
in the study described in this Chapter.
The general protocol for the preparation of the lipid extracts from biological
materials for shotgun lipidomic analysis using ESI-MS/MS is summarised in Figure 5.1
where the subsequent phospholipid analysis is performed using a triple quadrupole
(QqQ) instrument with an ESI source. An ESI mass spectrum from a crude lipid extract
provides a profile of the lipids that ionise in the chosen mode (i.e. positive or negative).
However, since the mass accuracy of some MS instrument used for these experiments
may be low and the crude lipid extract (with potentially thousands of lipids) is
complicated, the complementary technique ESI-MS/MS is often employed to confirm
molecular identification [20]. ESI-MS/MS can be achieved through the use of a QqQ
mass spectrometer, shown in Figure 5.1. In a traditional ESI-MS/MS experiment in a
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QqQ, the ion of interest (parent ion) is isolated in Q1, followed by collision-induced
dissociation (CID) in q2 (collision cell) (Fig. 5.1). This involves fragmentation of the
[M + H]+ or [M − H]− ions by collision with an inert gas (such as argon) in q2, with
mass analysis of the resulting ionic fragments occurring in Q3. Specifically, CID of
phospholipids in positive ion mode causes cleavage of the phosphate-glycerol bond
resulting in elimination of the polar head group as a charged or neutral species [21].
The polar head group fragments (or product ions) are characteristic of each
phospholipid; therefore, targeted scans (known as precursor ion or neutral loss scans)
enable the detection and structural elucidation of each of the precursor phospholipid
molecules contained in a sample while excluding other (sometimes more abundant)
ions [17].

Figure 5.1: Schematic representation of the shotgun lipidomic profiling method by tandem
mass spectrometry using a triple quadrupole (QqQ) MS instrument.
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5.1.2 The structure of glycerophospholipids
The general chemical structures of several common glycerophospholipids are
shown in Figure 5.2a. Glycerophospholipids are amphipathic molecules that contain a
polar head group linked to a 3-carbon glycerol backbone in the sn-3 position, and two
fatty acyl molecules attached to the sn-1 and sn-2 positions of the glycerol backbone.
The fatty acyl molecules are bonded at the sn-1 position via an ester (diacyl
glycerophospholipids), alkyl ether (1-O-alkyl) or alkenyl ether (1-O-alkenyl)
linkage (Fig. 5.2a). The chemical structures of the PC, PE and PS head groups are
shown in Figure 5.2b. The head groups provide the glycerophospholipid with a
hydrophilic region.

The final components of phospholipids are the fatty acyl

molecules, which comprise the hydrophobic region of the glycerophospholipid
molecule (Fig. 5.2c). Fatty acyl molecules are classified by their chain length (number
of carbons, typically 4−30). The number and position of double bonds, including
saturated

(no

double

bonds),

monounsaturated

(one

double

bond)

and

polyunsaturated (more than one double bond), are further used to classify fatty acyl
chains. The number of glycerophospholipid head groups, and the varying carbon
chain lengths and number/position of double bonds of fatty acids, essentially means
that over 10,000 unique molecular species of glycerophospholipids could exist.
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Figure 5.2: Chemical structure of: (a) Glycerophospholipids, where the glycerol backbone is in
black, the hydrophilic region is highlighted in blue and the hydrophobic fatty acyl chains are
highlighted in red. (b) Common glycerophospholipid head groups. (c) A fatty acid (18
carbons in length) containing no double bonds (saturated), a single double bond
(monounsaturated), and two double bonds (polyunsaturated).
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5.1.3 Nomenclature of glycerophospholipids
The glycerophospholipid nomenclature used in this thesis is in accordance with
Fahy et al. [22]. Glycerophospholipids are named firstly by their head group and then
by their fatty acyl chains; for instance, a molecule with a phosphocholine head group
and two fatty acyl chains comprised of 16 carbons (sn-1 position) and 18 carbons with
one double bond (sn-2 position) would be referred to as PC (16:0/18:1). The
experiments reported in this Chapter were used to identify the total composition of
the glycerophospholipid molecule, but do not identify the individual fatty acyl chains.
In this instance, the sum composition (i.e. total quantity of carbons and number of
double bonds) is presented in the name. For example, a PC molecule containing a total
of 34 carbons in the fatty acyl chains and one double bond will be presented as
PC 34:1.
It must be noted that one of the limitations of the commonly employed MS
techniques (as in this study) is the inability to distinguish isobaric species with either
odd-chain or ether-linked fatty acyl groups. In addition, the MS method used does not
allow for definitively distinguishing between glycerophospholipids containing an
1-O-alkenyl ether versus glycerophospholipids with a 1-O-alkyl ether-linked fatty acyl
group containing a double bond, as it is not possible to determine the position of the
double bond along the fatty acyl chain. Therefore, it can only be determined that a
double bond is present in an ether-linked fatty acyl chain. This means a PC molecule
with m/z 746 can be assigned to three different molecules; PC 33:1 (odd-chain), PC
P-34:0 (1-O-alkenyl ether), or PC O-34:1 (1-O-alkyl ether).

Odd-chain fatty acids

constitute very minor components in mammals [23] and have been reported at low
concentrations in human cancer cell lines [3]. As such, molecules with isobaric species
will be designated as ether-linked, by the “O-” prefix, for the alkyl ether linked fatty
acid, and the “P-” prefix for the 1-O-alkenyl ether, or plasmalogen (e.g. PC O-34:1/
PC P-34:0).
5.1.4 Biological importance of glycerophospholipids
In eukaryotic cells the glycerophospholipids account for approximately 60 mol%
of lipid mass [19]. The most common phospholipid classes found in mammalian cells
are PC and PE, while PS, phosphatidylglycerol, diphosphatidylglycerol (or cardiolipin),
phosphatidylinositol and phosphatidic acid comprise less abundant phospholipid
species in mammalian cells [1]. In most eukaryotic membranes, PC and PE collectively
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comprise approximately 75 mol% of total phospholipid mass, and are present in an
approximately 3:2 (PC:PE) molar ratio [19]. Given the abundance of PC and PE within
the cell, these two glycerophospholipids were chosen for lipidomic examination in the
present study.
As phospholipids are the major structural lipids found in eukaryotic cell
membranes, the variation in the molecular structures of phospholipid molecules has
implications for cellular membrane properties including membrane fluidity and the
modulation of membrane-bound protein activity [1]. Phospholipids usually distribute
asymmetrically in the cell membranes where PC can be dominantly found in the outer
monolayer, whilst PE and PS are mainly present in the inner monolayer of plasma
membranes [19]. The composition of the phospholipids contained in the lipid
membranes surrounding individual types of organelles can also differ [1]. For
instance, PE is particularly enriched in inner membranes of mitochondria (∼35–40%
of total phospholipids) compared with other organelles (∼17–25%) [24]. Due to the
relative size of the PC head group, PC molecules are typically cylindrical in shape [25].
Alternatively, PE molecules contain a smaller head group, resulting in a typically cone
shaped molecule [26]. PE molecules alone cannot form membranes, rather their
insertion into the membrane is essential for important cellular processes such as
membrane fusion and fission and the embedding of membrane proteins [26]. PE is the
most abundant lipid on the cytoplasmic layer of cellular membranes, with significant
roles in cellular processes such as membrane fusion, cell cycle, autophagy, and
apoptosis [27]. PE molecules, similarly to PS, are translocated to the outer cell
membrane during apoptosis [27-29]. Phospholipids also play a role in cell signaling
pathways. For instance, the formation of the lipid mediators, prostaglandins and
leukotrienes,

are

derived

from

arachidonic

acid

sourced

from

the

lipid

membrane [30].
As

shown

in

Figure

5.2,

there

are

two

types

of

ether-containing

glycerophospholipids, 1-O-alkyl and 1-O-alkenyl. The ether-linked phospholipids
predominantly contain either a phosphocholine or a phosphoethanolamine head
group. Up to 50% of glycerophospholipids contain ether-linked fatty acyl chains, but
their functions remain largely unknown [31]. Ether-containing PC molecules tend to
contain the 1-O-alkyl bond and are typified by platelet activating factor [32, 33]. The
1-O-alkenyl glycerophospholipids contain a fatty acyl group that has a vinyl ether bond
(i.e. a double bond on the first carbon from the ether end, Fig. 5.2a) and are often
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termed plasmalogens. Plasmalogens are particularly susceptible to oxidative attack
due to the presence of the vinyl-ether bond; as such, plasmalogens have a reported
antioxidant effect towards reactive species including ROS and iron-induced
peroxidation [33]. In certain cell types (e.g., inflammatory cells, neurons, and tumour
cells), up to 70% of PE molecules contain an ether-linkage, rather than an acyllinkage [34].
5.1.5 Chapter Aims
The mechanism(s) of NSAID-induced apoptosis in cancer cells in vitro and in vivo
has yet to be fully determined, particularly in the case of COX-2 deficient cancer cell
lines (discussed in Section 1.2.4). It has been shown that a number of NSAIDs interact
directly with glycerophospholipids, resulting in changes to the hydrophobicity, fluidity
and permeability properties of membrane phospholipids [13-16]. Given that BiNSAIDand NSAID-induced apoptosis in the HCT-8 cells was identified in Chapter 2, and that
lipid variation was prominent in the SR-IRMS results (Chapter 4) it was of interest to
determine whether BiNSAID- and NSAID-induced apoptosis caused changes to the
glycerophospholipid composition of the most abundant cellular glycerophospholipids,
PC, PE and PS, in HCT-8 cells.
In this study, the analysis of cellular glycerophospholipids was performed using
shotgun lipidomics. The effect of two BiNSAIDs and their respective NSAIDs were
chosen for examination using lipid extraction. Bi(tolf)3 was assessed due to the fact it
exhibited highest toxicity against the HCT-8 cells, and Bi(difl)3 was chosen as the diflH
represented a salicylate acid structure versus the fenamate structural group of tolfH.
Additionally, Bi(difl)3 exhibited unusual toxicity with respect to the molar IC50 ratio,
BiNSAID:NSAID (as per the MTT assay results presented in Chapter 2).
The specific aims of this Chapter were to:
1. Determine whether BiNSAID treatment affected the composition and relative
quantity of abundant glycerophospholipid (PC, PE and PS) molecules in the
HCT-8 colon cancer cell line, and compare the effects to the corresponding
NSAID treatment.
2. Compare whether the effects on PC, PE and PS composition and their relative
quantities differed between BiNSAID treatment (Bi(tolf)3 and Bi(difl)3).
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5.2 Materials and Methods
5.2.1 Materials
All of the chemicals and materials used for the cell culture and treatment of the
cell samples in this Chapter have been previously described in Section 2.2.1.
Additional chemicals (specific to the experiments in this Chapter) include magnesium
chloride hexahydrate (MgCl2.6H2O, ≥99%) and 2-mercaptoethanol (>98%), which
were purchased from Sigma Aldrich (St Louis, USA). Quick StartTM Bradford Dye
Reagent, 1× and Quick StartTM bovine serum albumin (BSA) standard set (2 mg, 1.5 mg,
1 mg, 0.75 mg, 0.5 mg, 0.25 mg and 0.125 mg) were acquired from Bio-Rad (Hercules
CA, USA). Analytical grade ammonium acetate (≥97%), chloroform (≥99.5%), and
methanol (≥99.7%) and were sourced from Ajax Finechem (Seven Hills, Australia). A
methanolic internal standard mix (comprised of PC (19:0/19:0), 20 µM; PE
(17:0/17:0), 20 µM; PS (17:0/17:0), 20 µM) was generously provided by
Associate Professor Todd Mitchell (School of Medicine, University of Wollongong) and
prepared by Dr Jennifer Saville (School of Chemistry, University of Wollongong).
The glycerophospholipid standards were originally procured from Avanti Polar Lipids
(Alabaster, USA).
5.2.2 Cell lines
HCT-8 cells were sourced and employed as described in Section 2.2.3.
5.2.3 Preparation of cell lipid extracts
HCT-8 cells (1 × 106 cells, 5 mL) were seeded in 60-mm cell culture dishes and
incubated for 24 h, after which the growth medium was removed and the cells were
washed twice with PBS solution. Treatment solutions of the BiNSAID (Bi(tolf)3 or
Bi(difl)3) or NSAID (tolfH or diflH) were added to each dish (3 mL RPMI-1640,
2% DMSO v/v), while the control cells were incubated with vehicle (3 mL RPMI-1640,
2% DMSO v/v) for 24 h. HCT-8 cells were treated with the approximate IC50 doses of
each BiNSAID (as determined by MTT assays, Section 2.3.2), or an equimolar
concentration of the corresponding free NSAID. Following treatment, any detached
cells were collected. The adherent cells were washed with PBS solution (1 mL) and
any displaced cells were collected. Trypsin (0.25% in PBS, 2 mL) was then added to
each dish and the remainder of the cells was combined with the previous washings.
The resultant suspension was centrifuged (300 g, 5 min) and the cell pellet was
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washed with PBS solution to remove any trypsin. The cells were resuspended in
treatment medium (1 mL) and the cell suspension was divided into two 500-µL
aliquots; one aliquot was immediately assessed for protein content, while the second
aliquot was stored (37 °C, 5% CO2) for lipid extraction and ESI-MS/MS analysis.
The cells in the first aliquot were centrifuged and washed once with PBS solution.
The cells were then resuspended in ice-cold osmotic lysis buffer (200 µL, 10 mM
HEPES, 5 mM MgCl2.6H20 and 20 mM 2-mercaptoethanol) and incubated on
ice (30 min).

Following this incubation the swollen cells were sheared 10 times

through a 29-gauge syringe to cause disruption of the cell membrane. Lysis efficiency
was confirmed by light microscopy. The disrupted cells were centrifuged (20,000 g, 5
min) to collect lysed cellular debris and the supernatant (20 µL) was assayed for
protein concentration with Bradford reagent using BSA as a standard.
The second aliquot of cells, to be used for lipid extraction, was removed from the
incubator and the cells were resuspended. A calculated volume of the cell suspension
(normalised to protein concentration) was removed and the cells were centrifuged
and washed with PBS solution. They were then resuspended in methanol (500 µL)
and stored overnight at −80 °C. The cell samples (in methanol) were transferred to a
glass test tube, chloroform (1 mL) was added and the solution was vortexed briefly.
The cell samples were placed on an orbital shaker at low speed for 1 h to allow lipid
extraction to occur. Samples were spiked with a methanolic internal standard mix
(50 µL) such that he final concentration of each internal standard in all the cell
samples was 50 nmol/mg protein.

Following brief vortexing, ammonium acetate

solution (1 mL, 0.15 M) was added and the solution was vortexed and centrifuged
(5 min, 2,000 g). The organic phase was removed and 1 mL of chloroform:methanol
(2:1 v/v) was added to the aqueous phase and vortexed and centrifuged (5 min,
2,000g). The organic phase was combined with the previously collected organic phase
and a fresh aliquot of ammonium acetate (500 μL) was added. The resultant solution
was vortexed and centrifuged (5 min, 2,000g) following which, the aqueous phase was
removed using a Pasteur pipette. Care was taken to ensure that the organic phase was
not disturbed. The organic phase was then dried under nitrogen before reconstitution
in chloroform:methanol (1:2 v/v, 500 μL). Samples were stored at −80 °C until
ESI-MS/MS analysis was performed.
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5.2.4 Mass spectrometry
ESI-MS/MS analysis was performed on a Waters QuattroMicro™ QqQ mass
spectrometer with Masslynx 4.0 software (Waters, Milford, USA). Prior to infusion,
aqueous ammonium acetate (1 M, 25 μL) was added to all samples to produce a final
concentration of 50 mM. For ESI-MS analysis, samples were infused at a flow rate of
10 μL/min.

Table 5.1 contains the parameters used for ESI-MS and targeted ion

scan (MS/MS) analysis in positive ion mode. The collision energies for the targeted
ion scans used in this project are shown in Table 5.2. Spectra were typically obtained
over a mass range of m/z 600-900 in positive ion mode. For ESI-MS/MS, a scan rate of
200 Th/s was used, and 100 scans were combined. The spectra were then processed
using background subtraction and smoothing with a Savitsky-Golay algorithm.

Table 5.1: Instrument parameters used for ESI-MS and targeted ion scan (MS/MS)
analysis on the Waters QuattroMicroTM triple quadrupole mass spectrometer.
Parameter
Capillary (kV)
Cone (V)
Extractor (V)
RF lens (V)
Source temperature (°C)
Desolvation gas flow rate (L/h)
LM 1 resolution
HM 1 resolution
Ion energy 1
Entrance
Collision energy
Exit
LM 2 resolution
HM 2 resolution
Ion energy 2
Multiplier (V)
Gas cell pirani pressure

MS

MS/MS

3.0
50.0
2.00
0.0
80
320
15.0
15.0
0.5
50
2
50
15.0
15.0
0.6
650
< 1.0e−4

3.0
50.0
2.00
0.0
80
320
15.0
15.0
1.0
−2
see Table 4.2
1
15.0
15.0
1
650
3.0e−3

Table 5.2: Targeted ion (MS/MS) scans.
Scan Type

Targeted ion

Collision energy (eV)

Feature identified*

Precursor
m/z 184.1
35
PC
Neutral loss
141.0 Da
25
PE
Neutral loss
185.0 Da
22
PS
*PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine.
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5.2.5 Data analysis
In order to determine the limit of detection (LOD) and limit of quantification
(LOQ) of the instrument for each set of samples that were run over different days, the
LOD and LOQ were calculated for all precursor scans and neutral loss scans following
the conclusion of each run. Following background subtraction and smoothing, the
average noise was calculated in a region of the spectrum where no ionized lipids were
expected by averaging the total noise intensity over a 3 Th region. The mean and
standard deviation (s.d.) were calculated from the average of the total noise intensity
and the LOD and LOQ were determined using the following equations:
LOD = mean + (3 × s.d.)

(1)

LOQ = mean + (10 × s.d.)

(2)

The centroid function was applied to the spectra using peak areas to determine
the area under the curve. Any peaks with intensity below the LOD were not included
in further analysis. Peak intensities above the LOD, but below the LOQ, were reported
in the identification, but were excluded from quantitative analysis.
An Excel template (provided by Associate Professor Todd Mitchell) was used to
simulate isotopic distributions and the necessary corrections were applied to enable
quantification of individual and total lipids within the PC, PE and PS classes as
described in previous studies [35]. The relative ion abundance of the three
isotopologues was determined using the MassLynx isotope modeling function by
calculating the

13C

isotopic distribution for each molecule and input as a ratio of the

molecular ion. The analysis began with the smallest ion in order to correct for an
isotopologue of a lower m/z ion contributing at the mono-isotopic peak of a heavier
ion. The abundance could then be summed for all isotopes, eliminating discrimination
based on size and isotopic ratio differences. In order to quantify each individual
glycerophospholipid present within the class, the isotope sum for each ion was
normalised to the isotope sum of the internal standard.

5.2.6 Statistical analysis
Statistical analysis was performed using one-way ANOVA, followed by the TukeyKramer multiple comparison test using GraphPad Prism, Version 5.04 for Windows
(GraphPad Software, La Jolla, USA). The results were analysed as the vehicle versus
BiNSAID versus the corresponding NSAID, in order to draw a statistical comparison at
the same NSAID treatment concentration. In the cases where the ion abundance was
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not detected above the LOD or LOQ in at least 75% of the samples, the ion was
excluded from the statistical analysis [36]. Results are presented as mean ± standard
deviation (s.d.). A value of P ≤ 0.05 was considered statistically significant.

222

Chapter 5. Lipidomic profiling of glycerophospholipids using ESI-MS/MS

5.3 Results
5.3.1 Phosphatidylcholine (PC)
The effect of BiNSAID and NSAID treatment on the individual and total PC
molecules in HCT-8 cells was examined in two ways: (i) inspecting the changes in the
overall profile of the PC molecules (i.e. changes in the relative abundance of each PC
molecule as a proportion of the total of PC, Fig. 5.3−5.5) and (ii) calculating the overall
changes to the relative concentration of PC molecules (Fig. 5.6).
The profiles of the PC molecules (calculated as a percentage of total PC) detected
above the LOD using ESI-MS/MS in HCT-8 cell lipid extracts treated with vehicle,
Bi(tolf)3 or tolfH are shown in Figure 5.3, while the profiles following treatment with
vehicle, Bi(difl)3 or diflH are shown in Figure 5.4. For clarity, only molecules that
accounted for >0.5% relative abundance of the total PC molecules have been
presented in Figures 5.3 and 5.4. A summary of all the identified PC molecules above
the LOD can be found in Appendix 4.1. As shown in the left-most graphs of Figures 5.3
and 5.4, the three most abundant PC molecules present in the vehicle- and
BiNSAID/NSAID-treated HCT-8 cell lipid extracts were PC 34:1 (m/z 760),
PC 32:1 (m/z 732) and PC P-32:0/O-32:1 (m/z 718).

Notably, Bi(tolf)3 and tolfH

treatment exhibited very similar profile changes, which differed significantly from the
profile obtained from vehicle-treated cells (Fig. 5.3). Additionally, the Bi(difl)3 and
diflH treatment exhibited very similar profile changes, which differed significantly
from the profile obtained from vehicle-treated cells (Fig 5.4). However, the profile
changes induced by Bi(tolf)3/tolfH (Fig. 5.3) compared to Bi(difl)3/diflH (Fig. 5.4)
differed somewhat. For instance, the relative abundance of the most predominant PC
molecule, PC 34:1, decreased in the Bi(tolf)3/tolfH-treated cells (Fig 5.3), but increased
in the Bi(difl)3/diflH-treated cells (Fig 5.4) compared to the vehicle.
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Figure 5.3: Profile of phosphatidylcholine (PC) molecules in HCT-8 cells following 24-h treatment with vehicle (RPMI-1640, DMSO
2% v/v), Bi(tolf)3 (15 µM), or tolfH (45 µM), calculated as a percentage of total PC. Data are presented as mean ± s.d. (n = 3 (vehicle)
or n = 4 (Bi(tolf)3 and tolfH) replicates from one experiment. Significance with respect to the control is indicated by l p ≤ 0.05
(BiNSAID and NSAID), u p ≤ 0.05 (BiNSAID only), or n p ≤ 0.05 (NSAID only). For clarity only molecules that accounted for > 0.5%
relative abundance of the total PC molecules have been presented. Note: Odd or ether-linked fatty acyl chain (e.g. PC O-34:0/PC 33:1)
cannot be differentiated in this experiment.
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Figure 5.4: Profile of phosphatidylcholine (PC) molecules in HCT-8 cells following 24-h treatment with vehicle (RPMI-1640, DMSO
2% v/v), Bi(difl)3 (75 µM), or diflH (225 µM), calculated as a percentage of total PC. Data are presented as mean ± s.d. (n = 4
replicates from one experiment). Significance with respect to the control is indicated by l p ≤ 0.05 (BiNSAID and NSAID), u p ≤ 0.05
(BiNSAID only), or n p ≤ 0.05 (NSAID only). For clarity only molecules that accounted for > 0.5% relative abundance of the total PC
molecules have been presented. Note: Odd or ether-linked fatty acyl chain (e.g. PC O-34:0/PC 33:1) cannot be differentiated in this
experiment.
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In order to identify if fatty acid composition accounts for the changes seen in
Figures 5.3 and 5.4, the PC molecules were classified into the following categories:
those that contained fatty acids with no double bonds (saturated), one double bond
(monounsaturated), ≥ two double bonds (polyunsaturated), or an ether-linked fatty
acid. These were summed within the aforementioned categories and the results are
presented in Figure 5.5. It is important to note that in this context, the sum
composition of the two fatty acids have been reported and therefore saturated,
monounsaturated and polyunsaturated refers to the total number of double bonds
present. Although the identity of both acyl chains could not be determined with the
methodology used in the present study, it has been reported that the typical PC carries
one saturated and one unsaturated chain [1]. Following 24-h treatment with Bi(tolf)3
or tolfH, there was a slight, but significant decrease (Bi(tolf)3, P ≤ 0.01;
tolfH, P ≤ 0.001) in the proportion of PC molecules containing monounsaturated or
polyunsaturated

fatty

acids

compared

to

the

cells

treated

with

vehicle

alone (Fig. 5.5a). These changes were concurrent with a significant increase (Bi(tolf)3,
P ≤ 0.01; tolfH, P ≤ 0.001) in the proportion of PC molecules that contained
ether-linked fatty acids following 24-h treatment with Bi(tolf)3 or tolfH compared to
treatment with vehicle alone (Fig. 5.5a). No significant change to the proportion of
saturated PC molecules was observed (Fig. 5.5a). Additionally, no significant
differences were observed between the changes in the PC composition in
Bi(tolf)3-treated cells when compared to tolfH-treated cells (Fig. 5.5a).
Interestingly, Figure 5.5b shows that the opposite trends could be identified when
the Bi(difl)3- and diflH-treated samples were compared to the vehicle-treated samples
whereby there was a small (but significant) increase in the percentage of PC molecules
containing monounsaturated (Bi(difl)3, P ≤ 0.01; diflH, P ≤ 0.001), or polyunsaturated
fatty acids (both P ≤ 0.001) compared to the cells treated with vehicle alone. These
observations (Fig. 5.5b) were concurrent with a significant decrease in saturated
(P ≤ 0.001) and ether-linked PC molecules (both P ≤ 0.001).

Furthermore, while

Bi(difl)3 and diflH induced the same overall trends (i.e. concurrent increase or
decrease in relative proportion of PC in each fatty acid category, Fig. 5.5b), the
composition of PC between the Bi(difl)3 and diflH differed significantly in all cases
(unsaturated, P ≤ 0.001; monounsaturated, P ≤ 0.01; polyunsaturated P ≤ 0.01; and
ether-linked, P ≤ 0.001).
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Figure 5.5: The proportion of phosphatidylcholine (PC) molecules with fatty acid chains
containing saturated, monounsaturated, polyunsaturated or ether-linked fatty acids calculated
as a percentage of the total PC molecules identified in HCT-8 cell lipid extracts treated for 24 h
with: (a) vehicle (RPMI-1640, 2% DMSO v/v), Bi(tolf)3 (15 µM) or tolfH (45 µM); and
(b) vehicle (RPMI-1640, 2% DMSO v/v), Bi(difl)3 (75 µM) or diflH (225 µM). Data are
presented as mean ± s.d. ((a) n = 3 (vehicle) or n = 4 (Bi(tolf)3 and tolfH) replicates from one
experiment; and (b) n = 4 (vehicle, Bi(difl)3 and diflH) replicates from one experiment.
Significance with respect to the control (lower marking) or corresponding NSAID (upper
marking) is indicated by ** P ≤ 0.01, *** P ≤ 0.001; ns = not significant.

Figure 5.6 shows the comparison of the relative concentration of PC (normalised
to the respective total PC concentration of the vehicle-treated samples) extracted from
the HCT-8 cells following 24-h treatment with vehicle, BiNSAIDs or NSAIDs. A
significant decrease in the total PC concentration was observed between the Bi(tolf)3-,
tolfH- and diflH-treated cells compared to the vehicle-treated cells (Bi(tolf)3 and tolfH,
P ≤ 0.001; diflH, P ≤ 0.05) (Fig. 5.6). However, no significant decrease was observed in
the total PC concentration of the Bi(difl)3-treated cells compared to the vehicle-treated
cells (P > 0.05, Fig. 5.6b). Additionally, the total PC concentration in the tolfH-treated
cells was found to be significantly lower than that of the Bi(tolf)3- treated cells
(P ≤ 0.05) when the two treatments were compared (Fig. 5.6a).
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Figure 5.6: The normalised concentration of phosphatidylcholine (PC) molecules containing
saturated, monounsaturated, polyunsaturated or ether-linked fatty acids in HCT-8 cell lipid
extracts treated for 24 h with: (a) vehicle (RPMI-1640, DMSO 2% v/v), Bi(tolf)3 (15 µM) or
tolfH (45 µM); and (b) vehicle (RPMI-1640, DMSO 2% v/v), Bi(difl)3 (75 µM) or diflH
(225 µM). The values are normalised to the respective vehicle total PC concentration. Data are
presented as mean ± s.d. ((a) n = 3 (vehicle) or n = 4 (Bi(tolf)3 and tolfH) replicates from one
experiment; and (b) n = 4 (vehicle, Bi(difl)3 and diflH) replicates from one experiment).
Significance with respect to the control (lower marking) or corresponding NSAID (upper
marking) is indicated by * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; ns = not significant.

When the PC molecules were analysed by each fatty acid category (right-hand
side, Fig. 5.6) an overall decreases in the concentration of PC molecules containing
fatty acyl chains with saturated, monounsaturated, polyunsaturated and an etherlinked fatty acyl chains were observed in the Bi(tolf)3- and tolfH-treated cells
compared to the vehicle-treated cells (Fig. 5.6a). Notably, the diflH-treated samples
showed the same trends (Fig. 5.6b); however, the decrease was not significant
(P > 0.05) in the monounsaturated and polyunsaturated fatty acyl chain categories.
The Bi(difl)3-treated samples showed a decrease in the concentration of PC molecules
containing fatty acids with saturated (P ≤ 0.01, Fig. 5.5b). However, there was no
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significant decrease in the concentration of PC molecules with monounsaturated and
ether-linked fatty acids (P > 0.05, Fig. 5.5b). The slight increase in concentration of PC
molecules with polyunsaturated fatty acids in the Bi(difl)3-treated samples was not
found to be significant compared to the vehicle-treated samples (P > 0.05, Fig. 5.5b).

5.3.2 Phosphatidylethanolamine (PE)
Figure 5.7 shows the profiles of the PE molecules (calculated as a percentage of
total PE) detected above the LOD using ESI-MS/MS in HCT-8 cell lipid extracts treated
with vehicle, BiNSAIDs, or NSAIDs. As indicated in the left-most graphs of Figure 5.7,
the most abundant PE molecules identified in HCT-8 cells treated with vehicle,
BiNSAIDs or NSAIDs were PE 34:1, PE 36:2, PE 36:1, and PE 38:4. A summary of all
the identified PE molecules above the LOD is shown in the Appendix 4.1. The
calculated LOD and LOQ values were slightly higher for the Bi(difl)3/diflH-treated
samples compared to the Bi(tolf)3/tolfH-treated samples. As a result ion abundance
did not reach the LOD threshold and several molecules of very low abundance were
omitted from the results presented in Figure 5.7b.
Analysis of PE profiles reveals changes to the relative abundance of PE molecules
in vehicle-treated cells compared to the Bi(tolf)3- and tolfH-treated cells (Fig. 5.7). The
most prominent difference is seen in the ether-linked PE molecules, PE P-38:5/O-38:6
(m/z 750) and PE P-38:4/O-38:5 (m/z 752), which were approximately twice the
abundance in the Bi(tolf)3- and tolfH-treated cell samples compared to the vehicletreated cell sample (P ≤ 0.05).

Additionally, other lower abundance ether-linked

molecules showed an increase in relative abundance of PE molecules following
treatment with Bi(tolf)3 and tolfH, including PE P-32:0/O-32:1, PE P-36:4/O-36:5, PE
P-36:3/O-36:4, and PE P-40:5/O-40:6 (Fig. 5.7a). This was accompanied by a
significant decrease in the proportion of diacyl glycerol PE molecules, specifically PE
34:2, PE 36:2, PE 38:5, and PE 38:4.
Analysis of PE profiles also revealed changes to the relative abundance of PE
molecules between vehicle-treated cells, and the Bi(difl)3- and diflH-treated cell
samples (Fig. 5.7b).

Similarly to the Bi(tolf)3/tolfH-treated series (Fig. 5.7a), a

significant increase was observed in the abundance of the ether-linked PE molecules,
PE P-38:5/O-38:6 (m/z 750) and PE P-38:4/O-38:5 (m/z 752) in the Bi(difl)3- and
diflH-treated cell samples compared to the vehicle-treated cell sample (P ≤ 0.05).
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Figure 5.7: Profile of phosphatidylethanolamine (PE) molecules in HCT-8 cells following 24 h
treatment with: (a) vehicle (DMSO 2% v/v), Bi(tolf)3 (15 µM), or tolfH (45 µM); and (b) vehicle
(RPMI-1640, DMSO 2% v/v), Bi(difl)3 (75 µM), or diflH (225 µM), calculated as a percentage of
total PE. Data are presented as the mean ± s.d. ((a) n = 3 (vehicle) or n = 4 (Bi(tolf)3 and tolfH)
replicates from one experiment; (b) n = 4 (vehicle, Bi(difl)3 and diflH) replicates from one
experiment). Significance with respect to the control is indicated by l p < 0.05 (both BiNSAID
and NSAID), u p < 0.05 (BiNSAID only), or n p < 0.05 (NSAID only). Note: Odd or ether-linked
fatty acyl chains (e.g. PE O-34:0/PE 33:1) cannot be differentiated in this experiment.
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The proportion of fatty acyl chain unsaturation or ether-linked fatty acyl chains
calculated as a percentage of the total PE molecules identified in the vehicle-, Bi(tolf)3and tolfH-treated HCT-8 cell lipid extracts is presented in Figure 5.8a. Following the
24-h treatment with Bi(tolf)3 or tolfH, there was a slight (but insignificant) decrease in
the percentage of monounsaturated PE molecules, but a significant decrease (P ≤
0.001) in the percentage of polyunsaturated PE molecules compared to the cells
treated with vehicle alone (Fig. 5.8a). These changes were concurrent with a
significant increase (P ≤ 0.001) in the percentage of PE molecules containing etherlinked fatty acyl chains following the 24-h treatment with Bi(tolf)3 or tolfH (Fig. 5.8a).
No significant variation was observed between the Bi(tolf)3- or tolfH-treated samples.
The changes in the PE profile of the Bi(difl)3/diflH series (Fig. 5.8b) differed
slightly from the Bi(tolf)3/tolfH series (Fig. 5.8a) whereby Bi(difl)3 and diflH treatment
resulted in a significant decrease (P ≤ 0.001) in the percentage of monounsaturated PE
molecules, but a smaller decrease (Bi(difl)3, P ≤ 0.001; diflH, P > 0.05, not significant)
in the percentage of polyunsaturated PE molecules compared to the cells treated with
vehicle alone.

However, similar to the result in Fig. 5.8a, a significant increase

(P ≤ 0.001) in the percentage of PE molecules containing ether-linked fatty acyl chains
was observed following 24-h treatment with Bi(difl)3 or diflH (Fig. 5.8b). As observed
in Figure 5.8b, Bi(difl)3 treatment caused more pronounced changes to the overall
proportion of PE containing monounsaturated (P ≤ 0.01) and polyunsaturated (P ≤
0.05) fatty acyl chains when compared to treatment with diflH.
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Figure 5.8: The proportion of phosphatidylethanolamine (PE) molecules containing
monounsaturated, polyunsaturated or ether-linked fatty acids calculated as a percentage of the
total PE molecules identified in HCT-8 cell lipid extracts treated for 24 h with: (a) vehicle
(RPMI-1640, DMSO 2% v/v), Bi(tolf)3 (15 µM) or tolfH (45 µM); or (b) vehicle (RPMI-1640,
DMSO 2% v/v), Bi(difl)3 (75 µM) or diflH (225 µM). Data are presented as mean ± s.d.
((a) n = 3 (vehicle) or n = 4 (Bi(tolf)3 and tolfH) replicates from one experiment; and (b) n = 4
(vehicle, Bi(difl)3 and diflH) replicates from one experiment). Significance with respect to the
control (lower marking) or corresponding NSAID (upper marking) is indicated by * P ≤ 0.05,
** P ≤ 0.01, *** P ≤ 0.001; ns = not significant.
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A comparison of the relative concentration of PE (normalised to the respective
total concentration of the vehicle-treated samples) from the HCT-8 cells following
24-h treatment with vehicle, BiNSAIDs or NSAIDs is presented in Figure 5.9. Following
24-h treatment, an overall decrease in the total PE concentration of the Bi(tolf)3(P > 0.05), tolfH- (P ≤ 0.01) and diflH-treated (P > 0.05, not significant) cells compared
to the vehicle-treated cells (Fig. 5.9) was observed. However, an overall increase in
the concentration of PE was observed in Bi(difl)3-treated cells compared to the
vehicle-treated cells, although this was not statistically significant (Fig. 5.9b). As
shown in Figure 5.8a, the total PE was significantly decreased by tolfH treatment when
compared to Bi(tolf)3 treatment.
When the PE molecules were grouped according to fatty acid category (Fig. 5.9), it
was apparent that there was an overall decrease in the concentration of
monounsaturated PE molecules in the Bi(tolf)3- (P ≤ 0.05), tolfH- (P ≤ 0.01) and diflHtreated (P ≤ 0.05) cells compared to the cells treated with vehicle alone. No decrease
was observed following Bi(difl)3 treatment (Fig. 5.9b). As shown in Figure 5.9a,
Bi(tolf)3 and tolfH treatment also resulted in a significant decrease (both P ≤ 0.001) in
the relative concentration of polyunsaturated PE molecules relative to the vehicle
treatment. Treatment with diflH also resulted in a decrease (P > 0.05) in the relative
concentration of polyunsaturated PE molecules relative to the vehicle treatment;
however, no change was observed in the Bi(difl)3-treated samples (Fig. 5.9b). As
Figure 5.9 shows, all BiNSAID and NSAID treatments resulted in an increase in the
concentration of ether-linked fatty acid PE molecules compared to the vehicle-treated
cells, however, this was only statistically significant in the BiNSAID-treated samples
compared to the controls (P ≤ 0.01). In both treatment sets the BiNSAID-treated
samples showed a significant (P ≤ 0.05) increase in the concentration of ether-linked
molecules when compared to the NSAID treatment alone (Fig. 5.9a and 5.9b).
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Figure 5.9: The normalised concentration of phosphatidylethanolamine (PE) molecules
containing monounsaturated, polyunsaturated or ether-linked fatty acids in HCT-8 cell lipid
extracts treated for 24 h with: (a) vehicle (RPMI-1640, DMSO 2% v/v), Bi(tolf)3 (15 µM) or
tolfH (45 µM); and (b) vehicle (RPMI-1640, DMSO 2% v/v), Bi(difl)3 (75 µM) or diflH
(225 µM). The values are normalised to the respective total PE vehicle concentration. Data are
presented as mean ± s.d. ((a) n = 3 (vehicle) or n = 4 (Bi(tolf)3 and tolfH) replicates from one
experiment; and (b) n=4 (vehicle, Bi(difl)3 and diflH) replicates from one experiment).
Significance with respect to the control (lower marking) or corresponding NSAID (upper
marking) is indicated by * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001; ns = not significant.
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5.3.3 Phosphatidylserine (PS)
The relative abundances of PS molecules (calculated as a percentage of total PS)
detected above the LOD are presented in Figure 5.10. A summary of all the identified
PS molecules above the LOD can be found in Appendix 4.1.

Due to the low

concentration of PS present in the cell samples, only a small number of PS molecules
could be reliably detected above the LOD (Fig. 5.10). The most abundant PS molecules
identified were PS 34:1 (m/z 762) and PS 36:1 (m/z 790) (Fig. 5.10). The proportion
of the most abundant PS molecule, PS 36:1, was increased in all BiNSAID- and NSAIDtreated samples compared to the vehicle-treated samples (Fig. 5.10), although this was
only significant in the Bi(tolf)3-treated samples (P ≤ 0.05). The relative abundance of
PS 36:2

was

significantly

decreased

in

the

Bi(tolf)3-

and

NSAID-treated

samples (P ≤ 0.05) compared to the vehicle. As Figure 5.10 shows, the change in the
proportion of PS 34:1 differed between the two treatment sets whereby its abundance
significantly increased in the Bi(tolf)3- and tolfH-treated samples compared to the
vehicle, but was slightly (but not significantly) decreased in the Bi(difl)3- and diflHtreated samples compared to the vehicle. Additionally, there was some variation in
the detection of the lower abundance molecules between the two treatment
sets (Fig. 5.10).

Figure 5.10: Profile of phosphatidylserine (PS) molecules in HCT-8 cells following 24 h
treatment with: (a) vehicle (RPMI-1640, DMSO 2% v/v), Bi(tolf)3 (15 µM), or tolfH (45 µM);
and (b) vehicle (RPMI-1640, DMSO 2% v/v), Bi(difl)3 (75 µM), or diflH (225 µM), calculated as
a percentage of total PS. Data are presented as the mean ± s.d, ((a) n = 3 (vehicle) or n = 4
(Bi(tolf)3 and tolfH) replicates from one experiment; and (b) n=4 (vehicle, Bi(difl)3 and diflH)
replicates from one experiment). Significance with respect to the control is indicated by l p ≤
0.05 (both BiNSAID and NSAID), u p ≤ 0.05 (BiNSAID only), or n p ≤ 0.05 (NSAID only).
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Fig 5.11 shows the comparison of the relative concentration of PS (normalised to
the respective total concentration of the vehicle-treated samples) from the HCT-8 cells
following the 24-h treatment with vehicle, BiNSAIDs or NSAIDs. A decrease was
apparent in the total PS concentration of the Bi(tolf)3- (P ≤ 0.05), tolfH- (P ≤ 0.01) and
diflH-treated (P ≤ 0.05) cells compared to the vehicle-treated cells (Fig. 5.11). Similar
to the PE results (Fig. 5.9), an increase in the total concentration of PS was observed in
Bi(difl)3-treated cells compared to the vehicle-treated cells (Fig. 5.11b); however, this
result was not statistically significant (P > 0.05).

Figure 5.11: The normalised concentration of phosphatidylserine (PS) molecules in HCT-8 cell
lipid extracts treated for 24 h with: (a) vehicle (RPMI-1640, DMSO 2% v/v), Bi(tolf)3 (15 µM)
or tolfH (45 µM); and (b) vehicle (RPMI-1640, DMSO 2% v/v), Bi(difl)3 (75 µM) or diflH
(225 µM). The values are normalised to the respective total PE vehicle concentration. Data are
presented as mean ± s.d. ((a) n = 3 (vehicle) or n = 4 (Bi(tolf)3 and tolfH) replicates from one
experiment; and (b) n = 4 (vehicle, Bi(difl)3 and diflH) replicates from one experiments).
Significance with respect to the control (lower marking) or corresponding NSAID (upper
marking) is indicated by * P ≤ 0.05, ** P ≤ 0.01, ns = not significant.

5.3.4 Summary of results
The overall trends observed in Sections 5.3.1-5.3.3 are presented in Tables 5.3
and 5.4. In Table 5.3 and 5.4, a red colour indicates a decrease in prevalence, while a
green colour represents an increase, and grey indicates no change. The intensity of
the colour reflects the significance level, whereby the darkest shade indicates the most
significance (P ≤ 0.001). Table 5.3 shows the PC and PE profiles of the Bi(tolf)3- and
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tolfH-treated samples exhibited the same general overall changes compared to the
vehicle-treated cells. The Bi(difl)3- and diflH-treated cells also showed the similar
trends when compared to each other (Table 5.3). The PC results for Bi(difl)3/diflHtreated cells exhibited changes that were opposite to those observed for the
Bi(tolf)3/tolfH-treated cells (Table 5.3). In contrast, the same overall changes were

Table 5.3: Summary of the overall trend in glycerophospholipid (PC and PE) profile (% of
total) following treatment of HCT-8 cells with BiNSAIDs of NSAIDs (24 h) compared to
vehicle-treated cells (DMSO 2% v/v, 24 h).

PC

PE

-

Saturated
Monounsaturated
Polyunsaturated
Ether-linked
Monounsaturated
Polyunsaturated
Ether-linked
No change

â

Bi(tolf)3,
15 µM
−
â
â
á
â
â
á

tolfH,
45 µM
á
â
â
á
â
â
á

Decreased abundance, P > 0.05

â

Bi(difl)3,
75 µM
â
á
á
â
â
â
á

diflH,
225 µM
â
á
á
â
â
â
á

Decreased abundance P ≤ 0.01

â

Decreased abundance, P ≤ 0.001

á

Increased abundance, P ≤ 0.05

á

Increased abundance, P ≤ 0.01

á

Increased abundance, P ≤ 0.001

Table 5.4: Summary of the overall changes in glycerophospholipid (PC, PE or PS)
concentration following treatment of HCT-8 cells with BiNSAIDs of NSAIDs (24 h) compared to
vehicle-treated cells (DMSO 2% v/v, 24 h).

PC

PS

Saturated
Monounsaturated
Polyunsaturated
Ether-linked
Total
Monounsaturated
Polyunsaturated
Ether-linked
Total PE
Total PS

-

No change

PE

â

Bi(tolf)3,
15 µM
â
â
â
â
â
â
â
á
â
â

tolfH,
45 µM
â
â
â
â
â
â
â
á
â
â

Decreased concentration, P > 0.05

â

Bi(difl)3,
75 µM
â
−
á
â
â
−
−
á
á
á

diflH,
225 µM
â
â
â
â
â
â
â
á
â
â

Decreased concentration, P ≤ 0.05

â

Decreased concentration, P ≤ 0.01

â

Decreased concentration, P ≤ 0.001

á

Increased concentration, P > 0.05

á

Increased concentration, P ≤ 0.01
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observed

for

PE

composition

following

Bi(tolf)3/tolfH

and

Bi(difl)3/diflH

treatment (Table 5.3).
When examining the overall changes to the relative concentration of PC, PE and
PS induced by BiNSAID or NSAID treatment in Table 5.4, it was observed that Bi(tolf)3,
tolfH and diflH exhibited a similar overall trend, whereby an overall decrease in
concentration is observed in all PC and PE categories (with the exception of an
increase in PE ether-linked molecules), and total PS concentration following
treatment.

As observed in Table 5.4, the Bi(difl)3-treated cell samples displayed

several differences from the three other treatments examined, whereby some
categories showed an overall increase or no change in PC, PE and PS concentration.
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5.4 Discussion
The overall aim of the experiments described in this Chapter was to study the
most abundant glycerophospholipid classes in BiNSAID- and NSAID-treated HCT-8
cells using methods established within the laboratory [35-38]. The purpose of this was
to further investigate the results obtained in Chapter 4 which showed lipid changes in
BiNSAID/NSAID-treated

cells.

Specifically

lipidomic

analysis

of

the

glycerophospholipids, PC, PE and PS, using ESI-MS/MS was applied to two sets of
BiNSAID/NSAID-treated HCT-8 cell samples to determine: (i) whether changes could
be detected in the glycerophospholipid profiles of the drug-treated cells compared to
the vehicle-treated cells; (ii) if the relative concentrations of glycerophospholipids
were affected by BiNSAID/NSAID treatment; (iii) whether each BiNSAID and the
parent NSAID induced similar or different changes in the glycerophospholipid
composition or concentration; and (iv) whether any glycerophospholipid changes
induced by drug treatment were similar or differed between the two BiNSAIDs and
corresponding NSAIDs examined. The discussion will focus on these outcomes with
respect to several key observations that stemmed from changes to the relative
concentrations of glycerophospholipids (Section 5.4.1), the changes within the
glycerophospholipid saturation categories (Section 5.4.2), and the changes in the
abundance and relative concentrations of ether-linked glycerophospholipids
(Section 5.4.3).

5.4.1 Effect of BiNSAID and NSAID treatment on phospholipid concentration
The results in Section 5.3.1−5.3.3 indicated that the ESI-MS/MS technique was
sensitive

enough

to

detect

changes

in

the

overall

composition

of

the

glycerophospholipids selected for analysis. Additionally, the use of lipid internal
standards allowed for the relative quantification of individual PC, PE and PS molecules.
The technique was particularly successful for analysing PC molecules, which generally
exhibit the highest abundance in mammalian cells [1]. The analysis of the lower
abundance molecules in the PE and PS samples approached the LOD for the
experimental conditions used.

As such, a more sensitive instrument such as a

nano-ESI [39] would improve the detection of low abundance molecules if future
investigations were required.

Overall, however, the ESI-MS/MS experiments

performed in this Chapter were a suitable starting point to investigate changes in the
dominant lipids and promising results have revealed some interesting changes in the
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relative concentrations of the PC, PE and PS molecules in HCT-8 cell samples following
treatment with BiNSAIDs and NSAIDs.
The overall decrease in the relative concentration of glycerophospholipids
following Bi(tolf)3, tolfH and diflH treatment (summarised in Table 5.4) is consistent
with other studies wherein a decrease in the concentration of PC and PE has been
reported in a number of cell lines undergoing apoptosis [3, 40, 41]. For instance,
Anthony et al. [40] showed that drug-induced apoptosis results in inhibition of PC
synthesis in HL-60 leukaemia cells. Niebergall and Vance [41] determined that the
percentage of apoptotic cells increased when both membrane PC and PE decreased in
mutant Chinese hamster ovary cell line, MT58. Finally, Li and Yuan [3] report that the
concentration of PC and PE decreased in HeLa human cervical cancer cells following
treatment with the anti-cancer drug paclitaxel. However, no change was observed in
the concentration of PS in the study [3], which contrasts the results in Section
5.3.3. The results from the tolfH-treated cells is consistent with the results from the
SR-IRMS studies, which suggested that following 24-h treatment with tolfH the HCT-8
cells have lower lipid concentration than the vehicle-treated cells. The results from
the lipidomic analysis of HCT-8 cells indicate that the SR-IRMS observation could be
contributed to by lowered glycerophospholipid (PC, PE and PS) concentration in the
tolfH-treated cells.
Interestingly, Bi(difl)3 treatment resulted in no significant changes to PC, PE or PS
concentration in HCT-8 cells (Table 5.4). However, the diflH-treated cell samples (at
an equimolar treatment concentration), showed a significant decrease in the relative
concentration of PC and PS, similar to the Bi(tolf)3/tolfH-treated samples (albeit a
slightly less significant decrease, Table 5.4). The results observed from the ESI-MS/MS
analysis for the Bi(difl)3-treated cells were consistent with some of the other
experimental observations reported in this Thesis (PGE2 assays and SR-IRMS
experiments, Chapter 2 and Chapter 4, respectively), whereby Bi(difl)3 displayed a
different effect on the HCT-8 cells compared to the Bi(III) fenamate complexes,
Bi(tolf)3 and Bi(mef)3. The difference in the biomolecular response of the HCT-8 cells
to Bi(difl)3 versus diflH was evident in the SR-IRMS results (Chapter 4), although there
is some deviation from the results observed from the lipidomic analysis (Section 5.3).
Specifically, the SR-IRMS results suggested that 24-h treatment of the HCT-8 cells with
diflH caused an increase in lipids, which was hypothesised to occur as a result of the
accumulation of lipid droplets. Lipid droplets are composed of a core containing the
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neutral lipids, triacylglycerols and cholesterol esters, surrounded by a phospholipid
monolayer (generally comprised of PC, PE, phosphatidylinositol and lysoPC, and
lysoPE) [42]. The results obtained from the lipidomic analysis (Section 5.3) suggest
that this increase is not due to an increase in PC, PE or PS concentration. This implies
that instead an increase in the relative concentration of neutral lipids (such as
triacylglycerols and cholesterol esters) may be responsible for the large increase in
lipid SR-IRMS bands observed in the spectra of the 24-h diflH-treated cells. As such,
future work could potentially expand the lipidomic analysis to include neutral species
including triacylglycerols, cholesterol esters and diacylglycerols.
5.4.2 The effects of BiNSAID and NSAID treatment on fatty acyl chain saturation
While DNA is considered an important target for chemotherapeutics, researchers
have also considered the importance of the plasma membrane as a target for
anticancer therapies for a number of decades [43, 44]. As there is little evidence to
suggest that NSAIDs (or BiNSAIDs, Section 3.3.2) interact with DNA, other means of
cell death have been previously discussed, as described in Section 1.2.4. It is
important to consider the plasma membrane as a target for NSAIDs, since a number of
NSAIDs have been shown to interact with lipids, and in particular, phospholipids [13,
15, 45] as previously discussed in Section 4.4.4.2. One particularly important property
of the plasma membrane is fluidity. This comes from recognising that molecules that
modulate membrane fluidity may sensitise resistant tumour cells to chemotherapyinduced cell death [46]. The level of unsaturation of fatty acids is an important
influence on the fluidity of membranes. For instance, the greater the number of
double bonds a fatty acyl molecule contains, the more physical space it occupies,
therefore influencing the fluidity of the bilayer. As such, changes in the relative
abundance and concentrations of the saturated and unsaturated PC and PE molecules
were compared between vehicle-, BiNSAID-, and NSAID-treated cells.
In the current study, the Bi(tolf)3- and tolfH-treated cells displayed a decrease in
the relative abundance and concentration of PC and PE molecules containing
monounsaturated and polyunsaturated fatty acids compared to the vehicle-treated
cells (Table 5.3). This is consistent with other studies [3] that reported that a decrease
in polyunsaturated fatty acids primarily correlated with the overall reduction in the PE
concentration in HeLa cells following paclitaxel-induced apoptosis. Li and Yuan [3]
also observed that in the PC class both polyunsaturated fatty acids and
241

Chapter 5. Lipidomic profiling of glycerophospholipids using ESI-MS/MS

monounsaturated fatty acids contributed almost equally to the observed decrease in
concentration in the HeLa cells, with a substantial decrease in saturated PCs also
observed. The marked reduction in the quantity of unsaturated fatty acids suggested
there was a potential decrease of membrane fluidity in HeLa cells following paclitaxelinduced apoptosis [3].
In contrast, no significant decreases were observed in the concentration of PC
molecules containing polyunsaturated fatty acids following treatment with Bi(difl)3 or
diflH in the HCT-8 cell lipid extracts. Instead, the abundance of the unsaturated PC
molecules was significantly increased in the Bi(difl)3/diflH-treated cells compared to
the vehicle-treated cells, which was opposite to the trend observed in the
Bi(tolf)3/tolfH-treated samples. These results might suggest that Bi(difl)3 and diflHtreated cells, experience an increase in membrane fluidity. It has been suggested that
polyunsaturated fatty acyl chains are more susceptible to peroxidation, rendering cells
more susceptible to oxidative stress-induced cell death [10]. Therefore, an increase in
the abundance of polyunsaturated PC and PE molecules stimulated by Bi(difl)3 or diflH
treatment may be an advantage for inducing cell death in the HCT-8 cells as there may
be increased potential for lipid peroxidation to occur. Future experiments could be
performed to examine whether the generation of reactive oxygen species (ROS) is
implicated in the apoptotic pathways induced by the BiNSAIDs/NSAIDs examined in
this Thesis and whether there is any potential correlation with lipid peroxidation.
The differences in the abundance and the saturation levels of the PC and PE
molecules may, in turn, result in variations in fluidity between the membranes of the
Bi(tolf)3- and Bi(difl)3-treated cells. It is not yet clear if the insertion of Bi(tolf)3 versus
Bi(difl)3 into the phospholipid bilayer surrounding the cell may affect the fluidity of
the cell membrane, or if cellular events related to cell death (or a combination of both
factors) cause the observed changes. As mentioned previously (Section 3.4.1), work
has commenced to examine the interactions of BiNSAIDs with bilayer mimetics using
neutron reflectometry (Brown and Dillon [47] and unpublished work). The results to
date show that Bi(tolf)3 interacts with the head groups of lipid bilayer membrane
mimics and partitions into the tail region of the membranes (comprised of POPC
molecules). While these results were determined in a cell-free system, it shows that
the Bi(tolf)3 complex is able to displace lipid molecules and potentially partition into
lipid bilayers. Further studies are planned to introduce other integral membrane
components (including cholesterol and membrane-bound proteins) in order to more
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closely mimic the cell membrane (personal communication). Additionally, it is
tempting to speculate that subsequent cell membrane variations (such as membrane
fluidity and the implications for active or passive drug uptake) may be responsible (in
part) for the large proportional difference in the uptake in Bi observed in the Bi(tolf)3
and Bi(difl)3-treated cells (Chapter 3), although further work is needed to determine if
this is the case.
5.4.3 The effects of BiNSAID and NSAID treatment on ether-linked molecules
One of the most interesting observations from the combined PC and PE profile
comparisons was the effect that the BiNSAID and NSAID treatment imparted on the
relative abundance (Fig. 5.5 and Fig. 5.8) and relative concentration (Fig. 5.6 and Fig.
5.9) of ether-linked molecules. Some caution must be taken when interpreting etherlinked molecules due to the inability to distinguish these molecules from odd-chain
molecules as explained in Section 5.1.4. However, it is reported that plasmalogens
constitute ~ 15−20% of total phospholipids in cell membranes [32]. As such, it is
reasonable to assume that a substantial number of plasmalogens, and other etherlinked species, are present in the HCT-8 cells.
The results from the BiNSAID- and NSAID-treated cells indicate a general increase
in the abundance of ether-linked PE molecules (Table 5.3), accompanied by an overall
increase in the relative concentration of the ether-linked PE molecules (Table 5.4).
Additionally, it was observed that Bi(tolf)3 and tolfH caused an increase in the
abundance of PC molecules containing ether-linked fatty acids when compared to the
percent of the total PC (Fig. 5.5), although the relative concentration of all PCs
decreased (Fig. 5.6). An increase in PC and PE ether-linked phospholipids has been
observed in hematopoietic progenitor cells undergoing apoptosis following growth
factor withdrawal, which was accompanied by a decrease in the relative content of
glycerophospholipids [48]. Fuchs et al. [48] speculated that an increase in etherlinked phospholipids may serve as a reservoir for arachidonoyl residues released by
the breakdown of diacyl-glycerophospholipids, in order to reduce further metabolism
of arachidonic acid to pro-inflammatory prostaglandins. The BiNSAID/NSAID-treated
HCT-8 cells may cause accumulation of arachidonic acid since they act at the active site
of the COX-1/COX-2 enzymes to prevent arachidonic acid conversion to
prostaglandins. Additionally, the HCT-8 cells may upregulate arachidonic acid to
compete with the NSAIDs as tolfH and diflH are competitive/reversible COX-1/-2
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inhibitors. As such, the aforementioned hypothesis proposed by Fuchs et al. [48] may
potentially provide one explanation for the increase in ether-linked molecules in the
BiNSAID/NSAID-treated HCT-8 cells since the cells would require a mechanism to
remove excess arachidonic acid.
Schonfeld et al. [49] observed the enhanced synthesis of PE plasmalogens in PC12
cells stimulated with nerve growth factor and docosahexaenoic acid. The authors [49]
speculated that an increase in plasmalogen content was a possible reason for
enhanced resistance of nerve growth factor-differentiated cells to oxidative stress
allowing the cells to accumulate excessive intracellular Fe without undergoing cell
death. A number of studies [50-54] have reported that NSAIDs can cause uncoupling
of oxidative phosphorylation mitochondria, an event that is synonymous with the
production of ROS production and oxidative stress during apoptosis. As such, future
experiments should be performed to determine if BiNSAID-induced apoptosis leads to
ROS production in HCT-8 cells in order to shed light onto the importance of etherlinked phospholipid production.
One of the disadvantages of using constant neutral loss of 141 Da (as performed
in the present study), in order to determine ether-linked PE content in lipid mixtures,
is that plasmalogen PE do not undergo neutral loss of the PE head group to the same
extent as diacyl-PE molecules [21]. This is most likely attributed to the unique gas
phase ion chemistry imparted by the vinyl ether substituent which alters the favorable
CID mechanism of the neutral loss of 141 Da from PE species [21]. As such, the
experimental conditions employed in the present study may potentially underestimate
the presence of ether-linked PE species. Overall, the results from the ESI-MS/MS
analysis of the HCT-8 cells suggested that ether-linked PC and PE molecules may play
an important role in response to BiNSAID/NSAID treatment and the implications of
this response should be investigated further.
5.4.4 Overall summary of the results and future directions
The lipidomic analysis of vehicle-, BiNSAID- or NSAID-treated HCT-8 cells
suggested that, in addition to the glycerophospholipid changes which occurred as a
result of apoptosis, there were also additional effects resulting from each drug
treatment. A combination of these effects has resulted in substantial differences of the
PC and PE profiles (and to a lesser extent the PS profile) of the BiNSAID- and NSAIDtreated cells compared to the vehicle-treated cells. The lipidomic analysis of HCT-8
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cell lipid extracts suggests that Bi(tolf)3/tolfH treatment results in the activation of
different apoptotic responses compared to Bi(difl)3/diflH that influence the cellular
composition and relative concentrations of PC, PE and PS in the HCT-8 cells. These
results further demonstrate the difference in the biological response induced by
Bi(tolf)3 and Bi(difl)3 on the HCT-8 cells, which was observed in other experiments
presented in this Thesis (reported in Chapters 2-4).
While there were some consistencies between the observations obtained from the
two techniques, the connection is speculative at this stage since it remains unclear
whether the glycerophospholipid changes detected using ESI-MS/MS analysis are
directly responsible for the changes detected in the SR-IRMS experiments (Chapter 4).
Gasper et al. were not able to correlate mass spectra and infrared bands related to
νas(CH2), νs(CH2), νas(CH3), νs(CH3) (i.e. between 3025 and 2800 cm−1) [5]. As such, the
authors concluded that the overall global changes in lipid chains could not be
correlated with any particular lipid species resolved by mass spectrometry as all lipid
contributions are overlapped in this spectral range [5]. Consequently, the results from
the ESI-MS/MS experiments performed in this study should be considered as a
compliment to the data obtained using SR-IRMS (Chapter 4).
While the results from the current study show that there are changes to the
profile and relative concentrations of PC, PE and PS in HCT-8 cells treated with
BiNSAIDs or NSAIDs when compared to vehicle-treated cells, it could not be
determined whether these changes are a direct or indirect effect of the drug treatment.
That is to say, it remains unknown whether BiNSAID or NSAID interaction with the
identified glycerophospholipids leads to apoptosis, or whether the BiNSAID- or
NSAID-induced apoptosis results in the observed changes to the profiled
glycerophospholipids. Further experiments (lipidomic and apoptosis assays) could be
performed at earlier time points (< 24 h) to determine if glycerophospholipid profile
changes are observed prior to the appearance of early apoptotic biomarkers (i.e. PS
exposure). Any future ESI-MS/MS experiments should also examine the effects of Bi
alone and other anti-cancer agents, such as cisplatin, to draw a direct comparison
between these drugs and the BiNSAIDs/NSAIDs in HCT-8 cells. Unfortunately, the
preparation of the aforementioned samples was limited by time and resources (in
particular, the expense of phospholipid internal standards required to prepare an
increased number of samples) in the present study. If this barrier can be overcome,
further ESI-MS/MS experiments could also be expanded to other lipid species with
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relatively high abundance in mammalian cells including: sphingomyelins, cholesterol
esters, triacylglycerols, diacylglycerols, and cardiolipins.
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5.5 Chapter Summary
Lipidomic analysis of treated HCT-8 cells using ESI-MS/MS was used to determine
whether BiNSAID/NSAID treatment affects the composition of common phospholipids,
namely PC, PE and PS. Specific observations included:
(i)

Treatment of the HCT-8 cells with BiNSAIDs or NSAIDs significantly
altered the abundance of several individual PC, PE and PS molecules
compared to treatment with vehicle alone.

(ii)

The changes to the abundance of the individual PC, PE and PS molecules in
the overall profiles of the BiNSAID-, and the respective NSAID-treated cells
also displayed many similar changes when compared to the vehicle. There
were some differences between the changes induced by Bi(tolf)3/tolfH
treatments compared to the Bi(difl)3/diflH treatments, suggesting that the
HCT-8 cells responded differently to the fenamate compounds compared
to the salicylate compounds.

(iii)

Changes were observed in the total concentration of PC, PE and PS
between the BiNSAID and NSAID-treated cells compared to the vehicletreated cells. However, when the PC and PE molecules were grouped
according to fatty acid categories, it was observed that there were some
differences to the overall trend (i.e. increase or decrease) between the
Bi(difl)3 and diflH-treated cells compared to the vehicle-treated cells,
whereas the Bi(tolf)- and tolfH-treated cells induced similar changes.

(iv)

The overall abundance of the ether-linked PC and PE molecules was
increased by all BiNSAID and NSAID treatments, which was accompanied
by an increase in the relative concentration of ether-linked PE molecules
(but not ether-linked PC molecules).

In summary, BiNSAID and NSAID treatment resulted in changes to the PC, PE and
PS composition of HCT-8 cells that was detected using ESI-MS/MS analysis. The
general observation from the lipidomic analysis was that BiNSAID- and NSAIDs alter
glycerophospholipid abundance and concentration in HCT-8 cancer cells. Similar to
the results obtained from the MTT assays, flow cytometry, and PGE2 assays
(Chapter 2), the presence of Bi in the Bi(tolf)3 complex did not appear to substantially
alter the effects of tolfH, whereby the glycerophospholipid changes induced by tolfH
were minimally affected by the presence of Bi in the Bi(tolf)3 complex. In contrast,
there was some variation between the results obtained from Bi(difl)3 and diflH-treated
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HCT-8 cells. As such, further work into the implications of phospholipid changes in
drug-induced apoptosis should be investigated as these may have implications for the
mechanism of action for the BiNSAIDs and NSAIDs (in addition to COX inhibition).
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Chapter 6.
Exploration of the in vitro toxicity of new Bi(III)
aminoarenesulfonate, indole-carboxylate, and
hydroxamate complexes

Following promising results (Chapter 2) that showed that a selection of BiNSAIDs
exhibited toxicity towards the HCT-8 colon cancer cells, other Bi complexes were also
investigated for prospective anti-cancer activity against this cell line. Several nonNSAID Bi(III) complexes, which included homoleptic tris-Bi(III) aminoarenesulfonates,
indole-carboxylates, and hydroxamates, were selected for this in vitro screening based
on the fact that the ligands were derivatives of biologically active compounds. The
purpose of the work described in this Chapter was to identify new lead Bi(III)
complexes to provide direction for future studies (such as those described in
Chapters 2−5).
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6.1 Introduction
As previously discussed in Section 1.4.1.4, several classes of Bi(III) complexes
have shown both in vitro and in vivo anti-cancer potential. The focus in Chapters 2−5
has been on the anti-cancer potential of Bi complexes of NSAIDs based on the
hypothesis that COX-2 over-expression is associated with cancer and that NSAIDs are
strong inhibitors of COX. It is evident from the literature (Chapter 1) that Bi(III)
complexes of other ligands also display anti-cancer potential in vitro. To date, there
have been no investigations of homoleptic Bi(III) complexes of aminoarenesulfonic
acids (Section 6.1.1) [1], indole-carboxylic acids (Section 6.1.2) [2], and hydroxamic
acids (Section 6.1.3) [3, 4]. While most of these ligands are not known to inhibit COX,
they have been shown to be biologically active, as discussed in Sections 6.1.1−6.1.3.
As such, the Bi(III) complexes of these ligands warrant investigation.

6.1.1 Sulfonic acids and Bi(III) aminoarenesulfonates
A number of simple sulfonic acid (general formula RSO3H) molecules play
important roles in biological systems. For instance, the glycine analogue,
aminomethanesulfonic acid (Fig. 6.1), has demonstrated similar hepatoprotective
effects as glycine in isolated Kuppfer (liver) cells [5].

The aspartate analogue,

L-cysteic acid (Fig. 6.1), is a potent and effective agonist towards several rat
metabotropic glutamate receptors [6]. Taurine (Fig. 6.1), is naturally present in high
levels in the brain and is believed to play a role in neurological processes including
osmoregulation, antioxidant activity, neuromodulation, and the control of calcium
influx [7]. In addition, experimental evidence suggests that taurine and the synthetic
analogue, homotaurine (Fig. 6.1), reduce protein aggregation of amyloid-β proteins
involved in the formation of plaques in Alzheimer’s disease [8, 9]. Recently, it has
been shown that a synthetic sulfonic acid, anthraquinone-2-sulfonic acid (Fig. 6.1)
confers protection in primary rat cortical neurons exposed to hydrogen peroxide or
staurosporine; as a result this sulfonic acid may present a novel therapeutic agent for
neurological protection [10].
Of relevance to this work are reports of the anti-cancer potential of a number of
sulfonic acid derivatives, whereby it was shown that, in some instances, the sulfonic
acid derivative showed improved activity compared to the original drug [11, 12].
For instance, indirubin-5-sulfonic acid (Fig. 6.1), a derivative of the anti-leukemia drug
indirubin, was found to be a more potent inhibitor of cyclin-dependent kinases when
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compared to indirubin [11]. However, indirubin-5-sulfonic acid showed limited
activity when tested against the T-lymphoblastic Jurkat cell line, which was believed to
be a result of poor cell uptake of the compound [11]. In another study, the vitamin E
analogue, RRR-α-tocopheryloxybutyl sulfonic acid (Fig. 6.1), was designed to prevent
hydrolysis by gastric esterases, a problem which is believed to compromise the in vivo
anti-tumour activity of α-vitamin E succinate [12]. The analogue showed significantly
reduced tumour volumes compared to α-vitamin E succinate following the 6-week
treatment of PC3 prostate cancer cell xenografted nude mice [12]. The serum levels of
RRR-α-tocopheryloxybutyl sulfonic acid- and α-vitamin E succinate-treated mice were
determined to be 15 μM and 2 μM after one month of dosing, respectively, which is
consistent with the improved bioavailability and anti-tumour activity of the
analogue [12].

Figure 6.1: The chemical structures of biologically active sulfonic acids.

255

Chapter 6. Anti-cancer activity of Bi(III) complexes

Importantly, a wide range of sulfonic acids have been shown to be relatively
benign in mammals; for example, LD50 doses in excess of 1000 mg/kg body weight
(often exceeding 5000 mg/kg body weight) are required to induce acute toxicity in
rats dosed orally, regardless of the sulfonic acid tested [13]. In addition, a large
number of sulfonic acids possess little to no mutagenic and carcinogenic activity
towards mammalian cells [13].
The Andrews group have investigated sulfonates as ligands for Bi(III) complexes
in the development of anti-bacterial drugs with improved potency over traditionally
used Bi compounds (BSS, CBS and RBC) for the treatment of H. pylori
infections [1, 14-16]. To this end, several homoleptic tris-Bi(III) aminoarenesulfonate
complexes of the form [Bi(O3S-RN)3] (where O3S-RN represents the deprotonated
ligands

of:

ortho-aminobenzenesulfonic

acid

(oAB-SO3H,

Fig.

6.2);

meta-

aminobenzenesulfonic acid; para-aminobenzenesulfonic acid (pAB-SO3H, Fig. 6.2);
6-amino-3-methoxybenzenesulfonic acid; 2-pyridinesulfonic acid; 4-amino-3-hydroxy1-naphthalenesulfonic acid (4A3HN-SO3H, Fig. 6.2); 2-amino-1-naphthalensulfonic
acid (2AN-SO3H, Fig. 6.2); 5-amino-1-naphthalensulfonic acid (5AN-SO3H, Fig. 6.2); or
5-isoquinolinesulfonic acid) were synthesised and tested for in vitro anti-bacterial

Figure 6.2: The chemical structures of the aminoarenesulfonic acids used to synthesis the five
Bi(III) aminoarenesulfonate complexes, (Bi(oAB-SO3)3, Bi(pAB-SO3)3, Bi(4A3HN-SO3)3,
Bi(2AN-SO3)3, and Bi(5AN-SO3)3), investigated in the present study.
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activity against H. pylori [1]. Importantly, the associated poor aqueous solubility did
not appear to affect the bactericidal properties of the Bi(III) aminoarenesulfonate
complexes against three standard laboratory strains of H. pylori [1]. The Bi(III)
aminoarenesulfonate complexes showed increased anti-bacterial activity compared to
BSS, CBS, RBC, and the uncomplexed aminoarenesulfonic acids [1].
In the present study, five Bi(III) aminoarenesulfonate complexes were chosen for
in vitro anti-cancer screening based on their ease of solubility in the vehicle used in the
MTT

assays

Bi(4A3HN-SO3)3,

(Chapter

2).

Bi(2AN-SO3)3,

The
and

complexes,

(Bi(oAB-SO3)3,

Bi(5AN-SO3)3),

and

the

Bi(pAB-SO3)3,
corresponding

uncomplexed aminoarenesulfonic acids, were selected for screening.

6.1.2 Indoles and Bi(III) indole-carboxylates
Indoles are heterocyclic compounds that consist of a fused six-membered
and five-membered nitrogen-containing pyrrole ring. Naturally occurring indole
molecules that confer biological activity include tryptophan (Fig. 6.3), which is the
precursor of the neurotransmitter serotonin. Indole-3-lactic acid (ILA-H, Fig. 6.3) is
one example of a number of tryptophan metabolites found in human plasma, serum
and urine [17, 18]. A diverse range of drugs exist that incorporate an indole moiety in
their structures (reviewed in [19]). Indole-containing molecules have a wide variety
of medicinal uses, including treatment of asthma, cancer, depression, HIV infection,
hypertension, microbial infection, and inflammation (reviewed in [19]). Of particular
interest to the work performed in this Thesis are the anti-cancer and
anti-inflammatory effects of indole-based compounds. For instance, some commonly
used NSAIDs (e.g. indoH, Fig. 1.2) contain an indole moiety. While several high
molecular weight indole-containing molecules are currently marketed as anti-cancer
drugs (e.g. Vincristine, Fig. 6.3) [19], a relatively simple, low molecular weight
compound, indole-3-carbinol (Fig. 6.3), has been extensively studied as a potential
anti-cancer agent against several cancer cell types, namely breast, colon, endometrium
and prostate (reviewed in [20]).
Pathak et al. [2] have recently synthesised and evaluated the in vitro anti-bacterial
and anti-parasitic activity (against H. pylori and Leishmania promastigotes,
respectively) of several homoleptic Bi(III) complexes derived from indole-carboxylic
acids,

namely

Bi(2-(1H-indol-3-yl)acetate)3,

Bi(3-(1H-indol-3-yl)propanoate)3,

Bi(4-(1H-indol-3-yl)butanoate)3, Bi(1-methyl-1H-indole-3-carboxylate)3, or Bi(2-(1H257
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indol-3-yl)-2-oxoacetate)3 (referred to herein as Bi(IGA)3, where IGA-H = indole-3glyoxylic acid (Fig. 6.3)).
In the present study, two Bi(III) indole-carboxylates, Bi(IGA)3 and Bi(ILA)3, will be
assessed for anti-cancer activity against the HCT-8 cell line since their potential anticancer properties had not been assessed previously.

Figure 6.3: The chemical structures of biologically active indoles, and the indole-carboxylic
acids used to synthesise the two Bi(III) indole-carboxylate complexes, Bi(ILA)3 and Bi(IGA)3,
investigated in this study.

6.1.3 Hydroxamic acids and Bi(III) hydroxamates
Hydroxamic acids (general formula RCONR´OH) are weak acids that represent an
important family of organic bioligands [21]. Hydroxamic acids play a role in a variety
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of biological processes, which is largely due to the ability of hydroxamic acids to form
stable chelates with metals such as Fe(III) [21, 22]. One of the first recognised
biological roles of hydroxamic acids was their use as siderophores in microbial Fe(III)
sequestration and transport [21]. Hydroxamic acids are used in the treatment of
bacterial infections [23], thalassemia [24], and inflammation [25]. Additionally,
hydroxamic acid molecules have been investigated as potential treatments for a
variety of ailments including cancer [26], malaria [27], and Alzheimer’s disease [28].
The structurally simple hydroxamic acid, acetohydroxamic acid (Fig. 6.4), is a
potent inhibitor of nickel-dependent ureases [29, 30]. In 1983, the FDA approved
acetohydroxamic acid for the treatment of urinary tract infections [23].
Benzohydroxamic acid (BHA-H, Fig. 6.4) has also been shown to inhibit urease [31].
The similarly structured salicylhydroxamic acid (SHA-H, Fig. 6.4) is employed in the
treatment of urinary tract infections and urolithiasis [32]. SHA-H has also shown

potential in the treatment of Candida albicans infection [32, 33].
Importantly hydroxamic acids also inhibit enzymes including Zn-dependent
MMPs [34, 35], histone deacetylases, and COX [36-38], which has sparked interest in
their use as potential anti-cancer drugs. The hydroxamic acid-based drugs,
Batimastat (Fig. 6.4) and Marimastat (Fig. 6.4), are MMP inhibitors that have been
investigated in Phase III clinical trials for the treatment of cancer [39, 40].
Unfortunately, neither drug has progressed beyond Phase III trials due to poor efficacy
and adverse side effects [40]. Vorinostat (Merck & Co., Inc., Fig. 6.4) is an orally
delivered, potent inhibitor of histone deacetylase that was approved by the FDA for
the treatment of cutaneous T-cell lymphoma in 2006 [41, 42]. More recently, the
histone deacetylase inhibitor, Belinostat (Spectrum Pharmaceuticals, Fig. 6.4) was
approved by the FDA for the treatment of peripheral T-cell lymphoma [43].
The development of diverse new ranges of hydroxamic acid-based molecules that
inhibit histone deacetylases can be found in a recent review [44].
A number of hydroxamic acids inhibit the activity of COX [36-38], an enzyme
implicated in the formation and progression of a number of types of cancer (as
discussed in Section 1.2.3). Notably, some hydroxamic acid molecules are able to
interact with both the POX and COX active sites; for example, tepoxalin (Fig. 6.4)
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Figure 6.4: The chemical structures of a selection of biologically active hydroxamic acids, and
the hydroxamic acids used to synthesise the three Bi(III) hydroxamate complexes, Bi(BHA)3,
Bi(SHA)3, and Bi(O-AcSHA)3, investigated in this study.

is a dual-inhibitor of the COX and POX active sites [36], and has also been reported to
inhibit lipoxygenase [25]. There is an interest in developing hydroxamic acids as new
generation COX inhibitors since hydroxamic acids may potentially provide potent COX
inhibition through dual COX and POX active site inhibition while also reducing side
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effects such as topical irritation, partially due to the fact hydroxamic acids are weaker
acids than the analogous carboxylic acids [21]. Two hydroxamic acids developed
specifically to target COX, O-acetylsalicylhydroxamic acid (O-AcSHA-H, Fig. 6.4) and
triacetylsalicylhydroxamic acid (Fig. 6.4), exhibited irreversible, non-selective binding
to both COX-1 and COX-2 with comparable or improved potency to aspH [37, 38]. It
has been shown that the mechanism of COX inhibition by O-AcSHA-H and
triacetylsalicylhydroxamic acid is the same as that exhibited by aspH whereby
Ser530 (COX-1) is irreversibly acetylated [37, 38]. Given this evidence, it may be
possible that hydroxamic acid inhibitors of COX may confer potential anti-cancer
activity, in a manner similar to traditional NSAIDs, particularly against cancer cell lines
that express upregulated levels of COX-2.
Due to the ability of several hydroxamic acids (e.g. acetohydroxamic acid,
BHA-H and SHA-H) to inhibit bacterial urease and their use as anti-bacterial agents,
Pathak et al. [3, 4] have synthesised several Bi(III) hydroxamate complexes under the
premise that they may exhibit improved anti-bacterial activity against H. pylori than
currently used Bi(III) compounds, BSS, CBS and RBC. Additionally, the toxicity of the
Bi(III) hydroxamates has been assessed against human fibroblasts [4]; however,
currently no studies have investigated the anti-cancer activity of these complexes
against human cancer cell lines. Three Bi(III) hydroxamate complexes, Bi(BHA)3,
Bi(SHA)3, and Bi(O-AcSHA)3, were chosen for assessment in the present study based
on their ease of solubility in the vehicle used in the MTT assays (Chapter 2).

6.1.4 Scope of this chapter
Following results that showed that BiNSAIDs exhibited in vitro toxicity toward the
HCT-8 colon cancer cell line (Chapter 2) it was of interest to expand the range of Bi(III)
compounds and identify other potential lead compounds. As such, Bi(III) complexes
derived from biologically relevant ligands were studied with the specific aims of:
1.

Assessing the in vitro toxicity of Bi(III) aminoarenesulfonate complexes,
Bi(III) indole-carboxylate complexes, and Bi(III) hydroxamate complexes,
and

2.

Comparing the toxicity of the above-mentioned Bi complexes to the
uncomplexed aminoarenesulfonic acids, indole-carboxylic acids and
hydroxamic acids using the human colon cancer cell line, HCT-8.
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6.2 Materials and Methods
6.2.1 Materials
The

Bi(III)

aminoarenesulfonate

complexes,

Bi(oAB-SO3)3,

Bi(pAB-SO3)3,

Bi(4A3HN-SO3)3, Bi(2AN-SO3)3, and Bi(5AN-SO3)3, were synthesised and characterised
by Dr Madleen Busse (Monash University, Australia) as previously described [1].
The Bi(III) indole-carboxylate complexes, Bi(IGA)3, and Bi(ILA)3, and the Bi(III)
hydroxamate complexes, Bi(BHA)3, Bi(SHA)3, and Bi(O-AcSHA)3, were synthesised and
characterised by Dr Amita Pathak (Monash University, Australia) as previously
described [2-4]. All aminoarenesulfonic acids (oAB-SO3H, pAB-SO3H, 4A3HN-SO3H,
2AN-SO3H, and 5AN-SO3H), indole-carboxylic acids (IGA-H and ILA-H), and
hydroxamic acids (BHA-H, SHA-H, and O-AcSHA) were supplied by Professor Philip
Andrews (Monash University, Australia) and were originally purchased from SigmaAldrich (St Louis, USA) or TCI America (Portland, USA) and used without further
purification as previously described [1-4]. The materials used for the cell culture
experiments described in this Chapter have been previously described in Section 2.2.1.

6.2.2 Cell Lines
HCT-8 cells were sourced and employed as described in Section 2.2.3.

6.2.3 MTT Assay
The MTT assay was performed as previously described in Section 2.2.4.
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6.3 Results
The MTT assay was used to evaluate the effects of the Bi(III) complexes and
ligands on cell viability in HCT-8 cells following 24 h exposure. Figure 6.5a-d shows
the representative concentration-response curves, graphed for the concentration of
each ligand (acknowledging that three mol of ligand are present per mol of Bi(III)
complex). For clarity, the MTT results for the less active compounds are provided in
Appendix 5.1. The IC50 values determined after 24-h exposure to the Bi(III) complexes
and ligands are summarised in Table 6.1.
The Bi(III) aminoarenesulfonates and corresponding aminoarenesulfonic acids
demonstrated little to no activity towards HCT-8 cells (Appendix 5.1), with the
exception of Bi(4A3HN-SO3)3 and 4A3HN-SO3H (Fig. 6.5a).

The complexation of

4A3HN-SO3 to Bi(III) increased the potency of the free 4A3HN-SO3H towards the
HCT-8 cells by approximately 11 times (Table 6.1).
The Bi(III) indolates, Bi(IGA)3 and Bi(ILA)3, exhibited low IC50 values (Fig. 6.5b,
Table 6.1) of 10 µM and 17 µM, respectively. As evident in Figure 6.5b, however, the
ligands exhibited low toxicity. For instance, IGA-H demonstrated no significant
reduction in MTT conversion up to 100 µM (Fig. 6.5b), and while this decreased
between 100-1000 µM with a small increase between 1000 µM to 2000 µM, IGA-H
failed to achieve greater than 50% inhibition of MTT conversion (Fig. 6.5b).
Comparatively, ILA-H demonstrated consistently low toxicity up to the highest
concentration assessed, 2000 µM (Fig. 6.5b). In both instances, it is apparent that the
Bi(III) indole-carboxylates exhibited greater toxicity than predicted for the ligands.
As summarised in Table 6.1, the IC50 values obtained for the Bi(III) hydroxamate
complexes, Bi(BHA)3 and Bi(SHA)3, were approximately 10 and 15 times higher,
respectively, than Bi(IGA)3. However, Bi(BHA)3 demonstrated the lowest IC50 value of
the three Bi(III) hydroxamates tested, and nearly 5.5 times greater activity than free
BHA-H (Table 6.1). Additionally, Bi(SHA)3 demonstrated greater toxicity than free
SHA-H, whereby the latter did not inhibit MTT conversion below 50% over the
concentration range tested (up to 2000 µM, Fig. 6.5d). As observed in Figure 6.5d,
Bi(O-AcSHA)3 induced some reduction in cell viability compared to the vehicle-treated
cells, but failed to produce 50% inhibition (maximum inhibition ~ 52% at 1000 µM).
Uncomplexed O-AcSHA-H (IC50 = 94 ± 13 µM) showed substantially greater toxicity
towards the HCT-8 cells in comparison to Bi(O-AcSHA)3 (Fig. 6.5d).
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Finally, the compounds, Bi(4A3HN-SO3)3, Bi(IGA)3, and Bi(ILA)3, were more toxic
towards HCT-8 cells than the anti-cancer drug, cisplatin (IC50 = 50 µM, Section 2.3.2),
and their respective free ligands, as indicated by their lower IC50 values (Table 6.1 and
Section 2.3.2).

Figure 6.5: Concentration-response curves obtained from the MTT assays of HCT-8 cells
treated (24 h) with the specified compounds and corresponding Bi(III) complexes:
(a) 4A3HN-SO3H or Bi(4A3HN-SO3)3; (b) IGA-H, Bi(IGA)3, ILA-H, or Bi(ILA)3; (c) BHA-H or
Bi(BHA)3; and (d) SHA-H, Bi(SHA)3, O-AcSHA-H or Bi(O-AcSHA)3. Error bars represent the
standard deviation from the mean (n = 6). One representative of three independent
experiments is shown.
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Table 6.1: IC50 values determined by MTT toxicity assays following treatment (24 h) of
HCT-8 colon cancer cells with the specified compounds.
IC50 (µM)a
Ligand (LH)
Complex [Bi(L)3]
Aminoarenesulfonic acids
oAB-SO3
pAB-SO3
4A3HN-SO3
2AN-SO3
5AN-SO3
Indole-carboxylic acids
IGA
ILA
Hydroxamic acids
BHA
SHA
O-AcSHA
aIC50

IC50 ratio
LH:Bi(L)3

> 2000
> 2000
131 ± 12
> 2000
> 2000

> 2000
> 2000
12 ± 0.2
> 2000
> 2000

10.9
-

> 2000
> 2000

10 ± 2
17 ± 1

> 200
> 118

582 ± 32
> 2000
94 ± 13

106 ± 8
159 ± 13
> 1000

5.5
> 12.6
< 0.1

value was determined using at least three independent MTT assays.
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6.4 Discussion
6.4.1 Bi(III) aminoarenesulfonates
The MTT assay results (Section 6.3.1, Table 6.1) showed that the Bi(III)
aminoarenesulfonates and the corresponding free ligands showed little activity
towards HCT-8 cells, with the exception of Bi(4A3HN-SO3)3 and 4A3HN-SO3H. Since
most of these Bi-aminosulfonates exhibited no toxicity against human cancer cells in
the present study, and have exhibited anti-bacterial activity in other studies [1], it
would be worthwhile to determine if the complexes also show a lack of activity
towards non-cancerous human cells as this would be a beneficial property for the use
of the Bi(III) aminoarenesulfonates for the treatment of H. pylori infection.
There are no recent publications that report the in vitro or in vivo anti-cancer
activity of the aminoarenesulfonic acids used in the present study [45-49]. As such,
the reasons why Bi(4A3HN-SO3)3 and 4A3HN-SO3H showed substantial toxicity
compared to the other Bi(aminoarenesulfonates)3 (Table 6.1) can only be speculated.
Factors such as pKa and logP may be less likely to contribute to the variation in activity
as the five tested sulfonic acids display similar pKa values (ranging from 1−3, [1]) and
logP values [45-49]. Additionally, the influence of chemical substituents needs to be
considered. For instance, the presence of a phenyl ring, a sulfonyl group and an amino
group are common features among the chemical structures of the aminoarenesulfonic
acids tested. While 4A3HN-SO3H shares a naphthalene skeleton with 2AN-SO3H and
5AN-SO3H, the presence of the hydroxyl group is unique to the structure of
4A3HN-SO3H. It is not clear whether the hydroxyl group (and the extra H-bonding it
provides), or its adjacent position to the amino group bears influence on the activity of
4A3HN-SO3H. However, it is more likely that the poor aqueous solubility contributes
to the lack of in vitro activity of the oAB-SO3, pAB-SO3, 2AN-SO3H, and 5AN-SO3H and
the respective Bi(III) complexes against the HCT-8 cells.
Interestingly, complexation of 4A3HN-SO3H with Bi(III) resulted in an increase in
toxicity of approximately 11-fold (Table 6.1). This was far higher than that observed
for Bi(difl)3 and diflH (Section 2.3.2) where it was speculated that the increase in
toxicity of Bi(difl)3 might be due to an additive effect between the Bi and the diflH
based on the comparable IC50 values of BiCl3 (383 µM) and diflH (401 µM). Instead it
could be speculated that Bi(4A3HN-SO3)3 is likely to remain intact upon entering the
cell. While it is beyond the scope of the aims of this Chapter, the stability of the
complexes in cell medium and cellular uptake of Bi and potential targets should be
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examined in future work.

For instance, it has previously been shown that the

compound, sodium 4-amino-3-hydroxy-1-naphthalene-sulfonate, which is structurally
similar to 4A3HN-SO3H, caused a substantial decrease in mitogenesis in Balb/c 3T3
fibroblasts that were stimulated by acidic fibroblast growth factor (an important
angiogenesis-promoting polypeptide) [50]. These results give credence to a
mechanism of toxicity of 4A3HN-SO3H that involves targeting an enzyme essential to
the cancer cell growth.
The fact that the toxicity of Bi(4A3HN-SO3)3 was comparable to the
BiNSAIDs (Section 2.3.2) provides precedence to explore the non-NSAID derived
Bi(4A3HN-SO3)3 in future experiments.

Consequently, studies of the toxicity of

Bi(4A3HN-SO3)3 towards normal human cell lines (e.g. healthy colon cells and human
peripheral blood mononuclear cells (hPBMCs)) would be worthwhile to determine the
potential effect on healthy colon cells if administered as a chemotherapeutic or
chemopreventive agent. The benefit of screening Bi(4A3HN-SO3)3 on non-cancerous
cells will be two-fold, whereby the results will not only establish selectivity towards
cancer cells, but will also provide insight into whether any potential side effects may
result from the administration of the complex as an anti-bacterial agent, as originally
proposed by Busse et al. [1].

6.4.2 Bi(III) indole-carboxylates
The MTT results (Section 6.3.1, Table 6.1) showed that the indole-carboxylic
acids, IGA-H and ILA-H, only displayed high toxicity towards HCT-8 cells when
coordinated to Bi as the Bi(III) complexes. Furthermore, the resultant complexes
displayed some of the lowest IC50 values (highest toxicity) of all the compounds
assessed.

Since ILA-H is a product of tryptophan metabolism [17], it was not

surprising that ILA-H did not show any toxicity towards the HCT-8 cells (up to 2 mM).
The comparatively lower IC50 values of the Bi(IGA)3 and Bi(ILA)3 (IC50 = 10 µM and
17 µM, respectively) cannot be explained by Bi(III) toxicity alone since it was
previously established (Chapter 2) that when Bi(III) was bound to the non-toxic Cl−
anion the IC50 value (383 µM) was considerably higher. If the Bi(IGA)3 and Bi(ILA)3
complexes remain intact, alternative toxicity pathways, mechanisms or targets would
be responsible for the toxicity.
Importantly, the homoleptic Bi(III) indole-carboxylate complexes, including
Bi(IGA)3, showed little toxicity towards human fibroblasts (up to 100 µM, 48 h) [2],
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making them excellent candidates for further testing as chemopreventive and
chemotherapeutic properties. Therefore, further investigation into their mechanism
of toxicity including determining mode of cell death and potential intracellular targets
should be performed. There is also scope to expand the compound library for future
testing as Pathak et al. [2] have synthesised several other Bi(III) indole-carboxylate
complexes.

6.4.3 Bi(III) hydroxamates
The results of the MTT assays (Section 6.3.1, Table 6.1) showed that the Bi(III)
hydroxamates, Bi(BHA)3 and Bi(SHA)3, exhibited moderate toxicity towards HCT-8
cells with increased activity compared to the corresponding hydroxamic acids, BHA-H
and SHA-H, at equimolar concentrations. Interestingly, Bi(O-AcSHA)3 demonstrated
substantially reduced toxicity compared to the free O-AcSHA-H ligand, which was the
only Bi(III) complex observed to exhibit such a reduced effect (Sections 2.3.2
and 6.3.1).
There are several possible reasons that Bi(O-AcSHA)3 displayed reduced toxicity
compared to O-AcSHA-H. Firstly, it was observed that, following the treatment period,
Bi(O-AcSHA)3-treated wells showed signs of precipitation in cell medium at
approximately 300 µM. Therefore the poor solubility of Bi(O-AcSHA)3 may contribute
to its limited toxicity. Secondly, as previously discussed in Section 6.1.3, O-AcSHA-H is
an irreversible COX inhibitor similar to aspH [37]. If the mechanism of toxicity of OAcSHA-H proceeds via inhibition of COX then it is conceivable that the lower activity
could be the result of the inability of the acetyl group to acetylate the Ser530 of the
active site of COX if the Bi(O-AcSHA)3 remains intact inside the cell. In order to
explicitly prove that this is the case, further work to determine the exact chemical
nature of the complex in the cell would be required; however, this would be quite
challenging. In addition, COX inhibition assays (with and without cells) should be
performed. Additionally, ELISA assays may be utilised to assess the ability of
Bi(O-AcSHA)3 and O-AcSHA-H to inhibit PGE2 production in order to determine how
effectively the compounds inhibit intracellular COX in vitro (as performed in
Chapter 2).
The improved toxicity of BHA-H (IC50 = 582 μM) over SHA-H (IC50 > 2000 μM)
may be attributed to the difference in the chemical structure and the resultant
physicochemical properties. The same trend was observed in another study [51],
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whereby BHA-H was found to be more cytotoxic than SHA-H, towards neuroblastoma
IMR-32 cells (IC50 = 218 μM and 249 μM, respectively) following 48-h treatment. In
the same study the Ru(III) complexes, [RuCl(H2O)BHA2] and [RuCl(H2O)SHA2], also
showed toxicity towards the IMR-32 cells (IC50 = 166 μM and 221 μM, respectively);
however, the Ru(III) complexes would be considered less toxic when accounting that
there are two moles of ligand per mole of Ru(III). It is notable that [RuCl(H2O)BHA2]
was determined to be more toxic than [RuCl(H2O)SHA2], which is consistent with the
trend observed for the Bi(BHA)3 and Bi(SHA)3 complexes assessed in Section 6.3.1.
The chemical structures of BHA-H and SHA-H differ only by the presence of a
phenolic –OH group in the SHA-H structure. Pathak et al. [4] determined that the
bidentate complexation of Bi(III) to these ligands occurs through the carbonyl and the
hydroxamic acid –OH group. The pKa values of the hydroxamic acid group of BHA-H
and SHA-H have been reported as 8.71 and 7.40, respectively [52]. The SHA-H
hydroxamic acid proton is more acidic due to intramolecular bonding of the conjugate
base with the phenolic OH (pKa 9.81) [52]. Due to the higher pKa, the BHA ligand may
elicit a stronger affinity for Bi at physiological pH (which is maintained in the cell
medium) compared to SHA; hence the increased propensity for coordination may
improve the stability and toxicity of the Bi(BHA)3 complex.
Alternatively, it cannot be ruled out that the BHA-H structure provides a higher
affinity towards an enzyme important to cancer cell function. For instance, BHA-H and
SHA-H both inhibit the enzyme ribonucleotide reductase [53], which catalyses the
formation of deoxyribonucleotides from ribonucleotides. In one study, SHA-H activity
was higher than BHA-H (IC50 = 150 μM and 400 μM, respectively) when assessed
against purified enzymes [53]; however, these experiments do not take into account
the cell medium or intracellular environment of the compounds. BHA-H has also been
shown to be a potent inhibitor of histone deacetylase 6 [54]. While determining the
aqueous stability, uptake and mechanisms of action was beyond the scope of the aims
of this Chapter, these criteria could be potentially examined in future studies.
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6.5 Chapter summary
The overall aim of this Chapter was to determine the cytotoxicity of Bi(III)
derivatives of aminoarenesulfonic acids, indole-carboxylic acids, and hydroxamic acids
against the human colorectal cancer cell line, HCT-8, in order to identify new lead
compounds for future studies. The results obtained from the MTT assays indicated
that the toxicity of the complexes is highly variable with respect to the ligands in the
Bi(III) complex. Specific observations included the following:
i.

Bi(III) aminoarenesulfonates displayed no toxicity towards HCT-8 cells
with the exception of Bi(4A3HN-SO3)3, which demonstrated reasonably
high toxicity, which was superior to the anti-cancer drug, cisplatin.
Additionally,

the

IC50

value

obtained

for

Bi(4A3HN-SO3)3

was

approximately 11 times lower than 4A3HN-SO3H.
ii.

Bi(III) indole-carboxylates, Bi(IGA)3 and Bi(ILA)3, displayed the highest
toxicities towards the HCT-8 cells, which were superior to the anti-cancer
drug, cisplatin.

Bi(III) coordination enhanced the toxicity of the free

ligands, which showed little toxicity against the HCT-8 cells (up to 2 mM).
iii.

Bi(III) hydroxamates, Bi(BHA)3 and Bi(SHA)3, showed higher toxicity
against the HCT-8 cells compared to the free ligands, BHA-H and SHA-H.
Conversely, the toxicity of Bi(O-AcSHA)3 was lower than O-AcSHA-H. The
IC50 values of Bi(BHA)3 and Bi(SHA)3 were 2-3 times lower than cisplatin.

This Chapter confirms for the first time that Bi(III) derivatives of selected
aminoarenesulfonic acids, indole-carboxylic acids, and hydroxamic acids display
cytotoxicity towards a human colon cancer cell line in vitro. The Bi(IGA)3, Bi(ILA)3,
and Bi(4A3HN-SO3)3 complexes showed promising toxicity, which was comparable to
Bi(tolf)3, assessed in Section 2.3.2. This is an important result and warrants further
investigation into the solution stability, drug uptake, mechanisms of action, and the
toxicity of these Bi(III) complexes against normal cells (e.g. fibroblast, hPBMCs) and
other cancer cell lines. Although many of the complexes tested in this study showed
positive activity against the HCT-8 colon cancer cells, the activity of Bi(4A3HN-SO3)3
against a non-cancerous cell line remains to be tested in order to assess the degree of
selectivity and subsequent adverse side effects. Further studies investigating whether
these Bi(III) complexes possess any anti-tumour activity in vivo could also potentially
be pursued.
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7.1 Conclusions
CRC is the second most common cancer in both men and women in Australia.
As the incidence of CRC has not improved since the 1980s, chemoprevention (the use
of a pharmacological or nutritional agent to prevent, reverse, or delay the progression
of carcinogenesis) has been suggested as a primary prevention strategy to reduce the
burden of this disease. The upregulation of COX-2, an enzyme expressed during
inflammation response, has been linked to a number of cancers, including CRC.
As such, inhibition of COX-2 may present a target for chemoprevention/chemotherapy.
To this end, over-the-counter COX inhibitors, NSAIDs, have been investigated as
potential chemopreventives. Several epidemiological and clinical studies provided
evidence that NSAIDs (in particular, aspirin and sulindac) reduce the risk of CRC when
taken regularly over periods of months to years. However, side effects, such as
GI bleeding, CV abnormalities and hepatotoxicity, limit the daily use of NSAIDs over
prolonged periods of time. As such, a method to make NSAIDs safer for long-term
administration is needed, without diminishing the chemotherapeutic potential of
the NSAIDs.
Several studies have shown that a number of metal-NSAID complexes reduce the
formation of GI ulceration compared to the non-complexed NSAIDs in animal models.
Importantly, [Cu2(indo)4(DMF)2] reduced aberrant crypt formation in the rodent colon
cancer model, while also exhibiting GI sparing properties. Bismuth, a group 15
post-transition metal, has been used to treat an array of GI diseases for centuries, with
an acceptable toxicity profile at low doses when administered over extended periods.
Thus, it is hypothesised that the combination of Bi and NSAID in a single compound
may potentially relieve the adverse GI side effects of NSAIDs if used daily as a
chemopreventive agent.

To this end, the suitability of Bi complexes of

NSAIDs (BiNSAIDs) as potential chemotherapeutics or chemopreventives needs to
be examined.
In order to determine the suitability of the BiNSAIDs, Bi(tolf)3, Bi(mef)3 and
Bi(difl)3, as a potential chemotherapeutic or chemopreventive agents against CRC, it
was necessary to evaluate the in vitro potential of the BiNSAIDs as a prelude to future
work that would involve in vivo studies. The experiments described in this Thesis
were divided into two goals: (i) to establish the chemotherapeutic potential of
BiNSAIDs by determining whether BiNSAIDs are able to kill transformed cells (toxicity
and cell death assays), and (ii) to establish whether BiNSAIDs demonstrate
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chemopreventive potential by determining whether BiNSAIDs are able to inhibit the
production of PGE2 (and thus inhibit COX) in transformed cells. A human epithelial
ileocecal colon cancer cell line, HCT-8, was employed as a model CRC cell line for the
evaluation of the BiNSAIDs, and the respective uncomplexed NSAIDs, tolfH, mefH
and diflH.
One specific aim of this project was to compare the toxicity of BiNSAIDs to that of
the uncomplexed NSAIDs. The toxicity of the BiNSAIDs and NSAIDs towards the
HCT-8 cells was assessed using the MTT assay (Chapter 2). The results showed that
the toxicity ranking of the BiNSAIDs paralleled those of the respective free
NSAIDs: diflH < mefH < tolfH. While the IC50 values of the BiNSAIDs (ranging between
16−81 μM) were lower than the free NSAIDs (ranging between 37−403 μM), it was
apparent that the toxicity of the BiNSAIDs was reflective of the molar ratio of the three
NSAID molecules contained in the BiNSAIDs, with the exception of Bi(difl)3. One of the
most important results from the MTT assays was the micromolar toxicity of Bi(tolf)3
and Bi(mef)3 towards HCT-8 cells which was comparable to the anti-cancer drug,
cisplatin (IC50 = 16 μM, 41 μM, and 50 μM, respectively).
The mechanism of cell death was investigated using phase contrast microscopy
and AnnV/7AAD staining (Chapter 2). The results from these experiments showed
that treatment with all BiNSAIDs and NSAIDs induced morphological changes
indicative of cell death via apoptosis. When considered with the results from the MTT
assays, it appeared most likely that the NSAID is the main contributor of the toxicity of
the BiNSAID complexes. The experiments described in Chapter 2 showed for the first
time that BiNSAIDs exhibit potential anti-cancer activity towards a human colon
cancer cell line in vitro and that cell death occurred via apoptotic pathway.
Furthermore, the toxicity of the BiNSAIDs was similar or improved compared to the
respective NSAIDs, indicating that the complexation with Bi did not negatively impact
the bioactivity of the NSAIDs.
The second focus of the in vitro studies was to determine if the BiNSAID could
inhibit COX activity in the colon cancer cells since this was the underlying mechanism
that had been hypothesised for NSAID chemopreventive behaviour. As such, assays
were performed to determine whether complexation with Bi affects the ability of the
NSAIDs, tolfH, mefH and diflH, to interact with COX in vitro, by quantifying PGE2
production by HCT-8 cells (Chapter 2). The inhibition of the prostaglandin, PGE2, was
studied since PGE2 has an established role in the promotion of cancer cell growth and
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fortification (Fig. 1.5). The results showed that the inhibition of PGE2 production of
HCT-8 cells treated with the BiNSAIDs paralleled those of the respective free NSAIDs:
diflH < mefH < tolfH.

There are two important conclusions from these

experiments. Firstly, the results indicated that the anti-cancer effects of the examined
NSAIDs were not substantially diminished by the coordination of Bi to the NSAIDs.
Furthermore, the results confirmed that treatment of HCT-8 cells with BiNSAIDs
caused a reduction in PGE2 (via COX inhibition), which is one of the mechanisms of
action hypothesised for the NSAID-chemoprevention of CRC.
Once the biological potential of the BiNSAIDs had been established in vitro,
Bi uptake and localisation studies were performed to further probe their intracellular
behaviour. Bi uptake was quantified using GFAAS (Chapter 3) where the highest
cellular Bi was observed following treatment with Bi(tolf)3. Since the NMR studies
(Chapter 2) indicated that Bi(tolf)3 was the most stable BiNSAID in cell medium, it
appears that Bi uptake is most likely facilitated by the NSAID. Treatment with
Bi(mef)3 and Bi(difl)3 resulted in substantial, but much lower uptake of Bi compared to
Bi(tolf)3, which correlated with their lower toxicities and increased reactivity
(potential dissociation) in cell medium as determined by NMR spectroscopy.
Microprobe SRXRF imaging (Chapter 3) showed that the intracellular fate of Bi
was similar for all BiNSAID treatments irrespective of the coordinated NSAID.
For instance, all BiNSAID-treated cells showed Bi accumulation in the cytoplasm
within 24-h exposure, typically in discrete hot spots. A number of possible reasons for
the localisation (including targeting of the nucleus and mitochondria) were considered
and two more feasible options were concluded based on correlation maps and reports
from the literature. The first was that hot spots correlated with lysosomes since the Bi
location and the size of the hot spots (0.3–5.8 μm2) were consistent. It was postulated
that this packaging of Bi might be the cells mechanism of detoxification. As many of
the hot spots were located near the nucleus, and acknowledging that COX-2 is located
the on nuclear membrane, the SRXRF results also indicate that Bi is capable of
intracellular movement. In the instance that the BiNSAID has remained intact this
would suggest that BiNSAIDs could locate in the vicinity of and target COX-2. It is
important to note, however, that the experimental methods utilised in this study only
provided information about the uptake and localisation of Bi. Consequently, it is not
possible to make any evidence-based conclusions about the uptake and intracellular
fate of the NSAIDs. While this could be addressed by tagging the NSAID, this too would
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be inconclusive if the tagging altered the cellular distribution of the BiNSAID.
SR-IRMS was utilised to probe cellular biomolecular changes associated with the
treatment of live HCT-8 cells with BiNSAIDs and NSAIDs (Chapter 4). A number of
factors were considered when analysing the spectra obtained from the live cell
populations. Firstly, while live cell analysis can reduce spectral artifacts, such as
RMieS, the IR spectra of water contains a vibrational mode (visualised as a broad band
at ~1643 cm−1) that overlaps with the amide I band, and to a lesser extent the amide II
band. The concern is that this can result in the distortion of the intensity ratio of the
amide I/amide II bands, thus confounding biomolecular changes resulting from drug
treatment. In order to determine whether the water band substantially influences the
biological information contained in the amide region, a correction strategy was
applied to remove the water bands from the cell spectra. The resultant PCA scores and
loadings plots revealed very little difference before and after the application of the
water band correction applied in this study. However, due to continued debate in the
literature about the ideal correction strategy, more work will need to be performed in
this area.
Subsequently, the SR-IRMS cell spectra were analysed in two ways, whereby the
spectra were analysed with and without the inclusion of the amide region. It was clear
from the PCA scores plots that intra-sample and inter-sample variance existed within
the vehicle-, BiNSAID-, and NSAID-treated populations. Examination of the PCA
loadings plots indicated that in the majority of BiNSAID- and NSAID-treated cell
populations, the loadings associated with lipids dominated the PCA loadings plots.
Following 4-h treatment, Bi(tolf)3 and tolfH induced similar biomolecular effects
on the HCT-8 cells in comparison to the vehicle, which were primarily attributed to
effects on the lipids with some contribution from proteins. However, following
removal of the amide region, discrimination between the two compounds was
apparent and attributable to ν(C=O) and νas(PO2−), suggestive of difference in the effect
of the two compounds on phospholipids. Bi(mef)3 or mefH induced similar effects on
the HCT-8 cells, which were primarily attributed to lipids. DiflH induced biomolecular
effects on the HCT-8 cells, which were primarily attributed to proteins. However,
following amide removal from PCA analysis, diflH no longer showed any changes from
the vehicle. Treatment with Bi(difl)3 was distinguishable from diflH and the vehicle
following amide removal, which was primarily attributed to lipids.
Following 24-h treatment, tolfH induced biomolecular effects on the HCT-8 cells,
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which were primarily attributed to a possible reduction in lipids with some
contribution from proteins. Treatment of the cells with Bi(tolf)3 induced a varied
response within the Bi(tolf)3-treated population. Treatment with Bi(mef)3 and mefH
induced similar biomolecular effects on the HCT-8 cells, which were primarily
attributed to lipids. This result might be a reflection of the Bi(mef)3 dissociation such
that the effect of Bi(mef)3 treatment is primarily attributable to mefH. Interestingly,
treatment with Bi(difl)3 resulted in no distinguishable difference from the vehicletreated cell SR-IRMS spectra. However, treatment with diflH was distinguishable from
Bi(difl)3 and vehicle scores, which was primarily attributed to a strong association
with lipids. This was due to a large increase in the lipids contributions that were
visualised in the averaged SR-IRMS spectra of the 24-h diflH-treated cells.
Recognising that an overall change in lipids was the dominant observation from
the SR-IRMS experiments, ESI-MS/MS was used as a complimentary technique to shed
light on whether lipid changes were truly associated with BiNSAID/NSAID treatment
rather than intra-sample variation. The most abundant glycerophospholipids in
mammalian cells, PC, PE and PS, were chosen as a starting point to begin examining
the effects of BiNSAID/NSAID treatment.
The changes to the abundance of the individual PC, PE and PS molecules in the
overall profiles of the Bi(tolf)3- and Bi(difl)3-treated cells, and the respective
NSAID-treated cells, displayed many similar changes when compared to the vehicletreated cells. There were some differences between the changes induced by
Bi(tolf)3/tolfH treatments compared to the Bi(difl)3/diflH treatments. When the PC
and PE molecules were grouped according to fatty acid categories, the observed
changes in the Bi(tolf)- and tolfH-treated cells were similar to each other and showed
a significant decrease in the contribution of unsaturated PC and PE molecules, but a
significant increase in ether-linked molecules. The results obtained from the Bi(difl)3and diflH-treated cells showed similar changes in the grouped PE profile, but
conversely, the reverse trend was observed in the grouped PC profiles whereby the
contribution of the unsaturated PC and PE molecules significantly increased, but a
significant decrease in ether-linked molecules was observed. This may suggest that
while Bi(tolf)3 and Bi(difl)3 both induced cell death via apoptosis, the biomolecular
events that precede or occur during apoptosis differ between the two complexes
whereby the HCT-8 cells respond differently to the fenamate compounds compared to
the salicylate compounds.
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Additionally, changes were observed in the relative concentration of PC, PE and
PS in the BiNSAID and NSAID-treated cells compared to the vehicle-treated cells.
However, when the PC and PE molecules were grouped according to fatty acid
categories, it was observed that there were some differences to the overall trend
between the Bi(tolf)3 and tolfH-treated cells compared to the vehicle-treated cells.
Specifically, an overall decrease in the relative concentrations of PC, PE and PS was
also observed. This result was consistent with literature reports that PC and PE
concentrations are reduced in apoptotic cells, and the SR-IRMS studies, which
suggested that tolfH (and potentially Bi(tolf)3) were associated with lower lipid
content.
In contrast, some variation was observed between the response elicited by
Bi(difl)3 compared to diflH, whereby the diflH-treated cells exhibited lower PC, PE and
PS than the Bi(difl)3-treated cells. This was inconsistent with the SR-IRMS
experiments that showed that diflH-treated cells were associated with increased lipid
content in the PCA results (24-h results). As such, this result may indicate that
glycerophospholipids (specifically PC, PE and PS) were not associated with the
increase in the lipid signals and that other lipids, including neutral lipid classes (e.g.
cholesterol esters, triacylglycerides) should be examined in future studies.
Encouraged by the promising in vitro anti-cancer activity of the BiNSAIDs
against the HCT-8 cells, and recognising that Bi itself possesses anti-cancer
activity

(Section 1.4.1.4), several Bi(III) complexes of aminoarenesulfonates,

indole-carboxylates, hydroxamates were screened for potential anti-cancer activity
in vitro using the MTT assay. The complexes were chosen for investigation since the
aforementioned chemical classes comprise examples of biologically active molecules,
including anti-cancer drugs. The results from the MTT assays showed that of the five
Bi(III)-aminoarenesulfonate complexes tested, only Bi(4A3HN-SO3)3 and its ligand,
4A3HN-SO3H, displayed toxicity (IC50 = 12 μM and 131 μM, respectively) in the
concentration range tested (up to 2 mM). The Bi(III) indole-carboxylates, Bi(IGA)3 and
Bi(ILA)3, displayed two of the highest IC50 values (10 μM and 17 μM, respectively) of
all the tested Bi(III) complexes assayed in this Thesis, and were superior to the
anti-cancer drug, cisplatin (IC50 = 50 μM) when tested in the HCT-8 cells. In contrast,
the free ligands, IGA-H and ILA-H showed little to no toxicity against the HCT-8
cells (up to 2 mM) indicating that the complexation to Bi is essential for toxicity. The
Bi(III) hydroxamates, Bi(BHA)3 and Bi(SHA)3, showed higher activity (IC50 = 106 μM
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and 159 μM, respectively) against the HCT-8 cells than that expected for the molar
equivalent of the free ligands BHA-H and SHA-H (IC50 = 582 μM and > 2,000 μM,
respectively). Conversely, the toxicity of Bi(O-AcSHA)3 was lower than O-AcSHA-H
(IC50 = > 1,000 μM and 94 μM, respectively).
The studies reported in this Thesis suggest that Bi(tolf)3 is a strong candidate for
further testing in an animal model. Specifically, the Bi(tolf)3 complex was the most
potent BiNSAID towards cancer cells in vitro (displaying toxicity at a physiologically
relevant concentration), and appeared to maintain stability in the aqueous
environment used to simulate physiological conditions in vitro. Additionally, the
Bi(tolf)3 showed similar ability to inhibit the production of PGE2 (Chapter 2) and
induced similar changes to the phospholipid profile compared to tolfH at an equimolar
treatment concentration.

7.2 Future Directions
Overall, the results reported in this Thesis indicate that BiNSAIDs display
potential chemotherapeutic and chemopreventive properties against transformed
cells in vitro. In addition to the future directions suggested in the previous Chapters,
the longer term direction of the projects should include two general aims: (i) further
in vitro work, including screening against other cancer and healthy cell lines, and
(ii) ultimately, in vivo studies.
The studies reported in this Thesis were purposely limited to one cell line to gain
a fundamental understanding of the interactions of BiNSAIDs with a representative
CRC cell line. In future studies, it would be of interest to assess whether the BiNSAIDs
display greater potency towards cell lines that overexpress COX-2 (e.g. HT-29 colon
cancer cells) compared to a cell line that exhibits no expression of COX-2 (e.g. HCT-116
colon cancer cells), and thus whether there is any correlation between COX-2
expression and BiNSAID toxicity. These experiments have been commenced by Dillon,
Brown and Ranson (personal communication). It is anticipated that these studies will
provide insight into whether the inhibition of COX-2 or other off-target effects are
essential for the in vitro toxicity of BiNSAIDs. Furthermore, BiNSAIDs could also be
assessed in vitro against other types of GI cancer cell lines, including esophageal,
gastric and other cancers of the upper intestinal tract. It will also be essential to
determine whether the BiNSAIDs display any toxicity towards non-cancerous cells
including

primary

fibroblasts

(as

a

non-cancerous

colon

cell

line)

and
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hPBMCs (isolated from human blood).
In order for the BiNSAIDs to have any potential for use as chemotherapeutics or
chemopreventives, several outcomes must first be established in vivo. These include:
(i) comparing the GI toxicity of the BiNSAIDs to the free NSAIDs following dosing
(short- and long-term) in order to establish if the BiNSAIDs protect against GI
ulceration; (ii) comparing the BiNSAIDs and NSAIDs for the prevention of tumour
formation in the GI tract as a measure of chemoprevention, and (iii) measuring the
accumulation of Bi in the GI tract and vital organs (such as the liver, kidneys, and
brain) in order to determine the safety of the BiNSAIDs following long-term dosing.
Based on the work presented here, studies to examine the aforementioned
outcomes have been commenced (initially for Bi(indo)3, indoH, Bi(asp)3 and aspH) by
Dillon and Brown, et al. using rodent models (personal communication).
The preliminary data shows that BiNSAIDs are able to reduce the formation of lesions
in the small intestine of rats following a single dose (unpublished results). A longterm study is planned whereby the ability of the BiNSAIDs to prevent tumour
formation in an azoxymethane/dextran sulfate sodium colitis mouse model.
As discussed in Section 1.4.2, the accumulation of Bi in animal models has been
established and Bi toxicity has occurred in humans (albeit patients who have taken
extremely large doses of Bi). As such, it is important that animal studies address the
potential for accumulation and toxicity of Bi following treatment with BiNSAIDs. The
accumulation of Bi in the organs of the mice dosed with BiNSAIDs will be examined
using GFAAS to provide insight into the potential for Bi toxicity, and therefore, the
safety of the BiNSAIDs (Dillon and Brown et al., personal communication).
Overall, the results reported in this Thesis provide an indication that BiNSAIDs
display chemotherapeutic and chemoprevention properties against transformed cells.
The SR-IRMS and lipid ESI-MS/MS experiments indicate that the mechanism of action
of the BiNSAIDs may be multi-faceted and may provide a more robust
chemotherapeutic approach than some traditional chemotherapeutic drugs, whereby
cancer cells often develop chemoresistance. Additionally, the employment of
chemopreventive medications (particularly in populations at risk of developing CRC)
could be beneficial to society and reduce the costs associated with treating cancer.
Additional in vivo work will need to be performed in order to further reveal the
therapeutic potential of the BiNSAIDs.

283

Appendix 1

Appendix 1. Additional MTT assay and PGE2 assay results

Appendix 1.1: Concentration-response curve obtained from the MTT assay of DMSO (% v/v in
RPMI-1640) in HCT-8 cells after 24-h treatment. Error bars represent the standard deviation
from the mean (n = 6). One representative of two independent experiments is shown.
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Appendix 1.2: Concentration-response curves obtained from the MTT assays of: (a) tolfH and
Bi(tolf)3; (b) mefH and Bi(mef)3; and (c) diflH and Bi(difl)3; in HCT-8 cells after 4-h treatment.
Error bars represent the standard deviation from the mean (n = 6). One representative of
three independent experiments is shown.

285

Appendix 1

Appendix 1.3: Concentration-response curves obtained from the MTT assays of cisplatin, BiCl3
and BSS after 24-h treatment. Error bars represent the standard deviation from the
mean (n = 6). One representative of three independent experiments is shown.

Appendix 1.4: PGE2 production in HCT-8 cells after 4-h treatment with BSS. Results are
expressed as mean ± SD (n = 3 from three independent experiments).
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Appendix 1.5: Concentration-response curve obtained from the MTT assays of aspH in HCT-8
cells after 24-h treatment. Error bars represent the standard deviation from the mean (n = 6).
One representative of three independent experiments is shown.
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Appendix 2. Additional microprobe SRXRF thin-sectioned cell
maps
Appendix 2.1: Graphite furnace operating conditions used for the analysis of Bi.
Stage

Temperature
(°C)
Dry 1
110
Dry 2
130
Ash
1100
Atomisation
1700
Clean out
2450

Ramp
(sec)
1
15
10
0
1

Hold
(sec)
30
30
20
5
3

Gas flow
(mL.min-1)
250
250
250
0
250
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Appendix 2.2: Microprobe SRXRF elemental maps for toluidine-blue stained thin-section of
HCT-8 cells following 24-h treatment with: (a) vehicle only; (b) Bi(difl)3 (40 μM); (c) Bi(mef)3
(40 μM); (d) Bi(tolf)3 (40 μM), and (e) BSS (40 μM). The elements are specified to the left of
each row. Operating conditions include: beam energy = 13.45 keV, beam size = 0.3 × 0.3 μm2;
step size = 0.3 μm; dwell time = 2.5 s/pt and scan dimensions (H × V) = (a) 13 × 13 μm2;
(b) 19 × 19 μm2; (c) 17 × 14 μm2; (d) 21 × 22 μm2 and (e) 12 × 14 μm2.
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Appendix 2.3: Microprobe SRXRF elemental maps for toluidine-blue stained thin-section of
HCT-8 cells following 4-h treatment with Bi(mef)3 (40 μM). The elements are specified to the
left of each row. Operating conditions include: beam energy = 13.45 keV, beam size =
0.3 × 0.3 μm2; step size = 0.3 μm; dwell time = 2.5 s/pt and scan dimensions (H × V) = (a),
14 × 11 μm2; (b) 22 × 14 μm2.
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Appendix 2.5: Correlative light micrograph of a toluidine-blue stained thin-section of HCT-8
cells following 24-h treatment with: (a) Bi(difl)3 (40 μM); (b) Bi(mef)3 (40 μM); and
(c) Bi(tolf)3 (40 μM) and the corresponding microprobe SRXRF maps of P, Zn, Bi, and the
colocalisation (Col) of the three elements. Operating conditions include: beam energy =
13.45 keV, beam size = 0.3 × 0.3 μm2; step size = 0.3 μm; dwell time = 2.5 s/pt and scan
dimensions (H × V) = (a) 19 × 16 μm2 (i) and 19 × 19 μm2 (ii); (b) 22 × 15 μm2 (i) and
17 × 14 μm2 (ii); (c) 31 × 21 μm2 (i) and 21 × 22 μm2 (ii).
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Appendix 3. Additional SR-IRMS spectra

Appendix 3.1: (a) Averaged (n = 54), baseline corrected (rubberband baseline corrected, 64
baseline points), vector normalised HCT-8 cell spectra following 4-h incubation in vehicle
(RPMI-1640, DMSO 2% v/v) before (— ) and after (— ) water band compensation. Black
arrows indicate the spectral features affected by water compensation. (b) Unit vector
normalised, second derivative of the spectra shown in (a).
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Appendix 3.2: Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised, HCT-8 cell spectra following 4-h incubation in cell medium
(RPMI-1640; — , n = 54), or vehicle (RPMI-1640, 2% DMSO v/v; — , n = 59): (a) without the
application of water band subtraction, and (b) following water band subtraction. The
wavenumbers in black represent the medium-treated band positions, while band positions
that were shifted in the vehicle-treated spectra are represented in red.
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Appendix 3.3: Averaged second derivative (Savitzky Golay, 13 smoothing points), unit vector
normalised, HCT-8 cell spectra following 4-h incubation in cell medium (RPMI-1640; — ,
n = 54), or vehicle (RPMI-1640, 2% DMSO v/v; — , n = 59): (a) without the application of water
band correction, and (b) following water band correction. The wavenumbers in black
represent the medium-treated band positions, while band positions that were shifted in the
vehicle-treated spectra are represented in red (sh = shoulder).

294

Appendix 3

Appendix 3.4: Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 24-h incubation in cell medium
(RPMI-1640 alone; — , n = 39), or vehicle (RPMI-1640, 2% DMSO v/v; — , n = 54): (a) without
the application of water band correction, and (b) following water band correction. The
wavenumbers in black represent the medium-treated band positions, while band positions
that were shifted in the vehicle-treated spectra are represented in red.
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Appendix 3.5: Averaged second derivative (Savitzky Golay, 13 smoothing points), unit vector
normalised, HCT-8 cell spectra following 24-h incubation in RPMI-1640 alone (— , n = 39), or
vehicle (RPMI-1640, 2% DMSO v/v; — , n = 54): (a) without the application of water band
correction, and (b) following water band correction. The wavenumbers in black represent the
medium-treated band positions, while band positions that were shifted in the vehicle-treated
spectra are represented in red (sh = shoulder).
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Appendix 3.6: (a) Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 4-h incubation in vehicle (RPMI-1640,
DMSO 2% v/v, — , n = 59), Bi(tolf)3 (15 µM, — , n = 45) or tolfH (45 µM, — , n = 29). (b) Unit
vector normalised, second derivative of the spectra shown in (a).
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Appendix 3.7: (a) Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 24-h incubation in vehicle
(RPMI-1640, DMSO 2% v/v, — , n = 54), Bi(tolf)3 (15 µM, — , n = 33) or tolfH (45 µM, — ,
n = 100). (b) Unit vector normalised, second derivative of the spectra shown in (a).
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(a)

(b)

Appendix 3.8: (a) Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 4-h incubation in vehicle (RPMI-1640,
DMSO 2% v/v; — , n = 83), Bi(mef)3 (40 µM, — , n = 42) or mefH (120 µM, — , n = 54). (b) Unit
vector normalised, second derivative of the spectra shown in (a).
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(a)

(b)

Appendix 3.9: (a) Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 24-h incubation in vehicle
(RPMI-1640, DMSO 2% v/v; — , n = 54), Bi(mef)3 (40 µM, — , n = 95) or mefH (120 µM, — ,
n = 90). (b) Unit vector normalised, second derivative of the spectra shown in (a).

300

Appendix 3

Appendix 3.10. (a) Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 4-h incubation in vehicle (RPMI-1640,
DMSO 2% v/v, — , n = 59), Bi(difl)3 (75 µM, — , n = 34) or diflH (225 µM, — , n = 41). (b) Unit
vector normalised, second derivative of the spectra shown in (a).
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Appendix 3.11: (a) Averaged, baseline corrected (rubberband baseline corrected, 64 baseline
points), vector normalised HCT-8 cell spectra following 24-h incubation in vehicle
(RPMI-1640, DMSO 2% v/v, — , n = 54), Bi(difl)3 (75 µM, — , n = 66) or diflH (225 µM, — ,
n = 38). (b) Unit vector normalised, second derivative of the spectra shown in (a).
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Appendix 3.12: Percentage of early apoptotic and late apoptotic cells based on flow
cytometric analysis of cell death in the adherent only HCT-8 cells treated for 24 h with
vehicle (RPMI-1640, 2% v/v DMSO; Control), BiNSAIDs (Bi(tolf)3 (15 µM), Bi(mef)3 (40 µM) or
Bi(difl)3 (75 µM)); or the respective equimolar free NSAIDs. Each segment represents the mean
± s.d. (n = 3 replicates from one experiment). Statistical significance of the population of dying
cells (encompassing early apoptotic, late apoptotic and necrotic cell populations) compared to
the control is indicated by *** = P ≤ 0.001. Statistical significance of the BiNSAID-treated
samples compared to the respective NSAID-treated samples is indicated by ‡ = P ≤ 0.001. The
viable (AnnV−/7AAD−) and early necrotic (AnnV−/7AAD+) cell populations have been omitted
from the graph for clarity.
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Appendix 4. Additional ESI-MS/MS results
Appendix 4.1: Analytes identified above the LOD in HCT-8 cell lipid extracts treated with
vehicle (2% v/v DMSO, 24-h) using ESI-MS/MS.
Analyte
Precursor m/z 184.1

m/z

PC 27:0
PC 28:0
PC 29:0
PC 30:1

664
678
692
704

PC 30:0
PC O-32:1
PC O-32:0p
PC 31:0
PC 32:2
PC 32:1
PC 32:0
PC O-34:2
PC O-34:1
PC O-34:0/33:1
PC 33:0
PC 34:3
PC 34:2
PC 34:1
PC 34:0
PC O-36:4
PC O-36:3
PC O-36:2/35:3
PC O-36:1/35:2
PC O-36:0/35:1
PC 35:0
PC 36:6
PC 36:5
PC 36:4
PC 36:3
PC 36:2
PC 36:1
PC O-38:6/36:0
PC O-38:5

706
716
718
720
730
732
734
742
744
746
748
756
758
760
762
766
768
770
772
774
776
778
780
782
784
786
788
790
792

Analyte
Precursor m/z 184.1

m/z

PC O-38:4
PC O-38:3/37:4
PC O-38:2p
PC O-38:1p
PC O-38:0p
PC 38:6
PC 38:5
PC 38:4
PC 38:3
PC 38:2
PC 38:1
PC O-40:5
PC O-40:4
PC O-40:3
PC O-40:0
PC 40:7
PC 40:6
PC 40:5
PC 40:2

794
796
798
800
802
806
808
810
812
814
816
820
822
824
830
832
834
836
842

Neutral loss 185.0 Da
PS 32:1
PS 33:1
PS 34:1
PS 35:1
PS 36:2
PS 36:1
PS 38:4
PS 38:3
PS 38:2
PS 38:1
PS 40:6
PS 40:5
PS 40:1

m/z
734
748
762
776
788
790
812
814
816
818
836
838
846

Analyte
Neutral loss 141.0 Da

m/z

PE O-32:0
PE 32:1
PE O-34:1
PE O-34:0/33:1
PE 34:2
PE 34:1
PE O-36:4
PE O-36:3
PE O-36:2/35:3
PE O-36:1/35:2
PE O-36:0/35:1
PE 36:4
PE 36:3
PE 36:2
PE 36:1
PE O-38:6/36:0
PE O-38:5
PE O-38:4
PE O-38:3/37:4
PE 38:6
PE 38:5
PE 38:4
PE 38:3
PE O-40:6/38:0
PE O-40:5
PE O-40:4
PE 40:6
PE 40:5

676
690
702
704
716
718
724
726
728
730
732
740
742
744
746
748
750
752
754
764
766
768
770
776
778
780
792
794
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Appendix 5. Additional MTT assay results

Appendix 5.1: Concentration-response curves obtained from MTT assays of HCT-8 cells
treated (24 h) with the specified aminoarenesulfonic acids and corresponding Bi(III)
complexes: (a) oAB-SO3H or Bi(oAB-SO3)3; (b) pAB-SO3H or Bi(pAB-SO3)3; (c) 2AN-SO3H or
Bi(2AN-SO3)3; and (d) 5AN-SO3H or Bi(5AN-SO3)3. Error bars represent the standard
deviation from the mean (n = 6). One representative of three independent experiments is
shown.
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